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Abstract 
Introduction: Reducing inequalities in health is a public health imperative. In the 
UK and internationally policies are being implemented to try to reduce health 
inequalities, with limited success. This thesis examines the effect of socio-economic 
status (SES) on clinical outcomes, healthcare use and employment opportunities in 
people with cystic fibrosis (CF). Poorer socio-economic circumstances have been 
linked with worse outcomes in cystic fibrosis. Because CF is genetically determined, 
this offers an opportunity to investigate the impact of SES on health and social 
outcomes, in a chronic condition without a socio-economic gradient in incidence. 
This provides a useful case for understanding how health inequalities are generated, 
in order to develop more effective interventions, for people with CF and more 
generally. 
 
Methods: I analyse, for the first time, the national CF registers from the UK and 
Denmark, using longitudinal modeling techniques. Mixed-effects models are used to 
assess the association between measures of SES and longitudinal outcomes, 
adjusting for clinically important covariates. Study 1 explores longitudinal weight, 
height, BMI, %FEV1, risk of Pseudomonas colonisation, and the use of major CF 
treatment modalities, and their association with small-area deprivation (8055 people 
with 49,337 observations between 1996 and 2010). Study 2 explores longitudinal 
employment status in adults with CF in the UK, and its association with small-area 
deprivation, disease severity, and time in hospital. Study 3 presents a novel 
longitudinal analysis of the Danish CF registry (70,448 %FEV1 measures on 479 
patients seen monthly between 1969 and 2010), to understand the way %FEV1 
changes over time.  
 
Results: Compared with the least deprived areas in the UK, children with CF from 
the most deprived areas weighed less, were shorter, had a lower body-mass index, 
were more likely to have chronic P. aeruginosa infection, and have a lower %FEV1. 
These inequalities were apparent very early in life and did not widen thereafter. On a 
population level, after adjustment for disease severity, children in the most deprived 
quintile were more likely to receive intravenous antibiotics and nutritional treatments 
compared with individuals in the least deprived quintile. Patients from the most 
disadvantaged areas were less likely to receive DNase or inhaled antibiotic treatment. 
In adults deprivation, disease severity, and time in hospital all influence employment 
chances in CF. Furthermore, deprivation amplifies the harmful effects of disease 
severity on employment: the employment chances of people with CF with poor lung 
function from disadvantaged areas are damaged to a greater extent than for their 
counterparts living in the least disadvantaged circumstances. The Danish analysis 
quantifies the short-term variability in %FEV1 (SD 6.3%) and shows that lung 
function measures are correlated for over 15 years. 
Conclusions: In the UK, children with CF from more disadvantaged areas have 
worse growth and lung function compared with children from more affluent areas, 
but these inequalities do not widen with advancing age. Policies to reduce 
inequalities should thus focus on the early years. Clinicians consider deprivation 
status, as well as disease status, when making decisions about treatments, and this 
might mitigate some effects of social disadvantage. The differential social 
consequence of having CF in terms of employment is likely to be an important 
pathway for the amplification of health inequalities.  
 vi 
Contents 
Figures ....................................................................................................................... viii 
Tables .......................................................................................................................... xi 
Abbreviations ............................................................................................................ xiii 
Chapter 1: Introduction ................................................................................................ 1 
Relevance of the issue .............................................................................................. 1 
Previous research and gaps in the literature ............................................................. 2 
Objectives of the research ........................................................................................ 5 
Structure of this thesis .............................................................................................. 6 
Chapter 2: Literature review ........................................................................................ 9 
The policy context to health inequalities ................................................................ 11 
The effects of childhood disadvantage ................................................................... 14 
Understanding the causes of health inequalities .................................................... 19 
Studying tracer groups to better understand pathways to health inequalities ........ 33 
CF as a tracer condition .......................................................................................... 34 
Key features of CF ................................................................................................. 38 
Health inequalities and CF ..................................................................................... 56 
Gaps in the literature .............................................................................................. 61 
Summary ................................................................................................................ 62 
Chapter 3: Methods .................................................................................................... 64 
Source and extraction of UK SES data .................................................................. 70 
Danish dataset ........................................................................................................ 74 
Contrasting UK and Danish datasets ...................................................................... 78 
Statistical methods .................................................................................................. 80 
Pilot study and consideration of sample size ....................................................... 101 
Computation ......................................................................................................... 103 
Chapter 4: Study 1 – The effect of social deprivation on clinical outcomes and the 
use of treatments in the UK CF population: A longitudinal study ........................... 104 
Abstract ................................................................................................................ 104 
Introduction .......................................................................................................... 105 
Methods ................................................................................................................ 106 
Results .................................................................................................................. 108 
Discussion ............................................................................................................ 151 
Interpretation ........................................................................................................ 156 
Chapter 5: Study 2 – A longitudinal study of the impact of social deprivation and 
disease severity on employment status in the UK CF population ............................ 158 
Abstract ................................................................................................................ 158 
Introduction .......................................................................................................... 160 
Methods ................................................................................................................ 162 
Results .................................................................................................................. 166 
Discussion ............................................................................................................ 178 
Interpretation ........................................................................................................ 181 
Chapter 6: Study 3 – Understanding the natural progression in %FEV1 decline in 
patients with CF: A longitudinal study .................................................................... 182 
Abstract ................................................................................................................ 182 
Introduction .......................................................................................................... 183 
Methods ................................................................................................................ 184 
Results .................................................................................................................. 187 
Interpretation ........................................................................................................ 208 
 vii 
Chapter 7: Discussion .............................................................................................. 209 
Introduction .......................................................................................................... 209 
Key findings with reference to objectives ............................................................ 209 
How has this thesis contributed to the literature? ................................................ 216 
Contribution to our understanding of CF epidemiology ...................................... 216 
Contribution to the knowledge base around health inequalities .......................... 246 
Methodological advances ..................................................................................... 253 
Critique of overall study design ........................................................................... 255 
What are the implications for policy and clinicians? ........................................... 263 
Conclusions .......................................................................................................... 268 
Further research .................................................................................................... 268 
Research currently in progress from this thesis ................................................... 269 
References ................................................................................................................ 273 
Appendix 3 (Pertaining to Chapter 3, Methods) ...................................................... 305 
Appendix 4 (Pertaining to Chapter 4) ...................................................................... 325 
Weight .................................................................................................................. 325 
Height ................................................................................................................... 328 
BMI ...................................................................................................................... 332 
%FEV1 ................................................................................................................. 336 
Pseudomonas colonisation ................................................................................... 338 
Any IV antibiotic therapy..................................................................................... 340 
Any home IV therapy ........................................................................................... 341 
Nutritional therapy ............................................................................................... 343 
DNase ................................................................................................................... 344 
Any inhaled therapy <18 ...................................................................................... 345 
Illustrative regression diagnostics ........................................................................ 346 
Appendix 5 (Pertaining to Chapter 5) ...................................................................... 348 
Appendix 6 (Pertaining to Chapter 6) ...................................................................... 349 
Appendix (Publications from this thesis) ................................................................. 354 
 
  
 viii 
Figures 
Figure 1: Schematic overview of the studies in this thesis .......................................... 8 
Figure 2: Low birth weight; asthma admission rate; GCSE success rate; and life 
expectancy versus child poverty for wards in Liverpool 2011 .......................... 15 
Figure 3: Children achieving a good level of development at age 5 versus child 
poverty ................................................................................................................ 18 
Figure 4: The main influences on health .................................................................... 21 
Figure 5: The social determinants of health inequalities ............................................ 22 
Figure 6: A conceptual model for studying the effect of social position and social 
context on health ................................................................................................ 31 
Figure 7: Median FEV1 % predicted by paediatric centre/clinic all centres and 
networks. ............................................................................................................ 46 
Figure 8: Flowchart of included participants for weight analysis .............................. 68 
Figure 9: Data follow-up in the population aged <40 years ....................................... 69 
Figure 10: Year of birth for people included in the weight analysis 1996 to <2010 . 69 
Figure 11: Density plot comparing distributions of deprivation scores ..................... 73 
Figure 12: Cumulative density plot comparing deprivation score distribution for the 
whole UK population versus the CF population ................................................ 74 
Figure 13: Map of Denmark showing location of CF centres .................................... 75 
Figure 14: Histogram of year of birth for Danish dataset .......................................... 77 
Figure 15: Histogram of frequency and duration of follow up .................................. 78 
Figure 16: Twenty randomly selected %FEV1 profiles from the UK CF registry for 
people aged<20 .................................................................................................. 79 
Figure 17: Five randomly selected %FEV1 profiles from the Danish registry .......... 79 
Figure  18:  PubMed  results  containing  “longitudinal”  by  year,  1960-2012 ............... 80 
Figure 19: Spaghetti plot for %FEV1 versus age illustrating the longitudinal nature of 
the data. .............................................................................................................. 88 
Figure 20: Random intercept and slope model for %FEV1 decline ........................... 91 
Figure 21: A typical example of a theoretical variogram ........................................... 95 
Figure 22: Simulated data illustrating the unbiased estimates resulting from a mixed 
model analysis, where the data is assumed to be MAR, compared to the GEE 
estimate ............................................................................................................. 100 
Figure 23: Scatterplot of % predicted FEV1 versus age with smoothed mean ........ 102 
Figure 24: Logic model for %FEV1 analysis ........................................................... 107 
Figure 25: Logic model for IV therapy analysis ...................................................... 108 
Figure 26: Distribution of incident cases by deprivation quintile. ........................... 109 
Figure 27: Kaplan-Meier plot of time to diagnosis by deprivation quintile. ............ 111 
Figure 28: Anthropometric outcomes: mean cross-sectional weight, height, and BMI 
by age comparing extremes of deprivation quintile (red most deprived). ....... 114 
Figure 29: Modelled growth trajectories for children, comparing least (blue) and 
most deprived quintiles (red). ........................................................................... 115 
Figure 30: Spaghetti plot of weight SD score versus age in paediatric age group ... 116 
Figure 31: Piecewise modelling approach to weight z score trajectory ................... 117 
Figure 32: Exploratory analysis showing smoothed means of weight for age SD score 
versus age, stratified by covariates, for people<18 .......................................... 118 
Figure 33: Deprivation quintile contrast from final weight model <18 ................... 119 
Figure 34: Weight for age Z score versus age, illustrating the effect of sex, screening 
status, delta F508 carrier status, and ethnicity ................................................. 121 
 ix 
Figure 35: Piecewise modelling approach to weight SD score trajectory in analysis 
stratified by screening status ............................................................................ 122 
Figure 36: Deprivation effect on weight in screening stratified analysis................. 123 
Figure 37: Spaghetti plot of weight for age SD score versus age in adult age group
 .......................................................................................................................... 124 
Figure 38: Exploratory analysis showing smoothed means of weight for age SD score 
versus age, stratified by covariates, for people>18 .......................................... 125 
Figure 39: Deprivation quintile contrast from final weight model >18 ................... 125 
Figure 40: Weight for age versus age, illustrating covariate contrasts from the final 
longitudinal models .......................................................................................... 127 
Figure 41: Height for age versus age, illustrating covariate contrasts from the final 
longitudinal models .......................................................................................... 128 
Figure 42: BMI for age versus age, illustrating covariate contrasts from the final 
longitudinal models .......................................................................................... 129 
Figure 43: BMI for age versus age, illustrating covariate contrasts from the final 
longitudinal models .......................................................................................... 130 
Figure 44: Respiratory outcomes: Mean cross-sectional %FEV1 and P. aeruginosa 
colonization prevalence by age comparing extremes of deprivation quintile .. 131 
Figure 45: %FEV1 versus age from 5 to 40 ............................................................. 132 
Figure 46: GAMs showing the shape of the relationship between %FEV1 and 
deprivation score .............................................................................................. 133 
Figure 47: %FEV1 trajectories, illustrating the effect of deprivation, sex, screening, 
genotype, ethnicity, Pseudomonas, CFRD and BMI status ............................. 135 
Figure 48: %FEV1 versus age in the >18 group, illustrating sex and genotype effect
 .......................................................................................................................... 136 
Figure 49: Cross sectional and modelled longitudinal Pseudomonas prevalence by 
deprivation........................................................................................................ 137 
Figure 50: GAMs showing the shape of the relationship between risk of 
Pseudomonas colonisation and deprivation score............................................ 138 
Figure 51: Use of therapies: any IV antibiotic therapy, home IV antibiotic therapy, 
hospital IV antibiotic therapy, supplemental feeding, DNase, and inhaled 
antibiotics, by age comparing extremes of deprivation quintile ...................... 140 
Figure 52: Cross sectional and modelled longitudinal percentage of people using any 
IV therapy in the preceding year by deprivation in the <18 and >18 age group
 .......................................................................................................................... 142 
Figure 53: GAMs showing the shape of the relationship between log-odds of any IV 
therapy and deprivation score. ......................................................................... 142 
Figure 54: Scatterplot of log IV days (home and hospital) versus age, with fitted 
longitudinal trajectory by deprivation quintile ................................................. 144 
Figure 55: Cross sectional and modelled longitudinal percentage of people using any 
nutritional therapy in the preceding year by deprivation in the <18 age group 
and <18 age group ............................................................................................ 145 
Figure 56: Cross sectional percentage of people using any DNase therapy, and 
inhaled antibiotic, by deprivation quintile ....................................................... 146 
Figure 57: Cross-sectional full time and part time employment, by deprivation and 
sex .................................................................................................................... 163 
Figure 58 Logic model to inform analysis of employment status ............................ 164 
Figure 59: Cross sectional employment prevalence by age and year ...................... 169 
Figure 60: GAMs for risk of employment ............................................................... 170 
Figure 61: Empirical logit plots by age and SES for females in the dataset ............ 171 
 x 
Figure 62. Longitudinal employment trajectory versus age of people with CF in UK 
CF Registry, by deprivation quintile, sex, %FEV1, BMI SD score and days in 
hospital. ............................................................................................................ 174 
Figure 63: Exploratory analysis of interaction effect between deprivation and %FEV1 
on employment status. ...................................................................................... 175 
Figure 64: Longitudinal employment trajectory versus age, demonstrating the 
interaction between deprivation and %FEV1 ................................................... 177 
Figure 65: Scatterplot of %FEV1 versus age in Denmark, with a randomly selected 
individual highlighted in each panel ................................................................ 188 
Figure 66: All Danish data with smoothed mean trend ............................................ 189 
Figure 67: Residual plot for individual in Danish population .................................. 190 
Figure 68: Quantifying the variability in %FEV1 with the variogram approach ..... 191 
Figure  69:  Proportion  of  variability  in  an  individual’s  %FEV1 at follow-up time t that 
is explained by their %FEV1 at baseline. ......................................................... 192 
Figure 70: Comparison between empirical variogram and MLE variogram estimate
 .......................................................................................................................... 193 
Figure 71: Scatterplot of standardised residuals versus fitted values ....................... 194 
Figure 72: Simulated realisations from the final model ........................................... 194 
Figure 73: Comparison of conventional random-intercept and slope model over short 
and long follow-up periods, versus proposed Gaussian process model. .......... 197 
Figure 74: Univariate effect of pancreatic status ..................................................... 200 
Figure 75: Effect of key covariates on %FEV1 ........................................................ 201 
Figure 76: Scatterplot of data for post-1998 cohort ................................................. 202 
Figure 77: Scatterplot of data for 1988-1998 cohort ................................................ 202 
Figure 78: Logic model based on the Diderichsen model outlining exposures for poor 
outcomes in CF ................................................................................................. 228 
Figure 79: Effect of sex on lung function decline in the US and the UK ................ 237 
Figure 80: How risk reduction and health promotion strategies influence health 
development ..................................................................................................... 249 
Figure 81: Effect of parental education level on lung function decline in Denmark270 
Figure 82: Joint modelling of lung function and survival outcomes........................ 271 
Figure 83: Spaghetti plot of height for age SD score versus age in paediatric age 
group. ................................................................................................................ 328 
Figure 84: Exploratory analysis showing smoothed means of height for age Z score 
versus age, stratified by covariates ................................................................... 328 
Figure 85: Spaghetti plot of height for age Z score versus age in adult age group. . 329 
Figure 86: Exploratory analysis showing smoothed means of height for age Z score 
versus age, in adult age group, stratified by covariates .................................... 329 
Figure 87: Spaghetti plot of BMI for age Z score versus age in paediatric age group.
 .......................................................................................................................... 332 
Figure 88: Exploratory analysis showing smoothed means of BMI for age Z score 
versus age, stratified by covariates ................................................................... 332 
Figure 89: Spaghetti plot of BMI for age Z score versus age in adult age group. ... 333 
Figure 90: Exploratory analysis showing smoothed means of BMI for age Z score 
versus age, in adult age group, stratified by covariates .................................... 333 
Figure 91: Exploratory analysis showing smoothed means of %FEV1 score versus 
age, stratified by covariates .............................................................................. 336 
Figure 92: %FEV1 < 18 years, final model .............................................................. 346 
Figure 93: Any IV therapy < 18 years, final model ................................................. 347 
  
 xi 
Tables 
 
Table 1: National CF registries .................................................................................. 50 
Table 2: Domains and weights used to generate IMD scores for UK constituent 
countries ............................................................................................................. 72 
Table 3: Unadjusted characteristics of study population by deprivation quintile: UK 
CF registry 1996-2010 ..................................................................................... 110 
Table 4: Cox regression of time to diagnosis by deprivation quintile ..................... 111 
Table 5: Summary of adjusted effects of deprivation on clinical outcomes and use of 
therapies in the paediatric and adult CF population in the UK ........................ 112 
Table 6: Final linear mixed-effects regression models for growth in the <18 age 
group ................................................................................................................ 120 
Table 7: Final linear mixed-effects regression models for growth in the >18 age 
group ................................................................................................................ 126 
Table 8: Final regression models for %FEV1 in <18 age group .............................. 134 
Table 9: Final regression models for any IV therapy in 5 to <18 age group ........... 141 
Table 10: Comparison of characteristics of eligible population versus those not 
meeting the inclusion criteria ........................................................................... 147 
Table 11: Additional models fitted as robustness tests, based upon the final FEV1 
model ................................................................................................................ 149 
Table 12. Regression coefficients from explanatory models fitting deprivation as a 
five-level factor ................................................................................................ 150 
Table 13: Characteristics of study population in UK CF Registry by employment 
status at baseline ............................................................................................... 166 
Table 14: Baseline characteristics at entry to the dataset, stratified by deprivation 
quintile ............................................................................................................. 167 
Table 15: Log-odds for the final nested GLMMs. ................................................... 173 
Table 16: Percentage of people with CF in employment at age 30 ......................... 176 
Table 17: Baseline characteristics of Danish CF population ................................... 187 
Table 18: Univariate associations between covariates and %FEV1 ......................... 199 
Table 19: Estimates from final multivariate model.................................................. 201 
Table 20: Final regression models for weight SD score in <18 age group .............. 325 
Table 21: Final regression models for weight SD score in >18 age group .............. 327 
Table 22: Final regression models for height SD score in <18 age group ............... 330 
Table 23: Final regression models for height SD score in >18 age group ............... 331 
Table 24: Final regression models for BMI SD score in <18 age group. ................ 334 
Table 25: Final regression models for BMI SD score in >18 age group. ................ 335 
Table 26: Final regression models for %FEV1 in >18 age group ............................ 337 
Table 27: Final regression models for P. aeruginosa colonisation in <18 age group
 .......................................................................................................................... 338 
Table 28: Final regression models for P. aeruginosa colonisation in >18 age group.
 .......................................................................................................................... 339 
Table 29: Final regression models for any IV therapy age 18 to <40 ...................... 340 
Table 30: Robustness test: regression models for use of any IV therapy 5 to <18 .. 341 
Table 31: Final regression models for any home IV therapy age 5-18 .................... 341 
Table 32: Final regression models for any home IV therapy age 18-40 .................. 342 
Table 33: Final regression models for amount of any IV therapy age 5 to <18 ...... 342 
Table 34: Final regression models for amount of IV therapy age 18 to <40 ........... 343 
Table 35: Final regression models for any nutritional support <18 age .................. 343 
 xii 
Table 36. Final regression models for any nutritional support age 18-40 ................ 344 
Table 37. Final regression models for any DNase <18 age ..................................... 344 
Table 38: Final regression models for any DNase age 18-40 .................................. 345 
Table 39: Final regression models for any inhaled therapy <18 age ....................... 345 
Table 40: Final regression models for any inhaled therapy 18-40 years ................. 346 
Table 41: Log odds for the final GLMMs, with added educational variable. .......... 348 
  
 xiii 
Abbreviations 
%FEV1 Percent predicted forced expiratory volume in one second 
ADHD Attention deficit hyperactivity disorder 
ANOVA Analysis of variance 
BAL  Bronchoalveolar lavage 
BMI Body mass index 
BMI SD  Body mass index standard deviation 
CCG Clinical commissioning group 
CF Cystic fibrosis 
CFQ-R  Cystic fibrosis questionnaire-revised 
CFRD Cystic fibrosis related diabetes 
CFTR  Cystic fibrosis transmembrane conductance regulator 
CI Confidence Interval 
COPD Chronic obstructive pulmonary disease 
CVD Cardiovascular disease 
DNase Deoxyribonuclease 
ESCF Epidemiological study of cystic fibrosis 
ETS Environmental tobacco smoke 
FEV1 Forced expiratory volume in one second 
GAM Generalized additive model 
GDP Gross domestic product 
GCSE General certificate of secondary education  
GEE Generalized estimating equations 
GLM Generalized linear model 
GLMM Generalized linear mixed model 
HAZ Height for age Z score or SD score 
HR Hazard ratio 
HRQOL Health related quality of life 
ICD International classification of disease 
IMD Index of multiple deprivation 
IMR Infant mortality rate 
ISCED International standard classification of education 
IV Intravenous 
LDA Longitudinal data analysis 
LLSI Limiting long-standing illness 
LLSOA Lower layer super output area 
LME Linear mixed effects 
MANOVA Multivariate analysis of variance 
MAR Missing at random 
MCAR Missing completely at random 
MCS Millenium cohort study 
MDT Multidisciplinary team 
ML Maximum likelihood 
MRC Medical research council 
NHS National health service 
NMAR Not missing at random 
NS-SEC National statistics socio-economic classification 
OECD Organisation for Economic Co-operation and Development  
OLS Ordinary least squares 
ONS Office of national statistics 
OR Odds ratio 
PA Pseudomonas aeruginosa 
PI Pancreatic insufficiency 
POP Pulmonary outcome prediction score 
RCT Randomized control trial 
RIS Random intercept and slope 
SD Standard deviation 
SDH Social determinants of health 
SEP Socio-economic position 
 xiv 
SES Socio-economic status 
SGP Stationary Gaussian process 
TGF Transforming  growth  factor  β1  (CF  modifier  gene) 
TOBI® Tobramycin inhalation solution 
TPN Total parenteral nutrition 
UKCFS UK cystic fibrosis survey 
WAZ Weight for age Z-score or weight SD score 
WHO World Health Organization 
 1 
Chapter 1: Introduction 
 
Relevance of the issue 
Studies across the world have consistently shown that people from socio-
economically disadvantaged backgrounds experience worse health than those in 
more socio-economically advantaged positions. These inequalities in health 
outcomes are preventable, amenable to policy intervention, and they are unjust. In 
the UK and internationally, policies are being implemented to try to reduce health 
inequalities, with limited success, since for many important health outcomes, such as 
life-expectancy in the UK, inequalities appear to be widening. In order to develop 
more effective interventions we need a better understanding of how, and when, these 
health differences are generated and maintained. 
There is evidence of differences in survival for people with cystic fibrosis (CF) by 
socio-economic status (SES). Understanding the mechanisms by which these 
differences in survival are generated is important to improve care in CF. 
Furthermore, studying people with CF offers a unique opportunity to develop the 
evidence base around pathways to health inequalities more generally. Because CF is 
genetically determined, a socio-economic difference in incidence is not expected, but 
there may be important differences in   outcomes   over   the   course   of   people’s   lives.  
Studying the health of people with CF thus provides a valuable case study to 
investigate the impact of SES on health and social outcomes, in a chronic condition 
without a socio-economic gradient in incidence. Despite this ‘level playing field’ at 
the outset, the processes by which differential outcomes in CF are generated are 
unclear. Elucidating these mechanisms is important to inform policies, both to 
improve care in CF, and also to reduce inequalities in health more broadly. 
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Previous research and gaps in the literature 
There is a developing literature on the relationship between deprivation and poor 
outcomes for people with CF. As the commonest serious inherited disease in white 
populations, CF usually leads to premature death as a result of progressive lung 
infection and subsequent respiratory failure. Nowadays, we usually diagnose 
children with CF within in the first year of life, and they require intensive support 
from family and health care services subsequently. The improvement in survival over 
successive birth cohorts has been striking. Up until the 1950s, the majority of 
children with CF did not survive beyond infancy, but survival has increased 
dramatically since then, such that in the UK, estimates suggest children born in the 
21st century have a median survival of over 50 years of age (Dodge et al., 2007). 
These improvements in survival, however, have not been shared equally, and early 
studies in the UK and the US have indicated patterning of survival by SES. 
People with CF from more disadvantaged groups in the UK and US die earlier than 
those from more advantaged backgrounds. In the UK, the first study to look at social 
differences in survival in CF found a consistent trend from 1959 to 1986 towards 
higher age at death in CF patients in more advantaged social groups on the basis of 
occupational class (Britton, 1989). The authors speculated that the observed lower 
survival chances in lower social classes could relate to lack of access to the 
appropriate services, poorer nutrition, increased parental smoking, and poorer quality 
housing. Evidence from the US corroborated these findings, and indicated higher 
survival rates in the 1980s and 1990s among more advantaged socio-economic 
groups, measured by Medicaid status and area-based income, compared with their 
less advantaged counterparts (Schechter et al., 2001, O'Connor et al., 2003, 
Schechter, 2004). For instance the adjusted risk of death was around four times 
higher in CF patients with Medicaid cover, a surrogate for poverty, compared to 
those without Medicaid cover (Schechter et al., 2001). Having demonstrated a 
relationship with survival, subsequent studies predominantly from the US, have 
focussed on the potential mediating effect of health services on outcomes. 
The role of health services in the generation of inequalities in CF remains unclear. In 
many chronic illnesses, differences in access to specialist health care by SES are 
evident. These differences often contribute to the exacerbation of health inequalities, 
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since a bias towards more advantaged groups is widespread across health care (Stirbu 
et al., 2011). This could be particularly important in the context of inequalities in 
outcomes for a disease like CF, where treatment advances have had such a profound 
effect on survival. The studies exploring access to services and treatments from the 
US, however, have demonstrated a mixed picture, depending on the type of treatment 
under consideration, and the exact measure of SES used (Schechter et al., 2009, 
Schechter et al., 2011). For instance, one study showed greater access to intravenous 
(IV) antibiotics for older children, on the basis of area-based income, but also 
showed no difference in access to DNase, another important treatment in CF, using 
Medicaid status as a measure of SES (Schechter et al., 2009). Overall the US studies 
have played down the role of health service factors in the generation of health 
disparities in CF. However, it is debatable how much of this evidence can be 
generalized to other health care settings, especially to the UK context, where access 
to health services is free at the point of use.  
The literature on differential outcomes in CF in the UK is still in its infancy. To date, 
the research on the effect of SES on outcomes in CF in the UK is limited to studies 
of survival, using routinely collected death registration data (Britton, 1989, Barr HL, 
2011). It remains unclear how these differences in survival in CF in the UK are 
generated,  and  at  what  stage  in  people’s lives inequalities in health outcomes start to 
develop. For instance, in the early years, we can characterize CF by poor growth and 
under-nutrition, and a great deal of emphasis is placed on early diagnosis, and 
subsequent close growth monitoring and dietary supplementation. However, there is 
no data regarding socio-economic differences in early growth in the UK, though 
cross-sectional analyses from the US have suggested important differences in growth 
outcomes (Schechter et al., 2001). One can say the same for the acquisition of 
important lung infections, and lung function, which is perhaps the most important 
clinical outcome in CF, since it has been linked to survival. Thus there remain 
important gaps in our knowledge about the effect of SES on key clinical outcomes, 
which researchers have not studied in a systematic way over the life-course, in both 
paediatric and adult populations. Furthermore, the role of the National Health 
Service (NHS) in the UK in mitigating or potentiating any inequalities in outcomes 
remains unclear. 
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No-one has studied the effect of SES on social outcomes in CF, such as employment 
status. Understanding the social consequences of ill health is a key step in 
elucidating the pathways to health inequalities, since any adverse social outcomes 
that occur as a result of ill health can feedback and further damage health status. For 
example, ill health might lead to job loss, which can then have further adverse effects 
on health status, mediated by a range of physical and psycho-social mechanisms. 
Furthermore, there is evidence from social epidemiological studies to suggest that, in 
many settings, it is people from more disadvantaged backgrounds who particularly 
experience adverse health outcomes as a result of ill health – so called differential 
social consequences. What affect this pathway has on the generation and 
maintenance of health inequalities in CF remains an unstudied question. This gap in 
the literature is of particular concern, given that most people with CF born today will 
survive well into adulthood, and employment status is becoming an increasingly 
important consideration in the CF literature. 
The studies in this thesis aim to fill these important gaps in our understanding of the 
social patterning of outcomes in CF, by utilizing rich longitudinal datasets from the 
UK and Denmark, to investigate differences in a range of longitudinal clinical, and 
social outcomes by SES. Furthermore, a key question in this thesis is to clarify the 
importance of health care and the role of the NHS, in the pathways to differential 
outcomes in people with CF. Importantly, the findings of these studies are intended 
to produce generalizable insights into the influence of social factors on chronic 
disease outcomes over the life-course, and the influence of child health on later adult 
health. The final step is to develop recommendations for addressing any inadequacies 
in CF care or public policy that are uncovered. 
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Objectives of the research 
Following a review of the literature, this thesis proceeds from the assumption that 
low SES has an adverse effect on survival for people with CF. The overall aim of 
this thesis is to investigate the effect of SES on clinical outcomes, healthcare use and 
employment opportunities in people with CF. To this end the main objectives of this 
thesis are to answer the following questions: 
In people with CF:  
1. What is the relationship between SES and important 
longitudinal clinical outcomes, such as growth, and lung 
function? 
2. What is the relationship between SES and health service 
use? 
3. What is the impact of SES on longitudinal employment 
status? 
4. What are the policy implications of the above? 
 
At the outset of this thesis my intention was to analyse data from the Danish CF 
register, using similar approaches to those used to analyse the UK data, but utilising 
the individual level SES data available in Denmark through data linkage. However, 
due to the very frequent monthly follow-up of CF patients in Denmark, it was 
necessary to develop a new approach to analysing the Danish dataset, and thus the 
focus of the Danish analysis presented in this thesis is around the methodological 
challenges of modelling lung function decline in the Danish population. The 
objective of the Danish study is to describe a novel method to model how %FEV1 
changes over time, in a way that is useful for clinicians at both the individual and the 
population level.  Using this approach, research on the effect of SES on CF outcomes 
in Denmark is on-going. 
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Structure of this thesis 
Figure 1 provides a schematic overview of the three studies in this thesis. 
 
 Chapter 2 (Literature review) provides an introduction to health inequalities, 
and how these are generated. Then relevant aspects of CF are reviewed, 
before moving on to health inequalities in CF. The chapter finally highlights 
key gaps in knowledge. 
 
 Chapter 3 (Methods) describes the UK and Danish CF datasets and the 
longitudinal data analysis techniques used in the thesis 
 
 Chapter 4 (Results) presents and discusses the results of study 1. This is the 
longest of the results chapters, and focusses on an analysis of the effect of 
SES on clinical outcomes and health care use in the UK CF population. This 
addresses objectives 1 and 2 above, and also generates an in-depth 
description of longitudinal outcomes in CF in the UK.  
 
 Chapter 5 (Results) presents and discusses the results of study 2, in which I 
focus on employment outcomes in the UK CF population, and look for 
differential social consequences by SES. 
 
 Chapter 6 (Results) presents and discusses the results of study 3, in which I 
explore the dynamics of lung function decline in people with CF in Denmark, 
and apply a novel modelling approach. 
 
 Chapter 7 (Discussion) pulls together the key findings and themes from 
Studies 1 to 3. I then describe the contribution of the studies to the existing 
literature, which extends beyond the initial objectives, in three main areas: 
CF epidemiology; our understanding of health inequalities more generally; 
and specific methodological advances. There is then a discussion of the 
strengths and limitations of the overall approach and study design. I address 
Objective 4 of the thesis with a section on the policy implications arising 
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from the studies, and the chapter concludes with a description of on-going 
research. 
 
 There are additional appendices containing the data entry screens for the UK 
registry additional tables and plots to go with the analysis chapters, some 
R programming code, and finally the main publications from this thesis. 
Appendix 3 relates to Chapter 3, and so forth. There is no appendix 1 or 2. 
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Figure 1: Schematic overview of the studies in this thesis 
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Chapter 2: Literature review 
In Liverpool in the 1830s, a general practitioner named William Henry Duncan 
undertook a survey into the living conditions of parents in the city centre area. The 
population of Liverpool had boomed to almost one million, from 60,000 in 1770, 
putting huge pressure on housing in the city, and he had observed a concurrent rise in 
the prevalence of infectious diseases in the population, including tuberculosis (TB), 
whooping cough, and cholera. His survey showed that about one third of the 
population was living in the cellars of small back to back houses, with up to 16 
people occupying each room (Ashton and Seymour, 1988). Describing the situation 
of a woman who had recently given birth to her child, Duncan wrote (Wohl, 1983): 
“I   visited   a   poor  woman   in   distress…she  had  been   confined   only   a  
few days, and herself and infant were lying on straw in a vault...with 
a clay floor impervious to water. There was no light or ventilation 
and the air was dreadful. I had to walk on bricks across the floor to 
reach her bedside, as the floor itself was flooded with stagnant 
water...There are hordes of poor creatures living in cellars which are 
almost as bad and offensive as charnel-houses” 
Duncan   went   on   to   be   appointed   Liverpool’s   medical   officer   for   health,   the   first  
public health appointment of its kind in the world. His further studies, before the 
widespread use of statistical techniques such as standardization, documented 
differences in the in average age at death in 1848, comparing Liverpool, with an 
average of 19 years, to rural Wiltshire, at 36.5 years (Ashton, 1988). This was at a 
time when the first use of death registration statistics also showed shocking 
differences in the average age at death for different sections of the population. For 
instance, average age at death for ‘Gentry and professional’ classes in Rutland was 
52 years compared to 15 years for ‘labourers and artisans’ in Liverpool (Lancet, 
1843). Duncan’s work clearly linking adverse living conditions with poor health 
outcomes, along with that of other social reformers such as Edwin Chadwick, 
informed a public health movement, culminating in widespread sanitary reforms, and 
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government legislation such as the National Public Health Act in 1848 (Frazer, 
1947). 
Differences in life expectancy between Liverpool, and other areas of the country 
persist to this day; for example, there is over a 10-year difference in both male and 
female life expectancy at birth comparing a child born in Kensington in Liverpool 
(74.8 years for men, 79.2 for women), to a child born in Kensington and Chelsea in 
London (85.1 years for men, 89.8 for women) (ONS, 2011b). Furthermore, between 
small areas within Liverpool there are similar differences in life expectancy, of over 
10 years, comparing the least to the most deprived areas (DH, 2012a).  
We therefore begin with a number of propositions about the inequalities in life 
chances that are evident within countries wherever they are studied, whereby the 
most disadvantaged in society have poorer health outcomes. First, these differences 
are  not   ‘natural’,  or  biologically  pre-determined, since there is no plausible genetic 
basis for such large differences, and they largely result from exposure to adverse 
living conditions. Second these differences are unfair, because they are amenable to 
public health action, and thus to a large extent preventable (Whitehead, 1990). Third, 
addressing these differences is a key focus for public health efforts and a matter of 
social justice, since they constitute a loss of life  “on  a  grand  scale”  (CSDH, 2008); 
for example, a recent study of 30 member countries of the Organisation for 
Economic Co-operation and Development (OECD) estimated that around 10% of the 
adult mortality in the 15 to 60 age group in these countries, accounting for 1.5 
million deaths annually, could be avoided by reducing income-related inequalities to 
the median level (Kondo et al., 2009).  
Having set the scene, this literature review first describes some general theories 
pertaining to health inequalities, before building the case for studying CF in order to 
better understand pathways to health inequalities. I then move on to the relevant 
general CF literature, before focussing in on the key studies that describe inequalities 
in outcomes in CF. I shall begin with a description of the UK policy context with 
regards to health inequalities, and its focus on the health of children.  
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The policy context to health inequalities 
Reducing inequalities in health is a public health imperative at local, national and 
international levels, and strategies to reduce health inequalities have been developed 
in countries around the world (Judge et al., 2005), including most recently a high 
profile report from the US (Institute of Medicine, 2013), a country that has tended to 
shy away from explicit recognition of the health inequalities agenda. A major step-
forward has been the adoption of a ‘social determinants of health (SDH) approach’  
by the global health community, outlined in The World Health Organization (WHO) 
Commission on Social Determinants of Health in 2008. The report stated that the 
development of a society, rich or poor, should not only be judged by the overall 
quality of its population’s  health,  but  also  how  fairly  it   is  distributed  across  society  
(CSDH, 2008).  
The UK has traditionally led the way in terms of health inequalities research and 
policy, a history that can be traced from the Black report (Black et al., 1980), through 
the Acheson Inquiry (DH, 1998a), to the recent UK Marmot review (Marmot et al., 
2010b). Following the recommendations made in the Acheson report, and the 
election of the Labour Government in 1997 with their democratic mandate to address 
inequality, the UK became the first European country to systematically implement 
and evaluate policies aimed specifically at reducing health inequalities (Mackenbach, 
2011a). In particular, the government set targets to reduce the gap in life expectancy 
and Infant Mortality Rate (IMR) by 10% between the fifth of local authorities with 
the worst health and deprivation indicators (the Spearhead group) and the population 
as a whole, by 2010 (DH, 1999, DH, 2003). 
In order to address these targets a raft of policies was announced, including the 
introduction of a national minimum wage, higher benefits and pensions, and 
substantially increased spending on education, housing, urban regeneration, and 
health care. There  was  also  the  introduction  of  the  ‘Health  Action  Zone’  programme  
to improve health in deprived areas (DH, 1999). With regard to improving child 
health,   the   ‘Every   Child   Matters’   agenda   (Department for Education and Skills, 
2004) united a number of policies, including strategies to increase immunisation 
rates; achieve early antenatal care for disadvantaged groups; reduce obesity (Cross-
Government Obesity Unit, 2008); and reduce parental smoking (DH, 1998b). Most 
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notably, there were also high-profile targets set around poverty and social exclusion, 
particularly to cut and eventually ‘eradicate’ child poverty, within 10 to 20 years 
(Blair, 1999). These policies broadly focussed on three main areas (Judge, 2012): 
 Changes to the tax and benefits system – notably the tax credit system, 
which resulted in progressive improvements in the level of in-work and out-
of-work incomes for families with children, and which achieved high 
coverage. 
 Promoting parental employment – increasing incomes for those in low-paid 
work, and making work pay better for parents e.g. policies to increase the 
provision of universal, high quality pre-school care; to ensure flexible 
parental leave; and the requirement that local authorities ensure adequate 
provision of childcare for parents who want to work. 
 Policies  to  improve  children’s  life  chances – these focussed on the Sure Start 
centres, which aimed to reduce child poverty through the targetted provision 
of pre-school education as a means of improving early child development, 
and subsequent school readiness.  
Despite these efforts, by 2010, the UK had not met the target for life expectancy. The 
data for the two targets show substantial improvements in both life expectancy and 
infant mortality over the period in both the disadvantaged Spearhead areas, and the 
other local authorities, but the improvement was slightly greater in the more affluent 
areas for life expectancy (Marmot et al., 2010b), which has led to an increase in the 
life expectancy gap. With regard to IMR, there was initially a pronounced increase in 
the gap, which peaked at 19% between 2002 and 2004 but has narrowed 
subsequently. We await the final data for the infant mortality target (three year 
rolling average data) later this year, and it is possible this target may have been 
achieved, if the recent narrowing of the gap has continued. 
There has been much soul searching amongst the health inequalities community, in 
the UK and internationally, in response to the limited success of the concerted UK 
drive to reduce health inequalities (Bambra et al., 2011, Mackenbach, 2011a). 
Various explanations have been put forward. The Marmot review suggests that not 
enough has been done to address the root causes of inequalities in the social 
 13 
determinants, and that actions have not been sufficiently co-ordinated across sectors 
(Marmot et al., 2010b). Furthermore, the tendency for ‘lifestyle’ drift has been 
implicated, whereby policies start off with a broad recognition of the need to take 
action on the wider social determinants of health but end up focussing on individual 
lifestyle factors (Whitehead and Popay, 2010).  Mackenbach’s   diagnosis   is   that   the  
strategy did not address the most relevant entry-points, did not use effective policies, 
and was not delivered at a large enough scale for achieving population-wide impacts 
(Mackenbach, 2011a). Furthermore he suggests that there was not the political will to 
address income inequalities, which continued to rise over the period. Our recent 
analysis supports this, and suggests that if inequalities in household income had been 
tackled, along with further reductions in unemployment in deprived areas, then the 
life expectancy target could have been met (Barr et al., 2012). Policy makers and 
researchers will continue to reflect on the UK experience as new policies are 
developed to reduce inequalities. 
A key theme that has emerged across all of these policies, from Black to Marmot, is 
the importance of investing in child health. The Commission on the Social 
Determinants of Health’s overarching recommendation, for instance, relates to 
improving daily living conditions for all and mandates a renewed focus on child 
health, with major emphasis on early child development (CSDH, 2008). This focus 
on the early years is echoed in the Marmot review of health inequalities (Marmot et 
al., 2010b), which remains the blueprint for action on inequalities in child health in 
the UK, along with the more recent Field (Field, 2010) and Allen reports (Allen, 
2011), which focus on the importance of early child development. As Law points 
out, reducing health inequalities is likely to require sustained action over time, and 
the effects may not immediately be apparent (Law et al., 2012). Indeed, the reduction 
in child poverty over the last decade as a result of the UK strategy, one of the few 
successes (Judge, 2012), has not yet been evaluated for its impact on health. Any 
health effects as a result of this intervention may take decades to become fully 
apparent, in terms of improved adult health. 
In addition to the social justice argument for addressing health inequalities, there is 
also a clear economic case. A recent study estimated that in the European Union 20% 
of health care and 15% of social security costs could be attributed to health 
inequalities, leading to a 1.4% reduction in gross domestic product (GDP) through 
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reduced labour productivity (Mackenbach et al., 2011). Furthermore, addressing 
disadvantage in the early years has been identified as being critical to tackling some 
of the most costly health and social problems, such as unemployment, adult chronic 
diseases, poor mental health, and drug addiction, all of which are related to early 
disadvantage (Field, 2010, Marmot et al., 2010b). For instance, a Joseph Rowntree 
Foundation report estimated that the additional cost to public services as a result of 
the consequences of childhood disadvantage in the UK was between £11.6 and £20.7 
billion in 2006/07 (Hirsch, 2008). Furthermore, the New Economics Foundation has 
estimated that the cost to the UK economy of continuing to address current levels of 
social problems related to childhood disadvantage will amount to almost £4 trillion 
over a 20 year period. This is an incredible sum; roughly five times the current 
annual budget of the whole of the NHS. The report suggests that increased 
investment in a combination of targeted early years interventions and universal 
childcare and paid parental leave could help address as much as £1.5 trillion worth of 
this sum, putting the UK on a par with the Scandinavian countries in terms of child 
wellbeing (Aked et al., 2009). 
Maintaining a focus on reducing inequalities in child health is critical if we are to 
mitigate the long-term effects of the current economic recession on health (Sell et al., 
2010). Child poverty levels are set to rise, and recent analyses of current austerity 
policies in the UK suggest that children are amongst the groups being hit hardest by 
these changes (Browne, 2012). Furthermore budget cuts to local authorities are 
heaviest in the most deprived areas, which is likely to further exacerbate health 
inequalities (Taylor-Robinson and Gosling, 2011). Before discussing the 
mechanisms that generate health inequalities, the next section reviews some of the 
evidence on the corrosive effects of early disadvantage, particularly child poverty, on 
health outcomes. 
The effects of childhood disadvantage  
Child health in the UK and other OECD countries continues to improve, with on-
going average declines in IMR, childhood deaths, and improvements in life 
expectancy. Despite this, unacceptable inequalities persist between rich and poor 
within the UK. For example, children living in poverty (<60% median income) in the 
UK are more likely to: die in the first year of life; be born small; be bottle fed; be 
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exposed to second-hand smoke; become overweight; perform poorly at school; die in 
an accident; become a young parent; and to die earlier (Roberts, 2012).  
In order to provide an illustrative example of the associations between child poverty 
and health and social outcomes, we turn to contemporary data from Liverpool, one of 
the most deprived local authorities in the UK. Figure 2 shows the association 
between relative poverty (<60% median income), and the prevalence of low birth 
weight; asthma admissions; GCSE success; and life expectancy at ward level in 
Liverpool. 
Figure 2: Low birth weight; asthma admission rate; GCSE success rate; and life 
expectancy versus child poverty for wards in Liverpool 2011 
Asthma admission rate is per 10,000 per year. GCSE success defined as 5 or more C 
grades or above. Data from Liverpool PCT for 2011, supplemented with child 
poverty data at ward level from http://www.endchildpoverty.org.uk/why-end-child-
poverty/poverty-in-your-area (accessed 14th May 2013). Plots generated by author 
with ordinary least squares (OLS) regression lines in blue 
 
 
Children from poorer areas are born small (Figure 2 top left panel), and in 
longitudinal studies this has been associated with poor growth, cognitive 
development, and chronic diseases later in life, such as diabetes and hypertension 
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(Kuh et al., 2004). Maternal smoking in pregnancy is one of the important avoidable 
causes of low birth weight. In a recent study in Liverpool maternal smoking in early 
pregnancy was about six times more common in women from the most deprived 
quintile (based on Index of Multiple Deprivation [IMD]) compared to the least 
deprived, and was associated with increased rates of preterm birth and low birth 
weight (Taylor-Robinson et al., 2011). In the first few years of life, children living in 
deprived areas are also more likely to be exposed to passive smoking (Field, 2010), 
and are less likely to be breastfed (Kelly and Watt, 2005), illustrating how health-
damaging factors begin to cluster and interact at an early stage. 
Low birth weight, being bottle-fed, and exposure to second-hand smoke are all 
associated with a higher risk of developing asthma, which is the most common 
chronic illness in childhood (Panico et al., 2007). Asthma admissions in Liverpool 
are accordingly closely associated with levels of child poverty (Figure 2, top right 
panel). The association between poverty and poor health in the early years extends to 
many other physical conditions and threats to health in childhood, including chronic 
ear infection, pneumonia, tooth decay, obesity, and particularly accidents, both fatal 
and non-fatal (Hirsch D, 2008, Marmot et al., 2010b). Children growing up in 
poverty are also more likely to suffer a wide range of behavioural and emotional 
problems: child poverty is related to higher rates of attention deficit hyperactivity 
disorder (ADHD), bedwetting, self-harm and suicide (Bradshaw, 2011).  
The first years of life are crucial for brain development and provide the foundations 
for  children’s  capacities   to   learn  (Allen, 2011). Furthermore there is good evidence 
to show that if children fall behind in early cognitive development, they are more 
likely to fall further behind at subsequent educational stages (Ferguson et al., 2007). 
Educational   trajectories   thus   track   over   the   course   of   children’s   lives,   and   within  
wards in Liverpool, the strength of the relationship between child poverty and GCSE 
success (five or more A to C grades) is striking (Figure 2, bottom left panel). Figure 
3 below shows a measure of ‘school readiness’ for local authorities in England. This 
is a routinely collected assessment of children's development at the age of five, based 
on their behaviour and understanding. In order to be school ready, children should be 
able to share, self-motivate, co-operate and concentrate by the time they start school 
(Marmot et al., 2010b). The plot shows the stark relationship between levels of child 
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poverty and school readiness in the UK, and demonstrates that many children in the 
UK are not achieving their early educational potential. 
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Figure 3: Children achieving a good level of development at age 5 versus child 
poverty 
Data for upper-tier local authorities in England, 2010, data source London Public 
Health Observatory, plot generated by author with OLS regression line in blue 
 
 
 
There is great concern amongst policy makers that disadvantage in early life means 
that children who grow up in poverty are less likely to be in work, to live in a decent 
home, to earn a decent wage, and to report good health and wellbeing as adults 
(Field, 2010, Marmot et al., 2010b, Allen, 2011). Thus children who have grown up 
in poverty are more likely to face recurring poverty and other disadvantages harmful 
to their health as adults. It is this accumulation of health damaging exposures over 
the   course  of  people’s   lives   that   is   likely   to   explain   the  close   relationship  between  
levels of child poverty, and life expectancy at birth in Liverpool (Figure 2, bottom 
right panel).  
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Understanding the causes of health inequalities 
This section focusses on some of the key theories and concepts that have been 
developed to explain how health inequalities are generated: the social determinants 
of health (SDH) approach; socio-economic position; material, behavioural, and 
psychosocial explanations of social causation; health selection; and the life-course 
perspective. After discussing these issues, we turn to the Diderichsen model for 
understanding pathways to inequalities in health, which will inform the analyses in 
this thesis. 
Social determinants of health 
The SDH approach, adopted by the WHO for the global Commission on Social 
Determinants of Health, and subsequently the UK Marmot review of health 
inequalities in the UK, recognises that health inequalities are caused by social 
inequalities, and arise as a result of differences in living conditions, and the 
exposures  and  consequences  that  follow.  The  social  determinants  are  the  “conditions  
in  which  we  are  born,  grow  up,  work  and  live”  (Marmot et al., 2010b), and include 
things such as a decent education, adequate housing quality, being able to access a 
nutritious diet, and having the financial resources to engage fully in society (Taylor-
Robinson and Schechter, 2011).  
The SDH approach is the dominant paradigm for understanding health inequalities. 
Its history can be traced back to the likes of Dr Duncan, introduced earlier, and the 
great social reformers. Engels, for instance, in his studies of the living conditions of 
the English working class in Manchester vividly described how inequalities in living 
and working conditions – social determinants – led to ill health in the poor: 
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“All   conceivable   evils   are   heaped   upon   the   poor…they   are   given  
damp dwellings, cellar dens that are not waterproof from below or 
garrets   that   leak   from   above…   They   are   supplied bad, tattered, or 
rotten clothing, adulterated and indigestible food. They are exposed 
to the most exciting changes of mental condition, the most violent 
vibrations between hope and fear... They are deprived of all 
enjoyments except sexual indulgence and drunkenness and are 
worked every day to the point of complete exhaustion of their mental 
and physical energies.” (Engels, 1845) 
 
Likewise Thomas McKeown turned to the social determinants in his explanation for 
the dramatic fall in mortality due to infectious diseases from 1850 onwards in 
England and Wales. These dramatic changes preceded the introduction of specific 
clinical interventions such as vaccination, and he hypothesised that the changes were 
due mainly to improvements in living conditions and nutrition (McKeown, 1979). 
The focus on structural and material determinants of health can be further traced 
through the Lalonde report in Canada (Lalonde, 1974), and the WHO Health for All 
agenda in the late 1970s, which aimed to achieve a decent level of health for all by 
2000 (WHO, 1981). 
The Dahlgren and Whitehead rainbow is one of the clearest contemporary 
expressions of the SDH approach (Dahlgren and Whitehead, 1993) (Figure 4).  
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Figure 4: The main influences on health  
Used with permission source (Dahlgren and Whitehead, 2007) 
 
 
In the rainbow, we see the individual situated at the centre of concentric layers of 
influence.   Thus   individual   characteristics   such   as   age   and   one’s   genetic   make-up 
have an important influence on health status, but we cannot change these. Then there 
are the behaviours one adopts – what we choose to eat and drink, whether or not we 
smoke, and who we have sex with for example. While we can change these the 
model recognises that these factors are influenced in turn by our social and 
community networks – our immediate surroundings, the neighbourhoods we live in, 
and the families and friends that exist around us. Then come the leviathans of the 
SDH approach – the building blocks of health – including the education system, the 
labour market, systems of food production, and health services. Finally, these factors 
are in turn influenced by the broader socio-political and physical environment, which 
can have profound effects on downstream factors in the segments of the rainbow 
below. 
The issue remains, however, as to the underlying mechanisms by which the social 
determinants exert an influence on health, and a further step required to explain how 
differential effects arise (Graham, 2004). There has been much conceptual 
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development in this area, and there are now a number of frameworks that attempt to 
capture the processes by which the social determinants of health can be linked to 
inequalities in health outcomes (Mackenbach et al., 1994, Diderichsen, 1998, 
Whitehead et al., 2000, Brunner and Marmot, 2006). Hilary Graham distils some of 
the key features of these models in her generic model (Graham, 2007) (Figure 5).  
Figure 5: The social determinants of health inequalities 
Adapted from Graham, 2007  
 
 
In   Graham’s   model   it   is   the   unequal   distribution   of   the   ‘upstream’ social 
determinants of health, which make up the social structure or context, which first 
lead to inequalities in ‘social position’. Differences in social position between groups 
and individuals then result in inequalities in exposure to intermediate factors that 
influence health, and consequently to health inequalities between individuals or 
groups on the basis of their social position. 
Social position 
There are many dimensions of social position, for instance all of us occupy 
differential positions in society with regards to gender, culture, ethnicity, sexuality 
and levels of physical impairment. In this thesis, we are particularly interested in 
‘socio-economic position’ (SEP): the position individuals or groups hold within the 
structure of a society derived on the basis of social and economic factors (Galobardes 
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et al., 2007). SEP is a complex concept that cannot be considered in any depth here, 
but many of the theories around SEP can be traced back to those of Marx and Weber 
(Lynch and Kaplan, 2000).  Marx’s  focus  was  on  social  class,  as  defined  by  degree  of  
control over the means of production (e.g. land or factories), whereas the Weberian 
approach suggests that societies naturally become categorised into hierarchical 
structures, along many dimensions, leading to shared experiences and life chances in 
particular groups (Galobardes et al., 2006a). Several measures of SEP are used 
within social epidemiology, and these can be applied at the individual or aggregate 
level (Galobardes et al., 2006b), but Kunst and Mackenbach have argued that the 
most important of these are occupational status, level of education and income level 
(Mackenbach et al., 1997, WHO, 2007). 
Social causation 
The mechanisms by which unequal social position leads to inequalities in health 
outcome – the process of ‘social causation’ – need unpacking further. Hilary 
Graham’s  model  suggests  that  the  effect  on  health  inequalities  is  indirectly  mediated,  
through a range of more specific intermediate influences that promote or harm 
health, which are differentially distributed across socio-economic groups. The 
unequal distribution of these factors subsequently induces higher or lower prevalence 
of health problems. In terms of understanding which intermediate factors are 
important in this process, there are more theories to contend with, hotly debated in 
social epidemiology in terms of their relative importance (Judge, 1995, Lynch et al., 
2000, Marmot and Wilkinson, 2001). These relate to material, behavioural or 
cultural, and psychosocial explanations. 
Material explanations focus on the relationship between SEP and unequal access to 
tangible resources at various levels, and was the explanation favoured by the authors 
of the Black report (Black et al., 1980, Blane et al., 1997). These include, for 
example, at the individual level, inequalities in access to resources for health, such as 
food, clothes, and decent housing; and at the aggregate level, sanitary environmental 
conditions, and safe neighbourhoods and working environments. Beyond the bare 
necessities for survival it is also necessary to consider the resources required to live a 
full life in contemporary society (Morris et al., 2000) – a mobile phone, home 
computer, and a holiday from time to time perhaps – these may also be important in 
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determining inequalities in health outcomes. Neo-materialist theories are related, but 
focus on the relationship between resources spent at an aggregate level on factors 
such as infrastructure, welfare, and the education system, and the magnitude of 
health inequality (Mackenbach, 2012). 
Behavioural explanations focus on the distribution of health behaviours such as 
smoking and alcohol consumption, by social position (Blaxter, 1990). We can take 
this in a number of directions. Bartley suggests that implicit in the direct behaviour 
model is the suggestion that people in less advantaged positions are more likely to 
adopt unhealthy behaviours because they are less endowed with some personal 
characteristics, read as intelligence, education, self-control, or resilience (Bartley, 
2004). The cultural explanation, on the other hand, sees particular behavioural 
patterns  as  being  “embedded  within  the  social  structure”  (Black et al., 1980). 
The Whitehall studies made use of the finely graded social hierarchy in the British 
civil service to explore inequalities in health outcomes. Marmot et al. showed that 
the social gradient in cardiovascular disease outcomes amongst civil servants was 
only partly explained by behavioural risk factors, suggesting that there were other 
mechanisms at play (Marmot et al., 1984, Marmot et al., 1991, Marmot et al., 1997). 
This has led on to psychosocial explanations for health inequalities that focus on the 
role of stress, mediated by neuro-endocrine pathways, caused by living under 
conditions of relative social disadvantage. For example, increased risk of exposure to 
negative life events, job strain, stressful living circumstances, high debt, and lack of 
social support associated with low SES may have direct effects on physiological 
systems. Stress may also affect health indirectly by leading to harmful health 
behaviours such as smoking and excess drinking (Kawachi et al., 2002). 
Furthermore, the Wilkinson hypothesis suggests that the stress caused by constantly 
comparing oneself with other people in unequal societies is an important driver of 
health inequalities (Wilkinson, 2005, Wilkinson and Pickett, 2010). Based upon 
ecological country level analyses in OECD countries and individual states in the US, 
Wilkinson suggests this can influence overall population health, making more 
unequal societies unhealthier overall. This approach has been used to relate income 
inequality to poor health (Wilkinson, 1992), including measures of child wellbeing in 
the UK and the US (Pickett and Wilkinson, 2007). 
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Health selection 
In contrast to the theories of social causation described above, the selection 
perspective assumes that health determines SEP, instead of SEP being the starting 
point, leading on to differences in health. The basis of the selection hypothesis is that 
health influences social mobility, both between generations (inter-generational), and 
over   the   course   of   people’s   lives   (intra-generational). The health selection 
perspective suggests that people who are in poor health drift down the social scale, 
whilst the healthy move up. ‘Direct selection’ suggests that health directly influences 
social trajectories, such that sickly children are more likely to find themselves in a 
lower social position as adults. Indirect selection is more nuanced, and suggests that 
health status is correlated with other behaviours and attributes (e.g. intelligence, 
personality, or coping style) that are then associated with social mobility. This thus 
implies that social mobility is associated with determinants of health, not health itself 
(West, 1991, Goldman, 2001). 
Two contrasting questions arise with regard to health selection. The first 
consideration is whether health status influences subsequent social mobility and 
social outcomes, and the second consideration is to determine any effects of selection 
on inequalities in health outcomes. There is empirical evidence from the UK (Power 
et al., 1996, Manor et al., 2003), Sweden (Lundberg, 1991) and the Netherlands (van 
de Mheen et al., 1998) suggesting that illness in childhood does reduce intra-
generational social mobility but these effects were not evident in adulthood – for 
instance, there was little evidence that poor health influences social mobility in the 
cohort of civil servants in the Whitehall cohort (Chandola et al., 2003).  
In terms of the effect of health selection on health inequalities, the results have been 
mixed, with the majority of studies suggesting that that health selection may actually 
decrease health differentials (Power et al., 1996, Bartley and Plewis, 1997, Blane et 
al., 1999, Claussen et al., 2005), although some studies have suggested the opposite 
(Dahl, 1993, Manor et al., 2003). The mechanism for the reduction in health 
inequalities as a result of selection is that people who are downwardly mobile 
because of their health still have relatively better health than the people in the class 
of destination (Bartley 1997). 
Marmot et al offer a robust rebuttal of the health selection approach (Marmot et al., 
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2010a), in response to a critique of the Marmot review by the economists Chandra 
and Vogl (Chandra and Vogl, 2010). Chandra et al suggest that many of the 
associations between measures of income and health cited in the review, can 
essentially be explained by health selection (Chandra and Vogl, 2010). In response, 
after appealing to the writing of Dickens, Marmot et al ask (Marmot et al., 2010a): 
“Should we really assume, that these dark satanic mills and airless 
places, rather than causing terrible illness and shortened lives, 
selectively employed sick people and those whose backgrounds 
accounted for all their subsequent illness? That subsequent 
improvement in living and working conditions, thus abating Victorian 
squalor, and associated improvements in health were correlation not 
causation? That while medical care improved health, housing also 
got better, and an intellectually slack public health profession 
mistook the improvement in housing and working conditions for 
causes  of  improved  health?” 
Genetic explanations 
From time to time a genetic argument for health inequalities has been put forward 
(Davenport, 1916, Herrnstein, 1971 , Himsworth, 1984). Here genetic factors 
responsible for damaging health are hypothesized to be more common in people with 
lower SEP. The argument suggests that if a particular gene causes ill health, and 
people who are ill move down the social strata as a result of the selection process, 
then this could plausibly lead to the social distribution of genetic material responsible 
for causing illness, to the disadvantage of those further down the social strata. 
Furthermore, genes responsible for health promoting characteristics (e.g. cognitive 
ability, coping styles, control beliefs, personality, bodily and mental fitness) may 
move up the social scale, and influence inter-generational social mobility.  
Such arguments are difficult to sustain. Holtzman highlights key problems with 
genetic explanations, pointing out that single genes cannot explain complex social 
traits, and that the timescales required for selection effects cannot explain the more 
rapid socio-economic changes in health that have been observed in many countries. 
He concludes, as did the Black report, that   the  “roots  of  social  class  differences  do  
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not   lie   in  our  genes” (Holtzman, 2002). Mackenbach further highlights the lack of 
empirical data to support the genetic argument (Mackenbach, 2005). One of the clear 
problems with a focus on genetic or biomedical focus on health inequalities is that 
these explanations can be used as a smoke-screen for maintaining a particular ruling 
class and reducing social support for the poor, and can distract attention from 
determinants of health that are policy sensitive.  
Life-course approaches 
The life course perspective provides a framework for combining all of the 
aforementioned pathways, by considering the timing and ordering of exposures and 
outcomes, within   an   individual’s   life   course,   and  across  generations. The approach 
hypothesises that health-protective and health-damaging influences may be more or 
less important at particular times in life, and that these influences may have effects 
that accumulate, and interact over time. For example, children from more 
disadvantaged backgrounds are more likely to be born small, less likely to be breast 
fed and to have poorer diets subsequently, to be more exposed to passive smoking 
and some infectious agents, and to have fewer educational opportunities (Ben-
Shlomo and Kuh, 2002). Each of these exposures influences and interacts with the 
risk of subsequent exposures, to influence both health and social outcomes in later 
life (Galobardes et al., 2004, Kuh et al., 2004, Galobardes et al., 2008).  
This approach has played a key role in shaping our understanding of how factors in 
early life can influence subsequent health and social trajectories. A person’s SEP is 
not fixed, and can be considered as a trajectory that moves from parental SEP – the 
class into which one is born – to   one’s   final   adult  SEP, measured on the basis of 
education, income, or employment status for example. In parallel to this trajectory, 
there is the process of health and capacity development, and eventual decline over 
time. The life course perspective considers the complex interaction between these 
two processes, allowing for both social causation and selection over time, and 
longitudinal studies using individual level data have been the key to developing the 
evidence base. 
A recent systematic review of life course studies reviewed the effects of SEP in 
childhood on mortality in adulthood. Across 29 studies, the review found that 
children from less advantaged backgrounds had a higher risk of death in adulthood 
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across almost all conditions studied, including mortality from stomach cancer, lung 
cancer, haemorrhagic stroke, coronary heart disease, and respiratory-related deaths, 
accidents, and alcohol-related causes of death (Galobardes et al., 2004, Galobardes et 
al., 2008). These studies demonstrate that the conditions in which children grow up 
are not just critical for child health, they are also critical for adult health, and this has 
profound public policy implications. 
David Barker hypothesized that adult chronic disease, particularly cardiovascular 
disease, had its origins in the perinatal period, and focussed on the pathway from 
maternal under-nutrition, to low birth weight in children, and the subsequent 
association with higher rates of hypertension, type 2 diabetes and risk of 
cardiovascular disease (CVD) (Barker, 1997). Subsequent longitudinal studies have 
corroborated some of these associations, and there is now reasonable evidence to 
suggest that CVD risk can be traced back to the early years of life (Lawlor et al., 
2004) (Eriksson et al., 2001). Early childhood is a period of dramatic change and 
development, in terms of physical growth, cognitive development, and emotional and 
behavioural learning. Environmental exposures, and the effects of parenting and 
nurture (Waylen et al., 2008) are likely to be particularly important in this period, 
and the process of biological ‘embodiment’ of health risks and ‘plasticity’ have been 
described, whereby early experiences mould the growing child, actually influencing 
how genes are expressed (Halfon and Hochstein, 2002). 
Two approaches have been suggested in terms of the timing of exposures. The 
critical period model suggests that exposures acting at a specific time point can cause 
structural changes that have long lasting effect on health. Examples include the 
effects of thalidomide exposure on limb development, lead exposure on 
neurodevelopment, or to hepatitis B, where risk of liver cancer later in life is linked 
to early infection (Galobardes et al., 2004). However, the recognition of early-life 
influences on chronic diseases does not imply deterministic processes that negate the 
utility of later-life intervention, since the cumulative model suggests that effects later 
on in life may modify earlier exposures (WHO, 2007). This has been most 
extensively studied with respect to CVD risk. For example being overweight as an 
adult increases CVD risk more in people who were disadvantaged and underweight 
at birth (Rich-Edwards et al., 2005). 
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We can also observe the interaction of risks over the life course with regard to health 
behaviours. For example, childhood social circumstances influence risk of smoking 
in adulthood (Jefferis et al., 2004). Furthermore, these early risks are compounded by 
subsequent   exposures.   Hilary   Graham’s   elegant   study   using   the   Southampton  
Women’s  survey  studied  the  effect  of  longer  term  “biographies  of  disadvantage”  on  
adult smoking status. Eighteen percent of women with no exposure to disadvantage 
smoked, compared to 36% of those who were disadvantaged as children. However, 
63% of women smoked if in addition they left school early, became young mothers, 
and had other indicators of adult disadvantage.  
The pathway from disadvantage, through low birth weight and early adverse 
influences on nutritional status, to impaired cognitive development is considered 
particularly important in understanding these long-range effects. For instance there is 
a graded relationship between birth weight and parental occupational class, measured 
by national statistics socio-economic classification (NS-SEC) in the contemporary 
UK population in the Millennium Cohort Study (MCS) (Dex and Joshi, 2004). 
Furthermore increased birth weight has been associated with improved cognitive 
ability at subsequent ages in a range of studies (Machin and Vignoles, 2004, 
Waldfogel and Washbrook, 2010). A particular concern in the UK at the moment 
relates to the association between childhood disadvantage and ‘school-readiness’ (as 
in Figure 3). For example in the MCS, children born to parents from the most 
disadvantaged income quintile are almost a year behind those in the middle income 
quintile in terms of cognitive development, even before they enter the education 
system at age five (Waldfogel and Washbrook, 2010). The life course perspective 
suggests that this disadvantage is likely to track forward, and to influence adult 
health in later life. It also emphasises that exposures early in life are involved in 
initiating disease processes prior to clinical manifestations, and that differences in 
childhood exposure profiles can influence the timing of the onset of the symptoms of 
adult chronic disease (Halfon and Hochstein, 2002). 
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The Diderichsen model  
 
The Diderichsen model (Diderichsen et al., 2001) captures key concepts in our 
contemporary understanding of how health inequalities are generated, and was used 
as the conceptual basis for the work of the WHO Commission for Social 
Determinants of Health (CSDH, 2008). The framework conceptualises the generation 
of health inequalities occurring through four main pathways (Figure 6): through 
social stratification itself; because social stratification leads to differential exposure 
to risk factors; differential vulnerability at the same level of exposure; and 
differential consequences of ill health. A key feature of the Diderichsen model is that 
it incorporates both social causation and social selection mechanisms within a 
common framework, across the life-course. Importantly, the model also explicitly 
links the broader social environment to the causal pathway at the individual level and 
makes it clear that the social determinants of health are policy sensitive.  
Mechanism I: social stratification. The prime mover in the model is the process by 
which unequal structures in society lead to unequal social positions. Thus the model 
captures   the   ‘social   causation’   perspective,   whereby   health   is   an   outcome   of  
processes that begin with social structure in which social position is embedded. The 
societal structures in question include "those central engines of society that generate 
and  distribute  power,  wealth  and  risks”  (Diderichsen et al., 2001). So, for example, 
social inequalities in the education system, the labour market, and the distribution of 
wealth and resources, first lead to social stratification, as measured by differences in 
years of education, occupational social class, or income. 
Mechanism II: Differential exposure. Social stratification influences the degree to 
which individuals experience health damaging, and conversely health promoting 
exposures, since health risks vary between social groups in type, amount, and 
duration. Social position thus mediates exposure to intermediate material and 
behavioural risks. These include those distributed in the social and material 
environment of the home, workplace, or neighbourhood. In the absence of any other 
mechanism, differential exposure may go some way to explaining the differential 
health outcomes experienced by these groups. For example, children living in 
poverty are more likely to be exposed to second-hand smoke in the home, and this 
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may influence their risk of developing respiratory illnesses such as asthma (Panico et 
al., 2007) and bronchiolitis (Semple et al., 2011). Furthermore, health risks cluster by 
SES (Halonen et al., 2012), so children living in deprived circumstances are more 
likely to be exposed to multiple risk factors for respiratory illness, such as smoke 
exposure, not having been breast fed, and damp housing conditions (Aligne et al., 
2000, Almqvist et al., 2005). The life-course perspective recognizes that these 
exposures are also temporally structured, and occur at every level of development, 
from the intra-uterine period, through early childhood, childhood, adolescence, and 
into adulthood. These exposures can thus influence immediate health, and provide 
the basis for health or illness later in life (Ben-Shlomo and Kuh, 2002). 
Figure 6: A conceptual model for studying the effect of social position and social 
context on health  
Adapted from Diderichsen et al., 2001 
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Mechanism III: Differential vulnerability. This is perhaps the subtlest of the 
mechanisms, which hypothesises that even if a risk factor is evenly distributed by 
SEP, it can result in differential effects on health and can be understood in two 
different ways. Firstly, we can consider a biological mechanism, whereby a person in 
a lower social position is more vulnerable to a particular exposure. For example, 
children living in poverty are more likely to become ill or die following exposure to 
respiratory infections (Bor and Epstein, 1991), and other infections such as malaria 
or measles, because of the long-term effects of poverty on their host defences, 
mediated by factors such as malnutrition (Kaler, 2008).  
Secondly, we can understand this mechanism as the process of effect modification of 
exposures, whereby the effect of an exposure is amplified in a particular group, due 
to the differential level of another risk factor in that group. This is exemplified in risk 
of cardiovascular disease in adults. The early Framingham studies demonstrated that 
CVD risk factors modify one another, such that the risk of developing CVD is 
multiplicative in adults who smoke, have high cholesterol and high blood pressure 
(Theodorson, 1995). Thus high blood pressure is more harmful to health in 
individuals who smoke, and it follows that even if high blood pressure was evenly 
socially distributed, it could lead to differential effects by SEP because of the higher 
prevalence of smoking in less advantaged groups (Capewell and Graham, 2010).  
Mechanism IV: Differential consequences. Ill health, as a result of the mechanisms 
above, can lead to adverse social consequences, such as job loss, or dropout from the 
education system. For instance, children with type 1 diabetes have been shown to 
experience some disadvantage in later adult employment chances (Milton et al., 
2006). Furthermore, these consequences may be socially patterned, such that more 
disadvantaged groups are more likely to experience adverse consequences. For 
example, a study of people with epilepsy in the UK suggested more employment 
disadvantage in people from working class backgrounds, compared to their more 
advantaged counterparts (Scambler and Hopkins, 1980). Subsequent longitudinal 
studies in Sweden have demonstrated that people from less advantaged groups who 
experience cardiovascular events are more likely to become unemployed than 
individuals in more advantaged positions (Holland et al., 2009). This final 
mechanism completes the loop back to the social context, and thus incorporates the 
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theory of social selection, whereby health status influences SEP, resulting in a 
pattern of social mobility through which unhealthy individuals may drift down the 
social scale and the healthy move up.  
A great strength of the Diderichsen model is the identification of policy entry points. 
Thus the model includes a ‘social and policy context’  box that covers the full length 
of the individual causal pathway, demonstrating where policies might exert their 
influence. Policies to influence the process of social stratification (entry point A) 
would include labour market and welfare policies designed to reduce the gulf 
between people in different social positions. Policies to reduce exposures (entry point 
B) include the classic public health interventions such as improvements to housing, 
safer working conditions, sanitation, clean water, and universal health services. 
These may be applied universally across a population, but they have the greatest 
effect on reducing exposure in the worst off, because these groups are the ones 
suffering the worst conditions (e.g. improvements to working conditions to make 
them safer will benefit the workers in the unsafe working conditions the most, and 
the introduction of the NHS benefitted those who had poor access to health services 
previously). Policies to address differential vulnerability (entry point C) would 
include strategies that aim to address the multiplicative effect of multiple clustered 
risk factors, such as co-ordinated population level action on cardiovascular risk 
factors (Capewell and Graham, 2010). Finally strategies to reduce differential social 
consequences (entry point D), might focus on provision of health care and social 
safety nets in proportion to need, in an attempt to reduce any further social 
differentiation (Diderichsen et al., 2001). 
Studying tracer groups to better understand pathways to health 
inequalities 
Studying unique cases, or populations with specific characteristics that allow a new 
perspective on an issue, has led to important insights in epidemiology and public 
health. A classic example is the work undertaken by Doll and Peto to study the 
effects of cigarette smoking in doctors. The fact that doctors were easy to identify, 
follow-up, and as a whole reduced their cigarette consumption substantially during 
the period of observation led to some of the first irrefutable evidence that smoking 
harmed health (Doll 1976).  
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With regard to health inequalities, the Whitehall studies made use of the finely 
graded social hierarchy in the British civil service to explore inequalities in health 
outcomes, particularly CVD (Marmot et al., 1978, Marmot et al., 1991). Similarly, 
Whitehead et al have used certain groups in the population as ‘tracers’ - sensitive 
barometers to the prevailing policy and social conditions – to track the effects of 
policies on health inequalities. The idea is that some groups in the population provide 
an ‘early warning’ of the impact of changes in policies or services, if the groups most 
reliant on particular policies are carefully selected for study. Single mothers, for 
example, have been considered as a ‘litmus test’ for family policy components of the 
social welfare system because they are among the first to be affected by any changes 
to the system (Whitehead, Burström & Diderichsen, 2000; Burström et al., 2010).  
In a similar manner, we can use the experience of people with the same chronic 
illness   as   a   ‘tracer’   to   shed   light   on   the   social   causes   and effects of illness. For 
instance this approach has been used to examine a number of conditions across the 
life course such as low birth weight (Pharoah et al., 2003), asthma (Milton et al., 
2004), diabetes (Milton et al., 2006), musculo-skeletal conditions (Holland et al., 
2006) and end of life care (Hanratty et al., 2007a). Documenting and then analysing 
the social and health care influences on health inequalities for these groups allows 
policy recommendations to be made to mitigate the adverse outcomes usually 
experienced by the most disadvantaged in society. Accordingly, the studies in this 
thesis utilize the unique characteristics of CF. These hinge on the recessive genetic 
inheritance pattern, which produces a ‘level playing field’ at the outset, and the 
ability to explore variation in a range of outcomes across the life course.  
CF as a tracer condition 
CF is the commonest serious inherited disease among white populations (Davies et 
al., 2007). Intensive support from family and health care services is needed from the 
time of diagnosis onwards, and most patients die prematurely from their disease 
through respiratory failure. There is, however, a great deal of variation in disease 
progression and survival in CF, that is not explained by genetic differences 
(Schechter, 2004). This is against a background of astounding improvements in 
survival over successive birth cohorts in CF. Survival beyond the first few years of 
life was rare in the 1940s, but UK children born in the 21st century are now estimated 
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to have a median survival of over 50 years of age (Dodge et al., 2007). Survival in 
CF has increased under the influence of improved treatment and management, 
improved nutrition and better living conditions (Schechter, 2004, Davies et al., 
2007), but these improvements do not appear to have been shared equally, since 
studies in both the US and UK have demonstrated differences in survival by SES 
(Britton, 1989, Schechter et al., 2001, O'Connor et al., 2003). The social patterning 
of survival in CF suggests that social factors – the ‘social determinants of health’ – 
are having an important effect on outcomes. Utilising some of the unique 
characteristics of CF to explore the causes of these differences can offer broader 
insights. 
The rationale for studying CF in a public health PhD could be questioned. It is not a 
common disease of major public health importance at a population level, and does 
not appear in the global burden of diseases ranking for mortality or morbidity, for 
instance (Lozano et al., 2012, Murray et al., 2012). Furthermore CF is not identified 
as being an illness responsible for any significant proportion of the health 
inequalities ‘gap’ in mortality the UK, which is dominated by CVD, and other 
chronic diseases of adulthood (SEPHO, 2012).  
There are two main responses to this. Firstly, and most importantly, any social 
differences in CF outcomes are clearly of importance to people with CF, their 
families, and the clinicians and health services that support people with CF. On this 
basis alone, it is an important research area. Secondly, and this is what we will focus 
on here, CF is an interesting case conceptually for the study of pathways to 
inequalities in health: As a disease of autosomal recessive inheritance where carriers 
are unaffected, a socio-economic bias in disease incidence is not expected (Schechter 
et al., 2001, O'Connor et al., 2003), but there is potential for a social gradient in 
health care use, disease outcome, and social consequences to develop. CF thus opens 
up opportunities for inequalities research, because it offers both homogeneity, in 
terms of the population affected by the disease at the outset, and yet great variation in 
outcomes that can be explored. These two characteristics make for a promising tracer 
condition to improve our understanding of pathways to differential outcomes. 
The genetic inheritance pattern of CF has a number of implications that we can 
utilize. Firstly, there is no reason to expect a socio-economic gradient in risk of 
 36 
having CF in terms of incidence (Schechter et al., 2001, O'Connor et al., 2003). From 
an etiological perspective, we can subsequently follow up the CF population to 
explore the prospective effects of SES on outcomes, from an equal base. Secondly, 
cases of CF occur in children whose parents are unaffected by the disease 
themselves, because of the asymptomatic carrier state. Although more women with 
CF are living to reproductive age, and having children, genetic screening of partners 
of women with CF, and antenatal screening in pregnancy means women with CF 
giving birth to children with CF is a very rare occurrence. Furthermore, the majority 
of men with CF are infertile (Rowe et al., 2005). Thus from a health inequalities 
perspective, CF is a condition where the inter-generational transfer of ill health is not 
a complication in the analysis. Thirdly, because CF primarily effects white 
populations, the population is relatively homogeneous with regard to race/ethnicity, 
which are notoriously difficult to separate from SES when considering the causes of 
health inequalities, since they are intimately linked (Lorant and Bhopal, 2011). 
Finally the putative even distribution of CF cases by SES is helpful from a study 
design perspective, and potentially offers a better opportunity to explore differences 
in outcomes across the social gradient. This is in contrast to diseases where the 
incidence is socio-economically graded, where there are diminishing numbers of 
cases in more affluent social groups. 
CF allows variation in a range of clinical and health care outcomes to be explored 
over time, since for example nutrition is particularly important in the early years, 
whereas lung function is a key outcome in childhood and young adulthood. Despite 
its origins, explained by a single gene, there is significant variation in outcomes 
between individuals over time (Schechter, 2011), within individuals over time 
(Taylor-Robinson et al., 2012a), between clinical care centres (Johnson et al., 2003), 
and between national populations (Fogarty et al., 2000). This variation is a pre-
requisite to epidemiological studies. There have also been dramatic changes in 
survival over time, leading to significant cohort effects (Dodge et al., 2007), and it is 
possible that patterns of inequalities in outcomes may therefore change over time. 
There are parallels here with the broader health inequalities context, where one 
particular challenge has been to explain the persistence of health inequalities, despite 
the on-going improvements in average health across all groups (Graham, 2007).  
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Studying CF opens up opportunities to explore all of the major aforementioned 
theories regarding the generation of health inequalities. Considering material theories 
of social causation, CF is a respiratory disease where there are plausible links to the 
effects of housing and local environmental quality on disease outcomes, which may 
in turn be socially patterned (Britton, 1989). Behavioural factors, such as smoking, 
and exposure to environmental tobacco smoke (ETS) have been shown to influence 
CF outcomes (Smyth et al., 1994). With regard to psychosocial theories, stress 
pathways may be particularly important in the context of a family dealing with the 
burdens associated with caring for a child with a complex chronic illness like CF, 
over long periods of time (Taylor-Robinson and Schechter, 2011).  
Inequalities in health services are likely to be particularly important determinants of 
health inequalities in CF, and a key consideration is the role of health services in 
mitigating or potentiating differential outcomes. Investigating the existence of the 
‘inverse care law’, by which the availability of good medical care tends to vary 
inversely with the need for it (Hart, 1971), is a research priority in CF care in the UK 
(Taylor-Robinson and Schechter, 2011). Evidence from other diseases suggests that 
there is a lag time associated with accessing new treatments, such that more affluent 
groups benefit first (Lyratzopoulos et al., 2011). This may be important in CF, where 
new treatments are rapidly emerging.  
Investigating these factors from a life-course perspective is now possible thanks to 
the CF registries in many countries, allowing access to high quality longitudinal data 
on children with CF, captured from birth, across multiple outcomes. This allows the 
opportunity to separate age and cohort effects, and to more robustly demonstrate 
causal associations; it could also allow the exploration of cumulative effects of 
exposure across the life course. Since CF is severe, life-limiting illness, there is the 
potential to observe for differential effects over short time periods. Furthermore, CF 
is an illness where health selection is also plausible, since illness in childhood can 
affect learning and employment opportunities leading to subsequent effects on SEP.  
Having outlined the case for studying CF as a tracer condition to better understand 
pathways to health inequalities, the next section reviews some key aspects of CF in 
order to provide sufficient background and context to understand the analyses in this 
thesis.  
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Key features of CF 
CF is an inherited, chronic, progressive condition occurring in around 1 in 2500 live 
births in the UK, and affecting over 9000 individuals, with around 300 new 
diagnoses annually (Dodge et al., 2007, CF Trust, 2013a). CF is the commonest 
serious inherited disease among white populations, and is caused by mutations in the 
CF transmembrane conductance regulator (CFTR) gene, resulting in thick secretions 
that impair various organs, particular the respiratory and digestive systems. It is an 
autosomal recessive condition; inheritance requires receiving two copies of the 
defective CFTR gene, one from each parent (Davies et al., 2007). Most children are 
diagnosed in the first few months of life, and subsequently require intensive support 
from family and health care services. Most patients die prematurely from their 
disease through respiratory failure, and in the 1930s and 40s survival beyond 
childhood was rare.  There have been impressive improvements in survival over 
subsequent decades, such that the estimated median survival of a child born today 
with CF is over 50 years in the UK (Dodge et al., 2007). 
Basic defect 
CF is characterised by a generalized defect of all secretory glands in the body 
(exocrine function), resulting in the production of unusually thick secretions, which 
cause blockage and subsequent damage to the organs in question, particularly the 
lungs, and pancreas. Thus, CF used to be primarily a digestive and lung disease of 
young children but with increasing survival into adulthood, we can better understand 
it as a complex, multisystem disease. 
The thick secretions are the results of the defective opening of ion channels at the 
luminal surface of epithelial cell membranes, which leads to increased sodium and 
water absorption from the lumen. The failure of this liquid volume regulation on 
epithelial surfaces relates to a basic genetic defect in the gene that codes for the ion 
channel – the CFTR gene, which is located on the long arm of chromosome 7 (Rowe 
et al., 2005). Identification of the gene for CF in 1989, was a major breakthrough in 
understanding the aetiology of CF. The most common mutation is delta F508 – 
deletion of phenylalanine at position 508 (Kerem et al., 1989, Riordan et al., 1989, 
Rommens et al., 1989), but over 1600 mutations have been recognized and described 
subsequently (Wolfenden and Schechter, 2009). We can classify these mutations on 
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the basis of the mechanism by which they are believed to cause disease (class 1 to 6, 
with higher number being generally less severe). For instance class 1 defects include 
the complete absence of synthesis of the CFTR, whereas in a class 6 defects a 
functional CFTR is present at the cell surface, but there is increased turnover, leading 
to loss of function. Delta F508 is a class 2 defect characterised by defective protein 
maturation and premature degradation (Rowe et al., 2005). 
There is great variation, however, in phenotype in CF, which is not explained by 
genotype. This means that progression of lung disease, the key mediator of survival, 
has proven very difficult to predict in individuals. Thus, while the manifestations of 
lung disease, as well as mortality, are greatest in patients with the more severe class 
1-3 mutations (Wolfenden and Schechter, 2009), there is generally a loose genotype-
lung phenotype relationship, as demonstrated by significant variation in CF lung 
disease, even among individuals with identical mutations (Kerem et al., 1990a, 1993, 
Koch et al., 2001). This has led to a number of recent studies into modifier genes that 
may influence the effect of the CFTR mutation (Wolfenden and Schechter, 2009, 
Cutting, 2010), most notably the TGFBeta1 gene where there seems to be consistent 
evidence to support its association with poorer lung function (Drumm et al., 2005). It 
has also led to the recognition that despite having its origin in a single gene defect, a 
large amount of the variability in clinical course of CF is not determined by genetic 
factors (Wolfenden and Schechter, 2009, Schechter, 2011). A recent twin study by 
Collaco et al, for instance, suggested that approximately half of the variation in lung 
function is attributable to environmental and/or other stochastic (random) factors 
(Collaco et al., 2010), with the other half being due to genetic factors, affirming the 
potential role of genetic modifiers that require further investigation. 
Clinical presentation 
The clinical presentation of CF varies according to age. Genetic screening and 
counselling are offered to couples with a family history of CF. Prenatal diagnosis can 
then be undertaken by amniocentesis or chorionic villous sampling from around 
10 weeks gestation (Wald et al., 2003). CF may also be suspected on the basis of 
detecting echogenic bowel on antenatal ultrasound scanning (Scotet et al., 2002).  
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In the neonatal period (<28 days), diagnosis is usually as result of screening, or due 
to meconium ileus. All babies born in the UK are offered screening soon after birth 
for certain rare medical conditions, including CF, which has been universally 
available throughout the UK since October 2007 (NHS, 2011). The number of 
children diagnosed through screening has risen year on year in the UK subsequently, 
such that in 2010, out of 301 newly diagnosed cases of CF, 63% (189) patients were 
identified by newborn screening (CF Trust, 2013b). Neonatal screening is based on 
demonstration of low levels of immunoreactive trypsin in the Guthrie heel prick 
sample of blood (NHS, 2011).  
It is hoped that screening will allow more early intervention, before any lung disease 
is established, and this will lead to long-term benefits for patients with CF 
(Greasemann and Ratjen, 2013). The Cochrane review of randomised control trials 
(RCTs) suggested that severe malnutrition was less common among screened babies 
(Southern et al., 2009). Further support for newborn screening has come from 
observational registry based studies, which have tended to support the theory that 
early diagnosis within the first two months of life, followed by intensive treatment, is 
likely to improve nutrition, and early lung function, but evidence is lacking for a long 
term effects on survival (Salvatore et al., 2010). Furthermore, there has been a 
number of cross sectional studies using the UKCF database that have contributed to 
this body of evidence, comparing the outcomes of individuals screened on the basis 
of regional programmes instigated in the UK prior to universal coverage, to those 
diagnosed symptomatically: The first suggested the achievement of a significantly 
greater median height and a reduction in morbidity in screened patients as compared 
to controls matched for age and genotype (Sims et al., 2005b), and two subsequent 
studies suggested newborn screening led to less acute treatment requirements (Sims 
et al., 2005a), and reduced health care costs (Sims et al., 2007b). These findings were 
corroborated in another study by the same group, that demonstrated improved height 
z scores, but no difference in lung function, comparing screened to clinically 
diagnosed patients (Sims et al., 2007a).  
About 15% of neonates with CF present with meconium ileus at birth, caused by 
thick mucus blocking the small intestine. This is a life threatening condition if left 
untreated, usually requiring surgical intervention (van der Doef et al., 2011). Distal 
intestinal obstruction syndrome (DIOS), sometimes referred to as ‘meconium ileus 
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equivalent’,   has   a   similar   pathophysiology   to  meconium   ileus   and   occurs   in   older  
children and adults (Smyth, 2005). 
In infants and young children CF may be suspected due to recurrent respiratory 
symptoms (cough, wheeze, and pneumonia), or failure to thrive. About 90% of 
people with CF in the UK have pancreatic insufficiency (PI) (authors calculation 
from registry data), with consequent malabsorption of fat and other nutrients, leading 
to diarrhoea and subsequent poor weight gain in infancy. In older children and 
adults, respiratory symptoms, sinus disease or infertility, along with a range of less 
common presentations, may lead to suspicion of CF and further diagnostic testing 
(Davies et al., 2007).  
When CF is clinically suspected then the diagnosis is usually confirmed on the basis 
of the sweat test, by demonstrating an elevated level of sodium in the sweat. A raised 
sodium >60 mmol/L is considered diagnostic, and levels above 40 mmol/L are 
consistent with CF. Though definitive diagnoses are not possible in all cases, the 
majority of cases can be diagnosed by a combination of clinical features, sweat 
testing, or identification of CF specific mutations from DNA blood testing for the 
more common CFTR mutations (Rosenstein and Cutting, 1998) 
Lung disease in CF 
Lung disease in CF is particularly important, because the vast majority of deaths in 
CF are due to pulmonary causes – around 97% in one report (Smyth, 2005). Kerem 
et   al’s   seminal   study   in   673   patients   from   Toronto   was   the   first   to   quantify the 
relationship between levels of lung function, as measured by forced expiratory 
volume in 1 second as   a percentage of predicted (%FEV1) and survival, with a 
doubling of the risk of death within two years for each 10% decrease in %FEV1. For 
patients with a %FEV1 lower than 30% this corresponded to a 50% risk of death 
within the next two years. They also demonstrated female sex as an independent risk 
factor for premature death (Kerem et al., 1992).  
In terms of the clinical picture, persistent respiratory symptoms in infants (cough 
and/or wheeze) are often the first indication of CF, and in children, recurrent chest 
infections are common presenting features. The natural history of CF lung disease is 
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then characterized by a chronic progression with intermittent episodes of acute 
worsening of symptoms termed pulmonary exacerbations. Clinical features of these 
include increased cough and sputum production, shortness of breath, loss of appetite, 
loss of weight, and a decline in lung function (Goss and Burns, 2007)  
Bacterial lower respiratory tract infections, particularly those due to Staphylococcus 
aureus, Pseudomonas aeruginosa, Haemophilus influenzae and Burkholderia 
cepacia become established within viscid airway secretions in patients with CF and 
are not effectively eradicated (Rowe et al., 2005). Infection with P. aeruginosa can 
occur very early on in life (Rosenfeld et al., 2012a), and becomes increasingly 
common over childhood, such that by the age of 18 around 60% of the UK CF 
population are infected (Taylor-Robinson et al., 2013a). Infection with P. aeruginosa 
is clearly associated with worse outcomes, including survival, lung function, and 
nutritional status (Kosorok et al., 2001, Emerson et al., 2002, Konstan et al., 2007a, 
Taylor-Robinson et al., 2012a, Taylor-Robinson et al., 2013a).  
Pulmonary inflammation is another major cause of the decline in respiratory function 
in patients with CF. Recent evidence suggests that progressive pulmonary 
inflammation and damage in CF occurs very early in life (Sly and Brennan, 2004, 
Mott et al., 2012), and perhaps prior to the onset of airway infection (Stick, 2009, 
Ramsey et al., 2012). For instance, airway damage has been identified in infants with 
CF by four weeks of age (Mott et al., 2012). One of the key questions in current CF 
care relates to the effectiveness of early intervention, in pre-symptomatic infants and 
children, in terms of avoiding early lung function damage. Current thinking suggests 
that the infant and preschool age period (2 to 5 years) could represent a unique 
window of opportunity to postpone or even prevent the onset of CF lung disease, 
with presumed consequent effects on long-term survival (Greasemann and Ratjen, 
2013). This is a rapidly growing area, and a pre-requisite for clinical trials is the on-
going development of sensitive and reliable outcome measures in the early years – 
CT imaging, bronchoalveolar lavage (BAL) for early microbiological profiling, and 
inert-gas washout tests are current options (Greasemann and Ratjen, 2013).  
Regardless of the exact aetiology and timing of early lung disease in CF, by the time 
children reach school age (5 years of age), significant lung damage (bronchiectasis) 
is found in most patients despite lung function measures within the normal range (de 
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Jong et al., 2006). There has been much interest over the past couple of decades in 
quantifying the subsequent changes in lung function from school-age onwards, using 
%FEV1 as the most commonly used outcome. One of the first studies was that of 
Corey et al, in a single centre in Toronto, which was also the first to use modern 
longitudinal analysis techniques in CF. They demonstrated that pancreatic 
sufficiency, male gender, and non homozygote status for the delta F508 mutation 
were associated with a slower rate of pulmonary function decline (Corey et al., 
1997). There have been several important studies of risk factors for lung function 
decline in CF (Salvatore et al., 2012), using national disease registries, that are 
considered in further detail in a subsequent section.  
Management of CF 
The management of CF is multidisciplinary in the UK and includes specialist 
consultant paediatricians or adult physicians; clinical nurse specialists; 
physiotherapists; dieticians; clinical psychologists; social workers; pharmacists; 
secretarial support; and database coordinators (CF Trust, 2011). Following a 
description of the organisation of care in the UK, this section provides an overview 
of some of the key therapies in CF that are relevant to the studies in this thesis. 
Organisation of CF care 
The CF Trust in the UK, and their counterparts in the US, the CF Foundation have 
developed consensus guidelines (Flume et al., 2007, Flume et al., 2009a, Flume et 
al., 2009b, Robinson et al., 2009, Flume et al., 2010) and have promoted a network 
of CF care centres with expertise in the treatment of CF. The majority of people with 
CF in the UK attend or receive all or some of their care from one of these specialist 
CF centres, which are staffed by a multidisciplinary team (MDT) with appropriate 
expertise and training in the management of CF (CF Trust, 2008).  
CF care in the UK, and most other high-income countries, is delivered through these 
specialist clinics, where a critical mass of patients can be treated, and resources and 
expertise concentrated. Furthermore, clinicians and services need to have an 
adequate throughput of patients in order to maintain and improve quality of care. 
This is an established principle for adult conditions such as stroke (Chan et al., 2013) 
and cardiac services (Walker et al., 2012), and also for specialised paediatric surgery 
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(Gibbs and Cunningham, 2002, Stringer, 2008, Welke et al., 2008), and cancer 
services (Knops et al., 2013), where centre care has improved outcomes.  
The first evidence for improved outcomes as a result of centre based care in CF came 
from Denmark (Nielsen et al., 1988), where patients treated in the Copenhagen CF 
centre fared better in terms of lung function and prevalence of P. aeruginosa 
infection. Similar findings suggesting better pulmonary function, nutrition and 
survival in patients receiving centre care compared to those receiving local hospital 
based care have come from subsequent observational studies in the UK (Walters et 
al., 1994, Mahadeva et al., 1998), Australia (Phelan and Hey, 1984), Denmark 
(Merelle et al., 2001) and Germany, and the current consensus is that contemporary 
care for CF should be delivered by a specialist CF centre MDT (Kerem et al., 2005, 
CF Trust, 2011). Despite this, a recent systematic review of specialized care 
concluded that for CF, outcomes were not superior in specialized centres compared 
with other models of care, commenting on the inconsistency and poor quality of the 
observational studies in CF (Post et al., 2009). 
Doull points out that these early studies, which reflect on care over 20 years ago, 
may not be generalizable to modern CF care, which has evolved considerably over 
the last two decades (Doull et al., 2012). More recently, a ‘shared care’ model has 
been increasingly common (CF Trust, 2008); with similar outcomes demonstrated 
for children who received specialist care compared to those who received shared care 
(van Koolwijk et al., 2002, Thomas et al., 2008). Shared care means that the overall 
patient management is co-ordinated by the MDT based at a specialist centre, but 
some clinic visits are delivered on an out-reach basis in accredited network clinics. 
This allows patients to be seen closer to home, in their local paediatric units, usually 
in conjunction with a local paediatrician with a specialist interest in CF, thereby 
reducing travel times and disturbance to schooling and family life.  
A recent analysis of outcomes in South Wales identified three patterns of care (Doull 
et al., 2012): full centre care, where the child is seen every 6 to 8 weeks (including 
annual review) at the specialist CF centre; local clinic-based care (shared care), 
where the child is seen regularly by the local clinic team and has only their annual 
review performed locally by the visiting consultant from the specialist CF centre; and 
hybrid care, where the child is usually reviewed at least three times a year (including 
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annual review) by the specialist CF centre team (Doull et al., 2012). The study 
reported worse lung function in the shared care group. The authors suggest that 
frequency of review by the CF centre MDT is more important than the distance from 
the CF centre, and hypothesize that the differences observed between models of care 
may reflect the frequency of specialist CF team review in the first few years of life. 
Data from the US also suggests that the centres with highest lung function scores for 
their patients were characterized by more clinic visits, more respiratory tract cultures, 
and frequent treatment of patients, particularly those considered to have mild lung 
disease (Johnson et al., 2003, Padman et al., 2007). Notably, the current UK 
guidelines now recommend that the specialist MDT should see patients under shared 
care at least twice a year (CF Trust, 2011). It is evident that continuing research is 
needed to identify the optimum model of care in the UK, and elsewhere, as treatment 
strategies evolve.  
The establishment of clinical networks in the UK and US, taking a standardized 
multidisciplinary approach to CF care, has contributed to the on-going improvements 
in survival for people affected by the disease. There remains, however, significant 
variation in disease outcomes between centres. Data from the US (Schechter, 2012), 
UK (CF Trust, 2013b) and Germany (Stern et al., 2008) suggest that there is 
significant variation in outcomes such as lung function and nutritional status 
comparing centres. Most studies exploring reasons for centre-based variation have 
been from the US. For instance, registry based analyses using the Epidemiological 
Study of CF (ESCF), taking into account case-mix, have demonstrated centre based 
differences in use of therapies and patient monitoring (Konstan et al., 1999b, 
Konstan et al., 1999a), and have also shown that these variations in care impact 
directly on outcomes (Johnson et al., 2003). This has led to increased interest in 
benchmarking and quality improvement initiatives in the US in an attempt to drive 
up standards (Quinton and O'Connor, 2007, Schechter and Gutierrez, 2010, Quon 
and Goss, 2011). In a UK analysis, there was a threefold variation between CF 
clinics in the prevalence of poor nutritional status (<10th centile for weight), and 
Metha et al suggest that further investigation is required into the factors that might 
explain such variability, in line with the on-going work in US CF clinics (Mehta et 
al., 2004). There remains significant variability in all measured unadjusted outcomes 
between centres in the UK (Figure 7)(CF Trust, 2013b), but no analyses to date have 
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taken into account case mix, and other factors such as social deprivation, so 
interpretation is difficult. 
Figure 7: Median FEV1 % predicted by paediatric centre/clinic all centres and 
networks.  
Red: centres. Gold: network clinics. Plum: all. * Centre/clinic with a dataset 
submission of less than 20 patients source (Cystic Fibrosis Trust, 2011) 
 
 
Respiratory management – antibiotic therapy 
Treatment of respiratory infections with antibiotics is a central pillar of CF therapy 
including for prophylaxis; eradication of infections; long-term treatment of chronic 
infection, and treatment of acute exacerbations. The aim is to prevent initial bacterial 
infection in children, and promptly treat acute infections using antibiotics.  
Younger children receive oral antibiotic prophylaxis for S. aureus in the UK, but this 
is not standard everywhere. Current evidence from RCTs suggests that this may 
prevent infection, but there are concerns relating to increased risk of P. aeruginosa 
acquisition with long term prophylaxis (Smyth and Walters, 2012a).  
P. aeruginosa is associated with increased morbidity (worse lung function and 
weight gain) and mortality (Emerson et al., 2002, Taylor-Robinson et al., 2012a), and 
management aims to prevent early infection. P. aeruginosa is widespread in the 
natural and domestic environment, including plants, soils, and surface water, 
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especially warm moist environments (Cohen-Cymberknoh et al., 2011). Concerns 
about cross infection between patients means that complete segregation of CF 
patients harbouring P. aeruginosa and other clinically significant organisms is 
considered best practice (Jones et al., 2005). There is increasing evidence that early 
antibiotic therapy initiated early after the initial onset of P. aeruginosa infection is 
effective, and can postpone chronic colonization in over 80% of people, but the long 
term benefits are unclear (Davies et al., 2007). No consensus currently exists 
regarding the best antibiotic protocol, and the Cochrane review found that nebulised 
antibiotics, alone or in combination with oral antibiotics were effective options 
(Langton Hewer and Smyth, 2009). 
Once P. aeruginosa infection becomes chronic, long-term treatment with inhaled 
antibiotics is recommended. The best evidence from RCTs is for inhaled tobramycin, 
but again the optimum treatment regimen is unclear in terms of dose and frequency 
of administration (Ryan et al., 2011). Inhaled tobramycin was shown to produce 
sustained improvements in lung function, improved patient nutritional status, 
hospitalization time, and the requirement for IV antibiotics (Ryan et al., 2011). Oral 
macrolide antibiotics have also been shown improve respiratory function, and are 
used to reduce inflammation in patients with CF colonized with P. aeruginosa 
(Southern et al., 2012). By contrast the Danes have advocated intensive IV antibiotic 
therapy delivered on a regular basis to improve outcomes in people colonized with P. 
aeruginosa, but this has not been adopted widely elsewhere (Frederiksen et al., 
1996).  
Acute chest infections (exacerbations) are treated with oral, nebulised, and/or IV 
antibiotics. It remains unclear whether the optimal treatment should be with oral, 
inhaled (Ryan et al., 2013), or IV antibiotics (Cohen-Cymberknoh et al., 2011), and 
whether this treatment should be provided in a hospital setting or at home (Balaguer 
and Gonzalez de Dios, 2012). 
Respiratory – other therapies 
Macrolides, mainly azithromycin, are being used to reduce inflammation in patients 
with CF colonized with P. aeruginosa. High-dose ibuprofen can also slow the 
progression of lung disease in people with CF, especially in children (Lands and 
Stanojevic, 2007). Several studies reported beneficial effects of systemic 
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corticosteroids, but there are risks of significant adverse effects, such as growth 
retardation, diabetes and cataracts, so these are not recommended (Balfour-Lynn and 
Welch, 2009). 
DNase is an inhaled mucolytic that breaks down the thick sputum in the lungs. This 
was first commercially available in 1992, and was the first treatment to demonstrate 
an improvement in lung function in CF (Fuchs et al., 1994). A recent systematic 
review of subsequent trials demonstrates improvements in lung function from long 
term DNase therapy (Jones and Wallis, 2010). Inhaled hypertonic saline is also used 
to improve airway clearance, and has been shown to improve quality of life and 
reduce pulmonary exacerbations, although it has not been shown to have a 
substantive effect on lung function (Wark and McDonald, 2009). Inhaled saline has 
recently been shown to be ineffective in improving outcomes in children under six 
years of age – it had been hypothesised that this may be an effective early 
intervention to reduce the rate of pulmonary exacerbations in children (Rosenfeld et 
al., 2012b). 
Daily physiotherapy exercises to improve mucous clearance are recommended for all 
patients. These include postural drainage, percussion, and vibration techniques, 
huffing and directed coughing, and can be facilitated with devices such as the flutter 
or oscillator vests. Although physiotherapy does appear to increase mucous 
clearance, at present there is no clear evidence from RCTs for long-term effects in 
respiratory function, quality of life or survival (Van der Schans et al., 2009). 
Nutritional support 
The main aims of nutritional support in CF are to achieve optimal nutritional status, 
and allow normal growth and development throughout childhood. Pancreatic enzyme 
insufficiency leads to malabsorption of fats, diarrhoea, and failure to thrive, and this 
is compounded by lung disease and infection, which further increases calorie 
requirements. Thus recommendations are for early nutritional support with adequate 
pancreatic replacement management, as this has been shown to improve growth and 
subsequent lung function (Konstan et al., 2003, Munck et al., 2009). Nutritional 
status has been independently linked to survival, and the experience of the Toronto 
CF Clinic suggested that that a high calorie diet may improve growth (Levy et al., 
1986). However this has not been corroborated in RCTs. The latest Cochrane review 
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suggests that oral calorie supplements do not confer any additional benefit in the 
nutritional management of moderately malnourished children with CF over and 
above the use of dietary advice and monitoring alone (Smyth and Walters, 2012b).  
Epidemiological studies of CF using national registries 
Registry studies have been critical to inform our understanding of the epidemiology 
of CF, and I have discussed some of the registry studies relating to newborn 
screening, and the evidence around centre care above. These observational studies 
have become increasingly common since the late 60s, due to the availability of 
registry data in a number of countries. Analysis of registry data has allowed insights 
into the changing demographics, outcomes, and treatments in CF. A recent series of 
systematic reviews have collated all of the registry trials in CF, identifying 168 
studies overall (Buzzetti et al., 2009, Salvatore et al., 2010, Salvatore et al., 2011, 
Salvatore et al., 2012). In their analysis of these studies the authors group the studies 
into the following outcomes: demographics; incidence/prevalence; survival/gender 
gap; genetics; nutritional status and growth; microbiology; complications; factors 
influencing diagnosis; factors influencing lung disease; socio-economic 
status/quality of life; therapeutic strategy evaluation; clinical trial methodology 
(Salvatore et al., 2012). Eleven CF registries are identified, summarised in Table 1 
below. 
In this section I provide an overview of registry studies that focus on 
survival/mortality, nutrition/growth and lung function, mentioning some other non-
registry studies where appropriate, since these outcomes are of particular relevance 
to the studies in this thesis. CF registry studies that focus on the effect of SES are 
summarised later on. This overview highlights key emergent findings, and evidence 
from the UK, since this is the main data-source for this thesis, in order to identify key 
gaps in the literature.  
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Table 1: National CF registries 
Registry name  Start 
date 
Patients captured (alive and dead) to 
end of 2006 
USA-CFF Patient registry 1966 40,203 
USA-Epidemiologic Study of CF 1994 32,667 
Canadian CF Patients Data Registry 1966 5571 
Australian CF  Data Registry 1988 2312 
UK CF Database 1999 7046 
France-Observatoire National de la 
Mucoviscidose 
1992 4608 
Registro Italiano FC 1988 5064 
German CF Quality Assessm. Proj. 1995 7260 
Registre Belge de la Mucoviscidose 
(BMR-RBM) 
1998 1140 
Cystisk fibrose register Danmark 2001 460 
European Registry CF (ERCF) 1995 13,684 
 
Survival/mortality 
Two reviews identified 19 studies that focussed on changes in survival, and factors 
influencing survival in CF (Buzzetti et al., 2009, Salvatore et al., 2012), with one 
study identified from the UK (Dodge et al., 2007). The majority of these were from 
the US, as a result of the large size and longer follow-up period in the two US 
registries (Table 1).  
The most recent data show a median survival age (indicating the age at which a 
newborn of a given period has a 50% theoretical chance of surviving) of 36.4 years 
in France, based on 2003 data (Bellis et al., 2007), 37.4 years in Germany, based on 
2005 data (Stern et al., 2008) and 37.4 years in the U.S., based on 2007 data (CFF, 
2007). The study from the UK estimates survival at over 50 years for patients born 
after 2000 (Dodge et al., 2007). All these studies use life-table methods to study 
survival.   The   review   authors   comment   that   “improved   survival, increased number 
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and   increased   mean   age   of   CF   patients   worldwide   are   evident”   (Buzzetti et al., 
2009).  
Some studies have been able to study factors that influence survival, and notable 
among these are the large studies from North America that have used Cox regression 
to estimate the effect of various covariates on survival chances in registry 
populations (Corey and Farewell, 1996, Rosenfeld et al., 1997, Liou et al., 2001, 
O'Connor et al., 2002). Overall, the following negative influences on survival have 
been identified: female sex (the most commonly identified risk factor, see for 
example (Rosenfeld et al., 1997), one of the largest studies), early symptomatic 
diagnosis, poor nutritional status, poor respiratory function, diabetes, P. aeruginosa, 
B Cepacia infection, >4 respiratory exacerbations per year, homozygous delta F508 
status or heterozygous non delta F508 status, non-white ethnicity, and low income. 
Notably, only the effect of sex has been studied in the UK population (Buzzetti et al., 
2009). 
Turning in more detail to the UK studies, Dodge at al have undertaken a series of 
epidemiological studies describing survival (Dodge et al., 1993, Dodge et al., 1997, 
Lewis et al., 1999, Dodge et al., 2007). These have used similar approaches on the 
same underlying dataset, updated to cover larger follow up periods, and therefore we 
focus here on the most recent study (Dodge et al., 2007). In order to calculate 
survival, two main sources of data are required: a complete census of the population 
and follow-up of that population to capture mortality data (WHO, 1977). Dodge et al 
used the UK CF Survey (UKCFS), a precursor to the UKCF Registry, which was 
originally under the auspices of the British Paediatric Association and the British 
Thoracic Society, and funded by the CF Trust. This enumerated all of the people in 
the UK population with CF, through direct enquiry with individual clinicians, from 
1968 to 1997, with an estimated coverage of over 95% (Dodge et al., 2007). 
Therefore the dataset captured the prevalent population in 1968, and incident cases 
born subsequent to this up to 1997. The Office of National Statistics (ONS) collected 
mortality data by requesting all CF related International classification of disease 
(ICD) codes, and this was linked back to the survey data. There has been 
standardised ICD coding for CF since 1968, whereas prior to this ICD did not 
separate CF from other diseases of the pancreas, so death certification data is 
unreliable (Dodge et al., 2007). Using this information the authors were able to 
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calculate cohort survival, and left truncated-survival, and then go on to estimate 
current survival for the CF population in 2003, on the basis of a number of 
assumptions.  
Cohort survival was calculated from the observed data, based on the survival for 
incident cases captured subsequent to 1968. This method requires a long follow up 
period, and estimates of median survival derived from such data are unlikely to be 
relevant to newly born cases because of improvements in treatment leading to a 
longer lifespan (Lewis, 1998). Using an actuarial life table method (Armitage et al., 
2008), they generate survival curves and age/sex specific mortality rates for birth 
cohorts in three-year age groups, stratified by sex, up to 1994. These data 
demonstrate improving survival with successive birth cohorts, and a sex difference in 
survival, whereby males have improved survival chances. This sex difference 
narrows with successive birth cohorts, and is particularly marked prior to 1987. 
The left censored survival curves apply to prevalent cases alive in 1963. For these 
people, they again group them into birth cohorts, and infer the proportion of the 
original birth cohort alive in 1963 at the outset of data collection. This was achieved 
by collecting UK population birth data for the relevant cohort, and then assuming an 
incidence of one in 2381 of these births will be CF cases, the incidence calculated in 
their study. They then applied the same life table approaches to the survivors to 
calculate survival probabilities going forward in time. The resulting analysis again 
demonstrates a cohort effect, and also the survivor bias inherent in left censored 
datasets: the individuals alive in the dataset in 1963 are a group of essentially 
healthier survivors from the original birth cohort. 
The authors go on to apply the age specific mortality rates from the most 
contemporary birth cohort (1992 to 1994) to the current CF population alive in 2003, 
and on this basis are able to estimate the current survival for the CF population, 
estimated to be around 40 years overall, with median survival for men at around 45 
years, and that for women at 35 years. They point out, however, that since cohort 
survival appears to be improving year on year, the estimated median survival for 
children born since 2000 is likely to be around 50 years. Other key findings from this 
analysis include the marked reduction in infant mortality in the CF population with 
successive cohorts, attributed to improved treatment in the first year of life, 
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particularly of meconium ileus. They also point out that the continued growth of the 
adult CF population by around 145 patients per annum had national and local 
implications. This study illustrates some of the technical difficulties inherent in 
estimating survival in CF populations (Lewis, 1998), and did not allow exploration 
of the effects of covariates other than sex and birth cohort on survival. The authors 
further suggest that international comparisons present serious technical and 
methodological problems, due to different methods of data collection (Dodge et al., 
2007). 
Recognising the difficulty of undertaking studies of cohort survival across countries 
due to the lack of standardised data, Fogarty et al compute median age at death for 
people with CF in 17 countries in Europe, Australia and North America up to 1994 
(Fogarty et al., 2000). Trends in median age at death are likely to indicate trends in 
overall survival. The study shows improving trends across all countries from an 
international median of eight years in 1974 to 21 years in 1994, but note that that 
median age of death significantly underestimates median survival in a disease such 
as CF where cohort survival is improving over time. They also demonstrate marked 
sex differences, with women having greater chances of dying at a younger age, and 
apparent differences between countries, with survival chances in the US being the 
highest, compared to those in Scotland (Odds Ratio (OR), 0.39, 95%CI 0.30 to 0.52 
relative to United States the sex-adjusted proportion of people dying from CF at an 
age above the international median age of death for their year of death). The authors 
recognize the limitations of the analysis; differences in coding practices between 
countries; the high sensitivity of the calculation to misclassification of deaths in the 
first year of life; and small numbers in some countries. Nevertheless they suggest 
that differences between countries require further investigation, and may relate to 
socio-economic factors, and access to evidence based treatments (Fogarty et al., 
2000). 
Finally, in an earlier study of survival from the UK of note, Elborn et al estimated the 
number of children born each year with CF from 1959 to 1986, and used this 
together with annual mortality data to generate cohort life tables. They then 
developed regression models to make forward predictions up to year 2000. These 
predictions allowed production of life tables for annual cohorts from 1959 to 2000 
and hence to estimate the size of the CF population for each year up to 2000. Their 
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model suggested improving survival in successive birth cohorts, and suggested a 
linear increase in CF prevalence, predicting a population of around 6000 by the year 
2000, with 3400 (57%) aged under 16. The median life expectancy of children with 
CF born in 1990 was estimated at 40 years, double that of the estimate 20 years 
beforehand (Elborn et al., 1991). 
Nutritional status 
Regarding nutritional issues, Salvatore et al identify 17 studies focussed in this area 
(Salvatore et al., 2010, Salvatore et al., 2012), with only one from the UK, which 
explored the relationship between obesity and overweight, and lung function. The 
study demonstrated a positive association between high BMI, and lung function even 
at BMI z-score levels of 1 to 2, and the authors argue against calorie restriction in 
relatively overweight children with CF (Kastner-Cole et al., 2005). The other studies 
on nutrition have generally confirmed the association of good early nutritional status, 
with better subsequent lung function, and some have suggested that this is related to 
reduced risk of death. This evidence suggests that aggressive and early nutritional 
intervention is particularly important in the first few years of life. The importance of 
nutrition was first demonstrated in a study comparing outcomes in Toronto and 
Boston, using the Canadian and US registries, which showed improved growth and 
survival in the Toronto clinic population, attributed to more aggressive nutritional 
therapy (Corey et al., 1988), and this was subsequently corroborated in a population 
level comparison (Lai et al., 1999). This study further demonstrated an equalization 
of nutritional status between the US and Canadian CF populations, as the US adopted 
more aggressive nutritional regimens, more in line with the Canadian approach. 
A few studies have used multivariate regression approaches to quantify the 
association between nutritional status, and subsequent clinical status. Zemel et al 
used a subset of the US registry to show a positive association between nutritional 
status (weight and height z scores), and longitudinal lung function trajectory (Zemel 
et al., 2000),   results   corroborated   in   Konstan’s   study,   which   showed   that  
malnourished children at age three had reduced pulmonary function at age six 
(Konstan et al., 2003). Furthermore, in one of the larger studies of growth in 19,000 
children in the US registry, Beker et al demonstrated a three to five fold increased 
risk of death in children who were stunted at age five (<5th height centile) (Beker et 
al., 2001). A study using the German registry further demonstrated that improved 
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early nutrition was associated with reduced P. aeruginosa prevalence, and that 
malnutrition coupled with P. aeruginosa was particularly detrimental to average lung 
function, and increased lung function decline over a year in a longitudinal analysis 
(Steinkamp and Wiedemann, 2002). 
Taken together with the evidence for newborn screening from registry studies 
mentioned earlier (Salvatore et al., 2010), the registry studies on nutrition suggest 
that early nutritional status may play a pivotal role in the chain of events leading 
from early diagnosis, to later improved lung function, and therefore survival. 
Furthermore, there are plausible biological mechanisms to support this, since very 
early life is a critical period for the formation of alveoli in the lungs (Lai et al., 
1999). Salvatore et al highlight the importance of further studies that investigate the 
interaction of early nutritional status, socio-economic status, P. aeruginosa 
acquisition, and nutritional status, especially in settings outside the US, with different 
health care systems based on universal access (Salvatore et al., 2010). 
Lung function 
Between 2001 and 2012, 15 registry studies have focussed on lung function 
(Salvatore et al., 2011, Salvatore et al., 2012). None of these are from the UK. Here I 
review the studies of particular relevance to the work in this thesis. The first of these 
was a large cross-sectional study of 7010 people in the European registry, which 
showed that a range of factors were associated with a 10 percentage point lower 
%FEV1 than expected: low body weight, haemoptysis, pulmonary symptoms at 
onset, P. aeruginosa infection, use of oral steroids, anti-inflammatory drugs, DNase, 
oxygen requirement and mechanical ventilation (Navarro et al., 2001). Konstan et al 
undertook the largest subsequent study of risk factors for lung function decline in 
around 5000 children in the US. The authors prospectively assessed the effect of 
various risk factors on lung function trajectories over three four year age periods, in 
children in the US registry. High baseline %FEV1 and persistent crackles were 
significant independent risk factors for %FEV1 decline across all age groups. Female 
gender, P. aeruginosa infection, low weight-for-age, daily sputum production, 
wheezing, sinusitis, pulmonary exacerbations treated with intravenous antibiotics, 
abnormal liver test results, and pancreatic insufficiency were also identified as 
independent risk factors in some age groups (Konstan et al., 2007a). 
 56 
 
Vandevanter et al extended this work, to propose a scoring system to identify 
patients at risk of significant deterioration in lung function, based upon the 
aforementioned risk factors (Vandevanter et al., 2010). The same authors develop 
this idea further to suggest that staging of lung disease based on cross sectional 
measures %FEV1 needs to be developed further to take into account the more 
dynamic age related changes in lung function (Konstan et al., 2009). A further study 
from the US explored factors associated with failure of recovery of lung function 
following pulmonary exacerbations, including female sex, poor nutrition and 
persistent P. aeruginosa infection (Sanders et al., 2010), and the same group went on 
to show that increased frequency of pulmonary exacerbations was associated with 
increased lung function decline in children and adults (Sanders et al., 2011). Liou et 
al undertook a recent large study of 20,000 people in the ECFS, to quantify annual 
changes in %FEV1 in individuals aged 6 to 45 years old. The authors further contrast 
individual level changes in %FEV1, with population level changes. They show that 
% predicted FEV1 decreases by one to three points per year for individuals, with 
maximal decreases in 14 to 15 year olds. Furthermore, there is a large degree of 
within individual variation. They also show that within individual decline continues 
in adulthood, but this is not reflected in aggregate measures, which flatten out due to 
survivor bias in the sample of people over the age of 30 years (Liou et al., 2010). 
Two other notable studies have examined the association between environmental 
factors and lung function in CF. Goss et al demonstrated an association between 
levels of air pollution and the risk of pulmonary exacerbations, and more rapid 
decline of lung function in 11,000 people in the US registry (Goss et al., 2004), and 
Collaco et al demonstrated that exposure to passive smoking was associated with 
worse lung function in a study of 812 people in the US CFF registry (Collaco et al., 
2008). In a more recent study using data from the US, Australia, and New Zealand, 
Collaco et al further demonstrate an association between warmer temperatures, risk 
of P. aeruginosa, and worse lung function (Collaco et al., 2011). 
Health inequalities and CF 
The starting point for the studies in this thesis rests on a handful studies of 
undertaken in the UK and the US, since 1989 (Britton, 1989, Schechter and 
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Margolis, 1998, Schechter et al., 2001, O'Connor et al., 2003). Though the evidence 
base has evolved somewhat since starting this thesis (Schechter et al., 2009, Quittner 
et al., 2010, Stephenson et al., 2010, Barr HL, 2011, Schechter et al., 2011, Taylor-
Robinson et al., 2013a), the former remain the key studies on the effect of SES on 
outcomes in CF. The first observations by John Britton and his group in Nottingham 
in the UK demonstrated an apparent difference in survival in CF by SES (Britton, 
1989). Michael Schechter and colleagues explored this further in the US, first in a 
single care centre (Schechter and Margolis, 1998), and then in a key publication the 
following year on a US-wide registry population (Schechter et al., 2001). These 
studies confirmed a difference in survival on the basis of health insurance status in 
the US, and also indicated differences in other CF outcomes. Finally, Gerry 
O’Connor’s   study,   again   in   the   US   registry   population,   demonstrated a social 
gradient in survival, and also some intermediate CF outcomes (O'Connor et al., 
2003). In this section we review each of these key trials in more detail, and other 
relevant literature, before turning to the gaps in the literature. 
Britton’s  study  (Britton, 1989), showing that the chances of age at death at above the 
median for the general CF population were greater for people in non-manual groups, 
compared to manual occupations, was motivated by a case-series report from the 
Royal Brompton Hospital, UK, in 1980 (Penketh et al., 1987). This observational 
case series reviewed all of the 317 patients attending a specialist centre in London, 
and found that 56% of patients attending the centre were from social class I and II, 
using the Registrar General's classification of social class by occupation, compared 
to  an  expected  20%.  The  authors  suggested  that  this  may  “reflect  the  type  of  patients  
who seek to be referred to a national centre and are able and prepared to travel.”   
On the basis that these differences in service use by SES may be more widespread in 
the UK, and that this may result in differences in outcomes between centres, Britton 
et al analysed death registration data for people with underlying cause of death coded 
as CF between 1959 and 1986, and for each year calculated the median age at death 
(Britton, 1989). At this time there was on-going debate about the role of specialist 
centres in CF, and Britton hypothesised a relationship between  the apparent better 
performance seen in specialist centres and social class effects. They then went on to 
show that more advantaged individuals were more likely to have a higher age at 
death in a particular year (ORs for death at age above the median for the year of 
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death was 1.47, 95% confidence interval (CI) 1.16 to 1. 87, non-manual to manual 
occupations). In the absence of cohort data on which to undertake formal survival 
analysis to demonstrate premature mortality, this provided initial compelling 
evidence of differences in survival by SES. Commenting on reasons for the observed 
differences, whilst accepting the possibility of reverse causation, the authors 
speculated that this might be due  to  factors  such  “lack  of  resources  to  permit  visits  to  
hospitals or the local doctor or to provide medicines and dietary supplements, or by 
factors such as increased parental smoking, poor quality or overcrowded housing, 
and  lower  levels  of  education”  (Britton, 1989). 
Ten years after the Britton study, Michael Schechter and colleagues showed that 
survival chances were greater in people who never used Medicaid based insurance in 
the US, compared to those that always used Medicaid, using Medicaid status as a 
proxy for poverty (Schechter and Margolis, 1998, Schechter et al., 2001). This 
association was first documented in a care centre based sample of 281 patients aged 
under 21 years in North Carolina (Schechter and Margolis, 1998), and then followed 
up in a large-scale study using the US CF registry population (Schechter et al., 
2001). In the US, individuals who cannot afford private health insurance are eligible 
for Medicaid, and the association of Medicaid use with poverty was utilised in this 
study, since no other indicators of SES were available. The study had two 
components – a longitudinal survival analysis, and a cross-sectional analysis of other 
outcomes.  
In the longitudinal survival analysis of 20,390 people aged under 20 in the registry 
from 1986 to 1994, Schechter et al found that people on Medicaid, compared to those 
never on Medicaid, had a hazard ratio for death of 3.70 (95% CI 3.06 to 4.46) after 
adjusting for age, race, and genotype, which are known to influence survival, but 
were not considered to be in the causal path linking SES to survival. After 
adjustment for level of %FEV1 at entry to the analysis, however, the effect of 
Medicaid on SES became non-significant. In the cross-sectional component of the 
analysis all patients in the registry in 2000 were analysed. Schechter reports 
significantly lower %FEV1 at age five in the Medicaid patients (9.2 percentage 
points, 95% CI 7.1 to 11.4), and this gap increased slightly in an age dependent 
manner up to age 20.  
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Furthermore, there was a greater chance of being under the 5th centile for weight or 
height in the Medicaid group. The authors also examined reported use of in-hospital 
treatments, and found that children using Medicaid, compared to those who never 
used Medicaid, were more likely to be treated for pulmonary exacerbations with IV 
antibiotics (OR 1.58, 95% CI 1.27 to 1.96), and were also more likely to spend time 
in hospital. There was no difference in the age of diagnosis of children, or number of 
clinic visits by Medicaid status. Whilst acknowledging some of the limitations of 
using Medicaid as an indicator of low SES – one issue being that sicker patients are 
more likely to be eligible for Medicaid, and thus there is the possibility of reverse 
causation – the authors speculate that a range of factors that cluster with poverty may 
explain the associations: poor nutrition or stress influencing immune function; 
exposure to outdoor or indoor air pollution, including cigarette smoke; earlier 
exposure to respiratory viral infections, respiratory syncytial virus; stress effects on 
family function influencing adherence to medications; difficulties in accessing 
primary care. Otherwise, the authors suggest that decreased access to specialist care 
was not playing a major role in generating adverse outcomes. 
Gerry  O’Connor   et   al   extended   the  work   of   Schechter’s   team   by   demonstrating   a  
social gradient in the relationship between area-based income in the US, and 
mortality rates (O'Connor et al., 2003). Studying essentially the same population as 
in  Schechter  et  al’s  analysis  a  few  years  later  (23,817 white patients under 18 years 
of age between 1991 and 2000 in the CF Foundation  Patient  Registry),  O’Connor  et  
al demonstrated a graded relationship between area based income and risk of death, 
with a relative risk of 1.44 (95% CI 1.20 to 1.73, adjusted for sex, age at diagnosis, 
and mode of presentation of CF) comparing individuals in the lowest area-linked 
income bracket (<$20 000), compared with the highest (>$50 000). The study also 
longitudinally modelled %FEV1, and weight centile, and demonstrated a monotonic 
gradient in these outcomes by income category. Thus children in the lowest income 
category had a lower %FEV1 by 5.5% points at age 6 (P <0.001, adjusted for the 
same covariates as above), and this gap remained fairly constant up the age of 18. A 
similar pattern was observed with weight centile, with a gap of 7.3 percentage points 
(P   <   .001).   O’Connor’s   study   also   explored   differences   in   the   use   of treatments 
recorded in the CF registry, and showed that children from more deprived areas, as 
measured by area-based income, tended to have increased use of nutritional 
 60 
supplements (50.7% in the lowest income category, compared to 33.9% in the 
highest), and were more likely to be screened for CF related diabetes. However, there 
was no significant trend between income categories and the use of DNase, or inhaled 
antibiotics (aerosolized TOBI®). The authors point out the limitations of the 
ecological (area-based) measure of SES used in their analysis, and suggest that the 
associations observed may be due to poor adherence to medications, or local 
environmental conditions. 
In summary, at the outset of the work in this thesis, one study in the UK had 
demonstrated a difference in survival for people with CF, on the basis of 
occupational social class. Two US studies corroborated this finding, demonstrating 
worse survival in the US population on the basis of both Medicaid status, and area-
based income. Furthermore, these studies demonstrated inequalities in other 
important CF outcomes, such as nutritional status, and lung function in the US, and 
these  differences  were  socially  graded  in  the  O’Connor  study.  The  evidence  from  the  
US did not suggest that poor access to specialist care was a major factor in the 
pathway to adverse outcomes. 
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Gaps in the literature 
The review of the literature has identified a number of gaps in knowledge of the 
effects of SES on outcomes in CF. 
 
1. Current studies have focussed on the US population. Two studies in the UK 
have explored the effects of SES on risk of death, but otherwise there have 
been no population level studies in the UK, or other European countries, 
exploring the effect of SES on longitudinal outcomes in CF. Studies should 
be undertaken in countries with contrasting social and health care policy 
contexts to those found in the US.  
 
2. Population level studies in the UK characterising the age-related changes in 
key CF outcomes such as lung function, growth, and risk of Pseudomonas 
colonisation are lacking. Developing an understanding of these age-related 
changes is a pre-requisite to assessing the longitudinal effects of SES on these 
outcomes. 
 
3. Previous studies of differential effects by SES in the US or elsewhere have 
almost exclusively focussed on the paediatric population, and little is known 
about the effects of SES on outcomes in the adult CF population after the age 
of 20 years. As people are living longer with CF, understanding the effects of 
SES on the adult population is increasingly important. 
 
4. No previous studies have used a validated, small-area based measure of social 
deprivation. The studies using ecological measures in the US are limited by 
the large number of individuals linked to each zip code, relative to measures 
available in the UK, such as the Index of Multiple Deprivation (IMD). 
 
5. Given the increasing availability of high quality longitudinal CF registries, 
with repeated measures on individuals over time, modern longitudinal data 
analysis techniques appear to be under-utilised. Cross-sectional analyses have 
been favoured in some studies to characterise age related changes in CF 
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outcomes by SES, and this is particularly the case for use of CF related 
treatments, which have not been characterised longitudinally.  
 
6. Previous studies have not been informed by a theoretical perspective, or 
model for understanding pathways to health inequalities. Perhaps as a result 
of this, current studies in CF have focussed on health outcomes, and how 
these differ by SES. There is a knowledge gap around the differential social 
consequences of CF, by SES, especially with regard to the employment 
consequences. 
 
7. Little is known about the intermediate factors that may mediate any effects of 
SES on CF outcomes. Health care, as a mediator, has been studied in the US, 
but not elsewhere. There are significant gaps regarding behavioural, 
psychosocial and environmental risk factors that may mediate any SES 
related effects on CF outcomes. 
 
8. Little is known about the effect of newborn screening for CF in the UK, and 
whether this may have any differential effects by SES. 
 
This thesis seeks to address some of these gaps in the literature using CF registry 
data from the UK and Denmark. 
 
Summary 
Conceptually, CF is an interesting case for the study of pathways to inequalities in 
health: as a disease of autosomal recessive inheritance where carriers are unaffected, 
a socio-economic bias in disease prevalence is not expected (Schechter et al., 2001, 
O'Connor et al., 2003), but there is potential for the development of a social gradient 
in health care use, disease outcome and consequences.  
The studies described here set out to make an important contribution to this 
developing agenda around health inequalities. They investigate the mechanisms by 
which inequalities in health and social outcomes are manifested in CF. The 
distribution of CF is not socially determined, and any differential outcomes are likely 
to be the result of the complex interaction of genetic, socio-environmental and health 
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care factors during childhood and over the life course. The studies aim to improve 
our understanding of how influences in early life, and the health system in the UK 
mitigate or contribute to differential outcomes in health and employment outcomes 
in CF. The studies also set out to generate an in-depth longitudinal description of the 
health, health care and social outcomes for people with CF, thus contributing to our 
understanding of the clinical and social epidemiology of CF. The UK study in this 
thesis scrutinises the degree to which equity of service delivery is achieved for key 
elements of CF care in the NHS, whereas the Danish study offers the opportunity to 
analyse a unique longitudinal dataset. In addition to developing methodological 
approaches, and building research capacity around health inequalities, the findings 
from this thesis are likely to be relevant to other conditions, and will inform policies 
to improve patient care more generally within the NHS. 
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Chapter 3: Methods 
 
I begin by describing the data sources for the studies in this thesis: the UK CF 
registry, the sources of social deprivation data in the UK, and the Danish CF registry. 
I will outline the criteria for extracting the analysis datasets in the UK and Danish 
studies, along with a description of the size and shape of the final longitudinal 
datasets. I then move on to a general discussion of longitudinal data analysis 
techniques, before focussing on the specific methods used in each of the studies. 
 
UK CF registry 
The UK CF Registry is the data source for Studies 1 (clinical and treatment 
outcomes) and 2 (employment outcomes) in this thesis. The Registry is supported 
and co-ordinated by the UK CF Trust (Adler et al., 2008, CF Trust, 2013a), and 
records information about the health and treatment of patients from diagnosis 
onwards. Over 50 British CF specialist centres routinely collect data in a 
standardized fashion. Patients attending the British centres are seen in the outpatient 
clinic for a comprehensive annual review, including evaluation of clinical status, 
pulmonary function, microbiology of lower respiratory tract secretions, and use of 
major CF related therapies. The Registry is estimated to include nearly all people 
with CF in the UK population (Mehta et al., 2004) and is therefore ideally suited to 
the study of outcomes and treatments across the whole socio-economic spectrum in 
the UK society.  
The registry data have been used previously in a number of epidemiological studies 
in CF (Adler et al., 2008, Chamnan et al., 2010), but have not been analysed 
longitudinally before. The data source utilised in this study contains data collected 
between 1996 and 2010, and has been through rigorous quality control by data 
managers at the CF Trust, and external consultants at Imperial College, London, who 
prepare the annual review reports (CF Trust, 2013a). This includes regular 
monitoring visits to the CF centres to ensure that data entry staff are given training 
and support; checking of data entries to ensure accuracy; random review of sets of 
patients’  notes;;  screening for removal of duplicates, and tracking of patent transition 
from paediatric to adult centres (CF Trust, 2013b). Deaths were verified by checking 
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with ONS. Data were collected from all UK centres from 1999 onwards, and in 
2000, the dataset was estimated to contain biographical information on over 92% of 
the estimated UK CF population (Mehta et al., 2004), and registrations have 
increased year on year subsequently. Furthermore the CF Trust have written to every 
paediatrician and adult chest physician in the UK to obtain data on CF patients, and 
on this basis the estimated coverage is above 99% (CF Trust, 2013b). 
The UK registry started as the UK CF Database, which was established at the 
University of Dundee, Scotland in 1995. Initially data were collected from 56 
paediatric and adult CF clinics, using standardised forms, and validated through a 
system of double data entry, range checking, and error correction (Mehta et al., 
2004). Between 2005 and 2007 the data collection system changed from a paper 
based return system to utilise the online ‘PortCF’ software used in the US registry. 
During this transfer there was extensive retrospective data cleaning and checking, 
undertaken by independent contractors. At this point, full postcode data were 
collected for each patient, whereas previously this had been sporadically collected. 
The UK CF Registry and its current software programme, PortCF, are now in its fifth 
year with the production of five annual reports (CF Trust, 2013a). Data are collected 
in over 200 fields. The number of patients for whom a ‘complete’ data set, defined as 
the data required to produce the range of clinical outcomes presented in the annual 
reports, was recorded at 82% in 2009, and this has increased year on year (CF Trust, 
2013a), with the figure up to 89% for the latest annual report for 2011 (CF Trust, 
2013a). The coverage for core variables such as weight and %FEV1, used in the 
analysis in this thesis is higher, and almost all of the people fulfilling the study 
inclusion criteria had data in these fields (Figure 8). However, for other variables not 
routinely summarised in the annual report, the data coverage can be poor. For 
instance, Port CF contains a field asking about parental education level, but this was 
completed in less than 5% of individuals. 
Ethics 
NHS research ethics approval (Huntingdon Research Ethics Committee 07/Q0104/2, 
available on request) has been granted for the collection of data into the UK 
database. Each patient provided written informed consent for collection of data in the 
registry, and for use of anonymised data in research. The CF Trust database 
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committee approved the use of anonymised data in this study, under the terms of the 
NHS ethics approval (see letter of support from CF Trust in appendix 3). 
Entry criteria 
I undertook a longitudinal retrospective cohort study of individuals in the UK CF 
registry under the age of 40 at last follow-up, with at least one outcome measurement 
of interest and a valid postal code between 1996 and 2010. The age range for 
inclusion in the analysis varies between the two studies. For instance, the analyses in 
Study 1 (clinical and treatment outcomes analyses) are stratified into people <18 
(‘paediatric’ analysis), and the adult population (>=18 and <40 years). However, 
%FEV1 can only be recorded from around age five onwards, so the analysis for 
%FEV1 spans the >5 to <18 age range for the paediatric analysis. For the analysis of 
employment outcomes I selected ages >20, on the basis that most individuals will 
have left the education system at this point. Only a small proportion of the data relate 
to people aged over 40 (5% of the annual reviews). Including these data extends the 
age range for the analysis up to 78 years of age, and this was excluded for 
consideration in future analyses. 
Primary outcomes and covariates 
At annual review, data were collected across the full range of fields in the PortCF 
system. Appendix 3 contains screenshots from the data entry screens, as viewed by 
clinicians and members of the MDT as they enter the data. From this dataset, pre-
specified primary outcomes and co-variates were selected, informed by the literature 
review. 
Study 1 
The primary clinical outcomes were weight, height, BMI, %FEV1 and chronic 
Pseudomonas colonisation prevalence. Anthropometric values were converted into 
standard deviation scores using the UK reference population (Pan and Cole, 2002). 
Pulmonary function tests were performed according to international 
recommendations (Miller et al., 2005), measuring FEV1, expressed as a percentage 
of predicted values for sex and height using reference equations from Wang or 
Hankinson (Wang et al., 1993, Hankinson et al., 1999). 
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The primary health care outcomes were use of therapies in the previous year (yes or 
no): IV antibiotics; supplemental nutritional support; DNase; and inhaled antibiotic 
therapy. Conditional on the use of any IV therapy, I also used the log total number of 
days on IV therapy as an outcome. Supplemental nutritional support included 
patients receiving nutritional supplements orally, by nasogastric tube, gastrostomy 
tube, jejunal tube, or total parenteral nutrition (TPN). Any inhaled antibiotic therapy 
included Tobramycin solution for inhalation, other inhaled aminoglycoside, Colistin 
and Promixin. 
Study 2 
The primary outcome was any employment in the preceding year (yes or no), which 
included people recorded as being in either full or part-time employment at annual 
review. 
The primary exposure measure of interest in both of the studies was a small-area-
based measure of deprivation of area of residence, described in the next section. 
Postcodes were used to derive IMD scores for the constituent UK countries, 
facilitated using the online GeoConvert application (GeoConvert, 2011). Each person 
was allocated to a deprivation score on the basis of the first recorded postcode on 
entry to the dataset. Other baseline covariates in the analyses included: sex; genotype 
coded as the number of delta F508 alleles (0, 1 or 2); year of birth; screening status 
(diagnosis by neonatal screening or otherwise) and ethnicity (Caucasian or 
otherwise). Time varying covariates included age, presence of CF related diabetes 
(CFRD) and pancreatic insufficiency (PI), determined by use of pancreatic enzyme 
supplementation. In the health care use and employment analyses, when it was 
necessary to make adjustment for disease severity, this was done on the basis of 
current %FEV1, body mass index (BMI) standard deviation (SD) score, and P. 
aeruginosa status where appropriate. 
Description of analysis dataset 
For the purposes of understanding the structure of the data, we consider the final 
dataset for the weight analysis here, since this is the most commonly collected 
outcome in the dataset, collected at 49,337 annual reviews on 8055 patients between 
1996 up to 2010 in the UK. The flowchart below (Figure 8) shows the number of 
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participants included in the analysis, after application of the eligibility criteria. An 
age based cut off is used to stratify the analysis. People with data straddling 18 years 
of age can thus contribute to both analyses. 
 
Figure 8: Flowchart of included participants for weight analysis 
 
 
Sixty six percent of individuals had five or more follow up measures (Figure 9), with 
a mean number of follow-up measures of 6.1 (SD 3.3), and total of 48,425 person-
years of follow up. The number of reviews per year increases up to year 2000, and 
stabilises subsequently, with a slight dip during the process of transfer over to 
PortCF. 
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Figure 9: Data follow-up in the population aged <40 years 
 
Figure 10 illustrates the distribution of year of birth for people included in the 
analysis. This illustrates the left censoring in the dataset. The prevalent population 
captured in the dataset in 1999 onwards, when there was complete UK coverage, 
represents selected individuals from earlier birth cohorts who have survived to that 
point. 2066 incident cases are captured subsequently, with birthdates in 1999 and 
beyond. 
Figure 10: Year of birth for people included in the weight analysis 1996 to 
<2010 
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Source and extraction of UK SES data 
In 2004 all CF centres were asked to collect full postcodes on patients attending for 
annual review. Completion of the postcode field is mandatory in PortCF and thus 
coverage of postcode has improved since the switch over to the web based interface. 
The postcodes were used to link individuals to small area deprivation measures in the 
UK. 
The datasets can be retrieved at the websites listed below, with the exception of the 
English dataset which is no longer available via the archived website:  
 
 English IMD 2007: 
http://webarchive.nationalarchives.gov.uk/+/http:/www.communities.gov.uk/
communities/neighbourhoodrenewal/deprivation/deprivation07/ (accessed 
26th March 2013). Technical appendix via same site. 
 
 Scottish IMD 2009: 
http://www.scotland.gov.uk/Topics/Statistics/SIMD/background2simd2009 
(accessed 26th March 2013). Technical appendix: 
http://www.scotland.gov.uk/Topics/Statistics/SIMD/simd2009technical 
(accessed 26th March 2013) 
 
 Northern Ireland IMD 2010 
http://www.nisra.gov.uk/deprivation/nimdm_2010.htm (accessed 26th March 
2013). Technical appendix: 
http://www.nisra.gov.uk/deprivation/archive/Updateof2005Measures/NIMD
M_2010_Report.pdf (accessed 26th March 2013) 
 
 Welsh IMD 2008 (revised 29/3/2011) 
https://statswales.wales.gov.uk/Catalogue/Community-Safety-and-Social-
Inclusion/Welsh-Index-of-Multiple-Deprivation/WIMD-2008 (accessed 26th 
March 2013). Technical appendix: 
http://wales.gov.uk/topics/statistics/publications/publication-
archive/wimd2008tech/?lang=en (accessed 26th March 2013) 
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The IMD scores for the UK are based on a methodology developed by the Social 
Disadvantage Research Centre at the University of Oxford, and separate indices have 
been constructed for England, Northern Ireland, Scotland and Wales (Noble et al., 
2006). Indices of multiple deprivation combine economic, social and housing 
indicators measured at the census into a composite deprivation score for small areas 
in the UK constituent countries (ONS, 2011a). The indices are based on domains, 
calculated from census indicators, which are then weighted and combined to create 
the overall score for each country (Table 2). There were 41,773 of these small areas 
in the UK, containing on average 1400 people (range 500-3700). 
The IMDs in the UK are widely used as measures of SES in epidemiological studies 
(Semple et al., 2011, Taylor-Robinson et al., 2011, Bergen et al., 2012) and are 
recommended for tracking health inequalities in UK government statistics (DH, 
2012b). The IMD methodology allows much finer resolution than analyses using ZIP 
codes in the USA, which contain on average 30,000 people (Krieger et al., 2002). I 
used the postcode first recorded at entry to the dataset to link an individual to an 
IMD score, in order to generate a fixed measure of area deprivation.  
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Table 2: Domains and weights used to generate IMD scores for UK constituent 
countries 
Domain England 
(N= 32482) 
Northern 
Ireland 
(N=890) 
Scotland 
(N=6505) 
Wales 
(N=1896) 
Income 22.5 25 28 23.5 
Employment 22.5 25 28 23.5 
Health 13.5 15 14 14 
Education 13.5 15 14 14 
Barriers to housing and 
services 
9.3 - - - 
Proximity to services - 10 - - 
Geographic access - - 9 10 
Housing - - 2 5 
Living environment 9.3 5 - - 
Physical environment - - - - 
Crime 9.3 5 5 5 
Adapted from ONS 2011 (ONS, 2011a) 
 
Although based on the same concept and general methodology, there are differences 
between countries in the weighting of the domains, the indicators used to generate 
the domains, the spatial scale at which the indices are calculated and the time points 
on which they are based (Noble et al., 2008). For instance the number of indicators 
used to construct each domain varies between countries, with Scotland using 37 
indicators, compared to 52 in Northern Ireland. Furthermore, the small areas on 
which the variables are derived are of similar size in England, Wales and Northern 
Ireland (approximately 1500 people), but are smaller in Scotland (approximately 750 
people) (ONS, 2011a). However, Figure 11 (top left panel) shows that the 
distribution of deprivation scores in the four countries is very similar. 
Since the composition of the deprivation scores for the UK constituent countries 
differs slightly, and following the advice of Peter Goldblatt, I explored standardising 
the IMD scores (subtracting the within-country mean, and dividing by the within-
country standard deviation), in order to generate more directly comparable measures. 
The distributions of the raw and standardised scores for the whole population, and 
the CF population of each country are shown in Figure 11. 
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Figure 11: Density plot comparing distributions of deprivation scores  
The top row shows the whole populations (England in black, Scotland in blue, 
Northern Ireland in green and Wales in red), raw scores and standardised. The 
bottom row shows the CF populations. 
 
 
All of these small areas were then ranked on the basis of the continuous deprivation 
SD (or Z score), and then  divided  into  fifths,  or  ‘quintiles’,  providing  the  following  
approximate cut-off points for normative deprivation quintiles. When comparing the 
results using this procedure, to those generated using unstandardized raw deprivation 
scores, this made little substantive difference, and the distributions were almost 
identical. Furthermore the distribution of IMD scores was indistinguishable on a 
cumulative density plot for the UK population, and the UK CF population (Figure 
12). For ease of interpretation, raw deprivation scores were used in the final analysis, 
using quintile cut-off points as follows: <8.31; 8.32 to 13.81; 13.82 to 21.20; 21.21 
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to 34.11, >34.11. For instance, the small area (lower super output area) linked to the 
postcode where I live has a deprivation score of 16.1, placing me in the middle 
deprivation quintile, in terms of deprivation of area of residence. 
Figure 12: Cumulative density plot comparing deprivation score distribution 
for the whole UK population versus the CF population 
 
 
In the analysis, although IMD is measured on a continuous scale, for descriptive 
summaries I have followed the common practice of grouping IMD into quintiles. 
However, reducing IMD to a categorical variable loses information, and also leads to 
models that are difficult to interpret, especially when this five-level categorical 
variable interacts with non-linear time effects. Thus for the analyses in the studies of 
clinical outcomes, and treatments, I retained IMD as a continuous variable, and the 
fitted beta coefficients for IMD score were then used to summarise the effect of 
deprivation by comparing a person in the mid-point of the most deprived quintile to 
one in the mid-point of the least deprived quintile.  
Danish dataset 
CF care in Denmark is delivered through two centres in Copenhagen and Aarhus. 
The Danish CF Patient Registry is one of the longest running CF registers. It is 
estimated that coverage of people with CF resident in Denmark is almost complete 
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from 1990 onwards, when CF care was centralised. This coverage and the 
unparalleled frequency of measurement (monthly) make this a unique dataset for 
epidemiological research (Taylor-Robinson et al., 2012a).  
The registry started in Copenhagen in 1989 and initially captured all patients alive in 
1989 under the care of the Copenhagen centre (around 300 patients), with individual 
lung function measures recorded monthly, some going back as far as the late 1960s. 
From 2001 the Copenhagen registry was merged with data from the Aarhus centre 
(around 150 patients), and thus achieved a full record of the whole of the Danish CF 
population (personal communication, Dr Tania Pressler). The register is administered 
in the Rigshospitalet in Copenhagen (Dr Tania Pressler), and Aarhus University 
Hospital Skejby (Professor Oluf Schiotz and Hanne Verbert Olesen) (Figure 13). 
Figure 13: Map of Denmark showing location of CF centres 
 
Source: http://www.mapsopensource.com/denmark-map.html 
At the outset my intention was to analyse data from the Danish CF register, using 
similar approaches to those used to analyse the UK data, but utilising the individual 
level SES data available in Denmark, particularly measures of parental education. 
Data linkage to social registers in Denmark, facilitated through Statistics Denmark 
on the basis of a unique identifier for everyone in the population, allows access to 
richer individual level socio-economic data than is available to epidemiologists in the 
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UK, on both patients and their parents. These linked data extend retrospectively to 
1981 and contains information on employment, income, healthcare expenditure, 
hospitalisations, and receipt of welfare benefits (Rasmussen et al., 2006, Carlsen et 
al., 2007, Rasmussen et al., 2007, Carlsen et al., 2008a, Carlsen et al., 2008b). 
However, due to the very frequent monthly follow-up of CF patients in Denmark, it 
was necessary to develop a new approach to analysing the Danish dataset, and thus 
the focus of the analysis presented in this thesis is around the methodological 
challenges of modelling lung function decline in the Danish population. Research on 
the effect of SES on CF outcomes in Denmark is on-going. 
Ethics 
The study using the Danish data was approved by the Danish Data inspectorate –
Datatilsynet (see appendix 3). 
Entry criteria 
All patients aged over five contributing %FEV1 data in the Danish CF database 
between 1969 and <2011 were eligible. Entry to the registry was contingent upon a 
diagnosis of CF made upon the basis of either two known CF-causing mutations in 
the CFTR gene, and/or two positive sweat-tests together with symptoms compatible 
with the disease. Post-transplant data from patients who had received a lung 
transplant were excluded.  
Primary outcomes and covariates 
Patients attending the two Danish CF centres (Copenhagen and Aarhus) are seen 
routinely every month in the outpatient clinic, for evaluation of clinical status, 
pulmonary function, and microbiology of lower respiratory tract secretions. The 
primary outcome for the analysis in this thesis is %FEV1. Pulmonary function tests 
were performed according to international recommendations (Miller et al., 2005), 
measuring forced expiratory volume in one second, expressed as a percentage of 
predicted values for sex and height using reference equations from Wang or 
Hankinson (Wang et al., 1993, Hankinson et al., 1999). Covariates in the analysis 
were: age; sex; genotype coded as the number of delta F508 alleles (0, 1 or 2); onset 
of chronic Pseudomonas infection (coded 0 or 1 as a time-varying covariate); PI 
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determined on the basis of pancreatic enzyme usage (coded 0 or 1 as a baseline 
covariate); birth cohort (six 10-year cohorts starting at 1948); and CFRD diagnosed 
using the WHO criteria (coded 0 or 1 as a time-varying covariate). 
Description of analysis dataset 
The dataset for the final analysis contains 70,448 lung function measures on 479 
patients seen between 1969 and 2010 in Denmark. The median number of %FEV1 
measures per person was 101 (range 2 to 597). Figure 14 is a histogram of year of 
birth for the people in the dataset. There is evidence of selective recruitment to the 
dataset in the earlier cohorts. 
Figure 14: Histogram of year of birth for Danish dataset 
 
The median follow-up period was 10.5 years (range 0.1 to 31.5), with a total of 6500 
person-years of follow up. 42 patients were followed up for more than 30 years. 
Figure 15 shows the frequency and length of follow up for people in the Danish 
dataset. 
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Figure 15: Histogram of frequency and duration of follow up  
 
 
Contrasting UK and Danish datasets 
The dataset for the UK weight analysis contains 49,337 measures on 8055 people 
with CF between 1996 and <2010, whereas the dataset for the Danish analysis 
contains 70,448 measures on 479 people between 1969 and <2011. The UK dataset 
thus contains short data traces, on many individuals, whereas the Danish dataset 
contains long data traces on a smaller number of individuals. Without any further 
analysis, these different data structures suggest that the UK dataset is likely to be 
better powered to identify cross-sectional differences between sub-populations, since 
there are more individuals in the analysis. However, the very long data-traces in the 
Danish dataset make it particularly suited to tracking changes in individuals over 
time. The spaghetti plots below illustrate randomly selected individual %FEV1 traces 
from the UK and Danish datasets (Figure 16, Figure 17). 
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Figure 16: Twenty randomly selected %FEV1 profiles from the UK CF registry 
for people aged<20 
 
 
 
 
 
Figure 17: Five randomly selected %FEV1 profiles from the Danish registry 
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Statistical methods 
In the studies in this thesis I use generalized linear mixed models for the analysis of 
repeated measurements over time. These methods allow examination of association 
between important binary and continuous CF outcomes and SES whilst allowing for 
correlation within patients, trends over time and missing values (Diggle et al., 2002). 
This section begins with an overview of some of the general features of longitudinal 
data, and a description of common approaches to analysis, before describing in detail 
the specific methods used in the studies. 
Longitudinal data 
Longitudinal data is ubiquitous in the biomedical sciences, but the statistical tools for 
analysing such data were limited, prior to the rapid development of methods, and 
widely available computing power since the 1980s. Despite this, the application of 
these modern data analysis techniques in the medical sciences, public health and 
epidemiology has tended to lag behind the statistical innovation, and studies have 
often used statistical techniques that fail to adequately take account of longitudinal 
study designs (Fitzmaurice and Ravichandran, 2008). As illustrated in Figure 18, it is 
only relatively recently that the use of longitudinal studies has really taken off. 
Figure 18: PubMed results  containing  “longitudinal”  by  year,  1960-2012 
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Characteristics of longitudinal data 
A longitudinal study is one in which measurements are collected repeatedly over 
time on each subject in the study. The raison-d’être for such analyses is typically to 
characterize the changes in the response of interest over time. The subject in the case 
of the studies in this thesis is an individual with CF. 
There are a number of general features of longitudinal data, which add richness to 
the types of analysis that can be undertaken but also increase complexity. Correlation 
of measures within individuals is the key feature that sets longitudinal studies aside 
from cross-sectional approaches. In longitudinal studies, we generally assume 
independence of subjects, but we cannot assume that repeated measures on the same 
subject are independent. Since most biological processes are not completely random, 
knowledge of the value of a response on one occasion provides information about the 
likely value of the response on a future occasion. For example, how one is feeling at 
a particular moment, is generally informative as to how one will be feeling a few 
hours hence, and generally measurements closer in time within an individual are 
likely to be more similar than those farther apart in time. Without this correlation 
between values, there can be no forward prediction, but this correlation between 
individuals needs to be modelled appropriately in order to make correct inferences 
from the data (Singer and Willett, 2003, Twisk, 2003). 
The average profile of change over time for a population can be complex, and 
individuals may exhibit considerable variability, which can change over time, so that 
the variance of the response changes over the duration of the study. Coupled with the 
correlation between individuals, these features violate the fundamental assumptions 
of independence and homogeneity of variance that are the basis of many cross-
sectional analysis approaches, such as multiple regression, or t-tests (Fitzmaurice and 
Ravichandran, 2008). Furthermore the data themselves may be collected in an 
‘unbalanced’ fashion, at unequally spaced intervals, and contain missing values. This 
is often the case even if the study design was intended to collect data in a balanced 
fashion, due to the practical difficulties of real-life follow up of large numbers of 
individuals over time, since there will almost always be people who miss their 
scheduled visit or date of observation. In the UK CF registry, for example, follow up 
is nominally on an annual basis, but the data are unevenly spaced, with different 
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follow-up times for individuals throughout the year. Missing data, considered in 
more detail later on, are a ubiquitous problem in longitudinal studies, and there are 
various approaches to addressing the issues raised by missing data. For example, 
complete case analysis is a common and simple method for handling incomplete 
data, whereby individuals with incomplete datasets are excluded from the analysis. 
However, this approach can not only be inefficient, but may also introduce bias, 
when the individuals who are excluded are not a random sample from the target 
population (Altman and Bland, 2007). Some of the earlier methods for analysing 
longitudinal data, such as multivariate analysis of variance for repeated measures 
(MANOVA) are restricted to datasets with the same, complete follow-up protocol for 
each subject. This requirement for fixed number of repeated measurements on all 
study participants at a set of common time points essentially meant shoe-horning the 
data to fit the analysis strategy, and making unrealistic assumptions (Weiss, 2005). 
Modern techniques have now eclipsed these approaches, by dealing with unbalanced 
follow-up protocols and missing data in a more sophisticated manner, with less 
stringent assumptions. 
Advantages of longitudinal data analysis 
In observational longitudinal studies, a measure on an individual at a particular time-
point can be influenced by age (time from birth), period effects (the date), and birth 
cohort effects (characteristics experienced by individuals born at a particular time 
(Twisk, 2003). Knowing two of these measures defines the third: one’s   age today 
and birthdate define the date today. Longitudinal studies allow one to separate these 
effects: age related processes within subjects (time-trends), from cross-sectional 
effects between subjects (cohort effects), whereas in cross-sectional analyses these 
are conflated (Diggle et al., 2002). In the case of CF, the literature review has 
highlighted the significant cohort effect, whereby the health of people with CF has 
improved incrementally over time (Dodge et al., 2007, Buzzetti et al., 2009). This 
process needs to be separated from the age-related trend in the opposite direction 
towards decreasing health over time; only longitudinal designs allow this. 
As argued in the previous chapter, this thesis aims to explore the consequences of 
SES on outcomes in CF, which is a disease that we hypothesise does not discriminate 
by SES in terms of incidence. In order to study these effects from a life course 
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perspective, considering the evolution of outcomes within groups of individuals over 
time, then longitudinal data are required. A longitudinal approach is essential to 
establish the direction of causation, and temporal ordering of influences over the life-
course (Kuh et al., 2004). Longitudinal data are also required to unpick mechanisms 
of social selection, versus those of health selection, described in the previous chapter. 
A major limitation of cross-sectional analyses, therefore, is that they do not allow 
conclusions about the direction of causality, because data are only collected at one 
point in time. In a cross-sectional study of lung function in adults with CF, for 
instance, if one observes a relationship with SES, it is not possible to determine if 
low SES has resulted in poor lung function, or vice versa. Schechter et al undertook a 
cross sectional analysis of the age related changes in lung function in population at 
different ages (Schechter et al., 2001). In this analysis, lung function measures at 
different time periods are pooled together, conflating age related changes, cohort 
effects, and dropout effects. Therefore this does not directly address the effect of 
ageing   on   a   particular   individual’s   lung   function, which requires the collection of 
data over time (Nakai and Ke, 2009). 
Longitudinal studies allow one to assess the influence of covariates on both average 
responses, and rates of change of response over time in subjects, and open up the 
possibility of prediction. In the studies here we are particularly interested in 
exploring average differences in outcomes and time-trends between groups of 
individuals on the basis of their SES. Longitudinal studies allow one to separate 
these trends over time within individuals from cross-sectional differences among 
individuals. In this respect each person in the study can be thought of as serving as 
her or his own control, and the influence of hidden or unobserved factors on the same 
person is cancelled out over time, allowing for quantification of the effect of ageing 
on outcomes of interest. 
Simple methods of longitudinal data analysis 
Approaches such as analysis of variance (ANOVA), ANOVA for repeated 
measurements, and derived variables methods are well described, and are technically 
simple to apply, in that no advanced computation is required (Diggle et al., 2002). 
They are mentioned here only briefly, since they are not used in this thesis.  
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Considering a continuous outcome, time-by-time ANOVA, involves undertaking a 
separate analysis at each particular time point, and thus assumes a common follow-
up protocol for each individual in the study. Similarly, if one was interested in 
comparing the mean response over time between two groups, one could undertake 
repeated t-tests at successive common time points. These approaches are simple, but 
lead to multiple inferences over time that are not independent, and thus cannot be 
easily combined (Diggle et al., 2002). Furthermore they fail to make use of the 
efficiency gains that are achieved by explicitly modelling the covariance structure. In 
repeated measures ANOVA, the population mean over time is modelled as a function 
of group, time, and group-by-time interaction effects, with time treated as a 
categorical factor in the analysis. Again this requires a complete, and common 
follow-up protocol for each individual, which is a major drawback. It assumes a 
constant correlation between repeated measures on an individual, regardless of the 
time-interval between observations. These approaches are not suited to assessing the 
effects of multiple covariates on outcomes, nor can they provide information about 
individual level change over time (Twisk, 2003, Fitzmaurice and Ravichandran, 
2008). 
Another simple way of analysing a longitudinal dataset is to derive summary 
variables for each individual, and thus reduce the problem to a cross-sectional one. 
For example, a continuous outcome trajectory over time for an individual might be 
modelled as a straight line in the simplest case, and summarised as an intercept 
value, and a slope.  
These derived variables can then be treated as separate outcome measures in a cross-
sectional regression analysis in order to assess the effect of baseline covariates. This 
approach assumes that an individual data profile can be summarised in a way that 
addresses the hypothesis in question, which is not always the case. Furthermore, it 
becomes invalid if there is missing data, or different numbers of follow-up measures, 
because the assumption of common variance for all observations is no longer 
satisfied. Methods have been proposed to weight the analysis, with data from each 
subject used to determine the weights (Matthews, 1993), but others have cautioned 
against this because it ignores the correlation structure of the underlying data (Diggle 
et al., 2002). 
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These ‘simple’ approaches to longitudinal data analysis (LDA) only estimate and 
compare the group means. They are not informative about individual level change. 
They have now been made somewhat redundant by the modern LDA approaches 
described below which can be readily implemented in software packages, and are not 
limited to balanced data, with largely compete follow-up.  
Modern longitudinal data analysis methods 
These methods are all forms of a generalized linear model (GLM) for longitudinal 
data and can be categorized into three groups: marginal, random effects, and 
transition models (Diggle et al., 2002). These approaches can be applied to linear, 
binary and ordinal outcome measures, by using the appropriate link function – the 
function that links predictors to outcomes. For example a binary outcome can be 
transformed using the logit link, and then modelled as a GLM (Weiss, 2005).  
To account for the features of longitudinal data described above, these models have 
two main components; a model that describes the effects of covariates on the mean 
response over time coupled with a model for the covariance among repeated 
measures (Fitzmaurice and Ravichandran, 2008). Which modelling option one 
chooses is partly determined by the hypothesis in question. Often the main focus of 
interest is in understanding factors that influence the mean response over time, but 
the inferences made here are dependent on choosing a robust model to take into 
account the covariance structure. By contrast, understanding the covariance structure 
itself may be the target of scientific interest, as in the study of lung function decline 
using the Danish dataset in this thesis (Taylor-Robinson et al., 2012a). In this study I 
develop a parametric model for the covariance structure of %FEV1 measures over 
time, which provides a description of how lung function changes within an 
individual with CF over time, and quantifies the predictive value of a baseline lung 
function measure for subsequent measures over time. 
Marginal, or population-averaged approaches to LDA are suitable when the 
hypothesis of interest relates to differences between groups or sub-populations that 
share common variables. In these models, the marginal expectation (sub-population 
average) is the primary focus, and the correlation is treated as a nuisance factor. 
Generalized estimating equations (GEEs), introduced by Liang and Zeger (Liang and 
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Zeger, 1986), represent a popular marginal approach to LDA, where the basic 
premise is that one is primarily interested in the regression parameter for the mean 
response, and not the variance-covariance matrix of the repeated measures. In GEE a 
‘working’ correlation structure is assumed, which ideally should be consistent with 
the structure of the data, since an incorrect choice of correlation structure reduces 
efficiency (Nakai and Ke, 2009). However, with large samples, this becomes less 
important, and the GEE approach becomes robust to mis-specification of the working 
correlation structure (Diggle et al., 2002). In practice, this means one can focus on 
the model for the marginal mean, and then try different correlation structures whilst 
checking that the parameter estimates and standard errors remain broadly consistent. 
Mixed- or random-effects models are used in the studies in this thesis, and are 
described in further detail with full statistical notation in a subsequent section. The 
primary contrast with marginal approaches is that random-effects models allow 
inference at the individual level (Diggle et al., 2002). These models focus on the 
regression relationship between outcomes and covariates for an individual, by 
incorporating two distinct components: A fixed-effect component, which describes 
covariate effects that are assumed to be identical for each subject, and thus common 
across the population; and a random-effects component, that extends the model to 
multiple individuals, by allowing each individual to vary from the population 
average in a prescribed manner. This heterogeneity between individuals reflects 
natural variability due to unmeasured factors that are not captured in the fixed-
effects. The fixed-effects in the model are estimated as discrete parameters, whereas 
the random-effects are drawn from a probability distribution, the characteristics of 
which are estimated in the model. Measurements on the same individual share the 
random-effects for that individual. The model also contains an error term, and 
together with the assumptions made about the random-effects this determines the 
correlation structure in the model (Diggle et al., 2002, Singer and Willett, 2003, 
Twisk, 2003, Weiss, 2005).  
Transition or Markov models appear to be less commonly used in epidemiology. In 
brief, these models incorporate lagged effects, whereby correlation exists because 
past outcome values explicitly influence the present observation. Thus the covariates 
and previous outcomes are included in the model as predictors for the current 
 87 
outcome. These models are suitable when you believe that the distribution of the 
current measurement depends directly on earlier measurements (Diggle et al., 2002).  
Exploratory methods 
Longitudinal data analysis, like other statistical analyses, begins with exploration of 
the data before moving on to confirmatory analysis. A key step is to visualise 
patterns in the data that are relevant to the hypotheses in question.  
For the analysis of continuous outcomes (e.g. weight, height, BMI, %FEV1, IV days 
in this thesis), the first step is to plot a basic scatterplot of the data for all individuals 
against time. We can then add lines to connect repeated measurements on 
individuals, to generate a so-called spaghetti plot (Figure 19). This becomes very 
overcrowded in a dataset with over 8000 individuals, so a common approach is to 
randomly select a subset of the data, thus thinning out an otherwise very large 
dataset. These plots can be further augmented by the addition of a smoothed cross-
sectional mean, which can be generated using a kernel smoother, more details of 
which are outlined below (Diggle et al., 2002). All of these features can be seen in 
Figure 19, which provides an initial exploratory analysis of lung function decline in 
the paediatric CF population in the UK.  
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Figure 19: Spaghetti plot for %FEV1 versus age illustrating the longitudinal 
nature of the data. 
Each dot represents a %FEV1 measure on a person in the dataset. The smoothed 
population average is shown in the red, and randomly selected individual 
trajectories are in black.  
 
 
This demonstrates the unbalanced nature of follow up for individuals in the dataset, 
with patients entering the analysis at different ages, and being followed up for 
different time periods. Overall one can visualise the age related decline in lung 
function, seen in both the scatterplot element of the figure, and then captured by the 
smoother mean in red. Plots of this kind thus allow one to determine the provisional 
model mean trajectory, which in the case of %FEV1 in the UK paediatric analysis is 
modelled as a straight line, whereas more complicated mean responses are necessary 
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for other outcomes, such as piecewise or broken-stick functions for weight and BMI. 
However, individuals deviate markedly from the smoothed mean: There are clear 
cross-sectional differences between individuals; and differences in the rate of decline 
of %FEV1 over time.  
Following exploratory analysis, I move on to fitting mixed-effects models to the 
data, the specific details of which are described in the next section. 
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Random-effects models 
Repeated measures on individuals are correlated, and this must be accommodated to 
obtain valid inferences. To analyse the continuous-valued outcomes in the UK 
analysis (weight, height and FEV1) I used a linear mixed model (Diggle et al., 2002).  
Specifically, denoting by Yij the jth repeated measurement on the ith individual and tij 
the age at the time of measurement, I assumed that: 
 
  Yij = µij + Ui + Vitij + Zij (1) 
 
µij are the expectations of the Yij and are described by a multiple linear regression 
model, so the mean response is specified as a linear combination of explanatory 
variables, hence 
 
  (2) 
 
In (2), the xijk can be any measured values, whether time-constant or time-varying; 
for example, sex or age. Despite the model’s title, non-linear effects can also be 
captured. Polynominal time-trends can be defined by including powers of age 
amongst the xijk. Spline functions can be obtained by including both powers of age 
and indicator variables at selected time-points, called knots. For example, a model in 
which xij1 =age and xij2 = 0 for age less than 10, xij2 = age − 10 for age greater than 
10, defines a linear spline with a single knot, also called a split-line or broken-stick 
model, with a change in slope at age 10. 
In (1) the (Ui,Vi) pairs are subject-specific intercepts and slopes, modelled as zero-
mean bivariate Normally distributed random variables independently realised for 
different subjects, with means zero, variances  and  and correlation ρ, and the 
Zij are residuals modelled as mutually independent, Normally distributed random 
variables with mean zero and variance τ2. This special case of the linear mixed model 
implies that the variance of the Yij increases with age, t, as the quadratic function τ2 + 
 + t2. 
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A random intercept and slope model for %FEV1 for the UK paediatric population is 
illustrated in Figure 20 below. Here the population average trajectory μij is the thick 
black line, and is modelled as a linear combination of regression coefficients. The 
grey lines represent individual trajectories, with each individual having their own 
deviation from the population average intercept and slope (Ui,Vi). These intercepts 
and slopes are drawn from a Normal distribution, the characteristics of which are 
estimated from the model. 
Figure 20: Random intercept and slope model for %FEV1 decline 
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The standard random intercept and slope model approach assumes that any deviation 
of   an   individual’s   trajectory   from   the   population   mean   is   linear   in   time   over   the  
whole of the follow-up period apart from independent random errors. This 
assumption is reasonable over short time-periods, but over longer time-periods the 
assumption of quadratic variance inherent in the RIS model means that individual 
data traces can diverge unrealistically. The increasing variance over time can be 
visualised in Figure 20 above, as the grey lines diverge at older ages. Thus this 
approach was suitable for analysis of the UK data, characterised by many 
individuals, followed up over relatively short periods of time. However, for the 
Danish data, characterised by much longer follow-up periods, an extension of the 
RIS approach was required. 
Extending the random-intercept model 
To analyse the Danish data, I used a linear mixed-effects model with longitudinally 
structured correlation (Diggle et al., 2002, Fitzmaurice, 2004), but model random 
variation in %FEV1 over time within an individual subject so that the strength of the 
correlation of the random variation between two values depends on the 
corresponding time-separation. This allows a flexible specification of the mean 
response and incorporates three qualitatively different components of stochastic 
variation about the mean response (Diggle et al., 2002, Fitzmaurice, 2004). The 
model thus decomposes the overall random variation in the data into three key 
components: between subjects; between times within subjects; and measurement 
error.  
The approach follows a number of steps. Firstly, I fitted a provisional model for the 
mean response by ordinary least squares (OLS) and used the empirical variogram of 
the residuals to provide initial estimates for the three components of variation, and 
for the shape of the correlation function of the between-times-within-subjects 
component. I then re-estimated all of the model parameters by maximum likelihood 
estimation, and used generalized likelihood ratio statistics to compare nested models, 
and Wald statistics to test hypotheses about model parameters. I then assessed 
associations between single or multiple covariates and the population mean %FEV1 
over time, and explore. The technical details follow. 
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I used a linear mixed-effects model with longitudinally structured correlation. Let Yij 
denote the jth repeated measurement (here, %FEV1) on the ith patient, and write 
 
 Yij =μij +Rij (3) 
 
where μij is the mean, population-averaged, response and Rij is the stochastic 
variation about the mean response. The mean response is specified as a linear 
combination of explanatory variables as per (1) above. 
To complete the model-specification we decompose the stochastic term Rij in (3) into 
three components, hence 
 
 Rij = Ui + Wi(tij) + Zij (4) 
 
where tij is the jth measurement time for the ith patient and the three components of 
Rij are specified as follows. Firstly, Ui describes how the average lung function of the 
ith patient varies about the population-averaged response for all patients with the 
same values of the explanatory variables xijk, for example all males aged 20 years. 
The model assumes that the Ui are independent copies of a Normally distributed 
random variable with mean zero and variance ν2. Secondly, the stochastic process 
Wi(t) describes how the actual lung function of the ith patient varies over time. The 
model assumes that the Wi(t) are independent copies of a stationary Gaussian process 
with mean zero, variance σ2 and correlation function ρ(u)   =   Corr{Wi(t), Wi(t−u)}  
(Fitzmaurice, 2004). Typically, ρ(u) decays towards zero as u increases. In study 3, I 
used an exponential correlation function, ρ(u)  =  exp(−|u|/φ), in which the parameter 
φ describes the rate at which the correlation decays towards zero with increasing 
time-separation, u. The exponential correlation function is a special case of the 
Matérn family, which includes a second parameter that allows the correlation 
function ρ(u) to assume different shapes if the exponential model does not give a 
good fit (Matern, 1960). Thirdly, Zij describes how the imperfectly measured lung 
function of the ith patient at their jth measurement time, tij, differs from their 
underlying actual lung function, i.e. measurement error. In principle, the properties 
of the measurement error could be estimated directly by repeated measurement of 
%FEV1 within a single follow-up session. In practice, the Zij represent the sum of 
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two sources of variation: pure measurement error and within-patient variation in 
lung-function on shorter time-scales than the shortest time-interval between 
successive measurement times, tij and ti,j+1. The model assumes that the Zij are 
independent copies of a Normally distributed random variable with mean zero and 
variance τ2. The model also assumes that the decomposition of the covariance 
structure of the Rij, as shown in (3), is common to all individuals.  
Exploratory analysis for the extended model 
Exploratory analysis again consists of identifying a suitable form for the set of mean 
responses µij and secondly obtaining initial estimates of the parameters in the model 
for the stochastic terms Rij. 
For the first of these tasks, I used a combination of ordinary least squares fitting of a 
regression model, and kernel smoothing. Ordinary least squares gives unbiased 
estimates of baseline explanatory variable effects whatever the structure of the Rij, 
whilst kernel smoothing allows the investigation of possibly non-linear time-trends 
after adjustment for baseline effects. A kernel smoother is an estimate of the form 
 
  
 
in which the rij are the residuals from the regression on baseline explanatory 
variables whilst the smoothing weights wij are scaled to add to 1 and are proportional 
to f(t − tij), where the kernel function, f(u), is a probability density function 
symmetric about u = 0; a common choice is a Normal probability density function 
with mean zero and standard deviation h. In exploratory analysis, the value of h can 
be chosen subjectively so as to obtain a smoothly varying estimate s(t).  
For the second task, I first re-defined the residuals rij to adjust for the estimated 
smooth time-trend s(t). To estimate the covariance structure of these residuals we use 
the variogram, whose definition is as follows. Let vijk = (rij − rik)2/2 and uijk = |tij − 
tik|. Pick a grouping interval h, let nr be the number of uijk that lie between (r − 1)h 
and rh and !the sample mean of the corresponding vijk. A plot of !against (r − 
0.5)h is called the sample variogram (Diggle et al., 2002, Taylor-Robinson et al., 
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2013a). It estimates the function V(u)   =   τ2 +   σ2{1   −   ρ(u)}, called the theoretical 
variogram. The sample variance of the residuals estimates the quantity τ2 +  ν2 +  σ2. 
Hence, as illustrated in Figure 21 below, by sketching a smooth curve to fit the 
sample variogram we can obtain initial estimates of the variance components τ2,  ν2 
and σ2, and of the correlation function ρ(u). 
Figure 21: A typical example of a theoretical variogram 
Dashed horizontal lines represent a partitioning of the variance into three 
components, reading from  bottom  to  top,  τ2 =  0.15,  σ2 =  0.6  and  ν2 = 0.25. Solid line 
is  the  curve  τ2 +  σ2{1  −  ρ(u)}. 
 
Random-effects models for binary data  
To analyse binary outcomes (chronic P. aeruginosa status, use of therapies in past 
year), I used a generalized linear mixed model. This specifies a logistic regression 
model for the effects of covariates on the probability of, for example, Pseudomonas 
acquisition, but adjusts the standard errors of the regression parameters to take 
account of the correlation structure of the repeated measurements in the same way as 
described above for the linear mixed model. 
Specifically, denoting by Yij the jth repeated binary outcome on the ith individual , tij 
the age at the time of measurement and pij the probability that Yij=1, I assumed that 
Variation between subjects (Ui) 
 
Variation between times 
within subjects (Wi(t)) 
Measurement error (Zij) 
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log( pij / (1- pij )) = µij + Ui + Vitij, where the µij are described by a multiple linear 
regression model and the (Ui,Vi) pairs are subject-specific intercepts and slopes, 
modelled as zero-mean bivariate Normally distributed random variables 
independently realised for different subjects, with means zero, variances 
€ 
σ u
2  and 
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2  
and correlation ρ.  
Inference 
I estimated all of the model parameters by maximum likelihood (ML) estimation. 
This is a popular approach to statistical estimation, due to its favourable properties as 
sample size increases. ML estimates are asymptotically unbiased, which means they 
converge on the true value as the sample size increases; they are asymptotically 
normally distributed, with a variance that can be calculated from the model; and they 
are efficient, in that ML estimates generate standard errors that are smaller than those 
obtained through other methods of estimation. Furthermore, functions of ML 
estimates are themselves ML estimates, which means that the trajectories plotted in 
this thesis are themselves estimates of the true trajectories, since they are plotted on 
the basis of ML estimates from a GLM – an intercept value and a slope for example 
(Singer and Willett, 2003). Asymptotic assumptions rely on large samples, and while 
the definition of a large sample can be debated, the two datasets analysed in this 
thesis are comfortably large enough to defend these assumptions. 
Conceptually ML estimates are the values of the unknown population parameters of 
interests that maximise the probability of observing the data. This requires 
maximising the likelihood function, which is the joint probability density specified 
by the model in question. Algorithms are used to search for values that maximise this 
function or the log of the likelihood function, usually on the basis of starting 
estimates, such OLS estimates, or those provided by exploratory analysis, for 
example the empirical variogram parameters outlined above (Singer and Willett, 
2003). This is a computationally intensive process, especially for large datasets like 
those used in this thesis, but can now be routinely undertaken using modern desktop 
computers. 
Likelihood based methods, specifically generalized likelihood ratio tests, can then be 
used to compare the fit of nested models (i.e. one is a special case of the other). If L1 
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and L0 denote the maximised values of the log-likelihood for nested models with p 
and p  −  q parameters, the generalized likelihood ratio test for the goodness-of-fit of 
the simpler model compares D = 2(L1 − L0) with critical values of the chi-squared 
distribution on q degrees of freedom. Furthermore, to test hypotheses about model 
parameters, we use Wald tests. These exploit the property that the maximum 
likelihood estimates are approximately unbiased and Normally distributed, with 
standard errors that can be computed from the fitted model; for the full algebraic 
details, see Diggle, Heagerty, Liang and Zeger (Diggle et al., 2002). Akaike 
information criterion (AIC) and Bayesian information criterion (BIC) values are also 
provided in the model tables, and can be applied to non-nested models. For both 
these  measures  a  lower  value  suggests  a  ‘better’  fit  (Singer and Willett, 2003).  
Visualising the results 
I plot the results of the fitted models where appropriate, to demonstrate visually the 
modelled effect of covariates of interest. For linear mixed effects models this 
involves plotting the modelled population average (fixed effects) at different values 
of the variable of interest (e.g. deprivation effect), whilst holding other variables in 
the model constant. For GLMMs the equivalent calculation needs to take into 
account the non-linearity of the model. This is achieved by presenting population-
averaged percentages or proportions by averaging individual-level fitted values over 
the population (Diggle et al., 2002). 
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Missing values 
Some discussion is required of the assumptions regarding missing data implicit in the 
choice of GLMs for the analyses in this thesis. Missing data, and thus an unbalanced 
data-frame, is inevitable in large longitudinal observational studies. Missing data on 
covariates or outcomes in the analyses of interest may occur because patients miss a 
wave of data collection, owing to a missed appointment, for example, and then they 
may subsequently appear in the dataset at a later date. Individuals may also drop out 
of the dataset because they have died, which would be captured in the registry, since 
deaths are well recorded in this intensively followed-up population, or for unknown 
reasons.  
This missing data is problematic for two main reasons. Firstly, most standard 
statistical methods assume complete case data, and ignoring missing data can cause 
serious bias in estimates, if for example the characteristics of people who remain in 
the dataset are systematically different from those who dropout (Armitage et al., 
2008). Secondly dropout may also result in a loss of information and statistical 
power, especially if a complete case approach is adopted (Diggle et al., 2002, Singer 
and Willett, 2003). The best way to avoid these issues is to plan to reduce 
‘missingness’ at the outset through well-designed experiments and surveys. Since CF 
is a serious illness, and patients are followed up in a systematic fashion, although the 
dataset is unbalanced with patients attending at regular intervals, most patients will 
be reviewed in the UK approximately annually. A key issue, however, is how the 
models used deal with dropout due to death. The language of missing data is 
informed by the seminal work of Rubin and Little, who describe three main types of 
missingness mechanisms (Little and Rubin, 1987): 
 
 Missing completely at random (MCAR): here the missingness is independent 
of  the  data,  and  essentially  each  person’s  observed records are assumed to be 
a random sample of the data from his or her underlying true trajectory. 
Furthermore the probability that an outcome is missing is the same for each 
individual. 
 Missing at random (MAR): here the missingness depends only on the 
observed data, whether this is a covariate included in the analysis, or previous 
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values of the outcome measure. Thus the probability of missingness is the 
same for individuals, given the covariates in the model. 
 Not missing at random (NMAR): here the missingness depends on both the 
observed and missing data. 
 
The assumption of MCAR is difficult to sustain for longitudinal data, since this 
would imply that the probability of assessment at a particular time is independent of 
time; the values of the substantive covariates in the model; and the values of the 
outcome (Singer and Willett, 2003). If the data are NMAR approaches such as 
selection models, and pattern mixture models are required. The former explicitly 
incorporates a model for the missingness process, and the latter approach stratifies 
the analysis on the basis of the observed missingness patterns (Diggle et al., 2002). 
The MAR assumption, however, is much less restrictive, and is implicit in the choice 
of mixed-effects models for the analyses in this thesis. When the data are MAR, the 
probability of missingness can depend on any of the observed data, either covariates 
or previous outcomes, and the ML estimates from the GLM will be unbiased 
estimates, even on the basis of the reduced dataset. Thus in the case of GLM with 
data assumed to be MAR, the missing values can be classified as ignorable, as long 
as important correlates of missingness are included in the model. By contrast, the 
assumptions for a marginal analysis with GEE are generally only consistent under 
the assumption of MCAR (Diggle et al., 2002). 
This is illustrated in Figure 22 below, where I have simulated %FEV1 data on five 
individuals, as illustrated in the black lines. Here, dropout from the dataset can be 
assumed to be due to death, where the risk of death is a function of an individual’s 
level of %FEV1, with individuals with lower lung function dropping out earlier.  
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Figure 22: Simulated data illustrating the unbiased estimates resulting from a 
mixed model analysis, where the data is assumed to be MAR, compared to the 
GEE estimate 
 
The red line is the population average as fitted using a mixed-effects model, and one 
can see that this is consistent with the estimate that would have been observed in the 
absence of dropout i.e. if fitted to the black and grey data. The missing data here can 
be considered MAR, since the risk death (missingness) is related to covariates in the 
model e.g. observed values of %FEV1. One can see, however, that the population 
level GEE analysis estimate in blue suggests that in this population of patients, lung 
function is improving over time, whereas this is entirely the result of selective 
dropout. 
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Diagnostics 
To test the overall goodness-of-fit of the final models, I analysed the residuals. Plots 
of residuals against fitted values should show random scatter. Plots of residuals 
against observed predictor values can also be used to assess patterns in residual 
variability. Index plots of residuals can be used to identify extreme values in binary 
models (Singer and Willett, 2003). For the extended model used to analyse the 
Danish data, the residuals should have approximately the same covariance structure 
as the fitted model, which I checked by comparing their sample variogram with the 
theoretical variogram of the model (Diggle et al., 2002). 
Pilot study and consideration of sample size 
Prior to accessing the UK CF Registry data, I confirmed the feasibility of using the 
UK CF Register for the studies in this thesis by cleaning and analysing data from two 
CF treatment centres with good coverage of postcode data (7713 observations on 
1423 patients in Liverpool and Belfast). Visual inspection and initial longitudinal 
analysis of the association between age and % predicted FEV1 showed the expected 
statistically significant decline in FEV1 as age increases, in line with previously 
published literature (Konstan et al., 2007a). Figure 23 shows the decline in %FEV1 
with age in a paediatric population from one centre. In a random-intercept and slope 
analysis the regression estimate equated to a fall of 0.58% per year (95%CI 0.29 to 
0.87). 
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Figure 23: Scatterplot of % predicted FEV1 versus age with smoothed mean 
 
 
The dataset subset allowed estimation of the between-subject (vb) and within-subject 
(vw) components of variance for %FEV1 (vb = 306.25 and vw = 87.61). Assuming a 
common correlation between any two measurements on the same subjects, the 
estimated standard error of a mean response calculated from n subjects, each of 
whom provides m measurements, is SE(n,m) = sqrt((vb+vw/m)/n) (Diggle et al., 
2002). The study initially envisaged approximately 10,000 subjects providing an 
average of about six measurements each. For an indicative power/precision 
calculation, we notionally divide the 10,000 subjects equally into groups of size 2000 
according to quintiles of deprivation score. Then, an estimate of the standard error of 
the overall mean response in each group is SE(2000,6) = 0.40, and an estimate of the 
standard error of the difference between the mean responses in any two groups is 
0.40*sqrt(2) = 0.566. Hence, a 95% CI for the difference would have width 
approximately 0.566*4 = 2.27%.  
O’Connor  et  al   report  an  absolute  difference  of  5.5%  in  %predicted  FEV1 between 
highest and lowest income quintiles (O'Connor et al., 2003). Schechter et al found a 
difference of 6.7% in %predicted FEV1 by Medicaid status, which increased to 9.2% 
with adjustment for various confounders (Schechter et al., 2001). The sample size 
calculation suggested that we would have sufficient precision to quantify differences 
such as these. Moreover, the above calculation was likely to prove conservative, for 
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at least two reasons. First, it treats deprivation as a five-level factor, rather than a 
continuously varying quantity; if mean outcome varies smoothly with deprivation, a 
regression analysis would be a more efficient way of estimating how the mean 
response changes with deprivation. Second, the calculation did not take into account 
the potential for further gains in efficiency through adjustment for the effects of other 
variables that are associated with the response. 
Computation 
All analyses were carried out using the R open-source software environment 
(www.r-project.org) (version 2.9.2 for mac). Maximum likelihood estimation, 
generalized likelihood ratio tests and Wald tests used the lme() function within the 
nlme package, together with the exponential class of correlation functions. 
Variogram calculations used a specially written R function developed by Peter 
Diggle. The R code for this is available in Appendix 6. Other packages used included 
the lme4, survival, Hmisc, memisc, mcgv and ggplot2 packages. Though there were 
some convergence problems whilst working up some of the more complex models, 
all of the modelling was successfully undertaken on a MacBook Pro, with some extra 
memory installed (2.8GHz Intel Core 2 Mac Book Pro with 8GB memory running 
64-bit version of R). The final multivariable model for the Danish analysis, for 
example, would take about 8 hours to converge on this system. 
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Chapter 4: Study 1 – The effect of social deprivation on 
clinical outcomes and the use of treatments in the UK CF 
population: A longitudinal study 
 
Abstract  
Background: Poorer socio-economic circumstances have been linked with worse 
outcomes in CF. This study explores, for the first time in a UK-wide cohort, 
longitudinal weight, height, BMI, %FEV1 , risk of Pseudomonas colonisation, and 
the use of major CF treatment modalities, and their association with deprivation. 
Methods: A longitudinal registry study of the UK CF population aged under 40 
(8055 people with 49,337 observations between 1996 and 2010). Mixed-effects 
models were used to assess the association between small area deprivation and 
clinical and healthcare outcomes, adjusting for clinically important covariates. 
Results: People from the most deprived areas have significantly lower weight (-0.3 
SDs, 95% CI -0.4 to -0.2), height (-0.3 SDs, 95% CI -0.4 to -0.2) and BMI (-0.13 
SDs, 95% CI -0.2 to -0.04) in childhood, are more likely to have chronic 
Pseudomonas infection (OR 1.9, 95% CI 1.3 to 2.7), and a significantly lower 
%FEV1 (-4·1 percentage points, 95% CI -5 to -3.2). These inequalities are apparent 
very early in life and do not widen thereafter. On a population level, there is striking 
evidence of positive discrimination,   or   ‘pro-poor’   bias   towards individuals in the 
most deprived quintile compared to the least, in provision of IV antibiotics (OR 2.5, 
95% CI 1.9 to 3.2) and nutritional therapies (OR 1.78, 95% CI 1.4 to 2.2), after 
adjusting for disease severity. In contrast, patients from the most disadvantaged areas 
are less likely to receive DNase or inhaled antibiotic therapy. 
Conclusions: More disadvantaged children with CF in the UK have significantly 
worse growth and lung function, but these inequalities do not widen at older ages. 
There is evidence that, in the NHS, clinicians making decisions about treatments for 
children, take deprivation as well as disease status into account, and this may 
mitigate some effects of social disadvantage. Questions remain for the NHS about 
the provision of therapies such as DNase to people living in disadvantaged areas.  
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Introduction 
CF is the commonest life-limiting inherited disease among Caucasian populations, 
with most patients dying prematurely from respiratory failure. Children with CF in 
the UK and other OECD countries are usually diagnosed in the first year of life 
(Cystic Fibrosis Trust, 2011), and subsequently require intensive support from family 
and healthcare services.  
CF is of particular interest in the study of mechanisms that generate health 
inequalities, because, as a classically inherited recessive genetic disease, there is no 
reason to suspect a social gradient in incidence of the condition. Inequalities can 
develop, however, in the outcomes experienced by people with the disease. For 
example, people with CF from socio-economically disadvantaged backgrounds die 
younger than those in more advantaged social positions in the UK and the US 
(Britton, 1989, Schechter et al., 2001, O'Connor et al., 2003, Barr HL, 2011). The 
adjusted risk of death was around four times higher in CF patients in the US with 
Medicaid cover (taken as an indicator of poverty), compared to those without 
Medicaid cover (Schechter et al., 2001). In England and Wales, Barr and Fogarty 
demonstrated a higher risk of age of death at an age above the median in more 
advantaged social classes, a pattern that has persisted for over four decades (Barr 
HL, 2011). As with other chronic diseases, this social patterning of survival in CF 
implies that social and environmental factors are playing a major role in influencing 
outcomes (Ben-Shlomo and Kuh, 2002, Marmot et al., 2010b). Inequalities in access 
to specialist healthcare may also be important, since in many health care systems 
provision and utilisation of services decreases with declining income of patients (van 
Doorslaer et al., 2006, Stirbu et al., 2011) the so-called   ‘inverse   care   law’ (Hart, 
1971). 
This analysis sets out to ascertain if there are differential health outcomes on the 
basis of SES in the UK CF population (see Diderichsen model in the introduction, 
Figure 6). To gain a better understanding of when and how inequalities in outcomes 
develop in CF, I undertook a longitudinal registry study to explore the effect of 
deprivation on growth, nutrition, lung function, risk of Pseudomonas colonisation, 
and the use of major CF treatment modalities in a UK-wide population cohort, in the 
context of a universal health care system, free at the point of use.  
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Methods 
An in depth description of the methods used is found in Chapter 3. An overview is 
provided here. 
Design, setting and data source 
I undertook a longitudinal retrospective cohort analysis of individuals in the UK CF 
registry under the age of 40 at last follow-up, with at least one outcome measurement 
and a valid postal code between 1996 and 2010. The UK CF Registry is supported 
and co-ordinated by the UK CF Trust (Adler et al., 2008, Cystic Fibrosis Trust, 
2011). The Registry is maintained to a high standard of data quality, and is estimated 
to include nearly all people thought to have CF in the UK population (Mehta et al., 
2004) and is therefore ideally suited to the study of outcomes and treatments across 
the whole socio-economic spectrum in the UK.  
 
Primary outcome and covariates 
The primary clinical outcomes were weight, height, BMI, %FEV1 and Pseudomonas 
colonisation prevalence. Anthropometric values were converted into standard 
deviation scores using the UK reference population (Pan and Cole, 2002). The 
primary health care outcomes were use of therapies in the previous year (yes or no): 
IV antibiotics; supplemental nutritional support; DNase; and inhaled antibiotic 
therapy. Conditional on use of IV therapy, I also used the log total number of days on 
IV therapy as an outcome. 
The primary exposure measure was a small-area-based measure of deprivation of 
area of residence. Postcodes were used to derive IMD scores for the constituent UK 
countries (GeoConvert, 2011) and each person was allocated a deprivation score on 
the basis of the first recorded postcode on entry to the dataset. Other baseline 
covariates in the analysis were: sex; genotype coded as the number of delta F508 
alleles (0, 1 or 2); year of birth; screening status (diagnosis by neonatal screening or 
otherwise) and ethnicity (Caucasian or otherwise). Time varying covariates were age, 
presence of CFRD and PI, determined by use of pancreatic enzyme supplementation. 
In the health care use analyses, I adjusted for disease severity on the basis of current 
%FEV1 , P aeruginosa status and BMI SD score. 
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Statistical Methods 
I fitted separate random intercept and slope models in the paediatric (<18) and adult 
age ranges (18-40). I approximated time-trends using linear functions (e.g. for 
%FEV1),   ‘piecewise’  or   ‘broken-stick’   functions   (weight,  BMI),  or  quadratics   (e.g.  
any IV therapy) as appropriate. For instance, population weight Z score increased to 
around age three, and then decreased subsequently. The modelling approach 
involved first fitting a model adjusted for age and the baseline covariates defined 
above, and then testing for the significance of adding deprivation. Finally, the time-
varying covariates were added to the model, to determine if the deprivation 
coefficient was modified. This is illustrated for the %FEV1 analysis in Figure 24. 
The headline results quoted for the effect of SES on outcomes are from the models 
adjusted for baseline factors that are not plausibly in the causal chain from SES to 
the outcome of interest. Additional analyses explore the potentially mediating effect 
of other covariates of interest.  
Figure 24: Logic model for %FEV1 analysis 
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For the analyses of treatment outcomes, I first fitted a baseline model adjusted for 
baseline factors, and also for disease severity. Then I added deprivation score to the 
model to ascertain if this has an additional significant effect (Figure 25). 
Figure 25: Logic model for IV therapy analysis 
 
 
I estimated all model parameters by maximum likelihood, using linear or generalized 
linear mixed effects models (Laird and Ware, 1982) and used generalized likelihood 
ratio statistics to compare nested models, and Wald statistics to test hypotheses about 
model parameters. Kaplan-Meier estimates and Cox regression were used to assess 
the effect of deprivation on time to diagnosis. 
Results 
Population characteristics 
The final dataset for weight, the most commonly collected outcome, contains 
information collected at 49,337 annual reviews on 8055 patients between 1996 and 
2010 in the UK. This is described in more detail in the methods chapter. 66% of 
individuals had five or more follow up measures, with a total of 48,425 person-years 
of follow up. There was a shallow gradient in the total proportion of individuals by 
deprivation quintile (19·1% in least deprived versus 20·2 in most deprived) (Table 
3), but there was no gradient in incident cases (Figure 26), or number of observations 
per person (Table 3). 
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Figure 26: Distribution of incident cases by deprivation quintile.  
Error bars represent 95% binomial CIs (n=2066) 
 
There was no difference in age at diagnosis combining screened and symptomatic 
diagnoses, sex ratio, birth cohort or neonatal screening by deprivation status. There 
was a shallow trend towards less heterozygote delta F508 carriers, more people with 
no delta F508 genes, and a greater proportion of non-white patients, with increasing 
level of deprivation (Table 3). 
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Table 3: Unadjusted characteristics of study population by deprivation quintile: 
UK CF registry 1996-2010 
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There was no association between deprivation and age at diagnosis in a survival 
analysis. Figure 27 shows the Kaplan-Meier estimates comparing extremes of 
deprivation quintile, and Table 4 shows the results of a Cox regression. There was no 
difference in time to diagnosis comparing the most deprived to the least deprived 
quintile (hazard ratio (HR) 1.00, 95%CI 0.97 to 1.03), and no consistent trend 
evident. 
 
Figure 27: Kaplan-Meier plot of time to diagnosis by deprivation quintile. 
There is no social gradient in age at diagnosis in the UK CF population.  
 
 
 
Table 4: Cox regression of time to diagnosis by deprivation quintile 
 exp(coef) exp(-coef) lower .95 CI upper .95 CI 
Quintile 2 1.0534 0.9493 1.0238 1.084 
Quintile 3 0.9881 1.012 0.9603 1.017 
Quintile 4 1.0032 0.9969 0.9755 1.032 
Quintile 5 1.0017 0.9983 0.9737 1.031 
(reference quintile 1, least deprived) 
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Summary of deprivation effect on outcomes and use of therapies 
Before considering each outcome in detail, I provide an overall summary of the key 
results of this study in Table 5 below. This demonstrates worse clinical outcomes in 
individuals from the most deprived areas. For IV and nutritional therapies, people in 
the most deprived quintile are more likely to receive treatment, after adjusting for 
disease severity. However, for inhaled therapies (DNase and inhaled antibiotics), 
people in the most deprived quintile are less likely to be treated after adjusting for 
disease severity. 
Table 5: Summary of adjusted effects of deprivation on clinical outcomes and 
use of therapies in the paediatric and adult CF population in the UK 
  Age<18 Age 18-40 
Clinical outcomes^   
%FEV1 (%) -4·12 (-5·01 to -3·19) -1·6 (-4·41 to 1·25) 
Weight-for-age (SD score) -0·28 (-0·38 to -0·18) -0·31 (-0·46 to -0·16) 
Height-for-age (SD score) -0·31 (-0·40 to -0·21) -0·31 (-0·43 to -0·19) 
BMI-for-age (SD score) -0·13 (-0·22 to -0·04) -0·12 (-0·25 to 0·01) 
OR for P. aeruginosa colonisation 1·89 (1·34 to 2·66) 1·78 (1·26 to 2·51) 
Therapies   
OR for any IV therapy* 2·52 (1·92 to 3·17) 1·89 (1·51 to 2·38) 
Mean difference IV days per year (%)* 15·9 (8·2 to 24) 10·6 (2·5 to 19·2) 
OR for supplemental feeding$ 1·78 (1·42 to 2·2) 2·38 (1·69 to 3·36) 
OR for DNase therapy* 0·40 (0·21 to 0·72) 0·37 (0·26 to 0·52) 
OR for inhaled antibiotics$ 0·66 (0·47 to 0·93) 0·40 (0·31 to 0·5) 
All estimates compare the most deprived quintile to the least deprived (reference) quintile. 95% CI in parenthesis 
^The outcomes are from separate longitudinal models adjusted for time trends, sex, genotype, screening status 
and ethnicity.  
*Adjusted for time trends, sex, genotype, screening status, %FEV1 and P. aeruginosa colonisation status  
$Adjusted for time trends, sex, genotype, screening status and BMI SD score 
 
The following sections present the analyses for the clinical outcomes, and treatment 
outcomes in more detail. The complete analysis is outlined for weight, along with all 
of the exploratory plots, but for subsequent analyses some of the tables and figures 
have been placed in the appendix for this chapter (Appendix 4). Robustness tests are 
in a section at the end of the results.  
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Anthropometric outcomes 
Weight, height and BMI SD scores were significantly lower in the UK CF population 
compared to the UK reference population in children (-0·37, 95% CI -0.43 to -0.35 
[35th centile]; -0·50, 95% CI -0.53 to -0.47 [30th centile]; -0·08, 95% CI -0.11 to -
0.06 [46th centile] respectively in longitudinal models ignoring time trends).  
First, I provide an overall summary for the three growth outcomes (weight, height 
and BMI). Figure 28 shows the cross sectional data for each growth outcome by age, 
stratified by derivation quintile (Figure 28). People with CF from the most deprived 
quintile (red line), compared to the least deprived (blue line) in the UK have a lower 
weight, height and BMI SD scores. 
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Figure 28: Anthropometric outcomes: mean cross-sectional weight, height, and 
BMI by age comparing extremes of deprivation quintile (red most deprived). 
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Summary of longitudinal analysis  
The plots in Figure 29 illustrate the contrast between deprivation quintiles from the 
final longitudinal models for the <18 age group. The trajectories are plotted at the 
reference values for other covariates in the final regression models: female sex, 
homozygote delta F508 carrier, not diagnosed by screening, white, born in 1991. 
Weight SD scores increased from the time of diagnosis to around age three, and then 
decreased. This is modelled as a split straight line with a break point (knot) at age 
three. 
 
Figure 29: Modelled growth trajectories for children, comparing least (blue) 
and most deprived quintiles (red). 
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Weight 
The mean weight for age Z score (WAZ or weight SD score) for the population over 
time (null model) was -0·37 (95% CI -0.43 to -0.35), which corresponds to around 
the 35th centile on a growth chart. Exploratory analysis begins with spaghetti plots, 
with smoothed means added to explore the form of the overall mean trajectory. 
Figure 30 shows the spaghetti plot for the <18 analysis. 
 
Figure 30: Spaghetti plot of weight SD score versus age in paediatric age group 
Mean smoother in red line, and randomly selected weight trajectories in black. 
 
 
 
Weight SD score in the population actually increases from the time of diagnosis to 
around age three, and then decreases subsequently. This is modelled as a split 
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straight line (piecewise regression) with a knot at age three in the under 18 age group 
(Figure 31).  
Figure 31: Piecewise modelling approach to weight z score trajectory 
The plot shows the broken stick model, fitted by OLS compared to smoothed mean. 
The smoothed mean weight z score increases to around age three and decreases 
subsequently.  This  was  modelled  as  a  piecewise  regression,  with  a  ‘knot’  at  age  
three.  
 
 
Undertaking exploratory analyses plotting smoothed cross-sectional means for 
baseline covariates of interest suggested important covariate effects, and also 
confirmed that the split-line time trends were consistent across covariate subgroups 
(Figure 32). 
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Figure 32: Exploratory analysis showing smoothed means of weight for age SD 
score versus age, stratified by covariates, for people<18 
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Moving now to the definitive longitudinal analysis for weight SD score in the <18 
group, the results of the final model are shown in Table 6. The important covariate 
effects are visualised in the subsequent plots. After adjustment for baseline factors, 
the weight of children in the most deprived quintile compared to the least was 
significantly lower around diagnosis (-0·54, 95% CI -0.73 to -0.34). The deprivation 
gap narrowed slightly up to age three, and from then on remained constant (-0·28, 
95% CI -0.38 to -0.18, comparing most to least deprived) (Figure 33). Addition of 
the time-varying covariates did not substantially alter the deprivation effects for 
weight (Appendix 4, Table 20), and the estimates were consistent with a monotonic 
dose response relationship with deprivation (see robustness tests section).  
Figure 33: Deprivation quintile contrast from final weight model <18 
Trajectories plotted at reference values for other covariates in the regression model: 
female sex, homozygote delta F508 carrier, not diagnosed by screening, white, born 
in 1991. 
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Table 6: Final linear mixed-effects regression models for growth in the <18 age 
group 
 weight_young height_young bmi_young 
Constant -0.76679*** -0.69634*** -1.43559* 
 (0.09124) (0.07615) (0.59086) 
age 0.17231*** 0.01154*** 0.15798*** 
 (0.01769) (0.00296) (0.02777) 
age2 -0.18983***  -0.17570*** 
 (0.01838)  (0.02880) 
Number of F508 alleles: 0/2 0.06228 -0.05825 -0.03069 
 (0.10612) (0.07068) (0.15020) 
Number of F508 alleles: 1/2 0.01447 -0.00004 -0.21288* 
 (0.06184) (0.04431) (0.08857) 
Male 0.03527 0.17969*** -0.09166 
 (0.05724) (0.04094) (0.08159) 
Non-white 0.33507* 0.23514* -0.02379 
 (0.14012) (0.10062) (0.18750) 
Screened 0.28633*** 0.27879*** 0.10080 
 (0.06427) (0.05056) (0.08734) 
Deprivation score -0.00932*** -0.00526*** -0.00229** 
 (0.00169) (0.00086) (0.00079) 
Age x Number of F508 alleles: 0/2 -0.04279 0.00184 0.00141 
 (0.03088) (0.00529) (0.05455) 
Age x Number of F508 alleles: 1/2 -0.02331 0.00582 0.05660 
 (0.01687) (0.00347) (0.03192) 
Age x male 0.05831*** -0.01218*** 0.11384*** 
 (0.01568) (0.00331) (0.02947) 
Age x non-white -0.17607*** -0.02756*** -0.12099 
 (0.04040) (0.00804) (0.07002) 
Age x screened -0.06239*** -0.01710*** -0.03067 
 (0.01666) (0.00407) (0.03215) 
Age x Deprivation score 0.00168***   
 (0.00045)   
age2 x Number of F508 alleles: 0/2 0.04497  0.00036 
 (0.03199)  (0.05688) 
age2 x Number of F508 alleles: 1/2 0.03611*  -0.04850 
 (0.01755)  (0.03332) 
age2 x male -0.07335***  -0.13381*** 
 (0.01636)  (0.03079) 
age2 x non-white 0.16692***  0.13337 
 (0.04254)  (0.07400) 
age2 x screened 0.06005***  0.03464 
 (0.01769)  (0.03407) 
Age2 x Deprivation score -0.00173***   
 (0.00047)   
Log-likelihood -25528.81159 -22657.81459 -28158.12899 
Deviance 51057.62317 45315.62917 56316.25798 
AIC 51167.62317 45409.62917 56428.25798 
BIC 51623.19488 45798.52902 56891.62221 
N 29235 28983 28980 
Groups 5775 5750 5745 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of 
the least and most deprived quintiles 
age2 is the coefficient for the split line at age three in the weight and BMI analysis 
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Higher weight SD score was associated with male sex, screened patients, 
heterozygotes for delta F508 and white patients in the <18 age group (Figure 34). 
Figure 34: Weight for age Z score versus age, illustrating the effect of sex, 
screening status, delta F508 carrier status, and ethnicity  
Trajectories plotted at reference values for other covariates in the final regression 
model: female sex, homozygote delta F508 carrier, not diagnosed by screening, 
white, born in 1991. 
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In a supplementary analysis for weight, I stratified the data by screening status, and 
allowed the break point in the split-line to vary in each group (Figure 35), and re-
fitted the longitudinal model separately to the screened and unscreened children. The 
point estimate for the inequality in weight was narrower in the screened group  
(Figure 36). I tested for an interaction between deprivation and screening status in 
the full dataset, and although the point estimate was in the direction that supports a 
narrowing of inequality with screening, it was not significant. 
Figure 35: Piecewise modelling approach to weight SD score trajectory in 
analysis stratified by screening status 
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Figure 36: Deprivation effect on weight in screening stratified analysis 
Screening is associated with a narrowing of inequality in weight 
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Adult Weight 
Following the same analysis sequence for weight in the adult age group, the spaghetti 
plot and exploratory cross-sectional analysis stratified by covariates of interest are 
shown below (Figure 37, Figure 38). The weight SD trajectory was modelled as a 
linear function in the adults (Figure 39). 
 
Figure 37: Spaghetti plot of weight for age SD score versus age in adult age 
group 
Mean smoother in red line, and randomly selected weight trajectories in black.  
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Figure 38: Exploratory analysis showing smoothed means of weight for age SD 
score versus age, stratified by covariates, for people>18 
 
 
 
Figure 39: Deprivation quintile contrast from final weight model >18 
Trajectories plotted at reference values for other covariates in the regression model. 
 
Age 
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The results of the final model for weight SD score are shown for the adult age group 
in Table 7. In adults the adjusted difference between deprivation quintiles remained 
constant (-0.31, 95% CI -0.46 to -0.16, comparing most to least deprived) (Figure 
39). Addition of the time-varying covariates did not substantially alter the 
deprivation effects for weight (Appendix 4, Table 21).  
Table 7: Final linear mixed-effects regression models for growth in the >18 age 
group 
 Weight>18 Height>18 BMI>18 
Constant -0.81353*** -0.22411** -0.17173 
 (0.10244) (0.08435) (0.09519) 
Age-18 0.01839*** -0.00508*** -0.07677*** 
 (0.00391) (0.00140) (0.01117) 
age2   0.10152*** 
   (0.01333) 
Number of F508 alleles: 0/2 0.02906 0.11796** -0.06111 
 (0.06518) (0.03626) (0.07592) 
Number of F508 alleles: 1/2 0.22908*** 0.10350** 0.18013*** 
 (0.04973) (0.03227) (0.05347) 
Male -0.33225*** -0.24207*** 0.00446 
 (0.04714) (0.03474) (0.04934) 
Non-white -0.54262*** -0.38022*** -0.27837 
 (0.14092) (0.08558) (0.15174) 
Screened 0.06145 -0.07743 0.04777 
 (0.07886) (0.04337) (0.08260) 
Age-18 x Number of F508 alleles: 0/2 0.01236 -0.00191 0.02537 
 (0.00633) (0.00238) (0.02019) 
Age-18 x Number of F508 alleles: 1/2 0.00123 0.00006 -0.00980 
 (0.00446) (0.00165) (0.01363) 
Age-18 x male 0.01053* 0.00018 -0.03934** 
 (0.00425) (0.00155) (0.01252) 
Age-18 x non-white 0.01385 -0.00119 0.03412 
 (0.01431) (0.00528) (0.03951) 
Age-18 x screened -0.01328 -0.00347 0.02532 
   (0.02234) 
age2 x Number of F508 alleles: 0/2   -0.01423 
   (0.02384) 
age2 x Number of F508 alleles: 1/2   0.01497 
   (0.01618) 
age2 x male   0.06495*** 
   (0.01495) 
age2 x non-white   -0.02708 
   (0.04852) 
age2 x screened   -0.05189 
   (0.02884) 
Deprivation score -0.00537*** -0.00530*** -0.00203 
 (0.00130) (0.00105) (0.00117) 
Log-likelihood -18646.75337 -3710.19476 -19860.93596 
Deviance 37293.50675 7420.38951 39721.87192 
AIC 37395.50675 7522.38951 39841.87192 
BIC 37799.39164 7926.13366 40315.94301 
N 20319 20263 19954 
Groups 4041 4046 4029 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of 
the least and most deprived quintiles 
age2 is the coefficient for the split line at age three in the BMI analysis 
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Higher weight SD score was associated with female sex, heterozygote status and 
white patients (Figure 40) in the >18 age group. 
 
Figure 40: Weight for age versus age, illustrating covariate contrasts from the 
final longitudinal models 
Trajectories plotted at reference values for other covariates in the regression model. 
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Height 
The mean height for age Z score (HAZ) for the population over time (null model) 
was -0·50 (95% CI -0.53 to -0.47), which corresponds to around the 30th centile on a 
growth chart. This was modelled as a linear trend in the paediatric and adult age 
ranges (see exploratory analysis for height in Appendix 4, Figure 83, Figure 84, 
Figure 85, Figure 86). As for weight, the average height of individuals in the most 
deprived quintile compared to the least was also about a third of an SD score shorter 
in the adjusted analysis (-0·31 95%CI -0·40 to -0·21 in the <18 analysis, Figure 29) 
and this effect remained constant across the paediatric and adult age range (Table 6, 
Table 7). Greater height SD score was associated with male sex and screened 
patients over the paediatric age range, and increased in white patients over time 
(Figure 41). In adults greater height was associated with female sex, non-
heterozygotes for delta F508 and white patients (Table 7). Addition of the time-
varying covariates did not substantially alter the deprivation effects for height 
(Appendix 4, Table 22, Table 23), and the estimates were consistent with a 
monotonic dose response relationship with deprivation (see robustness tests section).  
 
Figure 41: Height for age versus age, illustrating covariate contrasts from the 
final longitudinal models 
Trajectories plotted at reference values for other covariates in the regression model 
as above. 
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BMI 
The mean BMI SD score for the population over time (null model) was -0.08 (95% 
CI -0.11 to -0.06), which corresponds to around the 46th centile on a growth chart. 
BMI SD score was modelled in a similar way to weight SD score, with a split line at 
age three (see Appendix 4 for exploratory analysis, Figure 87, Figure 88, Figure 89, 
Figure 90). In the paediatric age range there was a deprivation gap of -0·13 (95% CI 
-0·04 to -0·22), which remained constant over time (Table 6, Figure 29). Higher BMI 
was associated with male sex in the paediatric age range. BMI SD score had a 
steeper rate of decline in delta F508 homozygotes after the age of three (Figure 42). 
The effects of sex and genotype in the adult age group are shown in Figure 43.  
 
Figure 42: BMI for age versus age, illustrating covariate contrasts from the 
final longitudinal models 
Trajectories plotted at reference values for other covariates in the regression model 
as above. 
 
  
 130 
Figure 43: BMI for age versus age, illustrating covariate contrasts from the 
final longitudinal models 
Trajectories plotted at reference values for other covariates in the regression model. 
 
 
 
In the adult age range the point estimate for the deprivation effect on BMI SD score 
was similar to that in the paediatric age group, but this did not reach significance at 
the conventional 5% level (-0.12, 95% CI -0.25 to 0.01). Addition of time-varying 
covariates did not substantially alter the deprivation effects for BMI (Appendix 4, 
Table 24, Table 25). 
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Respiratory outcomes 
First, I provide an overall summary for the two respiratory outcomes (% FEV1 and 
P. aeruginosa). Figure 44 shows the cross sectional data by age, stratified by 
derivation quintile. People with CF from the most deprived small areas in the UK 
have a lower %FEV1 in the <18 age group, and are more likely to be chronically 
colonized with P. aeruginosa. The social gradient in %FEV1 (around 4% between 
the most and the least deprived quintiles) in the UK population is already present as 
soon as children are able to perform spirometery at around the age of five, and does 
not widen further over the paediatric age range. The prevalence of chronic 
P. aeruginosa infection was greater in the most deprived quintile compared to the 
least (OR 1·9), after adjustment for baseline covariates, and this association 
remained after adjustment for level of %FEV1 . 
 
Figure 44: Respiratory outcomes: Mean cross-sectional %FEV1 and P. 
aeruginosa colonization prevalence by age comparing extremes of deprivation 
quintile 
 
 
The %FEV1 and P. aeruginosa analyses are now considered separately in more 
detail. 
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Lung function (%FEV1 ) 
Mean cross-sectional %FEV1 falls linearly with age, and then plateaus out between 
age 20 and 25 (Figure 45). This was modelled as a linear trend in time in the <18 age 
group, and as a split line function in the >18 age group (see Appendix 4, Figure 91 
for further exploratory analysis plots illustrating cross-sectional trajectories stratified 
by baseline covariates).  
 
Figure 45: %FEV1 versus age from 5 to 40 
Mean smoother in red. 
 
 
Exploratory analysis using a generalized additive model (GAM) suggested a dose-
response relationship between deprivation score and level of %FEV1 (Figure 46). 
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Figure 46: GAMs showing the shape of the relationship between %FEV1 and 
deprivation score 
%FEV1 decreases with increasing deprivation, and there is a dose-response 
relationship. 
 
 
 
In the final model for %FEV1 , in the paediatric age range there was a difference of  
-4.1 (-5 to -3.1) comparing children in the most deprived quintile to the least, 
apparent as soon as %FEV1 can be measured around age five years, but there was no 
evidence of an increased rate of decline of % FEV1 (Table 8, Figure 47). The 
estimates were consistent with a monotonic dose-response relationship between 
deprivation and %FEV1 (Figure 46). In the paediatric age group, higher %FEV1 was 
associated with male sex, screened patients, heterozygote delta F508 status, white 
patients, no CFRD, no P. aeruginosa colonisation, and higher BMI (Table 8, Figure 
47). Adding BMI SD score to the model reduced the %FEV1 deprivation gap to -3.5 
(95% CI -5.2 to -1.8). Further adjusting for B. cepacia status and care-centre did not 
change the deprivation effect on %FEV1 (see robustness test section). 
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Table 8: Final regression models for %FEV1 in <18 age group 
 final Add time varying Add BMI 
Constant 95.688*** 95.568*** 95.794*** 
 (1.276) (1.557) (1.529) 
Age-5 -1.719*** -1.539*** -1.541*** 
 (0.085) (0.136) (0.133) 
Number of F508 alleles: 0/2 -0.142 -0.258 -0.980 
 (1.402) (1.402) (1.411) 
Number of F508 alleles: 1/2 -0.258 -0.346 -0.062 
 (0.829) (0.828) (0.835) 
Male -0.924 -0.909 -1.355 
 (0.768) (0.764) (0.770) 
nonwhite -7.256*** -7.114*** -8.680*** 
 (2.149) (2.134) (2.147) 
Screened -3.599*** -3.584*** -3.435** 
 (1.064) (1.057) (1.065) 
Age-5 x nallele: 0/2 0.016 -0.003 0.135 
 (0.161) (0.161) (0.157) 
Age-5x nallele: 1/2 0.242* 0.233* 0.180 
 (0.100) (0.100) (0.097) 
Age-5 x sex: Male/Female 0.293** 0.274** 0.352*** 
 (0.094) (0.093) (0.090) 
Age-5 x nonwhite 0.353 0.361 0.742** 
 (0.266) (0.265) (0.257) 
Age-5 x screened 0.634*** 0.621*** 0.585*** 
 (0.131) (0.130) (0.126) 
Deprivation score -0.071*** -0.070*** -0.061*** 
 (0.016) (0.016) (0.015) 
Pseudomonas colonisation  -2.282*** -2.548*** 
  (0.609) (0.602) 
CFRD  -5.373** -7.269*** 
  (1.980) (1.945) 
Pancreatic insufficiency  0.380 -0.094 
  (0.954) (0.945) 
Age-5 x Pseudomonas colonisation  0.056 0.115 
  (0.073) (0.072) 
Age-5 x CFRD  0.212 0.396* 
  (0.198) (0.194) 
Age-5 x Pancreatic insufficiency  -0.129 -0.024 
  (0.114) (0.112) 
BMI Z score   -2.784*** 
   (0.107) 
Age-5 x BMI Z score   0.806*** 
   (0.027) 
Log-likelihood -80509.181 -80458.674 -79894.252 
Deviance 161018.362 160917.348 159788.503 
AIC 161100.362 161011.348 159886.503 
BIC 161424.362 161382.763 160273.668 
N 19979 19979 19957 
Groups 4445 4445 4443 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid 
point of the least and most deprived quintile 
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Figure 47: %FEV1 trajectories, illustrating the effect of deprivation, sex, 
screening, genotype, ethnicity, Pseudomonas, CFRD and BMI status 
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There was no significant association between %FEV1 and social deprivation in the 
adult age range -1.6 (95% CI -4.4 to 1.25) (Appendix 4, Table 26, Figure 91) though 
there were significant sex, and genotype effects, as illustrated in Figure 48: male 
patients initially have higher lung function, but this effect is attenuated at older ages, 
due to an increased rate of decline in men before the age of 25, whereas 
heterozygotes for delta F508 status consistently have higher %FEV1 . 
 
Figure 48: %FEV1 versus age in the >18 group, illustrating sex and genotype 
effect 
Trajectories plotted at reference values for other covariates in the regression model. 
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Pseudomonas colonisation 
The cross-sectional proportion of people with chronic P. aeruginosa increased 
steadily with age to around 60% by age 20, and was more common in the most 
deprived quintile, with an OR of 1·9 (95% CI 1.3 to 2.7) in the adjusted paediatric 
analysis for the most deprived quintile (Figure 49). Increased likelihood of 
P. aeruginosa colonisation was associated with female sex, homozygote delta F508 
status, CFRD, PI, and lower %FEV1, but adjusting for these factors did not 
substantially alter the deprivation effect. The estimates were consistent with a 
monotonic dose-response relationship between deprivation and risk of P. aeruginosa 
(Figure 50). The deprivation effect was similar in the adult age range with an OR of 
1·78 (95% CI 1.26 to 2.51) comparing the most to the least deprived quintile 
(Appendix 4, Table 27, Table 28). 
 
Figure 49: Cross sectional and modelled longitudinal Pseudomonas prevalence 
by deprivation 
Thick lines show the cross-sectional prevalence, and thin lines show the modelled 
longitudinal population average Pseudomonas prevalence for the most deprived 
(red) and least deprived (blue) quintiles 
 
5 10 15
0
10
20
30
40
50
60
Pseudomonas prevalence
Age
%
 w
ith
 p
se
ud
o 
in
 la
st
 y
ea
r
 138 
Figure 50: GAMs showing the shape of the relationship between risk of 
Pseudomonas colonisation and deprivation score 
Risk of Pseudomonas colonisation increases with increasing deprivation, and there 
is a dose-response relationship. 
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Use of therapies 
First I provide an overall cross-sectional summary for the use of therapy outcomes 
(IV therapy, nutritional, and inhaled therapies). People with CF from the most 
deprived areas in the UK are more likely to receive any IV therapy and supplemental 
feeding, compared to the least deprived areas, after adjustment for disease severity, 
but they are less likely to receive IV therapy at home, DNase and inhaled antibiotic 
therapy (Figure 51).  
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Figure 51: Use of therapies: any IV antibiotic therapy, home IV antibiotic 
therapy, hospital IV antibiotic therapy, supplemental feeding, DNase, and 
inhaled antibiotics, by age comparing extremes of deprivation quintile 
 
IV therapy 
The final regression model parameters for use of any IV therapy are shown in Table 
9. The use of any IV therapy, after adjusting for disease severity, was over twice as 
common in the most deprived children aged over five (OR 2.52, 95% CI 1.92 to 
3.17, Table 9), and this trend continued in adults (OR 1.89, 95% CI 1.51 to 2.38, 
Appendix 4, Table 29).  
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Table 9: Final regression models for any IV therapy in 5 to <18 age group 
 severity final final_bmi 
Constant -1.450*** -1.800*** -1.799*** 
 (0.196) (0.202) (0.202) 
Age-5 0.341*** 0.340*** 0.339*** 
 (0.036) (0.036) (0.036) 
(Age-5)^2 -0.016*** -0.016*** -0.016*** 
 (0.002) (0.002) (0.002) 
Number of F508 alleles: 0/2 -0.499*** -0.533*** -0.531*** 
 (0.127) (0.127) (0.127) 
Number of F508 alleles: 1/2 -0.366*** -0.388*** -0.390*** 
 (0.079) (0.079) (0.079) 
Male -0.365*** -0.374*** -0.373*** 
 (0.074) (0.073) (0.073) 
%FEV1 -0.036*** -0.036*** -0.035*** 
 (0.002) (0.002) (0.002) 
Pseudomonas colonisation 1.729*** 1.720*** 1.717*** 
 (0.065) (0.065) (0.065) 
Deprivation  0.016*** 0.016*** 
  (0.002) (0.002) 
BMI SD score   -0.056 
   (0.030) 
Log-likelihood -9469.776 -9447.085 -9436.755 
Deviance 18939.553 18894.170 18873.509 
AIC 19009.553 18966.170 18947.509 
BIC 19282.462 19246.877 19235.974 
N 17987 17987 17968 
Groups 4321 4321 4319 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between 
the mid point of the least and most deprived quintile 
 
The deprivation effect on use of any IV therapy is visualised in Figure 52. The 
estimates were consistent with a monotonic dose-response relationship between SES 
and use of any IV therapy (Figure 53), and further adjusting for care-centre did not 
change this effect (Appendix 4, Table 30). Use of any IV therapy was associated 
with female sex, homozygote delta F508 status, low %FEV1 and Pseudomonas 
colonisation (Table 9).  
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Figure 52: Cross sectional and modelled longitudinal percentage of people using 
any IV therapy in the preceding year by deprivation in the <18 and >18 age 
group 
Thick lines show the cross-sectional prevalence, and thin lines show the modelled 
longitudinal population averages for the most deprived (red) and least deprived 
(blue) quintiles 
 
Figure 53: GAMs showing the shape of the relationship between log-odds of any 
IV therapy and deprivation score. 
The likelihood of receiving any IV therapy increases with increasing deprivation, 
and there is a dose-response relationship. 
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When hospital and home IV therapy were analysed separately, it became clear that 
the higher prevalence of any IV therapy observed in the most deprived quintile was 
almost entirely due to delivery of IV therapy in hospital, rather than home as 
indicated in Figure 51. For home IV therapy there was evidence of an interaction 
between deprivation and time, such that the chance of home IV therapy became more 
common in the least deprived quintile with increasing age (Appendix 4, Table 31, 
Table 32). 
Conditional on IV therapy use, I modelled the log of the total number of IV days per 
year as a function of time and other covariates. The deprivation effect is 
demonstrated in Figure 54, which shows that people from the most deprived quintile, 
compared to the least, have more IV therapy, conditional on having any. After 
adjusting for disease severity, people in the most deprived quintile had 15.9% (95% 
CI 8.2 to 24) more IV therapy days in the paediatric age range, and 10.6% (95% 2.5 
to 19.2) more IV days in the adult age range per year. Use of more IV therapy days 
was associated with female sex, homozygote delta F508 status, low %FEV1 and 
Pseudomonas colonisation (see final regression tables in Appendix 4, Table 33, 
Table 34). 
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Figure 54: Scatterplot of log IV days (home and hospital) versus age, with fitted 
longitudinal trajectory by deprivation quintile 
Entry to the analysis is conditional on having one or more IV days 
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Nutritional therapy 
Prevalence of any supplemental feeding therapy in the previous year was more 
common in the most deprived quintile, compared to the least, across the entire age 
range from 0 to age 40 (OR 1.78, 95% CI 1.42 to 2.2, adjusted for baseline variables, 
P. aeruginosa status and BMI, in the 5 to 18 age group) (Figure 55). The estimates 
were consistent with a monotonic dose-response relationship between SES and use 
of any nutritional therapy. Use of any nutritional therapy in the preceding year was 
associated with homozygote delta F508 status, low BMI and Pseudomonas 
colonisation (regression models for nutritional therapy in Appendix 4, Table 35, 
Table 36).  
 
Figure 55: Cross sectional and modelled longitudinal percentage of people using 
any nutritional therapy in the preceding year by deprivation in the <18 age 
group and <18 age group 
Thick lines show the cross-sectional prevalence, and thin lines show the modelled 
longitudinal population averages for the most deprived (red) and least deprived 
(blue) quintiles 
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Inhaled therapies 
There was no significant association between DNase use and deprivation in the 
paediatric age range before adjusting for disease severity. After adjustment for 
disease severity, treatment was less likely in the most deprived quintile, in both 
children (OR 0.40 95% CI 0.21 to 0.72) and adults (OR 0.37 95% CI 0.26 to 0.52), 
though the association with deprivation was stronger in adults. A similar pattern was 
found for inhaled antibiotic therapy (Table 5, Figure 56, final regression tables in 
appendix Appendix 4, Table 37, Table 38, Table 39, Table 40).  
. 
Figure 56: Cross sectional percentage of people using any DNase therapy, and 
inhaled antibiotic, by deprivation quintile 
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Robustness checks 
Illustrative residual diagnostics for the models for %FEV1 and any IV therapy are in 
the appendix (Appendix 4, Figure 92, Figure 93). In addition, I undertook a range of 
additional analyses as robustness checks, including a comparison of the excluded and 
included population (Table 10). The excluded population is shifted towards older 
birth cohorts, reflecting improved collection of postcodes over time.  
Table 10: Comparison of characteristics of eligible population versus those not 
meeting the inclusion criteria 
 Excluded Included 
Total (%) 1198 8055 
Female (%) 587 (49) 3764 (46.7) 
Male (%) 611 (51) 4291 (53.3) 
No. delta 508: 2 (%) 621 (51.8) 4159 (51.6) 
No. delta 508: 1 (%) 356 (29.7) 2862 (35.5) 
No. delta 508: 0 (%) 221 (18.4) 1034 (12.8) 
Birth cohort >1957-01-01 (%) 77 (6.4) 261 (3.2) 
      >1967-01-01 (%) 235 (19.6) 835 (10.4) 
      >1977-01-01 (%) 415 (34.6) 1904 (23.6) 
      >1987-01-01 (%) 300 (25) 2528 (31.4) 
      >1997-01-01 (%) 143 (11.9) 2022 (25.1) 
      >2007-01-01 (%) 28 (2.3) 505 (6.3) 
White (%) 1155 (96.4) 7748 (96.2) 
Died 490 (40.9)  435 (5.4) 
%FEV1 at age 6  
(median and interquartile range) 94.29 (80.26 - 103.70) 92.93 (80.26 - 103.70) 
% with Pseudomonas at age 6 (95% CI) 8.8 (4.5 – 16.5) 10.9 (9.5 – 12.6) 
 
 
The robustness checks were applied to the final model for %FEV1 (Table 11), and 
the final model for any IV therapy (Appendix 4, Table 30).  
Changing deprivation scores 
Over the study period 18% of eligible individuals had more than one postcode 
recorded. As a robustness check, I repeated the analysis for %FEV1 , treating SES as 
a time-varying covariate, but this did not substantially alter the result (Table 11) . 
Adjustment for clustering by CF centre 
Differences between centres may mediate some of the effects of SES on outcomes, 
and explain some of the differences in treatments received. In order to explore this I 
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replicated the final models for %FEV1 , and for any IV therapy, adding in care centre 
as a fixed effect. This made no difference to the deprivation effect (Table 11). 
Excluding data pre-2000 or only including data >2005 
Excluding the data pre-2000, when recruitment to the cohort was increasing over 
time made no difference to the deprivation effect. Including data only after the move 
to Port CF also did not have a substantive effect on the conclusions (Table 11). 
Adjusting for B. cepacia status 
Of individuals in the %FEV1 analysis for the <18 group, 3.5% (156/4445) had B. 
cepacia. Addition of this variable to the model for %FEV1 made no difference to the 
deprivation effect (Table 11). 
Restricting the analysis to English data only 
This did not have any substantive effect on the conclusions (Table 11). 
Re-fitting models with deprivation treated as a five-level factor 
This did not have any substantive effect on the conclusions for any of the models 
(Table 12). 
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Table 11: Additional models fitted as robustness tests, based upon the final 
FEV1 model 
 final IMD as 
time 
varying  
 Final 
z score 
Final + 
care 
center 
Data <2000 
excluded 
Cepacia 
added 
English 
data 
Data>2005  
Constant 95.688*** 95.726***  94.137*** 89.83*** 95.609*** 95.641*** 96.176*** 96.133***  
 (1.276) (1.274)  (1.225) (1.88) (1.303) (1.274) (1.408) (1.818)  
Age-5 -1.719*** -1.719***  -1.719*** -1.69*** -1.722*** -1.705*** -1.712*** -1.771***  
 (0.085) (0.085)  (0.085) (0.09) (0.089) (0.085) (0.094) (0.142)  
Number of 
F508 alleles 
(nallele): 0/2 
-0.142 -0.135  -0.143 -0.54 -0.526 -0.140 -0.787 1.868  
 (1.402) (1.402)  (1.402) (1.38) (1.452) (1.401) (1.587) (2.041)  
Number of 
F508 alleles: 
1/2 
-0.258 -0.260  -0.259 -0.19 -0.258 -0.237 -0.694 -0.601  
 (0.829) (0.829)  (0.829) (0.81) (0.863) (0.828) (0.938) (1.220)  
Male -0.924 -0.921  -0.925 -1.11 -1.073 -0.919 -1.065 -0.257  
 (0.768) (0.768)  (0.768) (0.75) (0.800) (0.767) (0.863) (1.136)  
nonwhite -7.256*** -7.248***  -7.252*** -7.36*** -6.635** -7.176*** -7.323** -7.632**  
 (2.149) (2.148)  (2.149) (2.13) (2.203) (2.146) (2.234) (2.875)  
Screened -3.599*** -3.581***  -3.597*** -2.63* -3.809*** -3.601*** -2.640* -2.461  
 (1.064) (1.064)  (1.064) (1.15) (1.101) (1.062) (1.320) (1.536)  
Deprivation 
score 
-0.071***    -0.07*** -0.075*** -0.071*** -0.082*** -0.080***  
 (0.016)    (0.02) (0.016) (0.016) (0.017) (0.019)  
Age-5 x 
nallele: 0/2 
0.016 0.017  0.017 0.09 0.065 0.014 -0.023 -0.128  
 (0.161) (0.161)  (0.161) (0.16) (0.166) (0.160) (0.181) (0.243)  
Age-5x 
nallele: 1/2 
0.242* 0.242*  0.242* 0.25* 0.228* 0.242* 0.285* 0.309*  
 (0.100) (0.100)  (0.100) (0.10) (0.104) (0.100) (0.113) (0.154)  
Age-5 x sex: 
Male/Female 
0.293** 0.292**  0.293** 0.29** 0.302** 0.292** 0.294** 0.233  
 (0.094) (0.094)  (0.094) (0.09) (0.098) (0.094) (0.105) (0.145)  
Age-5 x non 
white 
0.353 0.354  0.353 0.31 0.285 0.343 0.444 0.517  
 (0.266) (0.266)  (0.266) (0.27) (0.273) (0.266) (0.276) (0.376)  
Age-5 x 
screened 
0.634*** 0.631***  0.634*** 0.53*** 0.667*** 0.637*** 0.519** 0.604**  
 (0.131) (0.131)  (0.131) (0.13) (0.136) (0.131) (0.160) (0.198)  
Deprivation 
score (time 
varying) 
 -0.073***         
  (0.016)         
Deprivation 
Z score  
   -1.128***       
    (0.251)       
Cepacia       -2.302    
       (2.415)    
Age-5 x 
cepacia 
      -0.194    
       (0.271)    
Log-
likelihood 
-80509.181 -80508.314  -80509.171 -80316.11 -74959.478 -80499.082 -66386.620 -
35910.394 
 
Deviance 161018.362 161016.629  161018.341 160632.21 149918.955 160998.164 132773.239 71820.788  
AIC 161100.362 161098.629  161100.341 160976.21 149994.955 161084.164 132855.239 71886.788  
BIC 161424.362 161422.628  161424.341 162335.43 150292.483 161423.969 133171.196 72120.466  
N 19979 19979  19979 19979 18577 19979 16420 8788  
Groups 4445 4445  4445 4445 4334 4445 3807 3318  
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least 
and most deprived quintile 
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Table 12. Regression coefficients from explanatory models fitting deprivation as 
a five-level factor 
 Weight Z score SE Height Z score SE 
BMI Z 
score SE   
quintile 2 -0.020 0.050 -0.030 0.050 -0.010 0.040   
quintile 3 -0.030 0.050 -0.070 0.050 0.020 0.040   
quintile 4 -0.050 0.040 -0.110 0.040 0.030 0.040   
quintile 5 -0.230 0.040 -0.250 0.040 -0.120 0.040   
 %FEV1  SE 
Pseudomonas 
colonisation SE     
quintile 2 -0.900 0.850 0.140 0.170     
quintile 3 -1.560 0.860 0.140 0.170     
quintile 4 -1.330 0.830 0.190 0.160     
quintile 5 -3.370 0.840 0.440 0.160     
 Any IV therapy  Nutritional therapy SE DNase SE 
Inhaled 
antibiotics SE 
quintile 2 0.080 0.120 0.050 0.110 -0.210 0.160 -0.040 0.140 
quintile 3 0.190 0.120 0.190 0.110 -0.050 0.160 -0.220 0.140 
quintile 4 0.430 0.110 0.190 0.110 -0.450 0.160 -0.520 0.140 
quintile 5 0.800 0.120 0.610 0.110 -0.570 0.160 -0.820 0.140 
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Discussion 
Children with CF from the most disadvantaged areas in the UK have significantly 
lower weight, height and BMI in the first years of life after diagnosis, are more likely 
to have chronic P. aeruginosa infection, and a significantly lower %FEV1 when it 
can first be measured (i.e. after the age of five), but these inequalities do not increase 
over time. 
There   is  evidence  of  positive  discrimination,  or   ‘pro-poor’  bias,   in   the  provision  of  
some key treatments, on the basis of socio-economic circumstances. I show that in 
the NHS, children with CF from the most disadvantaged areas are about twice as 
likely to receive IV antibiotic therapy (specifically in hospital) and nutritional 
support, after adjustment for disease severity. I  also  show  some  apparent   ‘pro-rich’  
bias in two other therapies – DNase and inhaled antibiotics – in that patients from the 
most affluent areas are significantly more likely to receive these treatments after 
adjustment for disease severity.  
Key strengths of this study include the population-wide coverage of the UK CF 
registry, the high quality of the data and the longitudinal analysis. There are 
limitations: First, it relies on retrospective, routinely collected data and use of a 
standard measure of deprivation of area of residence, the IMD. Each small area 
contains about 1500 people, and in this respect the IMD allows much finer resolution 
than the previous US analyses (O'Connor et al., 2003, Schechter et al., 2009, 
Schechter et al., 2011) that have used ZIP code linked income data, since each ZIP 
code contains about 30,000 people (Krieger et al., 2002). There is always the 
possibility of ecological fallacy, but this is unlikely, given that similar associations 
have been found in the US studies that use both area and individual measures of SES. 
Second, I had valid postcodes on only 90% of the sample, although my sample size 
was large, with no pronounced gradient in the proportion of patients by deprivation 
quintile. The excluded population is shifted towards older birth cohorts, reflecting 
improved collection of postcodes over time, but I do not believe that this has 
significantly biased the associations observed (Table 10). Third, there is a strong 
cohort effect in CF and, with datasets of this type, age and cohort effects confound 
one another, and cannot be completely separated (Taylor-Robinson et al., 2012a). I 
have adjusted for both in our analysis, to estimate the adjusted effect on deprivation.  
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This study quantifies the longitudinal weight trajectory of the UK CF population, and 
the effects of area deprivation, sex and genotype. In the first three years of life there 
is a period of improvement in weight SD score, presumably secondary to diagnosis 
and subsequent pancreatic enzyme supplementation with close attention to nutrition. 
Similar patterns have been observed in cross-sectional analyses of US registry data 
(Lai et al., 1999). Our study identified significant differences in sex-adjusted WAZ, 
with males being heavier from the outset. Other studies have shown differences in 
weight trajectories by sex in CF (Zemel et al., 2000), but when British reference 
standards are used, this sex difference appears greater, so this finding may partly 
represent a standardisation artefact (Lai et al., 1999). In addition genotype also had 
an effect, with homozygotes for delta F508 experiencing greater weight gain in the 
first three years, and greater weight loss subsequently. This probably relates to a 
greater diagnosis and treatment effect early on in life, followed by accelerated weight 
loss subsequently as a result of pancreatic insufficiency. 
 
Overall, the UK CF population is significantly underweight, and shorter compared to 
the UK reference population, by about a third of an SD score. Deprivation 
approximately doubles this effect, lowering the SD score by another third. It is not 
clear how much of the effect of SES on growth outcomes is specific to CF, and how 
much is a reflection of SES effects in the general population. Comparable data in 
contemporary representative cohorts in the UK is lacking, but the age related 
changes in growth in the general population are characterised by increasing obesity 
in childhood from the age of 4 onwards, with higher BMI in the more deprived 
populations (Howe et al., 2011, Howe et al., 2012), and this is opposite to the 
patterns seen in our study. In a large cohort, birth weight was lower in more deprived 
populations in the UK, by about 0.2 of an SD score, when comparing the most 
deprived Townsend score quartile to the least (Kinra et al., 2005). This difference is 
smaller than the projected weight difference at intercept in our study (-0.54), but this 
difference could be influenced by differences in the size of the subgroups compared 
(quartiles in the former and quintiles in ours). Another recent study found no 
difference in birth weight by SES measured using parental occupational class (NS-
SEC) (Wijlaars et al., 2011). I speculate that having CF is likely to amplify the 
effects of SES on nutritional status at birth, and in the first few years of life. 
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The inequality in weight is greatest at around the time of diagnosis, and becomes 
narrower over the first three years of life. This is an important finding, since a 
widening of inequalities over time is often the norm (Ben-Shlomo and Kuh, 2002, 
Whitehead and Dahlgren, 2007, CSDH, 2008). These findings suggest that extending 
the period of differential weight gain for as long as possible may reduce inequalities, 
further supporting neonatal screening programmes to facilitate early diagnosis and 
therapy (Southern et al., 2009). We can speculate that by extending this period of 
catch-up for as long as possible by early diagnosis (i.e. screening) we may see an 
attenuation of the deprivation effect over time. In this study, there was no difference 
in the age at diagnosis by deprivation, but screening was associated with improved 
weight, height, and lung function in children. Furthermore, our finding that the 
prevalence of supplemental feeding therapy was higher, after adjusting for disease 
severity, in the most disadvantaged patients suggests that NHS professionals are 
actively engaged in trying to boost the nutrition of poorer patients in particular, 
recognising their health disadvantage.  
The social gradient in lung function, evident as soon as it can be routinely measured 
at age five, points to the crucial role of environmental and health care factors 
operating in the early years of life to produce inequalities. It further reinforces the 
need for early diagnosis and action to prevent adverse consequences for children 
with  CF  living  in  disadvantaged  circumstances.  In  Schechter  and  colleagues’  cross-
sectional study of US data inequalities in %FEV1 by Medicaid status widened 
slightly from 5 to 20 years of age (Schechter et al., 2001). The magnitude of the 
inequalities   in   lung   function   at   age   five   found   in   Schechter’s study was larger 
(around 9% difference) than in our UK study (4%), as was the magnitude of 
inequalities   in   lung   function   found   in  O’Connor   and   colleagues’   US   study,  which  
found a difference of 5·5% between most and least deprived quintiles (O'Connor et 
al., 2003). Methodological differences between the studies, however, make a direct 
comparison between UK and US findings on the magnitude of the deprivation gap in 
lung function inappropriate. This study is the first to examine the relationship 
between deprivation and %FEV1 in a population level adult cohort. I did not find a 
significant association, despite the higher prevalence of P. aeruginosa. I speculate 
that this finding may relate to the complication of progressive drop-out in older 
 154 
patients, and the relative insensitivity of %FEV1 as an outcome measure in adults 
(Taylor-Robinson et al., 2012a). 
The increased prevalence of chronic P. aeruginosa infection in patients from more 
deprived areas, after adjusting for %FEV1, is an important new finding in a 
population-level cohort. In Schechter and colleagues study (Schechter et al., 2001), 
Medicaid patients were more likely than non-Medicaid patients to have 
P. aeruginosa, but when adjusted for %FEV1 there was no statistical difference, and 
a more recent US cohort study did not demonstrate an association (Rosenfeld et al., 
2012a). Previously identified risk factors for P. aeruginosa acquisition, which is 
associated with worse lung function, include female sex and genotype (both 
significant in this study), and exposure to other patients with P. aeruginosa 
colonisation (Schechter, 2011). My finding that more deprived groups are more 
likely to receive IV therapies in hospital may result in more deprived patients having 
greater exposure to other patients with chronic P. aeruginosa.  
Marked socio-economic differences were observed in the reported use of key CF 
therapies in two contrasting ways. First, children from the most deprived quintile 
were around twice as likely to receive hospital IV antibiotic therapy, and nutritional 
support, after adjustment for disease severity. I can speculate, from my knowledge of 
UK CF services, that clinicians in the NHS are more likely to bring children from 
more deprived areas into hospital for IV therapies because of concerns about the 
difficulties in delivering treatments in their home environment. Conversely, children 
living in more affluent circumstances may receive IV therapy at home because of 
judgements about the adequacy of support and adherence to therapy in the home 
and/or  because  of  the  families’  wish  to  avoid  disruption  to  schooling  and  family  life.  
This equitable model of care, with positive discrimination for socially disadvantaged 
children and adults with CF, is an uncommon finding in health systems, where often 
access, particularly to secondary care for adults, declines with increasing deprivation, 
after adjusting for differential need (Hanratty et al., 2007b, Stirbu et al., 2011). While 
several studies have found use of health services in general by level of deprivation, 
adjusted for need, to be more equal in relation to children than adults (Groholt et al., 
2003), I have found evidence in CF children that goes even further with a pro-poor 
bias in the NHS for specific therapies. Coupled with my findings of inequalities in 
outcomes by deprivation which do not widen over time, I speculate that the treatment 
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decisions being made by clinicians may mitigate some effects of social disadvantage. 
This provides encouragement that there are interventions that health services can 
make to reduce the adverse effects of deprivation on chronic conditions such as CF. 
In the US, using zip-code linked income of an area as the socio-economic indicator, 
there was no gradient in IV therapy use in children <12, but in young people aged 
13-18 years, those living in more affluent areas were more likely to be treated 
(13·8% in the lowest income category compared to 19·2% in the highest) (Schechter 
et al., 2011). 
My second, and contrasting, set of findings on CF therapies, however, point to an 
apparent pro-rich bias in two other therapies, more evident in adults than children: 
more affluent adults in the UK are more likely to receive DNase and inhaled 
antibiotics than their more disadvantaged counterparts. DNase is a relatively 
expensive therapy to reduce viscosity of sputum and to aid sputum expectoration, 
and there is some evidence that it prevents decline in %FEV1 (Pressler, 2008). These 
therapies, although relatively expensive, are free of charge to all patients in the NHS. 
One possibility for the social disparity in access to them is that they are both home-
based treatments, requiring regular and long-term administration. Socially 
disadvantaged patients with CF are less likely to adhere to treatments (Schechter et 
al., 2009) and if they report poor adherence, clinicians might be less likely to 
prescribe these drugs because they are unlikely to be as effective if taken 
inconsistently. Evidence from the US shows no significant difference in use of 
DNase in children by area income quintile, but children on Medicaid (i.e. receiving 
free or subsidised care) were more likely to receive DNase than non-Medicaid 
children (Schechter et al., 2009). 
Further research is needed to clarify which elements of the CF care model may 
contribute to a reduction in the adverse outcomes associated with deprivation. It is 
concerning that the burden of treatment for more disadvantaged families is higher 
and hospital admission to administer IV therapy, which is more disruptive to school 
and family life, is much more common. Furthermore the link with P. aeruginosa 
colonisation requires further investigation. Higher SES, as measured by parental 
education status, is associated with improved adherence to treatment in CF 
(Schechter, 2011), and further research to investigate the processes that lead to these 
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differences is required. Systems to support home IV therapy provision for more 
deprived groups in the UK should be explored.  
Differences in access to health care cannot explain the differences in weight and 
height, by SES, that are evident at the time of diagnosis, and are unlikely to explain 
the gradient in lung function evident at around age five. The UK CF registry does not 
capture data about smoking in the home and these early effects may be associated 
with the known differences in smoking prevalence by SES in the UK (Mackenbach, 
2011b). The effect of SES on growth in utero and in the early years in people with 
CF may be partially mediated by maternal smoking and ETS exposure, thus affecting 
subsequent outcomes and ultimately survival. 
In conclusion, this study has identified important longitudinal inequalities in weight, 
height, BMI, lung function, and risk of P. aeruginosa carriage by deprivation in 
people with CF in the UK, which start early in life, but do not increase over time. 
The strength of the effect size, dose-response relationship, timing, consistency across 
outcomes, coherence with previous research, existence of plausible mechanisms, and 
absence of any obvious alternative explanation suggest that the associations are 
likely to be causal.  
There is significant pro-poor bias in relation to IV therapies and nutritional 
supplementation, but evidence of reduced use of DNase and inhaled antibiotics after 
adjustment for need. Future studies should focus on interventions, such as reducing 
ETS exposure (Taylor-Robinson and Schechter, 2011), which may mitigate the 
effects of deprivation during the critical early years of life, and on identifying aspects 
of healthcare provision in CF that would help overcome the extra burden of adverse 
consequences of CF faced by patients living in disadvantaged circumstances.  
Interpretation 
Referring to the Diderichsen model outlined in the literature review (Figure 6) this 
study has demonstrated differential outcomes in CF on the basis of SES. There are 
important longitudinal differences in weight, height, BMI, %FEV1 and risk of 
P. aeruginosa colonisation (which could also be considered a differential exposure) 
by deprivation in people with CF in the UK, which start early in life, but do not 
increase over time. This analysis also suggests that there is differential vulnerability 
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(Figure 6) by SES, stemming from the same exposure to the underlying genetic risk 
factor for CF (e.g. two abnormal CFTR allelles). These pathways are discussed 
further in Chapter 7.  
Marked socio-economic differences were observed in the reported use of key CF 
therapies in the UK. People from more deprived areas are around twice as likely to 
receive hospital IV antibiotic therapy, and nutritional support, but less likely to 
receive DNase and inhaled antibiotics. Interventions to reduce inequalities in 
outcomes in CF need to be focussed in the antenatal period and the early years. 
Further research is needed to clarify which elements of the CF care model in the UK 
may contribute to a reduction in the adverse outcomes associated with deprivation, 
and to investigate identified differences in access to inhaled therapies.  
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Chapter 5: Study 2 – A longitudinal study of the impact of 
social deprivation and disease severity on employment 
status in the UK CF population 
 
Abstract 
Objective: People with CF in the UK and elsewhere are increasingly surviving into 
adulthood, yet there is little research on the employment consequences of having CF. 
Poorer socio-economic circumstances have been linked with worse outcomes in CF. 
Exploring broader social patterns in employment in people with CF and other 
chronic illnesses is a key step in understanding how health and social inequalities are 
generated and perpetuated. I investigated, for the first time in a UK-wide cohort, 
longitudinal employment status, and its association with deprivation, disease 
severity, and time in hospital.  
Design: I undertook a longitudinal registry study of adults with CF in the UK aged 
20 to 40 (3458 people with 15,572 observations between 1996 and 2010).  
Methods: Mixed-effects models were used to assess the association between small 
area deprivation and employment status, adjusting for clinically important covariates. 
Results: Around 50% of adults with CF were in employment. Male sex, higher 
%FEV1 and BMI, and less time in hospital were associated with improved 
employment chances. A person in the most deprived quintile was less likely to be in 
employment, after adjusting for disease severity, compared to their more advantaged 
counterparts (log-odds -2.66, 95% CI -3.1 to -2.26, comparing the most to the least 
deprived quintile). For men with a %FEV1 of 60 at the age of 30, this equates to 
67.7% employment in the least deprived quintile, compared to 50.2% in the most 
deprived, a difference of 17.5 percentage points. Comparing a population with 
relatively good lung function (a %FEV of 80), to one with poor lung function (a 
%FEV1 of 30), with all other things being equal (i.e. deprivation quintile 3, male 
sex), at the age of 30 there was a difference of 7.2 percentage points in employment 
chances. Furthermore, deprivation modifies the effect of lung function on 
employment chances – a 40 point contrast in %FEV1 was associated with a three 
percentage point reduction in employment chances in the most advantaged quintile, 
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compared to a 7.7 point reduction in the most deprived quintile. Genotype and use of 
home IV therapy were not associated with employment status. 
Conclusions: Deprivation, disease severity, and time in hospital all influence 
employment chances in CF. Furthermore, our analysis demonstrates that deprivation 
amplifies the harmful effects of disease severity on employment: the employment 
chances of people with CF with poor lung function from disadvantaged areas are 
damaged to a much greater extent than for their counterparts living in the least 
disadvantaged circumstances. This differential social consequence of having CF is 
likely to be a key pathway for the amplification of health inequalities in CF. Future 
studies should focus on understanding and mitigating the barriers to employment 
faced by people with CF.  
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Introduction 
CF is the commonest life-limiting inherited disease among Caucasian populations, 
with most patients dying prematurely from respiratory failure. Children with CF in 
the UK and other OECD countries are usually diagnosed in the first year of life 
(Cystic Fibrosis Trust, 2011), and subsequently require intensive support from family 
and healthcare services. People with CF in the UK and elsewhere are increasingly 
surviving into adulthood, with the median age of survival estimated to be over 50 
years for a person born in this century (Dodge et al., 2007). An implication of this is 
that increasing attention needs to be paid to the experiences of people with CF in 
adulthood, including the employment consequences of having CF. 
Employment is one of the ‘social determinants’ of health (Marmot et al., 2010b). 
Work influences health in a number of ways; it provides income to meet material 
needs, but also fulfils critical psycho-social functions, increasing self-worth, sense of 
identity and opportunities for social interaction. Numerous studies have identified 
unemployment as a potent risk factor for poor health, and equally, poor health can 
lead to reduced employment chances (Bambra et al., 2009, Bambra et al., 2010). 
People with chronic illnesses face numerous barriers to entering the labour market, 
and CF provides a case in point. Factors related to disease severity, such as reduced 
lung function may restrict employment choices for adults with CF, and the treatment 
burden further compounds this; adults with CF are generally expected to perform 
physiotherapy regularly and there are the added demands of taking large numbers of 
therapies, including frequent visits to hospital (Sawicki et al., 2009).  
Despite this, the evidence about patterns of employment for adults with CF is limited 
(Saldana and Pomeranz, 2012), and mainly based on cross-sectional studies of single 
centres, which cannot delineate the relationships between chronic illness and 
employment outcomes or whether these relationships indicate causality. 
Furthermore, Edwards et al (Edwards and Boxall, 2010), adopting the social model 
of disability, have criticised the approach taken to understanding employment 
outcomes in CF. They point out that most of the research, to date, focusses on the 
effects of disease severity on employment chances. They argue that this ‘impairment’ 
focus locates the problem within the individual, and ignores the significant structural 
and societal barriers to employment for people with chronic illness. 
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Exploring broader social patterns in employment in people with CF and other 
chronic illnesses is a key step in understanding how health and social inequalities are 
generated and perpetuated. CF provides a particularly useful case for studying these 
processes, because it is a classically inherited genetic disease, and unlike most 
chronic diseases, there is no difference in the incidence of the condition with SES 
(Taylor-Robinson and Schechter, 2011, Taylor-Robinson et al., 2013a). However, 
inequalities  develop  over  the  course  of  people’s  lives,  as  a  consequence  of  having  the  
disease. Informed by Diderichsen’s  analytic  framework  of  the  pathways  from  social  
context to health outcomes (Diderichsen et al., 2001), I have demonstrated important 
differential health consequences of having CF, by deprivation in the UK (see Study 
1, Chapter 4). For instance, in the UK there are clinically important differences in 
growth,   and   lung   function  by  deprivation,  which  are   evident   early  on   in   children’s  
lives (Taylor-Robinson and Schechter, 2011, Taylor-Robinson et al., 2013a). 
Furthermore, people with CF from socio-economically disadvantaged backgrounds 
die at a younger age than those in more advantaged social positions in the UK and 
the US (Britton, 1989, Schechter et al., 2001, O'Connor et al., 2003, Barr HL, 2011). 
The social patterning of outcomes in CF implies that differential exposure to social 
and environmental risk factors is playing an important role in influencing outcomes 
(Diderichsen et al., 2001, Ben-Shlomo and Kuh, 2002, Marmot et al., 2010b). 
Building on these findings, the next step is to look for any ‘differential social 
consequences’ of ill-health in the context of CF (Diderichsen et al., 2001). My aims 
in this study were to explore the effect of deprivation, disease severity, and time in 
hospital on longitudinal employment chances in people with CF and to investigate 
whether changes in lung function have differential effects on employment chances 
by  deprivation  (‘differential  social  consequences’   in  Diderichsen’s  model, Figure 6 
in Chapter 3). For instance, is low lung function in CF more damaging to 
employment chances in people from more disadvantaged areas? I undertook a 
longitudinal population level registry study of employment status in adults with CF 
in the UK to answer such questions.  
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Methods 
An in depth description of the methods used is found in Chapter 3. An overview is 
provided here. 
 
Design, setting and data source 
I undertook a longitudinal retrospective cohort study of annual review data on 
individuals between the ages of 20 and 40 with at least one outcome measurement 
and a valid postal code in the UK CF Registry between 1996 and 2010. The UK CF 
Registry is supported and coordinated by the UK CF Trust (CF Trust, 2013a). The 
Registry is maintained to a high standard of data quality, and is estimated to include 
nearly all people estimated to have CF in the UK population (Mehta et al., 2004) and 
is therefore ideally suited to the study of outcomes across the whole socio-economic 
spectrum in the UK society. 
Primary outcome and covariates 
The primary outcome was any employment in the preceding year (yes or no), which 
included people recorded as being in either full- or part-time employment at annual 
review (Figure 57). The primary exposure measure was a small-area-based measure 
of deprivation of area of residence. Postcodes were used to derive IMD scores for the 
constituent UK countries (GeoConvert, 2011) and each person was allocated to a 
deprivation quintile on the basis of first recorded postcode. Baseline covariates in the 
analysis were: sex; genotype coded as the number of delta F508 alleles (0, 1 or 2); 
and year of birth. I adjusted for disease severity in the analysis on the basis of lung 
function (measured by %FEV1) and body mass (measured by BMI SD score). 
%FEV1 is recognized as key outcome measure in CF, as it is strongly predictive of 
survival (Rosenfeld et al., 2005). As a measure of time spent administering therapies, 
we included the number of IV therapy days in the past year in our analysis, further 
disaggregated into IV days in hospital, and IV days at home. 
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Figure 57: Cross-sectional full time and part time employment, by deprivation 
and sex 
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Statistical Methods 
In brief, exploratory analysis involved: plotting the stratified raw data; fitting GAMs 
(Hastie and Tibshirani, 1990) to visualize the shape of associations; and plotting 
empirical logits (log-odds of employment binned by age) from the raw data. We then 
fitted GLMMs to the data across the age range. These model the log-odds of 
employment status as a linear function of the measured covariates and individual 
level random-effects (see methods chapter). Linear and quadratic models for the 
mean trajectory were explored as appropriate, as informed by the GAMs. The logic 
model for the analysis is shown in Figure 58. I first fitted a model adjusted for age 
and the baseline covariates defined above, which are unlikely to be in the causal path 
from SES to employment status. I then tested for the significance of adding disease 
severity measures, and service use measures, and finally added deprivation score to 
the model.  
 
Figure 58 Logic model to inform analysis of employment status 
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In this way I fitted sequential models adjusting for the covariates of interest, and 
estimated model parameters by maximum likelihood, using generalized likelihood 
ratio statistics to compare nested models, and Wald statistics to test hypotheses about 
model parameters (Laird and Ware, 1982). These longitudinal models take into 
account drop-out due to death, and implicitly estimate the chances of employment in 
a drop-out free population (Diggle et al., 2002). I present effect estimates as log-odds 
with CIs, since ORs can be misinterpreted when outcomes are common (Grimes and 
Schulz, 2008). To aid interpretation, I display population-averaged employment 
chances in the plots, by averaging individual-level fitted values over the population. 
 
Ethics 
NHS research ethics approval (Huntingdon Research Ethics Committee 07/Q0104/2) 
has been granted for the collection of data into the UK database. The CF Trust 
database committee approved the use of anonymised data in this study. 
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Results 
Population characteristics 
In total, 4062 people were recorded in the registry between the ages of > 20 and < 40 
years; 3495 of these had a valid postcode recorded and met the inclusion criteria and 
3458 individuals had full data on all baseline covariates. The final analysis dataset 
thus contained 3458 people, with 15,098 person-years of follow-up, and data 
collected at 15,572 annual reviews. The baseline characteristics of individuals at first 
recorded entry into the cohort, are shown in Table 13, stratified by employment 
status, and deprivation quintile (Table 14). At first entry to the cohort, 53% of people 
were in full-time employment. Of those in employment 14% were in the most 
deprived quintile, while of those not in employment 25% were in the most deprived 
quintile.  
 
Table 13: Characteristics of study population in UK CF Registry by 
employment status at baseline 
 
 Not in employment Employed Total 
Number of adults with CF (%) 1845 (53.4) 1613 (46.6) 3458 
Observations (%) 7287 (46.8) 8285 (53.2) 15572 
Deprivation quintile 1 (least deprived) 295 (16) 344 (21.3) 639 (18.5) 
Deprivation quintile 2 319 (17.3) 370 (22.9) 689 (19.9) 
Deprivation quintile 3 357 (19.3) 354 (21.9) 711 (20.6) 
Deprivation quintile 4 417 (22.6) 321 (19.9) 738 (21.3) 
Deprivation quintile 5 (most deprived) 457 (24.8) 224 (13.9) 681 (19.7) 
Number of F508 alleles:2 (%) 952 (51.6) 744 (46.1) 1696 (49) 
Number of F508 alleles:1 (%) 632 (34.3) 616 (38.2) 1248 (36.1) 
Number of F508 alleles:0 (%) 261 (14.1) 253 (15.7) 514 (14.9) 
Female 856 (46.4) 672 (41.7) 1528 (44.2) 
Non-white  54 (2.9) 27 (1.7) 81 (2.3) 
Birth cohort >1959-01-01 152 (8.2) 211 (13.1) 363 (10.5) 
     > 1969-01-01 409 (22.2) 573 (35.5) 982 (28.4) 
     >1979-01-01 1203 (65.2) 780 (48.4) 1983 (57.3) 
     >1989-01-01 81 (4.4) 49 (3) 130 (3.8) 
Median age at baseline (years) (IQR) 21 (20.4,24.5) 23 (20.7,29.3) 21.5 (20.5,27) 
Median %FEV1 at entry (IQR) 61.8 (41.8,82.2) 68.4 (49.9,85.2) 65.3 (45.8,83.7) 
%FEV1 >90 (normal) 286 (15.5) 302 (18.7) 588 (17) 
%FEV1 >70 and <90 (mild) 457 (24.8) 458 (28.4) 915 (26.5) 
% FEV1 >40 and <70 (moderate) 678 (36.7) 619 (38.4) 1297 (37.5) 
% FEV1 <40 (severe) 424 (23) 234 (14.5) 658 (19) 
Pseudomonas colonization at entry 1123 (60.9) 836 (51.8) 1959 (56.7) 
Median BMI SDS at entry (IQR) -0.6 (-1.4,0.1) -0.4 (-1.2,0.4) -0.5 (-1.3,0.3) 
Died 223 (12.1) 115 (7.1) 338 (9.8) 
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Table 14: Baseline characteristics at entry to the dataset, stratified by 
deprivation quintile 
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Exploratory analysis 
 
In each annual data collection wave in the registry, for all ages between 20 and 40, 
about 50% of the UK CF population were recorded as being in full- or part-time 
employment (Figure 59). When stratified by age, employment prevalence increased 
from 37% at age 20, before peaking at around 60% at age 30, and subsequently 
decreasing to 55% at age 40 (Figure 59). These overall trends hide important 
differences in employment prevalence by sex and deprivation status. As illustrated in 
the lower row of Figure 59, the cross-sectional prevalence of employment was 
greater in people from the least deprived quintile at all ages. In the least deprived 
areas, the prevalence of full-time employment increased to around 80% in men and 
70% in women, between the ages of 20 and 25 years, before decreasing gradually 
after the age of 30 years. By contrast, in people from the most deprived quintile, the 
prevalence of employment remained fairly constant, at around 30% to 40% for both 
men and women.  
The GAMs (Figure 60) suggested an approximately linear relationship between 
deprivation score and log-odds of employment, with increasing deprivation 
associated with decreased employment chances. Increasing %FEV1 and increasing 
age were associated with increased employment chances, and the relationship with 
birth cohort did not change over time. On this basis, birth cohort was included in the 
model as a continuous variable, rather than a factor. The empirical logit plots 
suggested important differences in employment chances by SES, and that a quadratic 
term may be necessary to model the age trajectory (Figure 61). 
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Figure 59: Cross sectional employment prevalence by age and year  
With 95% CIs (top row). Bottom row shows cross-sectional employment prevalence 
by age, stratified by deprivation quintile (most deprived quintile in red), for men and 
women. 
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Figure 60: GAMs for risk of employment 
GAMs showing the mutually adjusted cross-sectional effect of deprivation score (top 
left), age (top right), %FEV1 (bottom left) and (birthyear-1959) (bottom right) on 
scaled risk of employment. Y axis in the plots shows log-odds of employment. 
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Figure 61: Empirical logit plots by age and SES for females in the dataset 
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Definitive analysis 
Figure 62 illustrates the modelled independent population averaged effects of 
deprivation, sex, %FEV1, BMI and time in hospital on employment chances for 
people with CF in the UK, on the basis of the final model (Table 15, column 5). 
There are significant age-related effects. The general pattern is for the proportion of 
people in employment to increase to around age 30, and decrease subsequently. 
Genotype and use of home IV therapy were not associated with employment status in 
any of the analyses, and I excluded them from the final models.  
Of the covariates in the model, deprivation status explained more of the variance, 
and there was a dose-response relationship (Figure 62, Table 15): a person in the 
most deprived quintile was less likely to be in employment, after adjusting for 
disease severity, compared to their more advantaged counterparts (log-odds -2.66, 
95% CI -3.1 to -2.26, comparing the most to the least deprived quintile). For men 
with a %FEV1 of 60 at the age of 30, this equates to 67.7% employment in the least 
deprived quintile, compared to 50.2% in the most deprived, a difference of 17.5 
percentage points (Figure 62). Men were more likely than women to be in 
employment (log-odds 0.40, 95% CI 0.16 to 0.64 in adjusted model), which 
corresponds to 61.7% employment in men, compared to 58.7% employment in 
women at age 30, for people with a %FEV1 of 60, in the middle deprivation quintile 
– a difference of three percentage points. People with better lung function were more 
likely to be in employment, and this followed a monotone dose response relationship. 
For a population with relatively good lung function (a %FEV1 of 80) at age 30, this 
equates to 64.5% employment, compared to 57.3% in a population with relatively 
poor lung function (a %FEV1 of 30), with all other things being equal (i.e. 
deprivation quintile 3, male sex) (Figure 62). Higher BMI was associated with 
improved employment chances (log-odds 0.1, 95% CI 0.020 to 0.188 per one unit 
increase in BMI SD score), and more days in hospital were associated with lower 
employment chances (log-odds -0.023, 95% CI -0.027 to -0.019, per day in hospital). 
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Table 15: Log-odds for the final nested GLMMs. 
 Baseline Baseline 
+ 
severity 
Baseline 
+ 
Severity + 
Time in 
hospital 
Baseline + 
Severity + 
Time in 
hospital + 
Deprivation 
Baseline + 
Severity + 
Time in hospital + 
Deprivation*%FEV1  
Constant 0.663*** 0.761*** 0.997*** 2.047*** 2.058*** 
 (0.105) (0.106) (0.105) (0.172) (0.171) 
age 0.128*** 0.143*** 0.144*** 0.146*** 0.146*** 
 (0.016) (0.016) (0.016) (0.016) (0.016) 
age^2 -0.022*** -0.024*** -0.023*** -0.023*** -0.023*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Birthyear -0.057*** -0.059*** -0.046** -0.039** -0.039** 
 (0.014) (0.014) (0.014) (0.014) (0.014) 
Male/Female 0.446*** 0.485*** 0.443*** 0.410** 0.401** 
 (0.129) (0.128) (0.125) (0.125) (0.125) 
Random intercept SD (3.016) (2.893) (2.779) (2.640) (2.632) 
Random slope SD (0.450) (0.451) (0.438) (0.442) (0.441) 
%FEV1   0.026*** 0.020*** 0.021*** 0.013** 
  (0.002) (0.002) (0.002) (0.005) 
BMI SDS score  0.163*** 0.121** 0.106* 0.104* 
  (0.043) (0.043) (0.043) (0.043) 
Hospital IV days   -0.024*** -0.023*** -0.023*** 
   (0.002) (0.002) (0.002) 
Deprivation quintile 2/1    -0.270 -0.279 
    (0.202) (0.202) 
Deprivation quintile 3/1    -0.967*** -0.976*** 
    (0.200) (0.200) 
Deprivation quintile 4/1    -1.422*** -1.427*** 
    (0.198) (0.198) 
Deprivation quintile 5/1    -2.650*** -2.663*** 
    (0.207) (0.207) 
Deprivation quintile 2/1 
x %FEV1  
    0.010 
     (0.007) 
Deprivation quintile 3/1 
x %FEV1  
    0.010 
     (0.006) 
Deprivation quintile 4/1 
x %FEV1  
    0.006 
     (0.006) 
Deprivation quintile 5/1 
x %FEV1  
    0.016* 
     (0.007) 
Log-likelihood -7885 -7720 -7645 -7548 -7545 
N 15572 15430 15430 15430 15430 
Groups 3458 3451 3451 3451 3451 
Baseline variance 
explained (%) 
- 7.9 15.1 23.3 23.8 
*P  < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses 
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Figure 62. Longitudinal employment trajectory versus age of people with CF in 
UK CF Registry, by deprivation quintile, sex, %FEV1, BMI SD score and days 
in hospital.  
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In order to assess if there was an interaction between deprivation status and %FEV1 
level, I first undertook an analysis of individuals in deprivation quintiles 1 and 5 
only, and dichotomised these patients into those with high and low lung function, 
using a %FEV1 of 50 percentage points as the cut off. Figure 63 shows the raw data 
plotted by age, and this provided some evidence of an interaction, with an apparent 
larger effect of low lung function on employment chances evident in people in the 
most deprived quintile. Formally fitting a model to this data, with covariates limited 
to age, deprivation quintile, and dichotomised %FEV1 also showed a significant 
interaction (Figure 63). 
 
Figure 63: Exploratory analysis of interaction effect between deprivation 
and %FEV1 on employment status.  
Raw data (left panel) and fitted model (right panel) limited to deprivation quintile 1 
and 5, and %FEV1 dichotomised into high (>50) and low categories (<50). 
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Figure 64 illustrates the interactive effect of level of lung function and social 
deprivation on population averaged employment chances in men and women, in the 
final model fitted to all of the data. In the final model, a composite test for interaction 
between %FEV1 and deprivation quintile is not significant (P = 0.2), but the contrast 
between the most deprived quintile and %FEV1 is significant (log-odds 0.016, 95% 
CI 0.0028 to 0.03, per unit increase in %FEV1, P = 0.018) (Table 15). The fitted data 
for men and women at age 30 is shown in Table 16. This indicates that declines in 
lung function have more of an effect on employment chances in disadvantaged 
populations – at the age of 30, a contrast of 40 percentage points in lung function 
corresponds to a decline in employment prevalence from 69.2% to 66.1% (3.1 
percentage points difference) for men in least deprived quintile, compared to a 
change from 54.1% to 46.4% (7.7 percentage points difference) in the most deprived 
quintile (Table 16).  
 
Table 16: Percentage of people with CF in employment at age 30 
 Employment (%) MEN 
Employment (%) 
WOMEN 
No health or social disadvantage 
(good lung function and high SES) 69.2 66.8 
Health disadvantage only 
(poor lung function and high SES) 66.1 63.7 
Social disadvantage only 
(good lung function and low SES) 54.1 51.4 
Double disadvantage 
(poor lung function and low SES) 46.4 43.6 
Data from final interaction model 
%FEV1 fixed at 80 percentage points for good lung function, and 40 percentage points for poor lung 
function 
High SES fixed at least deprived quintile, and low SES fixed at most deprived quintile 
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Figure 64: Longitudinal employment trajectory versus age, demonstrating the 
interaction between deprivation and %FEV1  
The lines show the final modelled longitudinal trajectories from the interaction 
model (Table 15, column 5), contrasting the adjusted effects of deprivation, 
and %FEV1. Low %FEV1 is more damaging to employment chances in people living 
in the most disadvantaged areas. Other covariates in the final model are fixed. 
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Discussion 
I undertook a longitudinal registry-based study of employment status in the UK CF 
population, and found that deprivation status is a more important predictor of 
employment chances than either disease severity or time spent in hospital. 
Furthermore, deprivation modifies the effect of lung function on employment 
chances. Our analysis demonstrates that there are differential social consequences of 
poor health in the context of CF – poor lung function is approximately twice as 
harmful to employment chances in people living in the most deprived areas, 
compared to the least. As people are living longer, healthier lives with CF, it is more 
important than ever for strategies to promote employment to focus on the broader 
societal barriers to engagement in the workforce for people with CF, rather than 
taking   a   narrow   ‘impairment’   focus   solely   on   the   impact   of   disease   severity   on  
employment chances, as critiqued by Edwards et al (Edwards and Boxall, 2010).  
Key strengths of this study include the population-wide coverage of the UK CF 
registry, the high quality of the data, the longitudinal analysis, and the theoretical 
approach that responds to previous criticisms of the illness-focussed approach to 
understanding employment outcomes in CF. These findings are particularly relevant 
to the UK population, but could be cautiously generalized to other OECD countries 
with an universal health service. There are limitations: first it relies on retrospective, 
routinely collected data and we used a standard measure of deprivation of area of 
residence. It was therefore not possible to separate effects of socio-economic 
circumstances operating at the individual and area level. Second, I only had valid 
postcodes on 86% of the sample, though our sample size is large, with no 
pronounced gradient in the proportion of patients with valid postcodes by deprivation 
quintile i.e. missing postcode information is unrelated to deprivation. 
A recent review concluded that further research on CF and employment is necessary 
to improve occupational outcomes (Saldana and Pomeranz, 2012). The systematic 
review identified nine studies, that have looked at the relationship between CF and 
employment status, all of which were small, and based at one or two care centres. Six 
studies reported employment rates in all of these the employment rate was around 
50%. This review did not include the largest study to date, by Walters et al (Walters 
et al., 1993), which was a cross-sectional questionnaire survey of 1052 adults over 16 
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years of age with CF in the UK in 1990. Walters et al found that 55% of responders 
were working, whilst of those not employed, half gave ill health as the reason 
(Walters et al., 1993). In our study we find that the annual employment rate among 
CF adults in the UK appears to have remained unchanged between 50% and 55% 
over the last decade. Five previous studies focussed on the association between 
disease severity, as measured by %FEV1, and employment status, with mixed results: 
three studies conducted in the US (Burker et al., 2004), Canada (Frangolias et al., 
2003) and Australia (Hogg et al., 2007) concluded that %FEV1 was not related to 
employment status, and two from the US (Gillen et al., 1995) and Belgium 
(Havermans et al., 2009) suggested that it was related. The studies by Burker et al. 
(Burker et al., 2004), Gillen et al. (Gillen et al., 1995), and Hogg et al. (Hogg et al., 
2007) suggested that frequency of hospital admissions, demographic variables, 
mental health, and education level, may also influence employment chances.  
This study suggests that disease severity and time in hospital also influence 
employment chances in the UK, but these effects are not as large as one might have 
predicted. It is evident that people with significant respiratory impairment continue 
to work, and disease severity alone does not predict employment outcomes. 
Furthermore, there is a large amount of variability between individuals with similar 
characteristics (large random effects), which suggests that there are other important 
factors related to employment status that we have been unable to account for in our 
study. Highest educational attainment is one such factor, but these data were 
available only for 60% of the individuals in our analysis (see Appendix 4, Table 41) 
Adjusting for educational attainment did not change any of the substantive effects in 
our analysis, though it did reduce the random effects variance further. Other studies 
have also suggested that individual psychological factors and education status are 
correlated with employment status in CF (Burker et al., 2004). 
These previous studies on employment chances in people with CF tend to portray CF 
as  a  ‘serious  illness’,  which  causes  employment  problems.  In  contrast, Edward et al 
explored the employment experiences of adults with CF from a social model of 
disability perspective. They demonstrated barriers to employment that were similar 
to those experienced by other disabled people, as well as barriers related to the 
‘impairment   effects’   of   CF,   and   concluded   that   adults   with   CF   have   valuable  
perspectives to contribute to social model analysis and the development of 
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employment-related policy solutions (Edwards and Boxall, 2010). Our results not 
only corroborate, but also extend these observations, by demonstrating the 
interaction between disease severity related factors, and deprivation. 
These findings add to the extensive literature on the inter-relationship between 
chronic illness, SES, and employment opportunities (Holland et al., 2011b). In the 
UK in 2005 the age standardized employment rate for people of working age (25-59) 
was 80% in healthy women, compared to 50% in those with limiting long-standing 
illness (LLSI), and 93% compared to 59% in men (Holland et al., 2011b). 
Furthermore there was a striking social gradient for those with LLSI – the prevalence 
of employment was 66% in highly educated women with LLSI compared to 18% in 
those with low education, and in men 72% compared to 30% (Holland et al., 2011a). 
In our study the cross-sectional prevalence of employment was around 60% in the 
most affluent quintile, compared to 30% in the most deprived quintile in women, and 
70% versus 30% in men (Figure 57).  
Low employment in people with CF is a serious concern. Despite there being no 
difference in incidence of CF by SES, there are important differences in outcomes 
such as growth and lung function, and ultimately survival, in people with CF by SES 
in the UK and US (Schechter et al., 2001, Barr HL, 2011, Taylor-Robinson et al., 
2013a). Being out of work increases the risk of poverty and social exclusion, and is 
likely to further damage the health of the most disadvantaged people with CF. In this 
study I have demonstrated differential social consequences of illness in the context of 
CF, by which people with the double burden of chronic illness and low SES are more 
likely to be excluded from the labour market. We speculate that this may be an 
important pathway for the amplification of health inequalities in CF, whereby 
disadvantage builds on disadvantage. It is of particular concern that the most 
disadvantaged women have the poorest employment chances, since female sex is 
also an important risk factor for poor survival in CF (Barr HL, 2011). 
In conclusion, this study has identified important longitudinal inequalities in 
employment outcomes by deprivation in people with CF in the UK, which 
particularly effect women living in the most disadvantaged areas. Future studies 
should focus on policy interventions that would help overcome the extra burden of 
adverse consequences of CF faced by patients living in disadvantaged circumstances.  
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Interpretation 
People with CF are living longer so it is important to understand factors that 
influence adult employment chances. Previous studies have shown that people with 
CF from socio-economically disadvantaged backgrounds have worse outcomes. This 
longitudinal study explores how SES, disease severity, and time in hospital influence 
employment chances, in order to better understand how health and social inequalities 
in CF are generated and perpetuated. 
Around 50% of adults with CF were in employment. Lower social deprivation, male 
sex, higher %FEV1 and BMI, and less time in hospital were associated with 
improved employment chances. Crucially, our analysis demonstrates for the first 
time that deprivation modifies the effect of disease severity in CF: poor lung function 
is more harmful to employment chances for people living in the most disadvantaged 
circumstances compared to the least. Differential social consequences (see 
Diderichsen model in Chapter 2, Figure 6) of illness, demonstrated here in the 
context of CF, are important in the generation of health inequalities. Policies should 
address the extra burden of adverse consequences of CF faced by patients living in 
disadvantaged circumstances. 
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Chapter 6: Study 3 – Understanding the natural 
progression in %FEV1 decline in patients with CF: A 
longitudinal study 
 
Abstract 
Background 
Forced expiratory volume in one second as a percentage of predicted (%FEV1) is a 
key outcome in CF and other lung diseases. As people with CF survive for longer 
periods, new methods are required to understand the way %FEV1 changes over time. 
We present an up to date approach for longitudinal modelling of %FEV1 and apply it 
to a unique CF dataset to demonstrate its utility at the clinical and population level.  
Methods and Findings 
The Danish CF register contains 70,448 %FEV1 measures on 479 patients seen 
monthly between 1969 and 2010. I partitioned the variability in the data into three 
components (between patient, within patient and measurement error) using the 
empirical variogram. I then develop a linear mixed effects model to explore factors 
influencing %FEV1 in this population. Lung function measures are correlated for 
over 15 years. A baseline %FEV1 value explains 63% of the variability in %FEV1 at 
one year, 40% at three years, and about 30% at five years. The model output smooths 
out the short-term variability in %FEV1 (SD 6.3%), aiding clinical interpretation of 
changes in %FEV1. At the population level I demonstrate significant effects of birth 
cohort, pancreatic status and P. aeruginosa infection status on %FEV1 over time. 
Conclusions  
The modelling approach presented here provides a more realistic estimate of the 
underlying %FEV1 trajectory of people with chronic lung disease, compared to the 
random intercept and slope approach, by acknowledging the imprecision in 
individual measurements and the correlation structure of repeated measurements on 
the same individual over time. This method has applications for clinicians in 
assessing prognosis and the need for treatment intensification, and for use in clinical 
trials. 
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Introduction 
Understanding the long-term natural history of changes in lung function in people 
with lung diseases is a research priority (Holgate, 2007). In order to do this, objective 
measures of disease progression are necessary. The percent predicted forced 
expiratory volume in one second (%FEV1) is commonly used to monitor lung 
function, and to describe disease severity in CF (Davies and Alton, 2009) and 
chronic obstructive pulmonary disease (COPD) (Rabe et al., 2007). The %FEV1 is 
used to inform clinical decisions about changing or intensifying treatment, and as an 
outcome measure in clinical studies (Ramsey et al., 1993, Konstan et al., 2007a, 
Konstan et al., 2007b). Furthermore %FEV1 has been shown to be related to survival 
in CF. Kerem et al’s   study   in   1992  demonstrated   that   patients  with   a  %FEV1 less 
than 30 had a two-year mortality over 50 percent (Kerem et al., 1992), though a more 
recent study shows that survival rates at low levels of lung function have improved in 
subsequent cohorts (George et al., 2011). 
Interpreting the significance of changes in %FEV1 in CF to inform patient 
management and to counsel patients regarding prognosis requires an understanding 
of the inherent variability of %FEV1 measures within individuals, to determine what 
constitutes a clinically significant deterioration in %FEV1, rather than a change due 
to measurement error, or recoverable day-to-day fluctuation in lung function (Hnizdo 
et al., 2005, Corey, 2007). Furthermore, this variability needs to be understood to 
make valid inferences about the association between covariates and %FEV1 in 
observational studies. 
As survival in CF improves with successive cohorts, there are many more people 
surviving into late adulthood. An implication of this, coupled with the availability of 
long term follow-up data in CF registers, is that up to date methods should be 
adopted to interpret the long-term dynamics of lung function in CF. Statistical 
techniques for longitudinal data analysis have been the subject of much 
methodological development over the past 20 years, and the random intercept and 
slope model has become a popular analysis framework (Corey et al., 1997, Harber et 
al., 2007, Konstan et al., 2007a, Konstan et al., 2007b, Stern et al., 2007, van Diemen 
et al., 2011). While this is often appropriate for relatively short follow-up periods, 
there are theoretical reasons to suggest that this approach will lead to incorrect 
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inferences if applied over longer follow-up periods. One property of the method is 
that the modelled variability in %FEV1 increases as a quadratic function over time 
(in proportion to time squared), which leads to estimates that diverge unrealistically 
over longer time periods. Methods for undertaking these analyses over longer time 
periods have been described (Diggle et al., 2002), but have not been commonly 
applied.  
Now that people are surviving with CF for much longer, how can we optimally 
describe how %FEV1 changes over time, in a way that is useful for clinicians at both 
the individual and the population level? In this study I address this issue, and analyse 
a unique population-level dataset of people with CF that includes longitudinal 
%FEV1 measures taken monthly for up to 30 years. I develop a general model for 
%FEV1 decline that goes beyond the popular random-intercept and slope approach, 
and explicitly describes the variability in %FEV1 within individuals over time. I 
further show how this could be applied clinically to help interpret the significance of 
changes in lung function, and at a population level to explore the association of 
covariates (e.g. P. aeruginosa acquisition) with %FEV1 decline. In terms of the 
initial objectives of this thesis, being able to model lung function decline in the 
Danish population is a pre-requisite to exploring the effect of SES on such outcomes. 
Methods  
Subjects 
All patients aged over five contributing %FEV1 data in the Danish CF database 
between 1969 to 2010 were eligible. I excluded post-transplant data from patients 
who had received a lung transplant. Patients attending the two Danish CF centres 
(Copenhagen and Aarhus) are seen routinely every month in the outpatient clinic, for 
evaluation of clinical status, pulmonary function, and microbiology of lower 
respiratory tract secretions. It is estimated that coverage of people with CF, resident 
in Denmark is almost complete from 1990, when CF care was centralised. This 
coverage and the unparalleled frequency of measurement make this a unique dataset 
for epidemiological research. The Danish Data inspectorate (Datatilsynet) approved 
the study. 
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Lung function testing 
The primary outcome for this analysis is %FEV1. Pulmonary function tests were 
performed according to international recommendations (Miller et al., 2005), 
measuring forced expiratory volume in one second, expressed as a percentage of 
predicted values for sex and height using reference equations from Wang or 
Hankinson (Wang et al., 1993, Hankinson et al., 1999). 
Covariates 
Covariates in the analysis were: age; sex; genotype coded as the number of delta 
F508 alleles (0, 1 or 2); onset of chronic Pseudomonas infection (coded 0 or 1 as a 
time-varying covariate); PI determined on the basis of pancreatic enzyme usage 
(coded 0 or 1 as a baseline covariate); birth cohort (six 10-year cohorts starting at 
1948); and CFRD diagnosed using the WHO criteria (coded 0 or 1 as a time-varying 
covariate). 
Statistical analysis 
A detailed explanation is given in the methods chapter (Chapter 3). Repeated %FEV1 
measures on individuals are correlated, and this must be accommodated to obtain 
valid inferences. I use a linear mixed-effects model with longitudinally structured 
correlation (Diggle et al., 2002, Fitzmaurice, 2004), and contrast this approach with 
the widely used random-intercept-and-slope model (Laird and Ware, 1982), which 
assumes that repeated measures on individual subjects vary independently around a 
subject-specific linear time-trend, that itself varies randomly between subjects (Laird 
and Ware, 1982). For data consisting of short time-sequences of observations on 
each subject, this model often fits reasonably well. However, for longer time-
sequences it is too rigid. I therefore model random variation in %FEV1 over time 
within an individual subject so that the strength of the correlation of the random 
variation between two values depends on the corresponding time-separation. The 
model decomposes the overall random variation in the data into three components: 
between subjects; between times within subjects; and measurement error.  
Initially, I fit a provisional model for the mean response by OLS and used the 
empirical variogram of the residuals (see methods, Chapter 3) to provide initial 
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estimates for the three components of variation, and for the shape of the correlation 
function of the between-times-within-subjects component. I then re-estimated all of 
the model parameters by maximum likelihood, and use generalized likelihood ratio 
statistics to compare nested models, and Wald statistics to test hypotheses about 
model parameters. I assessed associations between single or multiple covariates and 
the population mean %FEV1 over time, and explored alternatives to a linear function 
for the population-averaged time-trend. 
To test the overall goodness-of-fit of the final model, I analysed the residuals as 
follows. First, plots of residuals against fitted values should show random scatter. 
Second, the residuals should have approximately the same covariance structure as the 
fitted model, which I checked by comparing their sample variogram with the 
theoretical variogram of the model. 
All analyses were carried out using the R open-source software environment 
(www.r-project.org). Maximum likelihood estimation, generalized likelihood ratio 
tests and Wald tests used the lme() function within the nlme package, together with 
the exponential class of correlation functions. Variogram calculations used an R 
function specially written by Peter Diggle. This R code, and some illustrative code 
used to generate the plots, and to fit the final model, can be found in the appendix for 
this chapter (Appendix 6). 
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Results  
Visualising the data 
Figure 65 shows the Danish dataset, with six individual trajectories selected in each 
panel. There are clear short-term and long-term components to the overall variation 
in %FEV1 over time. One of the key issues in this study relates to understanding the 
short-term dips (or improvements) in %FEV1 – are these catastrophic declines, or 
temporary changes from which individuals can recover? 
Population characteristics 
The dataset contains 70,448 lung function measures on 479 patients seen between 
1969 and 2010 in Denmark (Table 17). The median number of %FEV1 measures per 
person was 101 (range 2 to 597). The median follow-up period was 10.5 years (range 
0.1 to 31.5), with a total of 6500 person-years of follow up. Forty-two patients were 
followed up for more than 30 years (see methods section). In the earlier birth cohorts 
there was selection into the dataset, with patients surviving to contribute %FEV1 
measures appearing in the dataset, and some patients that had died being omitted. 
Only 3% of the sample did not carry at least one delta F508 allelle and 96% of the 
population had PI.  
Table 17: Baseline characteristics of Danish CF population 
  
Birth 
Cohort             
 >=1948 >=1958 >=1968 >=1978 >=1988 >=1998 Total 
N (%) 7 (1.5) 42 (8.8) 110 (23) 105 (21.9) 141 (29.4) 74 (15.4) 479 (100) 
Female  1 (14.3) 19 (45.2) 48 (43.6) 52 (49.5) 74 (52.5) 42 (56.8) 236 (49.3) 
No Delta F508 = 0 0 (0) 0 (0) 1 (0.9) 4 (3.8) 5 (3.5) 5 (6.8) 15 (3.1) 
No Delta F508 = 1 2 (28.6) 14 (33.3) 26 (23.6) 24 (22.9) 42 (29.8) 19 (25.7) 127 (26.5) 
No Delta F508 = 2 5 (71.4) 28 (66.7) 83 (75.5) 77 (73.3) 94 (66.7) 50 (67.6) 337 (70.4) 
Developed chronic 
Pseudomonas 6 (85.7) 31 (73.8) 84 (76.4) 55 (52.4) 20 (14.2) 5 (6.8) 201 (42) 
Missing infection 
information 0 (0) 5 (11.9) 2 (1.8) 2 (1.9) 1 (0.7) 0 (0) 10 (2.1) 
PI 7 (100) 42 (100) 105 (95.5) 99 (94.3) 133 (94.3) 73 (98.6) 459 (95.8) 
Copenhagen 7 (100) 38 (90.5) 83 (75.5) 72 (68.6) 79 (56) 50 (67.6) 329 (68.7) 
Alive 4 (57.1) 27 (64.3) 79 (71.8) 77 (73.3) 132 (93.6) 74 (100) 393 (82) 
Developed CFRD 3 (42.9) 21 (50) 41 (37.3) 31 (29.5) 22 (15.6) 1 (1.4) 119 (24.8) 
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Figure 65: Scatterplot of %FEV1 versus age in Denmark, with a randomly 
selected individual highlighted in each panel 
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Exploring the form for the population average 
Figure 66 shows all the %FEV1 measures over time in a scatterplot, with an added 
mean smoother in red. The mean smoother does not take into account the correlation 
of repeated measures within individuals. There appears to be a fairly linear decline in 
mean %FEV1 to about age 25, where the mean stabilizes, before becoming more 
erratic at older ages where the sample size is smaller. A piecewise OLS regression 
(blue line) with a change in slope at age 25 provides an improved fit over a straight 
line, and by eye one can see that this fits the smoother well. However, when one fits 
the same piecewise mean in the longitudinal model using ML estimation, then the 
change in slope at age 25 is not significant (green line). This indicates that the 
levelling off of the mean smoother to some extent reflects selective drop out (death) 
(see methods section). The final longitudinal model implicitly takes this drop out into 
account and generates the parameter estimates that one would expect to see if 
dropout had not occurred. I therefore modelled the population average as a straight 
line. 
Figure 66: All Danish data with smoothed mean trend 
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Quantifying the variability in %FEV1 over time 
Full technical details of the empirical variogram of the residuals are provided in the 
methods section (Chapter 3). A residual trajectory is shown in Figure 67 below. The 
empirical variogram function summarises the average variance within individuals in 
the population at successive time lags. For instance for the individual in Figure 67 
one can calculate the variance of the difference between %FEV1 comparing points A 
and B, at a time lag of five years, and likewise the variance of the difference at points 
A and C at a time lag of 20 years. Repeating this for all time lags in a particular 
individual, and pooling the results over the population yields the empirical 
variogram. 
Figure 67: Residual plot for individual in Danish population 
 
The empirical variogram estimates the three components of variability in the dataset 
(error, within individual over time, between individual) (Figure 68). The intercept at 
time zero represents measurement error, since there can be no true within-person 
variation at a time lag of zero. Of the total variance in the Danish dataset, about half 
is due to systematic differences between patients (e.g. genotype, sex or pancreatic 
status), two-fifths is within patients, representing change over time (disease 
progression), and one tenth is ‘measurement error’. In practice, this last component 
represents the combined effects of technical errors, and physiological variability 
occurring at time intervals less than the monthly interval of measurement, e.g. day to 
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day variability. This error variance equates to an average standard deviation of 6.3% 
for repeated measures on the same individual at short time-intervals.  
Figure 68: Quantifying the variability in %FEV1 with the variogram approach 
The figure shows the scaled empirical variogram for the Danish data. The solid line 
(variogram function) represents the variance of the difference between residual 
errors within individuals at time lags from zero to 30 years. The variogram function 
increases up to about 15 years, corresponding to a decreasing correlation between 
paired lung function measures with increasing time-separation. The variogram 
partitions the variability in the data into three components: within person, between 
person, and error.  
 
 
Hence, the sample variogram provides initial estimates of the variance components 
τ2,  ν2 and σ2, and of the correlation function ρ(u)  (see methods for further details). An 
alternative representation is to transform V(u) into a function R2(u), defined as 
 
 R2(u) = (1 – V(u)/  σ2)2   
This function is analogous to the conventional R2-value for a fitted regression model 
in the sense that it measures the proportion of within-patient  variation  in  a  person’s  
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lung-function at time t+u that can be explained by their lung-function at time t 
(Figure 69). 
Figure 69 shows the proportion of the within-person variability in %FEV1 at follow-
up time (t) that can be explained by their %FEV1 value at baseline. For example, 
about 50% of the within-patient variability at t = 2.5 years is explained by the 
baseline measurement, and about 30% at t = 5 years. Overall, the dependence on 
baseline measures gradually decays and is negligible at 15 years. 
Figure 69:  Proportion  of  variability  in  an  individual’s  %FEV1 at follow-up time 
t that is explained by their %FEV1 at baseline. 
This shows that the variogram can predict 63% of the variability from the population 
average at one year, which decreases to around 60%, 40%, 30% and 10% at 2,3,5 
and 10 years respectively. 
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Fitting the final model 
Figure 70 below compares the empirical variogram fit to the theoretical variogram 
plotted using the MLE estimates from the lme() function in R, with an exponential 
correlation. This shows that the modelled correlation function approximates 
reasonably to the empirical correlation in the dataset. 
Figure 70: Comparison between empirical variogram and MLE variogram 
estimate  
 
 
The estimated variance (%FEV1 2) components derived from the modelled variogram 
are as follows: total variance=625, within-person variance=229, between-person 
variance=356, error variance=40. 
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Assessing model fit 
Figure 71 below plots the standardised residuals against the fitted values. There are 
no trends in the residuals, and there is no evidence of non-constant variance. As a 
further check, I simulated trajectories from the fitted model, and compared them to 
raw data traces (Figure 72). This demonstrates that the model is generating 
individual level predictions that have a similar form to the real data. 
Figure 71: Scatterplot of standardised residuals versus fitted values 
 
 
Figure 72: Simulated realisations from the final model 
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Comparing the stationary Gaussian process (SGP) model to the random 
intercept and slope approach 
The high degree of short-term and long-term variation in predicted %FEV1 are 
illustrated in Figure 73. The standard random intercept and slope model approach is 
illustrated over long and short follow up periods in Figure 73 A and C. This approach 
assumes  that  any  deviation  of  an  individual’s  trajectory  from  the  population  mean  is  
linear in time over the whole of the follow-up period apart from independent random 
errors. One can see that this assumption is reasonable over short time-periods, as 
illustrated by the fit of the shorter dotted-line segments (Figure 73 A and C), but over 
longer time-periods the individual data traces diverge unrealistically from their fitted 
linear mean trajectories (long solid line). The proposed stationary Gaussian process 
(SGP) model produces a much closer fit to the data (Figure 73 B and D), and one that 
better reflects the relative magnitude of the three estimated components of variation 
in %FEV1 over time. The smoothed fitted trace is a better representation of the ‘true’ 
underlying lung function, and could be used in real time to guide the interpretation of 
sudden changes in lung function. For instance, the sudden drop to under 30% 
indicated by the arrow is not mirrored in the model trace, suggesting that this may be 
recoverable random fluctuation.  
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Clinical utility of the proposed model 
The model can be used to guide interpretation of sudden changes in lung function. 
Consider seeing the person in Figure 73 B at around age nine (as indicated by the 
arrow in the figure), when her lung function has dropped to below 30%. On the basis 
of this one-off measurement, one might be quite guarded in terms of prognosis. 
However, our modelled trace (thick black line in Figure 73 B) suggests that her 
underlying lung function is changing less dramatically, with a modelled %FEV1 of 
around 50%. I suggest that this estimate provides a more realistic assessment of 
underlying lung function by smoothing out the short-term variability. This could be a 
useful adjunct to clinical decision-making. As well as providing information about 
the significance of a sudden change in lung function, Figure 69 also quantifies the 
predictive value of a contemporary %FEV1 measure. In terms of counselling 
patients, this means that a higher %FEV1 today is associated with a higher %FEV1 at 
subsequent time points, but the predictive value deteriorates over time as illustrated 
in the figure.  
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Figure 73: Comparison of conventional random-intercept and slope model over 
short and long follow-up periods, versus proposed Gaussian process model.  
Panel A shows the data for a single individual, illustrating that a linear trend fits 
reasonably well over short time-periods,  but  gives  a  very  poor  fit  to  this  individual’s  
complete data; linear trends are fitted by OLS. Panel B shows the same data with the 
fitted trajectory of the stationary Gaussian process model. Panels C and D show the 
corresponding plots for a second individual. 
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Effect of covariates on lung function in the Danish population 
I explored the effect of covariates that have been associated with %FEV1 in previous 
studies, in order to demonstrate how this model can be used to answer questions at 
the   population   level,   as   per   Konstan   et   al’s   study   (Konstan et al., 2007a). I first 
explored univariate associations, which are shown in Table 18. Figure 74 
demonstrates the effect of pancreatic status in the univariate analysis.  
The final model included age, Pseudomonas status, pancreatic status, cohort and 
CFRD (Table 19). Note that the estimated covariate effects in Table 19 are 
population-averaged effects, i.e. they describe average values of %FEV1 for sub-
populations of individuals sharing the same explanatory characteristics, rather than 
for any one individual. The most prominent effects are associated with birth cohort, 
pancreatic function and the onset of Pseudomonas infection (Figure 75). There is 
clear separation between the three most recent birth cohorts, with a successive 
increase in the intercept term at age 5 (83% in the 1978 to 1988 cohort versus 96% in 
the post-1998 cohort) (Figure 75, Figure 76, Figure 77). There is a large change in 
the point estimate for the rate of change of lung function in the post-1998 (0.24%) 
compared with the 1988-98 cohort (-1% per year), such that the post-1998 cohort 
appears to be improving over the period of measurement. The three cohorts spanning 
the years 1948 to 1978 have a similar overall rate of decline around -0.3% per year, 
with an intercept at age five of 66%. PI is associated with a significantly steeper rate 
of decline of lung function (-0.92% per year 95%CI -1.7 to -0.3), as is acquisition of 
Pseudomonas infection (-0.5% per year 95%CI -0.72 to -0.3) (Figure 75). CFRD is 
associated with a drop in intercept of -2.5% (95% CI -3.6 to -1.37), but has no effect 
on the rate of decline of lung function.  
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Table 18: Univariate associations between covariates and %FEV1 
  Value (%FEV1) Std.Error p-value 
Genotype    
(Intercept) 90.530 6.656 <0.0001 
age (years) -0.785 0.454 0.0837 
Number delta F508=1 -2.801 7.075 0.6923 
Number delta F508=2 -5.758 6.803 0.3978 
age:Number delta F508=1 -0.070 0.466 0.8805 
age:Number delta F508=2 -0.219 0.458 0.6327 
Pancreatic insufficiency    
(Intercept) 92.101 7.144 <0.0001 
age (years) -0.060 0.362 0.868 
Pancreatic insufficiency -6.822 7.244 0.3468 
age:Pancreatic insufficiency -0.926 0.366 0.0114 
Sex    
(Intercept) 84.907 1.680 <0.0001 
age (years) -1.015 0.077 <0.0001 
Male 1.747 2.393 0.4657 
age:Male 0.091 0.105 0.3868 
Cohort    
(Intercept) 70.278 2.375 <0.0001 
age2 -0.640 0.084 <0.0001 
cohort>=1948 (reference 1968) 9.082 13.988 0.5165 
cohort>=1958 1.252 4.860 0.7968 
cohort>=1978 15.062 3.387 <0.0001 
cohort>=1988 22.492 3.159 <0.0001 
cohort>=1998 26.813 3.640 <0.0001 
age:cohort>=1948 -0.149 0.337 0.6571 
age:cohort>=1958 -0.024 0.149 0.8717 
age:cohort>=1978 -0.538 0.142 0.0001 
age:cohort>=1988 -0.356 0.178 0.0459 
age:cohort>=1998 0.884 0.464 0.057 
Pseudomonas    
(Intercept) 84.714 1.224 <0.0001 
age (years) -0.738 0.081 <0.0001 
onset of Pseudomonas -0.392 0.104 0.0002 
CFRD    
(Intercept) 85.670 1.198 <0.0001 
age (years) -0.928 0.054 <0.0001 
CFRD -2.861 1.219 0.019 
age:CFRD 0.024 0.064 0.701 
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Figure 74: Univariate effect of pancreatic status 
Raw data disaggregated by pancreatic status, with pancreatic sufficient individuals 
coloured in blue. 
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Table 19: Estimates from final multivariate model 
  Point estimate lower 95%CI upper 95%CI p-value 
Intercept at age 5 years 66.02 61.13 70.92 <0.001 
CFRD -2.47 -3.58 -1.37 <0.001 
age -0.26 -0.49 -0.03 0.025 
cohort>=1948 (reference 1968) 1.20 -25.50 27.90 0.930 
cohort>=1958 -0.75 -10.01 8.51 0.874 
cohort>=1978 16.60 10.15 23.05 <0.001 
cohort>=1988 25.19 19.11 31.27 <0.001 
cohort>=1998 29.81 22.85 36.78 <0.001 
Pancreatic sufficiency 2.78 -10.43 15.99 0.679 
P. aeruginosa infection -0.51 -0.72 -0.29 <0.001 
agexcohort>=1948 -0.03 -0.67 0.61 0.920 
agexcohort>=1958 0.06 -0.23 0.34 0.699 
agexcohort>=1978 -0.72 -1.00 -0.44 <0.001 
agexcohort>=1988 -0.72 -1.09 -0.35 <0.001 
agexcohort>=1998 0.50 -0.41 1.42 0.280 
agexPancreatic sufficiency 0.98 0.29 1.67 0.005 
 
 
 
 
Figure 75: Effect of key covariates on %FEV1 
The left panel shows the birth cohort effect in the final model. There is clear 
separation between the three most recent birth cohorts, with a successive increase in 
the intercept term at age five. The right panel illustrates the effect of PI and 
Pseudomonas infection on the predicted population trajectory for a person born in 
the 1988-98 cohort. 
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Figure 76: Scatterplot of data for post-1998 cohort 
Five individual traces randomly picked out, and linear population estimate from 
final model superimposed 
 
 
 
Figure 77: Scatterplot of data for 1988-1998 cohort 
Five individual traces randomly picked out, and linear population estimate from 
final model superimposed 
 
Age 
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Discussion 
In this study I describe a novel longitudinal modelling technique specifically aimed 
at analysing long sequences of repeated measurements, and apply this to %FEV1 
from a CF population. I show how this approach could be used to inform patient 
management, by aiding the interpretation of sudden changes in lung function, and by 
quantifying the predictive value of a baseline %FEV1 measure up to 15 years later. 
At the population level, I show how the model can be used to quantify the effect of 
covariates on populations or subpopulations. Translation of these methods into 
clinical practice is important, since people with CF are surviving for longer periods, 
and I have shown how commonly applied approaches are unhelpful over long 
follow-up periods.  
This study quantifies the short-term variability in %FEV1 in this population (SD 
6.3%), and demonstrates that %FEV1 measures within individuals are correlated over 
time-lags of 15 years or more. I have also explored the effect of previously studied 
risk factors for lung function decline in the Danish CF population, and have 
demonstrated significant effects of birth cohort, pancreatic status and Pseudomonas 
infection status. 
Clinical implications 
The findings from this study have a number of clinical implications. Quantifying the 
variability in lung function measures is essential in order to make correct clinical 
interpretation (Hnizdo et al., 2005). Exploiting the unusually high frequency of data 
collection in Denmark, this study implies that on average a change in %FEV1 of 
greater than 13% (i.e. twice the error SD, to give a 95% confidence range) is likely to 
represent true within-patient variation over time (disease progression), whereas 
anything less than this could be due to short-term fluctuation, which may recover. 
Stanbrook et al (Stanbrook et al., 2004) found a pooled within-subject %FEV1 SD of 
4.5% when measured over a nine-day period in 21 stable adults with CF. This 
population is different to the population in this study, who were measured regardless 
of clinical status, and one would therefore expect greater variability. Other studies 
have shown that people with CF, asthma and COPD have more short-term variability 
in lung function tests (Hruby and Butler, 1975, Pennock et al., 1981, Cooper et al., 
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1990) and that more impaired lung function is associated with greater variability 
(Enright et al., 2004).  
The presence of the significant measurement error described in this study presents a 
challenge to the use of isolated %FEV1 measures for long term prediction of 
prognosis. A number of methods have been proposed for predicting future changes in 
%FEV1 to inform clinical decision-making. Vandevanter et al have developed a short 
term pulmonary outcome prediction tool, for estimating the change in lung function 
over a 4-year period using cross sectional regression models (Vandevanter et al., 
2010). Konstan et al use random-intercept and slope models over short follow-up 
periods to develop a regression equation that estimates the effect of baseline 
covariates on subsequent lung function decline (Konstan et al., 2007a).  
At the population level we show how this approach can be applied to quantify the 
effect of covariates on changes in lung function. Furthermore, the partitioning of the 
variability in %FEV1 and the precise description of the correlation structure captured 
in the model provide important information for sample size calculations in 
longitudinal clinical studies with %FEV1 as an outcome. Increasingly longitudinal 
outcomes are being used in RCTs, and in order to undertake an a priori sample size 
calculation it is essential to have information on the correlation structure. 
Furthermore, the modelled %FEV1 trace could be used as an outcome in its own 
right.  
The modelling approach can be used to generate an underlying representation of an 
individual’s   ‘true’ lung function trajectory (Figure 73) that smoothes out the noise 
inherent in %FEV1 measures. These smoothed traces could be used to inform clinical 
decision-making – the model fit curves in Figure 73 provide more realistic estimates 
of underlying lung function, and more valid criteria for clinical decisions. I propose 
that this model could be used to develop a real-time smoothing tool embedded in 
electronic patient records to aid clinical interpretation of spirometry data. I further 
suggest that access to this information would provide some re-assurance to patents 
experiencing lower than expected lung function values, since lung function can 
recover quite dramatically, and these data suggest that a linear or stepwise decline in 
lung function over time is not the norm. 
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I have generated, for the first time to my knowledge, the variogram function for 
%FEV1 in people with CF over long follow-up periods. This precisely quantifies 
how %FEV1 measures are correlated over time. Furthermore, I have done this for the 
whole CF population of Denmark. This quantifies the degree to which a baseline 
%FEV1 measure can be used to predict subsequent %FEV1 measures over long 
follow-up periods, and is likely to be of interest to clinicians and patients. The 
analysis demonstrates a long-term correlation between levels of %FEV1 within an 
individual. This suggests that there is long-term predictive value in a high %FEV1 
measure – people with CF with a high %FEV1 at baseline are more likely to have a 
high %FEV1 up to 15 years later than individuals with a lower baseline %FEV1 
(Figure 69). However, the predictive value of a %FEV1 measure drops away rapidly 
over this period. We can say that on average an %FEV1 reading today explains about 
63% of the variability in %FEV1 at one year, 40% at three years, and about 30% at 
five years. 
This   corroborates   Rosenthal’s   study   (Rosenthal, 2008), which found that baseline 
%FEV1 explains 66% of the variability in %FEV1 one year hence and Mastella et 
al’s  study  of  European  registry  data  where  differences  in  lung  function  at  enrolment  
at age five, categorised as mild, moderate, or severe, tracked through the study to age 
40 (Mastella et al., 2000). Konstan et al also describe how a lower %FEV1 for a 
given age can be used to characterise the aggressiveness of lung disease (Konstan et 
al., 2009). Other studies have shown a high %FEV1 to be an independent risk factor 
for a greater rate of decline of %FEV1 over the next few years (Konstan et al., 2007a) 
(Vandevanter et al., 2010). This is not at odds with the findings here; a high %FEV1 
can be a risk factor for greater decline in the short term, whilst still being associated 
with a relatively higher %FEV1 over the longer term (Konstan et al., 2009).  
Novel modelling approach 
The approach to modelling changes in %FEV1 presented here can be applied over 
long follow-up periods. This is in contrast to the widely used random intercept and 
slope approach that has been applied in studies of CF and COPD, over short-term 
(Vestbo et al., 1999, Mastella et al., 2000, Konstan et al., 2007a, MacLean et al., 
2008) and longer-term follow up periods (Corey et al., 1997, Hnizdo et al., 2005, 
Stern et al., 2007, Kohansal et al., 2009). That approach has also been used to 
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quantify lung function decline in other diseases, such as sickle cell disease (MacLean 
et al., 2008) and bronchiectasis (Twiss et al., 2006). In a recent study McKay et al 
propose a novel approach to modelling lung function decline in an adult population 
(McKay et al., 2011), involving a linear mixed-effect model with a cubic spline to 
account for non-linear population-averaged decline in lung function with age and a 
standard random intercept and slope model to account for within-patient variability. 
The spline gives a more flexible set of models for the population-averaged trajectory, 
but our analysis of the Danish dataset shows that the random intercept and slope 
model is too rigid to capture the pattern of within-patient variability in %FEV1 over 
longer periods. The approach presented here can easily be combined with the spline 
model to describe non-linear population-averaged decline, since the form of the 
population average and the within-patient correlation structure are separate issues, 
but as illustrated above this was not needed for the Danish dataset. Note also that an 
adequate model for the correlation structure in the data is necessary for prediction at 
the individual patient level. 
Effect of covariates 
As with other studies of CF patients (Elborn et al., 1991), there is a striking cohort 
effect evident in this population. The treatment of CF lung disease has been 
transformed over the period captured in this analysis, from 1969 to the present day. 
In Denmark a regimen of elective IV antibiotics for 14 days every third month was 
introduced in 1976 for patients chronically infected with P. aeruginosa. Enteric-
coated pancreatic enzymes were introduced in the 1980s, and in the last two decades 
we have seen the introduction of inhaled therapies (bronchodilators, steroids and 
antibiotics), and DNase. Particularly impressive is the improvement in lung function 
in the post-1998 cohort by comparison with preceding birth cohorts. Although this 
group are early in their disease progression, the overall picture suggests that new 
therapeutic strategies are continuing to provide improvements in respiratory function 
in CF. 
Pancreatic sufficiency had an important effect on the overall rate of decline of lung 
function   (+0.9  %   per   year).   In  Konstan’s   study   (Konstan et al., 2007a) pancreatic 
sufficiency was the most important protective factor in the 6 to 8 year-old age group 
(+1.33% per year). The small number of pancreatic-sufficient individuals in the 
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Danish dataset (n = 20, 5%) have a notably different lung function phenotype, 
maintaining near-normal lung function over the period of follow-up (Figure 74). The 
onset of Pseudomonas infection was associated with a significant increase in the rate 
of decline of lung function, by around -0.5% per year, similar to that reported by 
Konstan where Pseudomonas colonization was associated with an increased rate of 
decline of FEV1 of -0.31% per year in the 6 to 8 age group, and -0.22 in the 9 to 12 
age group (Konstan et al., 2007a). This highlights the importance of firstly delaying 
the onset of chronic infection, and aggressive treatment subsequently. 
Strengths and limitations 
The development and testing of the new approach is facilitated by the nature of the 
Danish CF register – to my knowledge there are no other datasets that contain such 
frequent (monthly) measures of lung function on individuals measured over very 
long periods (up to 31.5 years). CF care in Denmark is free at the point of access, and 
delivered from two centres in Copenhagen and Aarhus. The Danish CF Centre was 
originally established in 1968 in Copenhagen, and all patients connected with the 
centre have been seen monthly in the outpatient clinic. A similar pattern of care is 
undertaken in the Aarhus centre, which was established in 2000.  
However, the fact that the data are from Denmark does not influence the validity of 
the methods we have described, since these are essentially context-free. Furthermore, 
this method does not exploit any features of the data that are unique to CF, and is 
equally applicable to other clinical areas that generate long sequences of repeated 
measurements. As a next step I recommend applying  this method to longitudinal 
data collected in other CF registries, such as the UK, to clarify how robust this 
approach is in terms of predicting changes in %FEV1 over time, and to better 
understand how this might inform clinical decision making. Future research could 
explore the utility of the proposed model in other diseases such as COPD. 
A limitation of this study is the likely influence of survivor bias on lung function 
estimates in the earlier birth cohorts. In the 1948 to 1978 period, the intercept at age 
five appears significantly lower than in the other cohorts, but there is also a 
shallower rate of decline of lung function. This is likely to be due to the incomplete 
capture of patients in earlier cohorts, with censoring due to death leaving only the 
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more stable survivors. This is a common problem in datasets of this type 
(Frederiksen et al., 1996). Fitting the model by maximum likelihood automatically 
corrects   for   selection   bias   that   depends   on   a   patient’s   observed   lung   function  
measurements prior to death, although not for any additional dependence on 
unmeasured features of their lung function trajectory (Diggle et al., 2002, 
Fitzmaurice, 2004). 
Interpretation 
The modelling approach presented in this study provides a more realistic estimate of 
the %FEV1 trajectory in CF, which clinicians could apply in real-time to help 
interpret the significance of changes in %FEV1. Furthermore, this approach 
quantifies the predictive value of a baseline %FEV1 measure, over three decades. 
This method is equally applicable to the longitudinal assessment of %FEV1 in other 
lung diseases, and can enable more robust comparisons of populations, including 
groups studied in clinical trials. As people are now living for many decades with 
these diseases, the development of tools better to understand the natural history of 
this important outcome will be essential for better clinical care, as well as being a 
key research priority (Holgate, 2007). 
Analysis of the Danish dataset from an equity perspective is on-going. This study has 
outlined the methods for analysing this unique dataset, and the next step is to use this 
approach in conjunction with data linked through the Danish social registers. At the 
time of writing, I have been able to undertake a preliminary analysis of the effect of 
parental education level on lung function decline in the Danish population, and this is 
presented briefly in Chapter 7, in the ‘Research currently in progress’ section. 
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Chapter 7: Discussion 
Introduction 
This chapter begins by summarising the key findings in relation to the objectives 1-3 
of this thesis. I then describe the contribution of the studies to the existing literature, 
which extends beyond the initial objectives, in three main areas: CF epidemiology; 
our understanding of health inequalities more generally; and specific methodological 
advances. There is then a discussion of the strengths and limitations of the overall 
approach and study design. I address objective 4 of the thesis with a section on the 
policy implications arising from the studies, and the chapter concludes with a 
description of on-going research. 
Key findings with reference to objectives 
 
Objective 1: In people with CF, what is the relationship between SES and 
important longitudinal clinical outcomes, such as growth, and lung function? 
 
Study 1 addressed the first objective of this thesis, with an in-depth longitudinal 
study of the effect of SES on a range of clinical outcomes in the contemporary CF 
population in the UK. The key findings were: 
 
People with CF in the UK from more deprived areas, as measured using the 
indices of multiple deprivation for the UK constituent countries, have worse 
growth outcomes (weight, height and BMI) from around the time of 
diagnosis.  
Comparing the most deprived quintile to the least, the difference in weight 
and height SD-score is about one third, whereas for BMI the difference is 
about one sixth of a standard deviation score (z-score). These differences in 
anthropometric measures are statistically significant, and are also clinically 
significant. For instance, CF is a condition that has a profound effect on 
nutritional status in the first few years of life, and this was demonstrated in 
study 1 by comparing the mean weight SD score in the UK CF paediatric 
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population, to that of the UK reference population, a difference that equated 
to about a third of an SD score. This is the same as the deprivation effect, 
comparing extremes of deprivation quintile. Thus having CF, and living in 
the most deprived areas of the UK effectively doubles the nutritional 
disadvantage experienced by a person with CF. 
 
The deprivation gap in weight is greatest in the first few months of life, at 
the time of diagnosis, and there is a narrowing of the gap up to around age 
three. 
Study 1 quantified the age related changes in the deprivation gap in 
anthropometric outcomes, and showed that this narrows over the first three 
years of life. Extrapolating the modelled trajectory to around birth, the 
analysis suggests that the gap in weight SD score, comparing extremes of 
deprivation quintile, narrows from around -0.54 SD scores (95% CI -0.73 to -
0.34) at birth to -0.28 (95% CI -0.38 to -0.18) at age three, and then the gap 
remains constant into adulthood. This analysis suggests a halving of the 
deprivation gap in the first three years of life. By contrast the analysis showed 
that the deprivation gaps for height (–0.31, 95% CI –0.40 to –0.21) and BMI 
(–0.13, 95% CI –0.22 to –0.04) did not change over time. 
 
People from the most deprived areas in the UK with CF have worse lung 
function when this can be routinely measured at around age five, but the 
deprivation gap does not increase after that age 
We currently consider %FEV1 the most important clinical outcome in CF, 
because it is related to survival. Study 1 demonstrates that people from the 
most deprived areas have significantly worse lung function (–4.12 percentage 
points, 95% C1 –5.01 to –3.19). Unlike some analyses from the US, the 
deprivation gap in %FEV1 did not increase over the paediatric age range, but 
remained constant over time. The finding of a fixed %FEV1 deficit in the 
most deprived children at age five has important policy implications, and 
suggests that deprivation has a detrimental effect on lung health in the early 
years  of  a  child’s  life. 
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The prevalence of chronic P. aeruginosa colonisation is higher in people 
from the most deprived areas of the UK, from an early age. 
Acquisition of P. aeruginosa can occur very early on in life in people with 
CF (Rosenfeld et al., 2012a), and becomes increasingly common over 
childhood. It is associated with worse outcomes, including survival, lung 
function, and nutritional status (Kosorok et al., 2001, Emerson et al., 2002, 
Konstan et al., 2007a, Taylor-Robinson et al., 2012a, Taylor-Robinson et al., 
2013a). Study 1 demonstrated for the first time in a population wide cohort 
that P. aeruginosa acquisition appears to be related to social deprivation, 
such that people from more deprived areas are more likely to have P. 
aeruginosa across the age range (OR 1·89 in the <18 age group, 95% CI 1·34 
to 2·66). Furthermore, this relationship persisted after adjusting for level of 
%FEV1. Acquisition of P. aeruginosa may be an important mediating factor 
in the relationship between social deprivation and poor outcomes in CF.  
In the adult population, growth and P. aeruginosa outcomes were worse in 
the most deprived adults, but no significant difference in lung function was 
detected 
Study 1 was the first to systematically document the effect of SES on an adult 
CF population. The lack of an association between SES and %FEV1 in the 
adult population is perhaps surprising, given the tendency for social 
inequalities in health outcomes to increase over time, and the possible reasons 
for this are discussed in further detail in a subsequent section. These findings 
may relate to limitations of the dataset in the adult population, for instance 
due to left censoring (survival bias), and less power to detect an effect in the 
adult age range.  
 
Objective 2: In people with CF, what is the relationship between SES and health 
service use? 
Study 1 addressed the second objective of this thesis, with an in-depth longitudinal 
study of the effect of SES on use of therapies and health service related factors in the 
contemporary CF population in the UK. The findings were: 
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There is no apparent difference in the age at diagnosis by SES for people 
with CF in the UK 
Study 1 assessed time to diagnosis by SES, and found no significant 
association. Furthermore, there was no significant social gradient in the 
proportion of individuals diagnosed by neonatal screening in the UK.  
 
People from more deprived areas of the UK with CF are MORE likely to 
use any IV therapy in the preceding year, after adjustment for disease 
severity 
Use of IV antibiotic therapy for the treatment of respiratory infections, and 
clinical exacerbations is a major treatment modality in CF. Study 1 
demonstrated that people in the UK from more deprived areas are about twice 
as likely to receive IV antibiotics in a particular year, after adjustment for 
disease severity, on the basis of %FEV1 and P. aeruginosa colonisation status 
(OR 2.52, 95%CI 1.92 to 3.17 in the <18 age group, and OR 1.89, 95%CI 
1.51 to 2.38 in the adult age group, comparing most to least deprived 
quintile). This apparent positive discrimination persists across the age range, 
from infancy up to 40 years of age. 
 
People from more deprived areas of the UK with CF are MORE likely to 
have more days of IV therapy, conditional on having any IV therapy 
If children and adults with CF are recorded as having any IV therapy in a 
particular year, then people from more deprived areas in the UK, compared to 
the least, are more likely to have more treatment days, after adjusting for 
disease severity (15.9% more days in the paediatric age group, 95% CI 8.2 to 
24, and 10·6% more days in the adult age group 95% CI 2.5 to 19.2). 
 
People from more deprived areas of the UK with CF are MORE likely to be 
treated with IV therapies in hospital  
Study 1 disaggregated the use of any IV antibiotics into use of therapies at 
home, and in hospital, and demonstrated that the positive discrimination in 
use of any IV therapy was almost entirely due to delivery of these therapies in 
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hospital, as opposed to home-based treatment. Overall, children from more 
affluent areas were more likely to be treated at home compared to their more 
disadvantaged counterparts. 
 
People from more deprived areas of the UK with CF are MORE likely to be 
treated with nutritional therapies 
Study 1 demonstrated that, as with the use of any IV therapy, people from the 
most disadvantaged areas of the UK are more likely to receive nutritional 
support (defined as receiving nutritional supplements orally, by nasogastric 
tube, gastrostomy tube, jejunal tube, or total parenteral nutrition), after 
adjustment for nutritional status, measured on the basis of BMI SD score (OR 
1·78, 95% CI 1.42 to 2.2 in the <18 age group, and OR 2.38, 95% CI 1.69 to 
3.36 in the adult age group, comparing the most to the least deprived 
quintile). This apparent positive discrimination in the delivery of nutritional 
support to the UK CF population was consistent across the age range studied, 
from infancy up to the age of 40. 
 
People from more deprived areas of the UK with CF are LESS likely to be 
treated with DNase and inhaled antibiotics 
Study 1 demonstrated inequality in the delivery of inhaled therapies to the 
UK CF population, after adjusting for measures of disease severity. 
Furthermore, this association becomes stronger in the adult age range. In 
children, there was no association between DNase use and SES, prior to 
adjustment for disease severity. However, after adjustment for disease 
severity, there was an apparent inequality, suggesting that DNase may not be 
delivered equitably in children. This association was clear in the adult 
population in both the unadjusted and adjusted association, with adults from 
more affluent areas being more likely to report using DNase or inhaled 
antibiotics in the preceding year.  
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There   was   a   ‘social   gradient’   for   most   of   the associations between 
deprivation status, and health and treatment use outcomes 
I have described and visualised the association between SES and outcomes in 
this thesis in the plots in terms of the gap between the least deprived and most 
deprived quintiles. However, for most of these associations (with the 
exception of BMI SD score, and DNase use in the paediatric age range) there 
was a graded dose response relationship, suggesting the existence of a social 
gradient. 
 
Objective 3: What is the impact of SES on longitudinal employment status in 
people with CF? 
Study 2 addressed the third objective of this thesis, with a longitudinal study 
of the effect of SES and disease severity on employment chances in adults 
with CF in the UK. The main finding was: 
 
All other things being equal, people from more disadvantaged areas in the 
UK are less likely to be in employment, and furthermore, social deprivation 
modifies the effect of disease severity in CF: poor lung function, as 
measured by lower %FEV1, is more harmful to employment chances for 
people living in the most disadvantaged circumstances compared to the 
least. 
 
In summary, in relation to the main objectives of this thesis, the studies 1 and 2 have 
demonstrated that people from more disadvantaged areas in the UK have worse 
health and social outcomes. They are more likely to have poor growth, lung function, 
and to acquire P. aeruginosa, and are less likely to be in employment. In contrast to 
this, the use of major therapies in the UK CF population shows a so called ‘pro-poor’ 
bias, with people living in the most deprived areas of the UK around twice as likely 
to be treated with IV antibiotics and nutritional therapies, after adjusting for disease 
severity. However, there was evidence of inequalities in the use of home IV 
therapies, DNase, and inhaled antibiotics. The final objective of this thesis, assessing 
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the policy implications of the findings around the effects of SES on the CF 
population is considered in a subsequent section.  
In order to determine the effect of SES on longitudinal outcomes in the UK and 
Denmark it was necessary to understand the overall changes in outcomes in the 
population, and the influence of other important covariates. This contribution to the 
knowledge base is described in more detail in the next section.  
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How has this thesis contributed to the literature? 
This section describes the substantive advances, and other key findings from the 
studies in this thesis, made in three areas: CF epidemiology; our understanding of 
health inequalities more general; and methodological advances. The findings are 
contextualised in relation to the current knowledge base.  
Contribution to our understanding of CF epidemiology 
Inequalities in outcomes in CF 
Establishing an association between SES and longitudinal health outcomes in CF in 
settings outside the US 
 
Study 1 builds on the findings from the US of an association between SES, and 
adverse outcomes in CF (Schechter et al., 2001, O'Connor et al., 2003), by 
examining the full range of growth measures (weight, height and BMI) and lung 
function, and extends the US findings to examine longitudinal P. aeruginosa 
acquisition. Furthermore, study 1 demonstrates the presence of a social gradient in 
CF   health   outcomes,   suggested   in   the   O’Connor   study   for   weight   and   %FEV1 
(O'Connor et al., 2003), and uses for the first time a validated measure of small-area 
deprivation. 
The findings from study 1 constitute a novel contribution to the literature, since this 
study is the first to examine CF outcomes, other than mortality, in the UK, from a 
health equity perspective. Two studies in the UK have explored the effects of SES on 
risk of death (Britton, 1989, Barr HL, 2011). The Barr study – an update of the 
Britton analysis published since the start of this thesis – showed that the socio-
economic divide in premature mortality in CF has persisted with no substantial 
narrowing for over four decades between 1959 and 2008. SES was measured on the 
basis of occupational social class, and in the most recent period the OR for survival 
above the median age at death was 1.89 (95% CI 1.20 to 2.97), comparing 
professional/managerial groups to routine/manual groups.  
Other than these studies, there have been no population level studies in the UK, or 
other European countries, exploring the effect of SES on longitudinal outcomes in 
CF. 
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A concern with extrapolating the findings from the US to the UK and elsewhere is 
that any social differences in outcomes could be the result of the very different health 
care and welfare systems operating on either side of the Atlantic. However, the 
results presented in this thesis suggest that SES is indeed a ‘disease modifier’ in both 
the US and the UK (Schechter, 2013). Appealing to Bradford-Hill’s   suggested  
second   criteria   for   establishing   causation,   ‘consistency’   of   findings   in   different  
places, and with different samples, strengthens the likelihood of an effect (Hill, 
1965).  
My on-going studies using the Danish registry, applying the methodology described 
in this thesis, will extend this knowledge base further, since it remains important to 
examine the extent of SES related inequalities in CF in other countries. This will 
open up the possibility of comparative studies, which may provide further insight 
into the precise mechanisms by which SES is exerting an effect on outcomes, 
particularly with regard to the influence of the macro-economic context.  
Establishing a deeper understanding of inequalities in CF over the life-course 
 
Study 1 is the first to use modern longitudinal data analysis techniques to quantify 
the age related changes in CF outcomes, stratified by SES, from infancy up to the 
age of 40 years. There are three important contributions to the literature discussed 
here: inequalities in outcomes from the outset; the finding of narrowing inequality in 
weight SD score in the first three years of life; and the lack of increasing inequality 
over time in the UK. 
The first important insight is the presence of inequalities that are evident from the 
time of diagnosis in the UK. Michael Schechter picks up on this in his editorial 
linked to the published version of study 1 (Schechter, 2013, Taylor-Robinson et al., 
2013a): 
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“[David Taylor-Robinson’s]  analysis substantiates previous reports 
of decreased weight, height, and body-mass index, and worse lung 
function in patients with cystic fibrosis living in the most 
disadvantaged areas, but also elucidates several additional details of 
interest. First is that deprivation seems to have its greatest effect on 
somatic growth and lung function in early childhood; disparities are 
maintained but do not seem to increase as children age. Infancy and 
early childhood are a period of vulnerability to adverse exposures 
associated with poverty, which suggests that interventions to mitigate 
such effects might be most effective and efficient if focussed on the 
early years of childhood.” 
The presence of significant differences in outcomes by SES early in the life-course 
were suggested in the US studies, and have been confirmed, and quantified in the 
analysis in study 1 of this thesis. In a cross-sectional  analysis,  Michael  Schechter’s  
study reported a greater chance of being under the 5th centile for weight or height in 
children using Medicaid in the US, and adjusted for age, but did not model age 
related changes in these outcomes. Lung function in  Schechter’s  study was modelled 
as a linear function of age, but this was limited to the cross-sectional relationship 
(Schechter et al., 2001).   O’Connor   et   al   demonstrate   a   social   gradient   in   weight  
percentile at around diagnosis in the US, and in %FEV1 from age five onwards, but 
do not develop a parametric model for the age related changes in these relationships 
(O'Connor et al., 2003).  
The finding of a social gradient in growth outcomes, evident from around the time of 
diagnosis, points to important effects of SES in utero, and/or in the initial period 
prior to diagnosis. Both are plausible, but a limitation of studies thus far has been a 
lack of data on birth-weight, which would complete the picture. As discussed in 
chapter 3, the association between low SES and low birth-weight, and length is well 
established in the general population (Spencer et al., 1999, Marmot et al., 2010b, 
Howe et al., 2011, Howe et al., 2012). The causes for this are likely to be multi-
factorial and relate to maternal health, including stress, diet, drug, alcohol and 
tobacco use during pregnancy (Marmot et al., 2010b). The question remains as to 
how having CF modifies this relationship. We can speculate that there may be an 
interaction, and that exposure to tobacco smoke in utero may be an important 
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influence. The importance of ETS exposure is discussed in more detail later on in 
this section.  
Direct comparison of the SES effect on growth in the CF population, and the general 
population is challenging, due to the lack of studies using comparable SES measures 
and birth cohorts, and due to the effect of the obesity epidemic in the general 
population, whereby a relationship between overweight and low SES emerges from 
around age four onwards (Howe et al., 2011, Howe et al., 2012). This is in contrast to 
CF, where children are consistently underweight compared to the UK reference 
population (Taylor-Robinson et al., 2013a).  
Further data on SES gradients in birth-weight in CF would clarify the extent to which 
the early growth differentials demonstrated are simply a reflection of the broader 
SES effects on birth-weight in the general population. Infants with CF not diagnosed 
by screening are generally underweight at the time of diagnosis in the US and 
Canada (Lai et al., 1999), and in the UK, as demonstrated in study 1. The UK 
registry does not capture differential weight loss by SES in the period prior to 
diagnosis, and this may be particularly important in the first few weeks of life, 
compounding any influence of SES on birth-weight. Data on these very early growth 
trajectories in CF, coupled with birth-weight data is emerging from recent studies in 
the US of babies diagnosed by new-born screening (Lai et al., 2009, Jadin et al., 
2011), but these are limited to small samples, and do not examine SES effects. It is 
likely that studies like these, focussing on babies diagnosed at birth, hold the key to 
unlocking this part of the puzzle, and the rollout of universal newborn screening in 
the UK offers great possibilities for examining this further.  
I hypothesise that newborn screening in the UK may reduce inequalities in CF 
outcomes. This was explored in the supplementary analysis of the effect of SES on 
weight trajectories, in the screened and unscreened population, presented in Chapter 
3 (Figure 36). The point estimates suggested a narrowing of the SES related weight 
gradient in the screened population of the UK, though these were not statistically 
significant. We can speculate that early diagnosis might reduce any early differential 
weight loss by SES, especially when coupled with more intensive delivery of 
nutritional therapies to children from more disadvantaged areas demonstrated in 
study 1. As the number of screened children in the UK increases, the power to test 
 220 
this hypothesis further will improve.  
This hypothesis is further supported by the second novel contribution to the 
literature, relating to the narrowing of inequality in weight SD score in the first three 
years of life. This suggests that diagnosis and treatment for CF in the NHS may be 
having a pro-poor, or ‘levelling-up’ effect, and further we can speculate that earlier 
diagnosis by screening would increase this effect. The third important finding, 
closely related to the decrease in inequality in weight SD score, is the lack of 
widening inequalities over time across all clinical outcomes studied in the UK. The 
O’Connor  study  in  the  US  suggested  that  this  may  be  the  case,  as  their  analysis  also  
did not suggest an age related increase in weight percentile and %FEV1 inequalities 
by zip-code linked income (O'Connor et al., 2003),   whereas   Michael   Schechter’s  
cross-sectional analysis suggested an increase in the age related deprivation gap in 
%FEV1 on the basis of Medicaid status (Schechter et al., 2001).  
 
The findings of decreasing inequality in early life for weight, and stable inequality 
subsequently for other outcomes are important. The life-course perspective suggests 
that the accumulation of risk with age tends to lead to increasing inequalities over 
time. For instance, the UK Marmot review states (Marmot et al., 2010b): 
“Central   to   the   Review   is   a   life   course   perspective.   Disadvantage  
starts  before  birth  and  accumulates  throughout  life.”  
Furthermore, the analysis in study 1 did not demonstrate an effect of SES on %FEV1 
in the adult population, and though the effect of SES on BMI SD score was of the 
same magnitude in adults and children, it just failed to reach significance (–0·12 SD 
scores, 95% CI –0·25 to 0·01, comparing most to least deprived quintile).  
There are a number of possible explanations for these findings. It may be a real 
phenomenon, and we can speculate that the pro-poor delivery of key therapies in CF 
(IV and nutritional therapies) is having a levelling-up effect, and that in the absence 
of the more intensive delivery of treatments to disadvantaged children, the counter-
factual situation would be for inequalities in outcomes to increase with age. If this is 
the case, this is important, as it provides evidence to suggest that health services can 
have a levelling-up influence on chronic diseases. The findings may, on the other 
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hand, be artefactual, possibly as a result of factors such as left-censoring in the 
dataset, selective dropout due to death, and reduced power to detect effects in the 
adult age range due to the smaller numbers of individuals, and the relatively short 
longitudinal data traces in the UK study. As argued in the methods section, the UK 
dataset, compared to the Danish data, is better suited to demonstrate cross-sectional 
differences between patients, rather than change over time. These issues are 
considered in more detail in the limitations section. This study is the first to explore 
SES effects in adults with CF at a population level, and our understanding of the 
effect of SES across the lifespan on clinical outcomes in CF would benefit from 
further studies in this age group (Schechter, 2013). 
 
Establishing a better understanding of the role of health services in the pathway to 
health inequalities in CF 
A key question is the role of health services in perpetuating or remediating against 
the generation of any health inequalities demonstrated in CF. Margaret Whitehead 
defines equity in healthcare as: 
 equal access to available care for equal need; 
 equal utilization for equal need; 
 equal quality of care for all (Whitehead, 1990). 
 
Study 1 thus explored aspects of CF care in the UK from an equity perspective, and 
overall the picture is mixed. There is no difference by deprivation status in age at 
diagnosis, or in the degree to which patients with CF are captured in the registry. 
This suggests that children with this chronic disease are entering the care system, and 
accessing the annual review follow-up process in an equitable manner. With regard 
to the major treatments for CF, study 1 provides evidence of more intensive 
treatment being delivered to both children and adults with CF, for two major pillars 
of CF care – treatment with IV therapies, and nutritional therapies – after adjusting 
for measures of disease severity. These findings provide evidence of a so-called ‘pro-
poor’ bias (Ravallion, 2001). Study 1 also demonstrates that children and adults from 
more disadvantaged areas are more likely to be treated in hospital with IV therapies, 
again after adjusting for disease severity. Aside from consideration of residual 
confounding by severity, one explanation for these findings is that clinicians are 
actively taking steps to address, and overcome the perceived excess disadvantage 
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faced by people living in more deprived areas. This explanation rings true with many 
of the paediatricians with whom I have discussed these results. Some have suggested 
that they take a more paternalistic approach to children with CF who are perceived to 
be living in more disorganised home circumstances, where there may be additional 
barriers to ensuring that they receive the care and treatments needed. In these 
situations, some clinicians have suggested they prefer to admit children to hospital, 
where a range of treatments can be delivered with certainty.  
This line of reasoning is corroborated in a recent case-report regarding a child with 
CF under the care of the Brompton hospital (Gupta et al., 2009). The article 
describes the dramatic improvement in the clinical condition of an eight-year old 
girl, following a change in her challenging home circumstances. The authors 
describe how she was regularly admitted to hospital for treatment optimisation and 
intensive physiotherapy, but that within weeks of discharge from hospital the 
benefits of her treatment would   ‘wear   off’.   Her   home   circumstance   changed  
following the imprisonment of her mother and brother, when she went to live with an 
older sister, and this coincided with a dramatic improvement in lung function, 
nutritional status, and reduced treatment requirements. The authors of the case report 
suggest that it may be appropriate to offer children living in more adverse conditions 
more intense standard treatment including additional supervised antibiotics, and 
physiotherapy, and further suggest that the efficacy of such approaches needs to be 
assessed (Gupta et al., 2009). The findings from study 1 suggest that such practices 
may already be widespread in the UK, and we can further speculate that this may be 
having a positive impact on the clinical condition of children from the most 
disadvantaged areas, as manifested by the reduction in weight inequality over the 
first few years of life, and the relatively stable inequalities gap demonstrated in study 
1, as opposed to a finding of increasing inequality.  
By contrast, the finding of inequality in the delivery of important inhaled therapies 
such as DNase, and inhaled antibiotics is of immediate concern, and requires further 
investigation. It is unclear if these differences are intended or not. These therapies 
are time-consuming to administer, and need to be taken consistently to deliver 
clinical benefits, with a recent systematic review demonstrating improvements in 
lung function from long term DNase therapy (Jones and Wallis, 2010). These 
differences may relate to conscious decisions made by clinicians relating to the 
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balance between the likelihood of benefit, and the burden of therapy in CF. 
Clinicians may be intentionally less likely to prescribe these long-term inhaled 
therapies in an attempt to reduce the burden of care if they feel that patients are less 
likely to benefit, because of concerns over adherence, or because patients actually 
report not taking them. The high burden of care is well documented for people with 
CF (Ziaian et al., 2006, Sawicki et al., 2009), and the addition of numerous aerosol 
treatments to physiotherapy routines means a treatment burden in excess of two 
hours per day for many individuals with CF (Geller and Madge, 2011). Furthermore, 
a recent study by Quittner et al (Quittner et al., 2010) has suggested that lower SES 
in the US, as measured by Medicaid status, is associated with a perceived higher 
burden of care in families of children with CF, after adjusting for disease severity. 
Added to this is the high non-compliance rate to treatments in CF, and the fact that 
this is likely to be related to SES (Schechter, 2011). Studies of non-adherence in CF 
have suggested rates ranging from 20% to 70% in the UK, US and Spain depending 
on the type of treatment and the method of measurement (Arias Llorente et al., 2008, 
Weiner et al., 2008). In addition compliance has been found to worsen with age and 
disease severity (Arias Llorente et al., 2008), which could explain the greater 
inequality in the adult population.  
On the other hand, these differences may be unintended, and reflect the marked 
variations in prescribed CF care that have been described in the US (Konstan et al., 
1999b, Konstan et al., 1999a, Schechter and Margolis, 2005) on a centre basis, that 
are also likely to occur in the UK. Study 1 provides some evidence of this, whereby 
adjusting for care centre effects reduced the SES effect on risk of any IV therapy use 
somewhat. Patients and families from more disadvantaged areas may be more 
susceptible to these unintended inconsistencies in the delivery of care because they 
are   less   able   to   ‘navigate’   the   care   system,   due   to   reduced   self-advocacy or self-
management skills (Schechter, 2013). 
Schechter et al have conducted two further studies aimed at exploring the differences 
in use of CF related treatments in the US (Schechter et al., 2009, Schechter et al., 
2011). In the paediatric population of the ESCF of around 10,000 children, these 
studies confirmed the tendency for children on Medicaid to be more likely to access 
treatments, whereas the picture was mixed when using other SES indicators such as 
area-based income. This is a further indication that access to free health care is 
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important in the ability to uptake appropriate treatments. For instance there was no 
difference in IV therapy use in children <12 by area-based income, but in young 
people aged 13-18 years, those living in more affluent areas were more likely to be 
treated (13.8% in the lowest income category compared to 19.2% in the highest) 
(Schechter et al., 2011).  
In contrast, another study from the US focussed on the association between SES and 
the chances of being accepted for lung transplant in 2167 adult patients with CF 
evaluated for transplant in the US, between 2001 to 2009 using data from the CF 
Foundation Patient registry (Quon et al., 2012). The authors found that people using 
Medicaid (low SES) were less likely to be accepted for lung transplant compared to 
people without Medicaid, and this association remained after adjustment for 
demographic factors, measures of disease severity, and contraindications to 
transplant. A similar association was found when using alternative methods of SES, 
including educational attainment and area-based household income.  
Interpretation of these studies that use Medicaid status in the US as a measure of 
SES, is more difficult when the outcome is health service use, as opposed to health 
status, since Medicaid use in the US is both an indicator of low SES, and an indicator 
of free access to health care. However, the general finding from the US studies is that 
children using Medicaid are also more likely to access treatment, with the exception 
of lung transplantation, after adjusting for need (Schechter et al., 2001, Schechter et 
al., 2009, Schechter et al., 2011). 
In summary, study 1 suggests that the NHS in the UK may be having an important 
influence on inequalities in outcomes in CF, in ways that differ across the life-
course, depending on the treatment modality. We can contrast these findings with 
those from the US, where studies have not demonstrated major differences in uptake 
for common CF treatments, with the exception of transplantation, and have tended to 
play down the role of health services in the generation of health inequalities. 
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Demonstrating differential social consequences in CF 
The findings from study 2 are novel. No previous studies have explored the interplay 
between SES, disease severity, and employment chances in people with CF, in the 
UK or elsewhere. People with CF are living longer so it is important to understand 
factors that influence adult employment chances. Previous studies have shown that 
people with CF from socio-economically disadvantaged backgrounds have worse 
outcomes (Schechter et al., 2001, O'Connor et al., 2003, Taylor-Robinson et al., 
2013a), and study 2 builds on this these findings to demonstrate how SES, disease 
severity, and time in hospital influence employment chances, in order to better 
understand how health and social inequalities in CF might be perpetuated. 
Around 50% of adults with CF were in employment. Lower social deprivation, male 
sex, higher %FEV1 and BMI, and less time in hospital were associated with 
improved employment chances. Crucially, study 2 demonstrates for the first time that 
deprivation modifies the effect of disease severity in CF: poor lung function is more 
harmful to employment chances for people living in the most disadvantaged 
circumstances compared to the least. Low employment in people with CF is a serious 
concern. Being out of work increases the risk of poverty and social exclusion, and is 
likely to further damage the health of the most disadvantaged people with CF. In 
study 2 I have demonstrated differential social consequences of illness in the context 
of CF, by which people with the double burden of chronic illness and low SES are 
more likely to be excluded from the labour market. We can speculate that this may 
be an important pathway for the amplification of health inequalities in CF, whereby 
disadvantage builds on disadvantage. It is of particular concern that the most 
disadvantaged women have the poorest employment chances, since female sex is 
also an important risk factor for poor outcomes in CF (Barr HL, 2011, Taylor-
Robinson et al., 2013a). These findings suggest that policies should be considered to 
address the extra burden of adverse consequences of CF faced by patients living in 
disadvantaged circumstances. 
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Applying the Diderichsen model to CF 
The studies in this thesis were informed by the Diderichsen model of pathways to 
health inequalities (Diderichsen et al., 2001). Taking each mechanism in the pathway 
in turn, we first consider differential exposure. The key feature of CF as a model to 
study health inequalities is that the risk of having two defective CF genes is not 
significantly socially graded, and therefore differential exposure to this risk factor 
does not explain inequalities in CF outcomes. However, I have demonstrated 
differential exposure to P. aeruginosa acquisition by SES, which is a key risk factor 
for disease progression in CF (Taylor-Robinson et al., 2013a).  
Study 1 provides an important example of differential vulnerability. This pathway 
hypothesises that even if a risk factor is evenly distributed by SEP, it can result in 
differential effects due to the synergistic action of other exposures. In CF, we are 
seeing differential consequences in terms of clinical outcomes, stemming from the 
same exposure to the underlying genetic risk factor for CF. This suggests that there is 
differential vulnerability in terms of having two CFTR mutations, on the basis of 
SES, which is likely to be due to the interaction of other exposures that are socially 
graded (e.g. second-hand smoke exposure, nutrition, stress, environmental 
exposures) that I have been unable to quantify using the data available in the CF 
registry. I will discuss these in further detail in the next section. 
As a result of the twin pathways of differential exposure, and differential 
vulnerability, I have clearly demonstrated differential health consequences in CF in 
terms of lung function, and growth (Taylor-Robinson et al., 2013a), and the studies 
by Britton and Barr suggest that these factors are likely to lead on to important 
differences in survival in the UK (Britton, 1989, Barr HL, 2011). Finally to close the 
loop in the Diderichsen model, study 3 demonstrates differential social 
consequences, whereby poor lung function is more damaging to employment 
chances in more disadvantaged areas. 
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Understanding inequalities in CF 
Having discussed the contribution of the studies in this thesis to our understanding of 
inequalities in CF outcomes, this section concludes with an overview of our current 
understanding as to the mechanisms and pathways that are likely to be important in 
causing the differences in outcomes that I have documented. Whilst I have been able 
to demonstrate the presence of differential exposures, vulnerability, outcomes, and 
consequences as discussed in the section above, there remain key exposures that are 
likely to be important that are not captured in CF registries. We can speculate about 
their likely relationship with SES, and adverse outcomes in CF, with reference to the 
broader literature.  
Figure 78 is an attempt to illustrate a range of exposures that are likely to be 
important in influencing CF outcomes, and that are likely to be differentially 
patterned by SES. The vertical ordering of the exposures aims to represent concentric 
layering of influences as per the Whitehead rainbow (see Chapter 2), whereby 
broader   ‘upstream’   socio-economic factors influence the distribution of the main 
determinants   of   health,   which   further   influence   ‘downstream’   behaviours.   Thus  
parental occupation and income will influence access to a good diet, and the dietary 
choices that are possible. 
The exposures are also distributed over time, and as I have argued, exposures in the 
early years may be particularly important. Furthermore, these effects may interact 
with one another over time, in ways that are difficult to entangle. For instance, I 
speculate that the intensive delivery of certain therapies to disadvantaged children 
may act to mitigate some of the adverse effects relating to the usual picture of 
accumulating health damaging exposures over time. The following sections consider 
the potentially important risk factors that have not been discussed in detail previously 
in this thesis, and that are not captured in the registry data, starting with tobacco 
smoke exposure, since this is likely to be particularly important. Health care has been 
discussed earlier in this chapter, and is not considered in any further detail in this 
section. 
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Figure 78: Logic model based on the Diderichsen model outlining exposures for 
poor outcomes in CF 
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The importance of tobacco smoke exposure 
We can speculate that tobacco smoke exposure in utero, and in the early years may 
be an important mediator of the relationship between SES and adverse outcomes in 
CF, since there are striking and persistent differences in smoking prevalence by SES 
in the general population (Marmot et al., 2010b), and ETS exposure is associated 
with poorer growth and lung function in CF (Rubin, 1990, Kovesi et al., 1993, 
Schechter, 2004).  
In 1990, Bruce Rubin first demonstrated a dose-response relationship between ETS 
exposure and poor lung function and growth in children with CF attending a summer 
camp in the US (Rubin, 1990). A US study of data collected since 2000 looked in 
detail at 800 participants in the US Cystic Fibrosis Twin and Sibling Study with data 
collected on ETS exposure (Collaco et al., 2008). In this study 23% of patients were 
exposed to ETS in the home and 17% were exposed to tobacco in utero. Furthermore 
exposure in the home was associated with significantly worse lung function, but not 
BMI, and in utero exposure was significantly associated with lower birth weight by 
150 g. The authors suggest that the detrimental effect of secondhand smoke exposure 
is equal to that expected for an additional 7.3 years of lung function decline. The 
study also suggested gene-environment interactions between ETS exposure non delta 
F508 CFTR mutations, and the CF modifier gene (TGF), with individuals carrying 
these genes being more at risk of the adverse effects of ETS exposure. Unusually, the 
authors did not find a relationship between SES (measured on the basis of parental 
education, and ZIP code linked income) and exposure to ETS, which suggests that 
the study population may not be representative of the general CF population. 
Furthermore they did not find a consistent independent association between SES and 
clinical outcomes, once ETS exposure was added to their regression model – there 
was an association with paternal education, but not for maternal education level or 
income. On this basis the authors suggest that SES and ETS should be considered as 
confounding one another, but I suggest that it is more appropriate to consider ETS 
exposure as a mediating factor, as in the social epidemiology literature (Taylor-
Robinson et al., 2011) (Morgen et al., 2008).  
In terms of data from the UK, a study of smoking in CF families in one UK centre 
showed a high prevalence, that did not change substantially over the period of 
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measurement: In 1993, 26/56 (46%) households contained at least one smoker 
(smoking households) compared with 23/52 (44%) in 1998 (Smyth et al., 2001). 
Environmental exposures 
Several studies have suggested that outdoor air pollution may have an important 
impact on the progression of CF lung disease (Goeminne et al., 2012, Farhat et al., 
2013, Jassal et al., 2013). A US registry study linked annual average exposures to 
particulate air pollution to increased risk of pulmonary exacerbations and a decline in 
lung function, suggesting a role of environmental exposures on prognosis in CF 
(Goss et al., 2004). Low SES has been linked to increased risk of exposure to 
pollution in England (Wheeler and Ben-Shlomo, 2005). Furthermore in the UK 
general population, low social class and poor air quality were independently 
associated with decreased lung function, and there was evidence of differential 
vulnerability, whereby the adverse effects of air pollution seem to be greater in men 
in lower social classes. It is reasonable to speculate that these effects might be 
amplified by the presence of a chronic lung disease like CF. Further studies using the 
UK registry could usefully explore linkage to datasets capturing information on air 
quality to investigate these associations further. 
Study 1 in this thesis has provided evidence of differential exposure to P. 
aeruginosa, for the first time in a population wide cohort. In Schechter and 
colleagues study (Schechter et al., 2001), Medicaid patients were more likely than 
non-Medicaid patients to have P. aeruginosa, but when adjusted for %FEV1 there 
was no statistical difference, and a more recent US cohort study did not demonstrate 
an association (Rosenfeld et al., 2012a). B. cepacia is another important organism in 
CF, shown to be associated with increased morbidity and mortality (Ledson et al., 
2002). In study 1, B. cepacia was associated with increased rate of decline in lung 
function, but the small numbers of people affected precluded analysis by SES as a 
main outcome (156/4445 in the %FEV1 analysis <18 age group). It remains to be 
seen if low SES is a risk factor for B. cepacia. Like P. aeruginosa, however, 
exposure to other patients with the organism is a risk factor for acquisition, and thus 
increased time spent in hospital (associated with low SES in study 1) may also be a 
risk factor (Ledson et al., 2002). In a similar manner, exposure to viral respiratory 
infections may be associated with adverse outcomes in CF (Hiatt et al., 1999, Asner 
 231 
et al., 2012), and a number of studies have suggested a relationship between low SES 
and more severe consequences of early respiratory viral infection (O'Donnell et al., 
2010, Leem et al., 2011).  
‘Community level resources’ is a catch-all phrase, but would include factors such as 
access to green space, and safe play areas in the local community, which may 
influence the relationship between SES and CF outcomes. For instance, access to 
green space has been related to levels of exercise and wellbeing in the general 
population. Furthermore there is a clear social gradient in exercise levels by SES 
(Geddes et al., 2011). In addition, we know that exercise has clear benefits in CF 
(Schneiderman-Walker et al., 2000). 
Material resources 
Material factors, directly related to level of income, are likely to have important 
effects on children and adults with CF at many levels, which are complex and 
difficult to capture completely. In the general population, for instance, insufficient 
income is associated with worse outcomes across virtually all domains, including 
long-term health and life expectancy (Marmot et al., 2010b). The Marmot review 
accordingly recommends the development of the concept of a minimum income for 
healthy living (Morris et al., 2000, Morris et al., 2007), which would ensure that all 
would receive an appropriate income for their stage in the life course, and would 
reduce overall levels of poverty as well as child poverty (Marmot et al., 2010b). With 
regard to CF, the influence of income on housing quality and access to a healthy diet 
are illustrative examples. Low income is linked to poor housing quality, with the 
presence of damp and mould, which in turn have been linked to adverse respiratory 
outcomes in diseases such as asthma (Krieger and Higgins, 2002). Nutritional status 
is an important influence on lung function and survival in CF, and study 1 has 
demonstrated an association between SES and nutritional status. Furthermore there 
are marked social differences in the quality of dietary intake in children in the UK by 
SES, with significantly lower rates of breast-feeding and access to a healthy diet in 
more disadvantaged areas (Marmot et al., 2010b).  
As well as material factors influencing health, it is clearly possible for a CF 
diagnosis to have a detrimental impact on family income. Furthermore, study 2 has 
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demonstrated differential social consequences for adults by SES. These pathways are 
also likely to be important for children, whereby a diagnosis of CF in a family 
imposes additional financial burdens. The literature in this area is limited, and 
economic analyses have tended to focus on the cost of CF to health care systems 
(Krauth et al., 2003), or the burden of out-of-pocket expenses to families in the 
context of the US heath care system (Lieu et al., 1999). However, there is a body of 
literature relating to other severe illnesses in childhood, demonstrating financial 
stress, employment loss, and overall a negative economic impact on families with a 
critically ill child (Jacobs and McDermott, 1989, Montgomery et al., 2002, Winthrop 
et al., 2005, Shudy et al., 2006). In CF, three older studies touch on this issue. A 
diagnosis of CF in the family has been shown to increase household expenses in 
Norway (Folleras et al., 1988). Another study from the US notes the significant 
hidden costs that follow a diagnosis of CF in the family, including expenses 
associated with clinic visits, loss of pay to either or both wage earners, car expenses, 
parkway tolls and fees, and cost of childcare for siblings of the patient (McCollum, 
1971). Furthermore, a small study in Norway also demonstrated striking differences 
between mothers of children with CF and controls with regard to their possibility of 
having a career. They found that while the education and professional career of the 
fathers of CF children were generally not influenced by having a chronically ill child 
to care for, mothers felt compelled to give up or adapt their education or professional 
career (Michalsen et al., 1988).  
Psycho-social factors 
There can be no doubt regarding the stress that a diagnosis of CF places on families, 
and it is highly plausible that these effects might be amplified by social disadvantage. 
Stress pathways have been shown to be important in the generation of health 
inequalities (Lynch et al., 2000, Marmot and Wilkinson, 2001), and in worse health 
outcomes in CF (Yohannes et al., 2012). However, of potentially greater importance 
for children with CF, is the parental experience of stress, which may lead to anxiety, 
depression (Cruz et al., 2009, Besier et al., 2011), and impaired personal and family 
function (Patterson et al., 1993, Schechter, 2011). A recent study of the ESCF 
population explored health related quality of life in children and families with CF, by 
SES, and showed differential effects (Quittner et al., 2010). This study concluded 
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that children with CF and their parents from more disadvantaged backgrounds, 
measured by Medicaid status, appear to have worse quality of life scores across all 
domains of the Health related quality of life (HRQOL data), using the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R), even after adjustment for disease severity. 
Furthermore, a recent review of the effects of paediatric illness on families indicated 
that pediatric critical illness is stressful for the entire family. The review, which 
included 115 studies, suggested negative effects on parents, siblings, and marital 
cohesion. The needs of family members in terms of rest, nutrition and 
communication were identified as being compromised in many studies. Furthermore, 
a permanent detrimental impact on siblings and marital relationships was described 
in some studies (Shudy et al., 2006).  
Behavioral factors 
At the outset, I should make it clear that I recognise the cultural explanation of 
behaviour and how it influences inequalities, as described in the Black report. Here 
particular   behavioural   patterns   are   seen   as   being   “embedded   within   the   social  
structure”  (Black et al., 1980), and are influenced by the material and psycho-social 
pathways described above. Thus dietary choices are restricted in disadvantaged 
areas, as discussed above. Furthermore stress leads to harmful health behaviours 
such as smoking (Kawachi et al., 2002). It is wholly understandable that the stress 
associated with dealing with a diagnosis of CF may increase the desire to have a 
cigarette in a parent who is a smoker, and the negative health consequences of this 
have been discussed above. Increased family stress may also directly influence 
factors such as adherence to medications, and the capacity for parents to adequately 
manage a child with CF. These issues were discussed in the previous section, where 
it was noted that the perceived burden of care is greater for more disadvantaged CF 
familes (Quittner et al., 2010), and non-compliance rates are also likely to be higher 
(Schechter, 2011).  
In summary there is evidence to support a number of plausible pathways that may 
help explain the differential outcomes demonstrated in study 1 (Taylor-Robinson et 
al., 2013a). Taken together, this literature should heighten awareness of the greater 
health and social risks faced by patients who are economically disadvantaged, and 
appropriate policy responses are discussed in a subsequent section. 
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Understanding longitudinal growth in CF 
Study 1 has described for the first time in a UK wide cohort the longitudinal growth 
trajectories for children and adults with CF. Furthermore, the study demonstrates the 
influence of important covariates on growth, such as sex, genotype, and screening 
status, as well as time-varying factors such as acquisition of P. aeruginosa. 
I describe the changes in weight and BMI in the first few years of life, whereby the 
population is markedly underweight at the time of diagnosis, and there is a period of 
improving nutritional status over the first three years of life, presumably secondary 
to diagnosis, and consequent attention to nutritional status and pancreatic enzyme 
replacement. There were important covariate effects, with higher weight SD score 
associated with male sex, screened patients, heterozygotes for delta F508 and white 
patients in the <18 age group (Figure 34), and with female sex, heterozygote status 
and white patients in the >18 age group. Higher BMI was associated with male sex in 
the paediatric age range, and had a steeper rate of decline in delta F508 homozygotes 
after the age of three, and was consequently associated with lower BMI SD score in 
adults.  
To date, this study represents the most comprehensive analysis of the dynamics of 
growth over time in a contemporary CF population, using modern longitudinal 
analysis techniques (Salvatore et al., 2012). Two studies have previously described 
longitudinal growth in the US and Canadian populations (Lai et al., 1999, Zemel et 
al., 2000). Zemel studied growth in 1000 children in the US with PI, using mixed-
effects models, but with a limited range of covariates, and showed that important 
sex-related differences in growth occur before puberty, with males faring better. The 
authors also correlate better nutritional status with improved lung function after age 
six (Zemel et al., 2000). Lai et al compared the entire US and Canadian CF 
populations, using a GEE approach, and they demonstrate early malnutrition around 
the time of diagnosis, that improves over the first few years of life in both 
populations, with slightly better outcomes in the Canadian cohort, where mean 
height and weight were 4 to 5 percentiles higher than those in the United States (Lai 
et al., 1999). Lai et al also demonstrate a male and heterozygote (delta F508) 
advantage with regard to weight, but this is on the basis of a stratified analysis, rather 
than the multivariable approach in study 1 in this thesis.  
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In this thesis I have developed a parametric longitudinal model describing growth 
trajectories in the UK, which builds on these previous findings, and describes the 
effect of SES on early weight trajectories. Current studies of growth are particularly 
focussed on the first few months of life. Lai’s  group,  for  instance,  have  undertaken a 
number of more recent studies of growth, using smaller populations identified 
through the Wisconsin neonatal screening programme, with a focus on the 
longitudinal dynamics of early nutritional trajectories, and how these relate to 
subsequent outcomes (Shoff et al., 2006, Lai et al., 2009, Jadin et al., 2011). As in 
study 1 presented here, diagnosis through screening leads to an early nutritional 
advantage, and these studies are focussed on explaining why some patients with CF 
respond to treatment initiation and succeed in recovering from malnutrition and 
growth faltering/failure experienced before diagnosis, whereas others fail to do so. 
For instance, in the Wisconsin studies early attainment of birth weight status after CF 
diagnosis is associated with significantly better pulmonary outcomes at 6 years of 
age (Lai et al., 2009), and exclusive breastfeeding in the first few months of life was 
associated with adequate growth and protected against P. aeruginosa infections 
during the first two years of life in CF infants who had PI (Jadin et al., 2011). 
Furthermore a recent study of children diagnosed by newborn screening in Australia 
demonstrated a longitudinal association between markers of pulmonary inflammation 
and worse nutritional status, though the direction of this relationship requires further 
investigation (Ranganathan et al., 2011).  
Height has been independently related to survival in people with CF, and it has been 
suggested that this may be mediated through greater lung capacity in taller people 
(Beker et al., 2001). Furthermore, Fogarty et al have suggested that measures of body 
habitus may partially explain the male survival advantage in CF (Fogarty et al., 2011, 
Fogarty et al., 2012). The findings from the analysis presented in this thesis suggest 
that SES has an important effect on height from the outset, and that this difference 
tracks through to adulthood, without the age related dynamics seen for weight and 
BMI. Further longitudinal analyses are required to understand how birth length, and 
the factors that influence it, may influence subsequent clinical outcomes and survival 
in CF. 
In summary, malnutrition and poor growth are major concerns in children with CF, 
and optimizing nutritional status appears to be important for subsequent lung health. 
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Study 1 in this thesis has provided a longitudinal description of growth in the UK CF 
population. Future studies in the UK should develop our understanding of the 
changes in nutritional status in the early years, particularly utilising data from the 
growing number of screened children in the UK, taking into account SES as an 
important early influence. 
Understanding changes in lung function in CF 
Study 1 and study 3 have added to the extensive body of literature on lung function 
decline in people with CF, introduced in Chapter 1 of this thesis, by describing 
factors influencing longitudinal lung function decline in both the UK and Danish 
population.  
Turning to the UK population first, study 1 modelled the effect of a range of 
covariates on lung function decline in the paediatric and adult population. In the 
paediatric population, a linear model for the population average change in lung 
function provided a suitable fit to the data, and the effect of covariates was assessed 
using a random intercept and slope approach. In the paediatric population, higher 
%FEV1 was associated with higher SES, male sex, screened patients, heterozygote 
delta F508 status, white patients, absence of CFRD and P. aeruginosa colonisation, 
and higher BMI. In the adult population, the population average was modelled as a 
split line, with a greater decline in lung function up to the age of 25, and there were 
similar significant associations between sex, and genotype, as in the paediatric 
analysis. 
Konstan et al have undertaken the largest studies to date of %FEV1 in both paediatric 
and adult cohorts (Konstan et al., 2007a, Konstan et al., 2012, Vandenbranden et al., 
2012). In their first study of 4923 children in the US ESCF, using a mixed-effects 
regression approach, Konstan et al showed that higher baseline %FEV1, P. 
aeruginosa colonisation, female sex, and poor nutritional status were amongst the 
factors associated with a greater decline in lung function (Konstan et al., 2007a). In 
this study, the analysis was stratified into three different age groups (6 to 8 years, 9 
to 12years, and 13 to 17 years), and whilst the covariate effects were broadly similar 
over the age range, the population level rate of decline in %FEV1 was shallower in 
the 6 to 8 age group, suggesting a population level acceleration in lung function 
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decline after the age of eight years. The study presented in this thesis identifies 
similar risk factors to those in the Konstan study, and although the models are not 
directly comparable, the findings are broadly consistent. Figure 79 below, for 
example, compares the effect of female sex on lung function decline in the US and 
UK paediatric population, with consistently worse lung function in females in both 
populations before the age of 18 years. 
 
Figure 79: Effect of sex on lung function decline in the US and the UK 
 
 
Vandenbranden et al published a study in 2012 focussing on the same ESCF 
population, exploring influences on lung function decline during the transition from 
late adolescence to early adulthood, since they hypothesized that there may be 
identifiable risk factors in adolescence associated with accelerated lung function 
decline during early adulthood that are amenable to intervention (Vandenbranden et 
al., 2012). Risk factors for substantial decline in early adulthood included slower rate 
of %FEV1 decline in adolescence, poor nutrition, P. aeruginosa and male sex. This 
corroborates the findings in our study, and it is notable that male sex was associated 
with an increased risk of substantial decline in the early adult period, as in Figure 48 
in my analysis of adults in the UK. There is the potential in the UK data to study 
these dynamics in more depth, with a greater focus in age related changes, but this 
was beyond the scope and purpose of the studies presented here. 
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In 2012 Konstan et al have published a study of the adult ECFS population (4161 
adults). Together with the data presented in study 1 (4026 adults) these represent the 
largest studies of lung function decline in adult CF populations, since previous 
studies of risk factors for lung function decline have not focussed specifically on 
adults with CF, or did not evaluate adults separately by age groups, possibly due to 
small numbers of patients available for analysis (Konstan et al., 2012). Although 
study 1 in this thesis explored different risk factors, there are important similarities 
with   Konstan’s   findings: Both studies identified a steeper rate of decline in lung 
function up to the age of 25, and both studies identified fewer significant covariates, 
including sex and P. aeruginosa effects, as compared to the comparable analyses in 
the <18 age group. These findings may be due to lower sample size in the adult 
population, and survivor effects, or they may be a true reflection of shifting risk 
factor effects with age. Another possibility is that risk factors that have been present 
for many years may no longer have a demonstrable effect on lung disease. It is, 
however, noteworthy that there were still demonstrable sex effects in adulthood in 
both studies. 
Studies like those undertaken by Konstan et al, and study 1 in this thesis, using 
longitudinal data on large numbers of individuals and mixed-effects model 
approaches, are ideal to delineate population level risk factors, and are important for 
a number of reasons. They allow clinicians to better understand, and predict the 
likely lung function trajectories of populations with similar characteristics, and thus 
allow identification of populations with multiple risk factors for lung function 
decline where a higher degree of vigilance might be appropriate. Furthermore there 
are implications for trial design, and assessment of new therapies, in that these 
results help triallists to identify populations with higher rates of lung function decline 
in which therapies may be studied in order to increase the chances of demonstrating 
significant effects. These studies also highlight the complexity of studying the 
potentially shifting effect of risk factors for lung function decline in populations. 
We can compare and contrast the insights gleaned from the UK analysis (study 1) to 
those from the Danish analysis of %FEV1 decline in study 3. The UK analysis, along 
with the Konstan et al studies discussed above, are adequately powered to assess the 
effect of covariates on between-individual differences in lung function trajectories, 
since these datasets contain a large number of individuals, with relatively short 
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longitudinal traces. By contrast the Danish analysis featured very long, and 
frequently measured %FEV1 trajectories, on about 500 individuals, and as described 
in study 3 this required a novel modelling approach. The Danish dataset thus 
provided the opportunity to study within-individual changes in %FEV1 in great 
detail, whereas it was less well powered to study between individual differences.  
Population averaged %FEV1 decline in the Danish population was significantly 
influenced by age, Pseudomonas colonization status, pancreatic function, birth 
cohort and CFRD (Taylor-Robinson et al., 2012a). These risk factors have been 
identified in other studies, including the Konstan studies, and study 1 of the UK 
population, and the PA effect was similar in Denmark to that found in the ECFS 
population (Konstan et al., 2007a, Konstan et al., 2012, Taylor-Robinson et al., 
2012a, Taylor-Robinson et al., 2013a). However, the Danish analysis in study 3 
suggested linear population average covariate effects over time, as opposed to the 
changing effects demonstrated in the US studies. This is likely to be a reflection of 
the small cross-sectional sample size in Denmark, as further suggested by the lack of 
a demonstrable sex or genotype effect. 
The key insights from the Danish analysis arise from the description of the 
variogram for %FEV1 decline, which has never been done before. This was largely 
the result of serendipity on my part. The initial rationale for the Danish study was the 
availability of individual level SES data through the Danish registers, and it was a 
fortunate surprise to come across such a rich dataset that had never been analysed 
longitudinally, in combination with the expertise and support of my supervisor Peter 
Diggle, who has developed many of the methods to analyse data of this nature.  
The key findings from the Danish analysis, with regard to the clinical 
epidemiology of CF are: 
 The large error in repeated measurements of %FEV1 within individuals 
(average within person SD of 6 percentage points). 
 The long-term, but exponentially decreasing correlation in %FEV1 
measures over time (up to 15 years), quantified in the variogram. 
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These findings have implications for the interpretation of abrupt changes in lung 
function at the individual level in CF, much of which may be due to recoverable 
short-term fluctuation, and measurement error. There are also implications for 
longitudinal study design, and RCTs with %FEV1 as the primary outcome, where 
separating a treatment signal from the noise is clearly a challenge, and requires large 
sample sizes.  
The findings of study 3 also raise questions about the plausibility of individual level 
prediction models for %FEV1 decline, like those suggested by Konstan et al  
(Konstan et al., 2007a, Vandevanter et al., 2010) which purport to assist prediction at 
the individual level. For instance,  Konstan’s  paper (Konstan et al., 2007a) suggests 
that one may be able to use the linear combination of fixed-effect covariates (risk 
factors for lung function decline) for an individual to predict the likely lung function 
trajectory over time. This does not, however, take into account the other components 
of variation – the measurement error, and the within person correlation over time 
(random effects), which the analyses presented in this thesis have suggested are 
important, and have an important bearing on the prospects for individual prediction. 
Furthermore in the Vandevanter analysis that outlines the development of a 
‘pulmonary  outcome  prediction  score’  (POP) system the abstract states (Vandevanter 
et al., 2010): 
“These   simple   integer-based POP algorithms employ variables 
available at clinic visits and can be used to predict the probability of 
different future pulmonary outcomes for individual patients and 
patient  populations.” 
Further research is required to understand the value of clinical tools such as these at 
the individual level, and researchers should be careful not to conflate individual and 
population level prediction.  
%FEV1 remains an influential driver for treatment of pulmonary exacerbations in CF 
(Rabin et al., 2004), and the key recommended outcome in clinical trials for new 
therapies (European Medicines Agency, 2009). Clearly it would be ideal if clinicians 
were able to predict the future for their patients on the basis of data routinely 
collected in clinic. However, the reality appears more complicated than this, and 
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some have begun to question the value of %FEV1 as the key clinical outcome 
measure   of   interest   in   CF.   Rosenthal’s   entertaining   piece   starts   thus   (Rosenthal, 
2009): 
“Whenever   I   see   a   CF   doctor,   my   mind   forever   superimposes   the  
scene from the film  The  Producers  where  Gene  Wilder’s  Leo  Bloom  
clutches his blue blanket but in this case the blanket has FEV1 written 
on it – we  are  obsessed  with  it.” 
(see http://www.youtube.com/watch?v=PTGZKmdfdzI) 
Rosenthal illustrates a serious point, however, and the Danish analysis presented in 
this thesis adds to this debate, and suggests some way forward: The modelling 
framework provides a more realistic estimate of the underlying lung-function 
trajectory of people with CF, by acknowledging both the imprecision in individual 
measurements over time and the correlation structure of repeated measurements on 
the same individual, issues that have all too often been disregarded in the past 
(Taylor-Robinson et al., 2012a, Taylor-Robinson et al., 2013b). 
Understanding longitudinal risk of chronic P.aeruginosa colonisation in CF 
Study 1 provides, for the first time, a multivariable longitudinal model for the risk of 
P. aeruginosa colonisation over time in the UK CF population. As well as 
demonstrating an association with social deprivation, this model describes the time-
dependent nature of P. aeruginosa acquisition, and suggests that female sex, 
homozygote delta F508 status, CFRD, PI, lower %FEV1, and not having been 
diagnosed through new-born screening are associated with an increased risk of 
chronic P. aeruginosa acquisition. Study 1 appears to be the largest longitudinal 
study to date of factors influencing P. aeruginosa colonization, and the only study at 
a population level (Kerem et al., 1990b, Kosorok et al., 1998, Maselli et al., 2003) 
(Rosenfeld et al., 2012a). Schechter  et  al’s  cross-sectional study of the effect of SES 
on P. aeruginosa in the US showed Medicaid insured patients were more likely to 
have P. aeruginosa infection than were patients who were not eligible for Medicaid 
insurance, but when adjusted for %FEV1 there was no statistically significant 
difference (Schechter et al., 2001). 
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P. aeruginosa is clearly associated with worse outcomes for people with CF, in terms 
of survival, lung function, pulmonary exacerbations and nutritional status (Emerson 
et al., 2002, Konstan et al., 2007a, Rosenfeld et al., 2012a), and the association with 
worse growth and lung function have been corroborated in study 1 as described 
above (Taylor-Robinson et al., 2013a). Further research is required to understand the 
interaction of SES, increased time in hospital, and risk of P. aeruginosa acquisition 
in  the  UK  population,  and  to  identify  modifiable  risk  factors.  Rosenfeld  et  al’s  recent  
study in a US cohort (Rosenfeld et al., 2012a) did not identify any modifiable risk 
factors that were associated with decreased age at P. aeruginosa colonization, 
including exposure to second-hand tobacco smoke, breastfeeding, day-care 
attendance, hot tubs, or wood burning stoves. They suggest a possible association of 
better nutritional status with delayed acquisition of P. aeruginosa, also demonstrated 
by Ranganathan et al (Ranganathan et al., 2011). These relationships could fruitfully 
be explored in further studies of the UK registry. 
Understanding the sex effect in CF 
The analysis of the UK CF registry presented here has, for the first time in a UK-
wide cohort, demonstrated worse outcomes for females from the outset, in terms of 
lower weight, height and BMI SD scores in the early years; increased rate of decline 
of %FEV1 from age five; and increased prevalence of P. aeruginosa colonisation in 
childhood and adulthood. These associations were independent of factors such as 
SES, and the association between female sex and higher prevalence of P. aeruginosa 
colonisation was not modified by adjustment for %FEV1, suggesting that female sex 
may have an independent effect on risk of P. aeruginosa acquisition. Study 1 did 
demonstrate a period of increased rate of decline of lung function in men in the early 
adult period, corroborated  by  Konstan’s study in the US (Konstan et al., 2012).  
Female sex has now been identified as a negative prognostic factor in CF in several 
countries, registries, and CF care centres (Buzzetti et al., 2009, Salvatore et al., 
2012). The effect of sex on morbidity and mortality in CF, with females having 
worse outcomes, has been a common finding in large epidemiological studies, first 
suggested in US centres (Kerem et al., 1992, Kosorok et al., 1996), and then 
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confirmed in US population level registry studies (Rosenfeld et al., 1997, O'Connor 
et al., 2002). There have been similar findings in the UK (Dodge et al., 2007), with 
Barr et al in the UK (Barr HL, 2011) suggesting that despite overall improved 
survival in the 21st century, females continue to be more likely to die below the 
median age of death compared to males, a pattern that has persisted since the 1960s. 
There has been recent debate about the sex gap, suggesting that this may be 
narrowing over time as a result of improving treatment (Verma et al., 2005, Viviani 
et al., 2011). In terms of use of health services, a large study in Canada has 
demonstrated increased risk of hospitalisation in females (Stephenson et al., 2011). 
The cause of the sex gap remains unclear, however. Some studies suggest that 
females may be more likely to become colonized with P. aeruginosa at an earlier age 
(Kerem et al., 1990b, Demko et al., 1995, Maselli et al., 2003, Levy et al., 2008, 
Rosenfeld et al., 2012a), and this may be related to the effect of oestrogen (Zeitlin, 
2008, Chotirmall et al., 2012). Other biological reasons have been suggested, 
including increased occurrence of CFRD (Barr HL, 2011). Social explanations have 
also been suggested. These may relate to gender roles, such as a possible propensity 
to less exercise in childhood in girls, and an increased tolerance of poor nutritional 
status in adolescent girls with CF, fuelled by the societal pressure to appear thin 
(Schechter, 2003, Schechter, 2004). 
Study 1 shows that the sex effect on outcomes is clearly apparent in the UK CF 
population. Future studies could usefully explore mediating pathways that may help 
explain the gap, focussing on the relationship between early nutrition, P. aeruginosa, 
and %FEV1. Furthermore, it may also be possible to test the hypothesis that the sex 
gap is reducing in successive cohorts. This was not pursued in the UK analysis, 
where the cohort effect was treated as a nuisance factor in the analysis. 
Understanding the effect of newborn screening on CF outcomes in the UK 
In the UK population, in the analysis presented in this thesis, screening was 
associated with improved weight and height for age, reduced risk of P. aeruginosa 
colonization, and a shallower rate of decline in lung function in the <18 analysis 
(Taylor-Robinson et al., 2013a). The study of the UK registry presented here builds 
on the papers from Sims et al that were amongst the first publications to use the data 
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from the UK CF database, which suggested a reduction in morbidity, treatment 
requirements and healthcare costs in screened patients (Sims et al., 2005a, Sims et 
al., 2005b, Sims et al., 2007a, Sims et al., 2007b). Furthermore these findings support 
the growing body of evidence that newborn screening improves outcomes in CF 
(Salvatore et al., 2010, Greasemann and Ratjen, 2013), and the results specifically 
corroborate the findings of the systematic review of RCTs of neonatal screening in 
CF which shows less malnutrition in infants diagnosed by neonatal screening 
(Southern et al., 2009).  
The finding of reduced prevalence of P. aeruginosa colonization in the UK screened 
population is important, since the Wisconsin Neonatal Screening Trial raised 
concerns that some of the benefits of screening may be offset by an increased risk of 
earlier P. aeruginosa acquisition (Kosorok et al., 1998), although this has not been 
supported in more recent studies (Wang et al., 2001, Sims et al., 2005b, Baussano et 
al., 2006, Rosenfeld et al., 2012a). 
The UK national CF screening programme offers rich opportunities for further 
research in combination with the registry. The screened individuals included in the 
analysis presented here (n = 1309), are mainly those individuals identified by the 
regional screening programmes for CF that were in place prior to the national new-
born screening programme. In England, all babies delivered in the East Anglia, 
Northampton, Trent and Leeds districts were screened for CF prior to the national 
roll-out (Pollitt et al., 1997, Southern, 2004, Sims et al., 2005a, Sims et al., 2005b).  
From the analysis presented in study 1 we can speculate that new-born screening 
may be associated with a narrowing of health inequalities in early weight gain, and 
this will be a testable hypothesis in a few years time once there are data on weight 
gain in the first three to four years of life in the screened population. Furthermore, 
studies of the incident screened population in the UK population offer a unique 
opportunity to study the mechanisms behind the early evolution of differential 
outcomes in CF, and their consequences over the life-course, in a homogeneous 
population at the outset. This will lead to a ‘cleaner’  dataset  and  population  than  the  
one studied in the analysis here, without the complication of survival bias, and any 
effects associated with missing data prior to diagnosis. The growing body of 
evidence around the evolution of early lung disease (Greasemann and Ratjen, 2013), 
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typified by the ARREST CF studies in Australia (Sly et al., 2009, Stick, 2009, Stick 
et al., 2009, Mott et al., 2012), has been dependent on these features of the CF 
population identified through new-born screening. I can see great potential for data 
linkage between the UK registry and smaller clinical studies of this type. Specially 
collected clinical data could be used to augment the data collected in the registry, and 
the registry could facilitate the long-term follow up of patients studied in clinical 
trials of early patho-physiological changes in infants and children with CF. Studies 
of this nature will be critical to assess the utility of early interventions, implemented 
before any lung disease is established, that have the potential to deliver long-term 
benefits for patients with CF (Greasemann and Ratjen, 2013).  
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Contribution to the knowledge base around health inequalities 
Using CF as a case-study to investigate pathways to health inequalities provides a 
rare opportunity to investigate how the interaction of social, genetic, and healthcare 
factors leads to differential outcomes, in a disease that does not have a socio-
economic bias at the outset. This has led to a number of key findings that contribute 
to our knowledge base around health inequalities more generally, which are 
discussed below. The WHO Commission on Social Determinants of Health, chaired 
by Sir Michael Marmot, emphasised the urgent need for a stronger focus on this type 
of research. In order to develop effective interventions, the report states that it is 
essential to measure the problem, expand the knowledge base and build research 
capacity (CSDH, 2008). The studies in this thesis add to the evidence base, and 
through undertaking this work I have developed key skills that build research 
capacity in this vital area.  
Social inequalities, even for genetic diseases 
The findings presented in this thesis pose a challenge to those who might wish to 
invoke narrow genetic or biological explanations for inequalities in health. The 
genetic argument for health inequalities suggests that inequalities stem from the 
social distribution of genetic material responsible for causing illness, to the 
disadvantage of those further down the social strata, but there is little empirical 
evidence to support this (Holtzman, 2002).  
CF is the archetypal classically inherited genetic disease that I first learnt about at 
school, caused by a single gene defect that is both a necessary and sufficient cause of 
a chronic illness. CF was one of the first diseases for which the precise genetic 
mechanism was elucidated, with the sequencing of the CFTR gene, and yet 
knowledge of the genetic mutation does not predict clinical outcome (Kerem et al., 
1990a, 1993, Koch et al., 2001, Schechter, 2004). Study 1 demonstrates an even 
distribution of incident cases in CF. Study 1 also shows a slight difference in the 
distribution of delta F508 alleles by SES, with a shallow trend towards fewer 
heterozygote delta F508 carriers and more people with no delta F508 genes with 
increasing level of deprivation. An explanation for this may be the greater proportion 
of non-white patients in more deprived groups. 
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The variability in clinical presentation among patients with identical genotypes is 
presumably due to a multitude of factors, both genetic and non-genetic, and there is 
currently great interest in the role of modifier genes in CF. This has led to a number 
of recent studies into modifier genes that may influence the effect of the CFTR 
mutation (Wolfenden and Schechter, 2009, Cutting, 2010), most notably the 
TGFBeta1 gene where there seems to be consistent evidence to support its 
association with poorer lung function (Drumm et al., 2005). The interaction between 
the TGF gene and ETS exposure has been mentioned previously, and is an area for 
further research (Collaco et al., 2008). Despite the genetic origin of CF, in this thesis 
I have shown that outcomes in CF are socially patterned, demonstrating that social 
factors are leading to profound differences in the course of the illness, which cannot 
be explained by genetic differences. 
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Inequalities from the start 
The finding that inequalities start early in the life course and then track through until 
later life, even for a genetic disease like CF, supports the growing evidence base 
around the early origins of health inequalities. The convergence between the 
inequalities literature, and the current direction of CF research is also striking, 
whereby both disciplines are suggesting that the early years are critical. In their 
recent piece on early lung disease, for instance, Grasemann et al state (Greasemann 
and Ratjen, 2013): 
“The   infant   and   preschool   age   could   represent   a   unique   period   of  
opportunity to postpone or even prevent the onset of cystic fibrosis 
lung  disease.” 
Compare this to possibly the key recommendation of the UK Marmot review 
(Marmot et al., 2010b):  
“Action   to   reduce  health   inequalities  must   start  before  birth  and  be  
followed through the life of the child. Only then can the close links 
between early disadvantage and poor outcomes throughout life be 
broken.” 
The findings of this thesis support the growing consensus that early disadvantage 
tracks forward, to influence adult health in later life, and that children who start 
behind tend to stay behind (Kuh et al., 2004, Galobardes et al., 2008, Marmot et al., 
2010b). This has important implications for public health policy, and suggests that 
children may have optimum or sub-optimum trajectories on the basis of early life 
experiences. As Figure 80 below illustrates, these early life trajectories can 
determine the point at which an individual becomes symptomatic for a particular 
adult chronic disease. Thus interventions targeted in the early years may thus delay 
the onset of limiting illness in later life.  
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Figure 80: How risk reduction and health promotion strategies influence health 
development 
Adapted from (Halfon et al., 2000) 
 
The Y-axis in Figure 80 represents some general phenomena relating to health 
development, but it is striking that this plot is increasingly cropping-up in the life-
course literature, with different measures of health on the Y-axis. For instance, this 
model has been applied to the development of lung health (Kuh et al., 2004), mental 
health capacity (Kirkwood et al., 2008), and features in a recent Lancet paper in a 
very similar form with ‘behavioural competence’ on the Y-axis (Walker et al., 2011). 
I consider the  policy implications of this – the need for increased investment in the 
early years –in more detail later in this chapter.  
Health services and heath inequalities 
We have discussed the variations in recorded use of treatments by SES for people 
with CF in the NHS. What do the studies in this thesis, using CF as a tracer 
condition, tell us more broadly about the role of health services in the fight against 
health inequalities? 
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An important starting point is to understand what equity in healthcare might look 
like?  Restating  Margaret  Whitehead’s  definition:   
 equal access to available care for equal need; 
 equal utilization for equal need; 
 equal quality of care for all (Whitehead, 1990). 
 
Need, in the context of the definition above, can be taken to relate not just to disease 
severity, but also to disadvantage. On this basis one can argue that equity is being 
achieved for certain aspects of CF care in the NHS, since the data suggests that 
clinicians are responding to both disease severity, and level of disadvantage when 
making treatment decisions.  
The Commission on Social Determinants of Health highlights that inequitable 
delivery of health care is an important factor in the generation of health inequalities 
(CSDH, 2008). Whilst health services are generally not the cause of health 
inequalities (Marmot et al., 2010b), they can play an important role in the 
amplification and perpetuation of disadvantage in a number of ways, for example 
through the so-called  ‘inverse  care  law’  (Hart, 1971) or  the  ‘medical  poverty  trap’  in  
health care systems that are not free at the point of access (Whitehead et al., 2001). 
The famous Inverse Care Law, described by the British GP Tudor Hart (Hart, 1971) 
states: 
“The  availability   of   good  medical   care   tends   to   vary   inversely  with  
the need for it in the population served. This inverse care law 
operates more completely where medical care is exposed to market 
forces,  and  less  so  where  such  exposure  is  reduced.” 
This describes the situation whereby those who most need high quality health care, 
end up receiving less and/or lower quality care. For this reason, striving for equity in 
health service delivery, as defined by equal use for equal need (Whitehead and 
Dahlgren, 2007), is a central principle for health care systems (Whitehead, 1992), 
including in the NHS.  
In the UK, the Darzi report noted the relationship between low SES and poor health 
and  suggested  that   the  NHS  has  a  pivotal  role  in  providing  excellent  services  as  “a  
matter  of  fairness”  (Darzi, 2008). The controversial new Health and Social Care Act 
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further enshrines in legislation explicit duties on the Secretary of State, NHS 
Commissioning Board and clinical commissioning groups (CCGs) to have regard to 
the need to reduce inequalities in access to, and to the outcomes of healthcare (DH, 
2012c). Many dissenting voices have suggested the legislation is likely to have 
significant adverse effects on health inequalities (FPH, 2010, Pollock et al., 2012a, 
Pollock et al., 2012b). Whist this may well be the case, the wording of the legislation 
could serve as a lever to hold those responsible for health services to account in 
terms of taking action to reduce inequalities in outcomes. 
In these troubled times for our NHS, Study 1 provides some evidence that the system 
can take into account the extra needs of disadvantaged children and their families in 
the UK to deliver care that may be effective in reducing, or at least limiting any 
increase in health inequalities. Identifying levelling-up interventions such as this is 
the   ‘holy-grail’   for   researchers   and   policy   makers   interested   in   reducing   health  
inequalities (Klasen, 2004), as Margaret Whitehead asserts in a paper for WHO 
(Whitehead and Dahlgren, 2007): 
“…the  only  way   to  narrow  the  health  gap   in  an  equitable  way   is   to  
bring up the level of health of the groups of people who are worse off 
to that  of  the  groups  who  are  better  off.” 
Study 1 presented here contributes to this evidence base, and provides 
encouragement that health services can make a difference in the early years. Further 
research in this area is required to address the so-called   ‘inverse   evidence   law’  
around interventions to reduce health inequalities (Milton B, 2011). 
Study 1 also sheds some light on potential differences between the delivery of 
chronic care for children versus that delivered to adults, by demonstrating an 
increasing propensity to inequality in delivery of both inhaled CF treatments in the 
adult population, as compared to the paediatric age group. This corroborates the 
broader literature, in terms of access to and use of care in chronic diseases, which 
suggests a different picture in adults and children: In adults, a systematic review of 
universal health care systems by Hanratty et al suggested a decline in need adjusted 
use with increasing deprivation, especially in use of specialist hospital services, but 
reasonably equitable access to primary health care (Hanratty et al., 2007b). A more 
recent European study found large inequalities in the utilisation of specialist care for 
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chronic diseases, which were not compensated by utilisation of GP services (Stirbu 
et al., 2011). In study 1 here I demonstrate a mixed picture for adults, with marked 
pro-poor bias for IV and nutritional therapies, but inequality in the use of inhaled 
therapies.  
This  contrasts  with  analyses  of  children’s  use  of  health  services  in  the  UK,  where  the  
studies have tended to show increased use with lower SES, and arguably equitable 
delivery of care in the studies that have adjusted for need, notwithstanding the 
difficulties of undertaking precise adjustment. Cooper et al found no evidence that 
children and young people's use of health services varied according to their SES, in 
an analysis that adjusted for need on the basis of self-reported health status, a rather 
crude measure, in an analysis of the British General household survey (Cooper et al., 
1998). Saxena et al demonstrated increased use of primary care for disorders such as 
infections, asthma, and injuries and poisonings in children with lower SES (Saxena 
et al., 1999). In a further study by the same author children's use of primary and 
secondary health services reflected health status rather than SES, and on this basis 
the authors suggest that equity of access has been partly achieved (Saxena et al., 
2002). A more recent study in the UK demonstrated a clear association between 
adverse SEP at the time of birth and increased hospital inpatient admissions, days, 
and costs during the first 10 years of life (Petrou and Kupek, 2005). A study of 
children in Nordic countries demonstrated equitable access to primary care, but 
inequality in use of specialist hospital services after careful adjustment for health 
status on the basis of questionnaire data (Halldorsson et al., 2002).  
It remains to be seen whether the increasing inequality observed in use of inhaled 
treatments in CF in adults reflects general differences between paediatric and adult 
care for chronic disease, or is specific to differences in the CF model of care, perhaps 
explained by the potential for paediatricians to act in a more paternalistic manner 
towards the children in their care, in contrast to the relationship between an adult 
patient  and  the  CF  care  team,  where  adult  patients  can  ‘vote  with  their  feet’.  Further 
studies should focus on identifying aspects of CF care in children, and adulthood that 
may be important in reducing health inequalities. 
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Methodological advances 
Using CF as a tracer condition 
The studies in this thesis are the first explicitly to recognise the utility of using an 
autosomal recessive condition as a tracer condition to study pathways to health 
inequalities, leading to the general insights described above. Sickle-cell disease, also 
autosomal recessive in inheritance, would provide another useful case-study, albeit 
possibly more complicated by the interaction with ethnicity. There have been a 
number of small studies suggesting social differences in outcomes and health care 
use in this disease (Okany and Akinyanju, 1993, Ellison and Bauchner, 2007, 
Hijmans et al., 2010, Animasahun et al., 2011), and there is the potential to develop 
this line of research further. 
Novel modelling approach 
Study 3 describes a novel modelling approach for analysing changes in %FEV1 over 
time, which can be applied at the individual level to interpret the clinical significance 
of sudden changes in %FEV1, and at the population level to quantify the effect of 
factors such as P. aeruginosa acquisition. This approach extends the commonly used 
random intercept and slope model. Whilst the statistical framework for this analysis 
is not new (Diggle et al., 2002), this approach has not been used to analyse lung 
function data, and is not in widespread use in epidemiology. In this respect study 3 
represents an important piece of knowledge transfer, whereby a methodology is 
introduced to a new disciplinary area.  
We can apply our approach to modelling changes in %FEV1 over long follow-up 
periods. This is in contrast to the widely used random intercept and slope approach 
that has been applied in studies of CF and COPD, over short-term (Vestbo et al., 
1999, Mastella et al., 2000, Konstan et al., 2007a, MacLean et al., 2008) and longer-
term follow up periods (Corey et al., 1997, Hnizdo et al., 2005, Stern et al., 2007, 
Kohansal et al., 2009). The development and testing of the new approach was 
facilitated by the nature of the Danish CF register – to my knowledge there are no 
other datasets that contain such frequent (monthly) measures of lung function on 
individuals measured over very long periods (up to 31.5 years). However, the fact 
that the data are from Denmark does not influence the validity of the methods, since 
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these are essentially context-free. Furthermore, this method does not exploit any 
features of the data that are unique to CF, and would be equally applicable to other 
clinical areas that generate long sequences of repeated measurements.  
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Critique of overall study design  
The strengths and limitations of each study were discussed briefly in Chapters 4-6. 
Below, I explore the strengths and limitations of the overall approach and study 
design, focussing on the data sources and the methods used to analyse the data. 
Key strengths of the datasets 
A key strength of the two longitudinal datasets analysed in this thesis is that they are 
population level datasets, capturing the vast majority of the prevalent population of 
people with CF in the UK and Danish population. For instance, the UK dataset is 
estimated to capture over 99% of the UK CF population (Taylor-Robinson et al., 
2013a). Furthermore, both datasets are of high quality, with systems for data 
cleaning and checking. The datasets are both large, in complementary ways. The UK 
dataset represents one of the largest national CF datasets outside of the US (Buzzetti 
et al., 2009), and this has provided the power to precisely estimate parameters in the 
UK analysis, especially with regard to between-individual differences. The Danish 
dataset, on the other hand, is characterised by extraordinarily frequent follow-up, 
over long periods of time, and this has allowed precise estimation of within-
individual changes, through estimation of the variogram function (Taylor-Robinson 
et al., 2012a).  
The UK Registry contains a wide range of clinical, health care, and social 
information, allowing for robust adjustment for appropriate covariates in the analyses 
in study 1. Although the Danish registry contains mainly clinical outcome data, 
linkage to national datasets in Denmark through the unique Danish ID number allows 
the data collected within the registry to be supplemented extensively. Patient 
registries such as these are powerful tools designed specifically to improve our 
knowledge of disease progression and management. They provide systematically 
collected data that reveal patterns in disease diagnosis, treatment and outcomes over 
time (Salvatore et al., 2012), and have provided some of the crucial insights into the 
epidemiology of CF, as outlined in Chapter 2 (Buzzetti et al., 2009, Salvatore et al., 
2010, Salvatore et al., 2011, Salvatore et al., 2012). 
The findings from the studies contained within this thesis thus provide information 
pertinent to the whole population of either the UK or Denmark, and this is one of the 
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great strengths of registry analyses. This is in contrast to studies that are conducted at 
a care-centre level, the findings of which can only be cautiously generalized (Stanton 
et al., 2011, Taylor-Robinson et al., 2011). For example, with regard to CF, study 1 
is the first to demonstrate a clear effect of SES on P. aeruginosa acquisition at a 
population level, with all of the previous studies having been undertaken in centre-
based or sub-national populations (Kerem et al., 1990b, Kosorok et al., 1998, Maselli 
et al., 2003, Rosenfeld et al., 2012a) .The findings from the studies in this thesis 
cannot therefore be easily dismissed as artefacts, due to quirks of data collection or 
practice particular to a specific centre.  
A further consequence of the high level of population coverage in the UK, coupled 
with a universal health care system, is that the analyses in study 1 cover individuals 
across the full range of the socio-economic spectrum in the UK. Concerns about 
generalizability of findings from the US have been discussed above, but a further 
issue regarding data on SES outcomes in the US is the extent to which studies 
capture the most deprived people in the population, and the extent to which there is 
any selection bias into the US registry (Gliklich and Dreyer, 2010). The studies on 
SES and outcomes in CF from the US pre-date  President  Obama’s  historic  affordable  
care act (Jaffe, 2012), and were undertaken during a period when the number of 
uninsured people in the US was up to 50 million people. The profile of uninsured 
people in the US has changed little over time, being largely the poor, ethnic 
minorities, new immigrants, the poorly educated, and those in poor health (Hoffman 
and Paradise, 2008). Furthermore, concerns were raised at the North American CF 
conference 2012 regarding access to care for children of ‘unregistered’ parents 
(illegal immigrants), whose parents could be subject to deportation if they follow the 
social-security proceedings necessary to secure access to Medicaid treatment for 
their children (Sufian, 2012). In such a context one can speculate that CF registry 
analyses in the US are more likely to miss the most disadvantaged individuals, and 
thus suffer more from selection bias, as compared to the UK.  
Key limitations of the datasets 
Registries can provide valuable insights into variations in clinical outcomes, quality 
of care, and the safety and/or effectiveness of treatments. In this respect they are 
powerful tools for research and quality improvement in the context of complex and 
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resource-intensive chronic diseases, such as CF. However, the usefulness and 
applicability of registry data relies on the quality of the data analysis, and appropriate 
interpretation, bearing in mind the shortcomings of the retrospective, routinely 
collected data (Gliklich and Dreyer, 2010, Salvatore et al., 2012).  
Both the UK and the Danish datasets are subject to left truncation, whereby the 
datasets capture the prevalent population at the inception of data-collection, and 
incident cases subsequent to this. This leads to potential survivor bias, whereby the 
prevalent population at the outset of data collection represent healthier individuals 
from their respective birth cohorts who have survived to the point of being included 
in the dataset. This is a common issue in registry analyses, and is a recognised 
feature of previous analyses in the US (O'Connor et al., 2002) and Denmark 
(Frederiksen et al., 1996). This is been particularly highlighted as source of bias in 
many of the studies that have estimated survival in CF, especially those using age-
specific survival rates (Corey, 1996, Frederiksen et al., 1996, Lewis, 1998). This was 
one reason for focussing the UK analysis in Study 1 on longitudinal clinical 
outcomes, rather than survival. There is the recognition that cohort effects in the 
dataset  are  likely  to  represent  a  mixture  of  survivorship  effects,  and  the  ‘true’  cohort  
effects representing improving treatment over time, as demonstrated in other studies 
(Buzzetti et al., 2009). Thus cohort effects were adjusted for carefully on the basis of 
year of birth in the main analyses, but these were treated as nuisance variables, which 
need to be adjusted for in order to identify independent SES effects.  
Furthermore, as a result of left-truncation we can speculate that the true SES effect 
on outcomes may potentially be underestimated in studies 1 and 2, due to failure of 
the registry to capture potentially sicker patients who died prematurely compared to 
their contemporaries. Whilst the longitudinal models used adjust for dropout due to 
death in individuals captured in the dataset, we could do nothing about any bias due 
to deaths prior to inception of the registry, other than acknowledge the issue. With 
longer follow-up as the UK registry matures, separating age and cohort effects will 
become possible, and eventually it will be possible to analyse incident individuals 
alone, ensuring that the longitudinal experience of all individuals from a particular 
birth cohort will be captured (Gliklich and Dreyer, 2010).  
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Although the UK registry contains a large amount of clinical information, important 
putative mediators of SES effects are not collected in the analysis, as previously 
discussed with reference to Figure 78. Data on exposure to smoking is the most 
notable. Ideally, data should be collected on exposure to smoke exposure in utero, 
coupled with data on birth weight, and consequent capture of exposure to parental 
smoking in the home environment. Notwithstanding the potential difficulty of asking 
questions about parental smoking sensitively, and the possibility of incorrect 
responses, it is a serious omission that these data are not collected in the UK 
Registry, or in the US and Denmark, in the core dataset for a chronic respiratory 
illness. Collecting such data would be a first step to quantifying the problem, and for 
organising appropriate referral for parents who would like help to quit smoking. 
Approximately 90% of individuals had a valid postcode. Some postcodes were 
invalid, predominantly due to incomplete or incorrect entry of postcode information, 
which meant that these could not be linked to area deprivation scores. This is 
unlikely to be a systematic process causing bias. However, since many postcodes 
were captured during the transition to the electronic data system, people who died 
prior to this are under-represented in the dataset, with improved postcode coverage 
evident in more recent cohorts. This is a potential source of bias, and we can 
speculate that this may lead to underestimation of any social gradient in outcomes, if 
more disadvantaged individuals are more likely to die and thus be missing. The even 
distribution of the overall population by SES, however, is reassuring, however, and 
means that I was able to estimate SES effects on the repeated longitudinal outcomes 
across the whole socio-economic spectrum. Furthermore, restricting the analysis to 
the period after 2005 did not materially alter the SES or other covariate effects in 
sensitivity analysis. However, the disproportionately missing postcode data on 
people that died poses significant challenges for conventional survival analysis. This 
represents an unfortunate omission in the overall picture presented in this thesis, 
meaning that I was unable to corroborate the findings of Britton (Britton, 1989) and 
Barr (Barr HL, 2011), who showed social gradients in CF mortality, using death 
certification data. 
Missing data on outcomes of interest is a perennial problem with longitudinal 
studies, but in study 1, after application of the eligibility criteria, there were very 
little missing data in the final analysis, since there is good coverage of the basic 
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demographic variables in the analyses, and clinical outcomes such as weight or 
%FEV1 are key variables for collection at annual review. Furthermore, as discussed 
previously, the modelling approach I used handles missing data under the assumption 
of MAR, given the covariates in the regression. Fitting the model by maximum 
likelihood   thus  automatically  corrects   for  selection  bias   that  depends  on  a  patient’s  
observed measurements prior to death, although not for any additional dependence 
on unmeasured features (Diggle et al., 2002, Fitzmaurice, 2004). 
Lack of data on other measures of individual level SES in the registry is an important 
limitation. The UK registry, since the transfer to Port CF, does collect data on both 
maternal and paternal educational level, but the coverage of this question was very 
poor (for example, approximately 5% of individuals <18 with data on maternal 
education). Corroborating the SES effects demonstrated at area-level with individual 
level measures would have improved the analysis of the UK data. Speaking to 
clinicians about the missing data in this field, some suggested that this question was 
difficult to ask, and risked irritating patients and parents, since it was not obviously 
related to clinical care. Collection of individual level socio-economic data, for the 
explicit purpose of measuring SES, has to be undertaken sensitively, since as 
Bourdieu (Bourdieu, 1984) and Wilkinson (Wilkinson and Pickett, 2010) note, we 
are all acutely sensitive to being ‘sized up’ by other people. Effective ways 
emphasising the importance of collection of data such as this should be explored 
further.  
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Key strengths of the analysis 
The analyses in this thesis have used the modern longitudinal data analysis 
techniques described earlier in the methods section. These approaches have been 
strongly recommended to study changes in lung function in patients with CF 
(Edwards, 2000), and allow one to distinguish cross-sectional effects between 
individuals and longitudinal age related effects within individuals. Furthermore, they 
permit us to model either binary or continuous outcomes, and account for the 
correlation between repeated measurements from the same individuals. In this thesis, 
these approaches have been applied for the first time to the large national datasets 
described above, leading to the novel findings described at the outset of this chapter. 
In addition, the data analysis was informed by Professor Diderichsen’s   (a  
collaborator) conceptual framework of the pathways from social context to health 
outcomes, which was employed by the WHO Commission for Social Determinants 
of Health. This is in contrast to previous analyses of SES and outcomes in CF that 
have not been explicitly informed by a theoretical perspective.  
Key limitations of the analysis 
All of the findings in this thesis are based on observational data, and there is thus 
potential for confounding due to omission of unmeasured variables, and residual 
confounding due to imprecise measurement of covariates included in the models. 
With observational studies of this nature one can always argue for the addition of a 
particular covariate in a model after the event. To guard against this the analyses in 
this thesis were based on a clear modelling strategy, which generally involved fitting 
a baseline model adjusting for factors unlikely to be in the causal chain between SES 
and the outcomes of interest (e.g. age, sex, birth cohort, and genotype). Then 
deprivation measures were added to the model in question, and finally subsequent 
models were fitted to explore the influence of other covariates of potential interest. 
The studies in the UK used an area-based measure as a proxy for individual SES, and 
the main analysis and conclusions were based on it. Ideally, the analysis would have 
employed both individual and area level measures, but no other measures of SES 
were useable in the UK Registry. The so-called ‘ecological fallacy’ – ascribing area 
level associations to individuals – is an important concern when an area level 
measure is used as the proxy measure for the individual level, and appropriate 
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caution should be exercised when interpreting and generalising the findings 
(Schwartz, 1994). However, this is partly addressed by being specific about the level 
at which the claim of association is being made. I have demonstrated associations at 
the small-area level, and cautiously suggest that these associations can be taken as 
proxies for individual level effects. 
Area based deprivation measures are commonly used as proxies for individual SES, 
especially in the UK (Galobardes et al., 2007) and the US, where their use in public 
health research is widespread (Krieger et al., 2002). It is accepted that this can 
potentially lead to biased estimates if individual level SES effects are the targets of 
inference. For instance, the area-level estimate of the association between SES and 
the outcomes studies could be an underestimate of the individual-level effect, 
because of the misclassification that arises through giving everyone in a small-area 
the same score. Furthermore, this problem increases with ecological areas of greater 
size (Smith et al., 1998). However, it is recognized that associations can be biased in 
both directions, and if there are large area level effects (e.g. pollution) that are 
independent of any individual level effects, then the area effect will be an 
overestimate (Geronimus, 2006, Subramanian et al., 2006, Galobardes et al., 2007, 
Galobardes, 2012).  
Whilst accepting the potential for ecological fallacy, this is minimised in the UK 
analysis, in comparison to the studies undertaken in the US, because the IMD 
methodology allows much finer small area resolution, down to the level of census 
lower layer super output areas (LLSOAs). The IMD score is a widely used measure 
of deprivation of area of residence for epidemiological studies in the UK (Semple et 
al., 2011, Taylor-Robinson et al., 2011, Bergen et al., 2012), and is used in national, 
local government, and NHS reports on tracking inequalities in health and in access to 
health services (DH, 2012b). Each small area contains about 1500 people, and in this 
respect the IMD allows much finer resolution than the US analyses (O'Connor et al., 
2003, Schechter et al., 2009, Schechter et al., 2011) that have used ZIP code linked 
income data, since each ZIP code contains about 30,000 people (Krieger et al., 
2002). Furthermore, it is reassuring that similar associations have been found in the 
US studies that use both area and individual measures of SES.  
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The lack of multiple measures of SES, whether at area level, or individual level, is 
also a clear limitation. The most commonly used measures of SES relate to 
occupation, education and income (Mackenbach et al., 1997). This is because each of 
these measures may potentially capture a different dimension of the complex 
construct that is SES.   Furthermore,   in   Schechter’s   more   recent   studies   of   health  
service use in CF in the US he was able to use maternal education, zip code linked 
area-based income, and Medicaid status (Schechter et al., 2009, Schechter et al., 
2011). The general principle that emerges is that multiple measures of SES enrich the 
analysis, and allow further insight into potential mechanisms. For instance, parental 
education may be a particularly important measure, reflecting parental disease 
management skills, independent of income.  
A further potential limitation regarding the measurement of SES is the approach 
taken to combining the deprivation scores from the four UK countries. There are a 
number of differences between the IMD that make combining them in a robust 
manner or making meaningful comparisons across the UK difficult (Payne and Abel, 
2012). In order to combine the IMD measures from England, Scotland, Wales, and 
Northern Ireland, I explored standardising these within each country, but this made 
little difference in the analysis, so the unadjusted raw scores were used. This may 
have led to some misclassification. Reassuringly, restricting the analysis to English 
data only made little difference to the effect estimates. Recent guidance has been 
developed for researchers wishing to combine deprivation scores across the four 
countries of the UK, and this approach could be applied in subsequent studies (Payne 
and Abel, 2012). 
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What are the implications for policy and clinicians? 
Michael Schechter, the author of the main studies in the US on inequalities in CF 
comments thus (Schechter, 2013): 
“The   effect   of   socioeconomic   status   (SES)   on   health   is   well  
established in the general public, and has been described in both the 
US and UK cystic fibrosis populations. In The Lancet Respiratory 
Medicine, David Taylor-Robinson and colleagues present a 
sophisticated longitudinal analysis of data from the UK Cystic 
Fibrosis Registry, assessing and confirming this association using 
small-area  deprivation  scores  assigned  by  postcode….  In  view  of  the  
fact that that there is now ample evidence of an important SES-
related health gradient in cystic fibrosis populations, at least in the 
USA and the UK, the logical next step is to develop approaches to 
alleviate  it.” 
I wholeheartedly agree that although there is much scope for further research in this 
area, now is the time for action. One of the strengths of the Diderichsen model, 
employed in this thesis, is that it provides a framework for considering appropriate 
policy responses (Diderichsen et al., 2001), and one can think of these at the level of 
the individual clinician treating a patient with CF, or at the broader public health and 
policy level. 
 
Individual clinically focussed actions 
For individual clinicians, low SES needs to be considered as a major risk factor for 
poor outcomes in CF, and appropriate responses to remediate against the adverse 
effects of low SES should be developed. An important first step is to acknowledge 
and measure the problem. Without on-going data collection to monitor health 
inequalities, there can be no policy response. The pioneers of health inequalities 
research, the likes of Dr Duncan, or Margaret Whitehead, began by demonstrating 
the extent of the problem. In terms of measuring the problem, the work undertaken in 
this thesis has been recognised by the UK CF Trust, who are now looking into how 
registry data could be routinely presented in a way to better understand and monitor 
the effects of SES. In their latest Registry report they state (CF Trust, 2013a):  
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“It   is   clear   to   us   that   outcomes   in   terms   of   lung   function   can   be  
affected by many factors including those related to care (such as use 
of CF therapies) and those related to the person with CF (such as 
genotype, age and socioeconomic status). We would like to be able to 
provide better comparisons of centres so that we can learn from each 
other  and  ensure  optimum  care  for  the  community…  We  will  expect  to  
see changes in the annual report over the next three years as a 
result…” 
Furthermore, the work presented in this thesis has been highlighted as part of the 
new UK CF Trust research strategy, in order to emphasise the utility of registry 
studies to inform best practice (CF Trust, 2013b). Thus the results of the studies in 
this thesis should go some way to raising awareness, and initiating debates about 
appropriate responses. 
There are a number of steps that could be taken to influence differential exposures. 
One obvious target for action is to protect newly diagnosed children from ETS, since 
this may be the single most important explanatory factor for SES-related inequalities 
in this disease (Taylor-Robinson and Schechter, 2011). Early identification of family 
members who smoke, collection of that data in the registry, and appropriate 
counselling and referral to smoking cessation services would be an effective 
intervention for all patients regardless of social position. Study 1 also demonstrated 
differential exposure to P. aeruginosa acquisition, and this requires further 
investigation. One concern is that this may relate to hospital-acquired acquisition of 
P. aeruginosa, from other patients with CF, as a result of more time spent in hospital. 
An appropriate policy response might be to ensure that mechanisms are put in place 
to facilitate equitable delivery of treatments at home, wherever possible. Home care 
has been shown to be as effective as hospital treatment for some patients (van 
Aalderen et al., 1995), but not others (Bosworth and Nielson, 1997, Thornton et al., 
2005). It is also less expensive and may be associated with improvement in quality of 
life (van Aalderen et al., 1995). Access to appropriate home care may also mean that 
children are less likely to miss school, which is important in terms of reducing the 
differential consequences of ill health.
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There are some further steps that individual clinicians and teams could take to reduce 
children’s  exposure  to  poverty,  and  its consequences. Whilst beyond the scope of full 
discussion here, an increased focus on a whole family approach to the care of the 
child with CF, with appropriate involvement of the full range of social services 
support available to children and families living in disadvantaged circumstances may 
help to mitigate some of the effects of low SES. This would include supporting 
parents to access all the benefits and services that they are entitled to, and working to 
reduce any perceived stigma associated with using these services. Support with the 
additional costs of childcare, travel to clinic appointments, and any additional 
medical expenditure would also help reduce the financial burden on the most 
disadvantaged families. This should be coupled with support to develop patient and 
family disease self-management skills (Goldman and Smith, 2002, Smith and 
Goldman, 2010). 
Social workers, and other members of the multidisciplinary CF team have an 
important role in helping people with CF navigate the welfare system, so that they 
are clear about the benefits that they are entitled to, and the support available to help 
people with chronic illness in the workplace. This is particularly important at the 
moment, in the context of the widespread changes to the welfare and benefits system 
in the UK, with the drive to reduce the number of people claiming Disability Living 
Allowance. A recent study by Nash et al demonstrated that the majority of adult 
patients with CF claim some benefits, and the majority of these were concerned 
about the planned reforms (Nash et al., 2011). Furthermore, the concerns of the CF 
community regarding the changes to the welfare system were outlined in a 
submission by the CF Trust to the Department of Work and Pensions (Department of 
Work and Pensions, 2011). Further efforts are required to identify effective 
workplace, rehabilitation, and other interventions to reduce the employment 
disadvantage experienced by people with CF, particularly for those from more 
disadvantaged areas.  
A key question for practicing physicians addressed in this thesis is what role health 
care delivery plays in mitigating or potentiating health inequalities in CF. In the UK, 
I have demonstrated a mixed picture, and action is required to understand the 
inequalities in access to inhaled therapies uncovered, and to promote the pro-poor 
delivery of care demonstrated for other treatments, that may be effective in limiting 
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increases in outcome inequality over time. The potential utility of systematically 
targeting more intensive therapy at children living in disadvantaged circumstances 
should be investigated further (Gupta et al., 2009). The adoption of system-based 
methods to optimize consistency in the use of best care practices might help further 
minimize variations in prescribed care (Schechter et al., 2009). Furthermore, the 
early appearance of inequalities, and the potential for decreasing inequality in weight 
in the first few years of life, focusses policies on the early years, and provides 
support for new-born screening programmes in CF.  
 
Broader interventions 
Ultimately, however, while individually focussed interventions may be of some 
limited success, the long term solution to health inequalities in people with CF and in 
the general population is likely to be one that takes broader action to address the 
“social  determinants  of  health”(CSDH, 2008). These  are  the  “conditions  in  which  we  
are born,   grow   up,   work   and   live”,   and   include   income   and   income   distribution,  
education, employment and working conditions, housing, food insecurity, 
race/ethnicity, and gender and gender roles. These factors provide a particularly 
important context for a family dealing with the stresses of caring for a child with a 
complex chronic illness like CF over a lifetime. The evidence is clear, unfortunately, 
that we have made little progress over the last few decades in reducing health 
inequalities (Marmot et al., 2010b). However, the findings in this thesis present 
further evidence that the early years represent the key period for targeting 
interventions to reduce inequalities. An important place to start would be to renew 
efforts in the UK to reduce children’s   exposure   to   poverty, thus reducing social 
stratification, by for instance (Marmot et al., 2010b): 
 
 maximising household incomes, by helping parents into employment; 
 providing affordable housing; 
 providing affordable, high quality child care; 
 providing affordable public transport; 
 helping families manage debt; 
 providing better social security support for families caring for children with 
chronic illness. 
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With reference to Figure 78 and Figure 80 above, policy makers should also act to 
reduce any inequitable distribution of health damaging and health promoting 
exposures over the  course  of  children’s  lives. Even achieving an equal reduction in a 
particular risk factor across the population by SES has the potential to reduce 
inequalities in outcomes, through the differential vulnerability pathway (Diderichsen 
et al., 2001). Reducing the consequences of poverty by focussing on child 
development in the early years is a good place to start. Actions could involve (Field, 
2010, Marmot et al., 2010b):  
 protecting investment in the early years in the face of budget cuts in the UK; 
 shifting expenditure towards the early years wherever possible; 
 providing high quality and consistent support and services for parents during 
pregnancy; 
 provision of high quality universal services in childhood; 
 supporting families to achieve progressive improvements in early child 
development, by providing good quality early years education and childcare; 
 providing support so that all children can access a healthy diet in the early 
years; 
 providing high quality home visiting services; 
 focussing on narrowing the educational attainment gap at all stages. 
As health deteriorates, the ability of people to remain in education and employment 
declines. Being out of work increases the risk of poverty and social exclusion, and is 
likely to further damage the health of the most disadvantaged. Actions to address 
differential social consequences could include (Holland et al., 2011a): 
 supporting people with chronic illness to find appropriate employment, with a 
focus on active labour market policies; 
 provision of better in-work social security support for people with chronic 
illness. 
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Conclusions 
CF is the commonest serious inherited disease among Caucasian populations. 
Intensive support from family and health care services is needed from the time of 
diagnosis onwards, and most patients die prematurely from respiratory failure. There 
have been astounding improvements in survival over successive birth cohorts in CF, 
such that it is estimated that British children born in the 21st century will have a 
median survival of over 50 years of age (Dodge et al., 2007). However, there remains 
a great deal of variation in disease progression and survival in CF, much of which is 
related to social and environmental rather than genetic determinants (Schechter, 
2004). Most pointedly, it has been known for over 20 years (Britton, 1989) that 
people with CF from socio-economically disadvantaged backgrounds die younger 
than those in more advantaged positions.  
CF offers a valuable case for understanding how health inequalities develop. It is an 
autosomal recessive disease with an asymptomatic (and, until recently, undetectable) 
carrier state, so unlike many other diseases, SES does not influence who gets CF. 
SES-related outcome inequalities develop due to the different patterns of exposure to 
harmful   and   protective   or   therapeutic   influences   over   the   course   of   people’s   lives. 
Studies from the US and UK show that significant inequalities in key intermediate 
CF outcomes such as growth and lung function begin early in childhood (Schechter 
et al., 2001, O'Connor et al., 2003, Taylor-Robinson et al., 2013a) and then persist 
over time. The early appearance and persistence of inequalities supports the need for 
interventions that are targeted at the early (and perhaps prenatal) years.  
Further research 
The studies in this thesis have highlighted a number of areas requiring further 
research. There are some important issues relating to our understanding of the 
clinical epidemiology of CF, which are outlined in the sections above. There is much 
that could be learned through study of the longitudinal clinical outcomes of the 
increasing number of children in the registry captured through new-born screening, 
with a focus on how early nutritional development influences lung function and 
ultimately survival. Any such analyses should consider the effects of SES. 
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The methods for modelling lung function decline described in study 3 could be 
usefully applied to longitudinal data collected in other CF registries, to clarify how 
robust this approach is in terms of predicting changes in %FEV1 over time, and to 
better understand how this might inform clinical decision making. Future research 
could also explore the utility of our proposed model in other diseases such as COPD. 
Research currently in progress from this thesis 
Analysis of the Danish dataset is on-going. Study 3 in this thesis has outlined the 
methods for analysing this unique dataset, and the next step is to use this approach in 
conjunction with data linked through the Danish social registers. Importantly, 
individual level data linkage in Denmark will allow access to richer individual level 
socio-economic data than is available in the UK, on patients and their parents. The 
linked data extends retrospectively to 1981 and contains complete information on an 
individual’s   employment,   income,   healthcare   expenditure,   hospitalisations, and 
receipt of welfare benefit. We can use this to explore the effects of a range of 
individual level parental and patient socio-economic exposures on CF outcomes, and 
also study changes in socio-economic conditions over time, before and after specific 
phases of disease development. 
At the time of writing I have been able to undertake a preliminary analysis of the 
effect of parental education level on lung function decline in the Danish population, 
and this is shown in Figure 81. The figure visualises the same model as that was 
published in the Thorax paper (Taylor-Robinson et al., 2012a), but with parental 
education level included, as measured by the International Standard Classification of 
Education (ISCED) classification. For the purposes of the analysis, this has been 
dichotomized to compare individuals with the lowest SES, to all the rest, due to the 
small numbers involved in the Danish analysis. This analysis shows an increased rate 
of decline of lung function in people with the lowest SES (-0.31, 95% CI 0.06 
to 0.56). Further confirmatory analysis using alternative measures of SES, and other 
CF outcomes (growth, P. aeruginosa status, and survival) in Denmark is ongoing. 
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Figure 81: Effect of parental education level on lung function decline in 
Denmark 
 
 
A further line of on-going enquiry in the UK and Denmark is an exploration of how 
aspects of an individual CF patient’s   longitudinal   profile   of  %FEV1 are related to 
their survival prognosis. This is intended as an update on the seminal Kerem analysis 
that first demonstrated the relationship between low lung function and increased 
mortality (Kerem et al., 1992). The headline figure from the Kerem paper was a 50% 
risk of death within the next two years, for patients with a %FEV1 lower than 30%, 
in the US centre-based sample (Kerem et al., 1992). One can see in Figure 82 below, 
from the Danish registry, that %FEV1 drops below 30% on a number of occasions in 
the first 10 years of life for this individual in Denmark, and we have argued that the 
error free lung function measurement estimated by the model in Study 3 provides a 
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better  estimate  of  an  individual’s true underlying lung function. The intention is now 
to develop a joint model, which relates aspects of this underlying trajectory to 
survival chances. 
Figure 82: Joint modelling of lung function and survival outcomes 
 
 
In collaboration with biostatisticians, I am using CF data with recently developed 
methodology for the joint analysis of repeated measurements and time-to-event 
outcomes. These methods allow us to examine the association between longitudinal 
changes in %FEV1 and survival chances, whilst adjusting for, allowing for 
correlation within patients, trends over time and potentially informative missing 
values. Key methodological challenges relate to accommodating cohort effects, and 
biased entry to registry cohorts, as described in the limitations section (Taylor-
Robinson et al., 2012b, Barrett et al., 2013). 
Finally, building on the work undertaken during the course of this PhD, as part of an 
MRC Population Health Scientist Fellowship, I have successfully obtained further 
funding to continue, and extend some of the lines of enquiry developed in this thesis. 
I intend to explore the effect of SES on the longitudinal risk of asthma, the most 
common chronic disease of childhood, in a contemporary, representative UK birth 
cohort called the  Millennium Cohort Study. This will involve developing and testing 
a logic model to explain how inequalities in asthma develop, by quantifying 
differential exposures to mediating risk factors (e.g. home environment measures, 
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breast-feeding, smoke exposure), differential outcomes (asthma risk), and potentially 
differential social consequences (e.g. school performance), by SES, over time.  
In this way, I will further develop the longitudinal analysis techniques outlined in the 
studies in this thesis, in continuing collaboration with experts in this field (Professor 
P Diggle, University of Liverpool; Dr J Barrett, MRC Biostatistics Unit), to explore 
the causal relationship between measures of early childhood disadvantage (e.g. child 
poverty, maternal education), and the development of adverse health outcomes in 
children. Comparing and contrasting the cases of CF and asthma will further improve 
our understanding of the social patterning of illness in childhood.  
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Appendix 3 (Pertaining to Chapter 3, Methods) 
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                          2 
Der skal vises særlig agtpågivenhed i forbindelse med brug af grafiske præ-­
sentationer i Excel og PowerPoint, da de uforvarende kan indeholde indlejre-
de persondata i form af regneark, tabeller mv. Præsentationer, der  gøres til-
gængelig  på internettet,  bør  derfor omformateres til Portable Digital Format 
(PDF), da dette fjerner eventuelle indlejrede Excel-tabeller. 
 
 
Eventuelle  ændringer af de forhold, som er omtalt i anmeldelsesblanketten, 
skal anmeldes til Datatilsynet efter reglen i persondatalovens  §  46. 
 
Anmeldelsen offentliggøres i fortegnelsen  på Datatilsynets hjemmeside. 
 
 
Med venlig hilsen  
 
Camilla Daasnes   
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Port CF screens: Demographic data 
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Encounter, General: 
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Encounter, nutrition: 
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Encounter, pulmonary assessments: 
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Encounter, pulmonary therapies: 
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Encounter, respiratory microbiology: 
 
 
  
 317 
Encounter, laboratory: 
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Encounter, complications: 
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Annual Survey Data 
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If   female   then   ‘Oestrogen’   will   replace   ‘Testosterone’in   the   growth   and   nutrition   section.
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 323 
 
 
  
 324 
If the patient is 16 or older the following will appear as socio-economic status: 
 
 
If patient is female and older than xxxx the following will appear in the annual survey: 
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Appendix 4 (Pertaining to Chapter 4) 
 
The presentation of the model tables for clinical outcomes follows the same basic 
format. The baseline model is presented first, adjusted for baseline covariates, then 
deprivation is added (final model – the main results are from these models), and then 
other covariates of potential interest are added (final_plus). See Figure 24, Chapter 4 
for further explanation. 
Weight 
Table 20: Final regression models for weight SD score in <18 age group 
 baseline final final_plus 
Constant -0.97609*** -0.76679*** -0.99648*** 
 (0.08326) (0.09124) (0.10440) 
age 0.20961*** 0.17231*** 0.25400*** 
 (0.01460) (0.01769) (0.02594) 
age2 (split line effect) -0.22797*** -0.18983*** -0.26711*** 
 (0.01516) (0.01838) (0.02732) 
Number of F508 alleles: 0/2 0.06410 0.06228 0.12097 
 (0.10624) (0.10612) (0.10659) 
Number of F508 alleles: 1/2 0.02148 0.01447 0.05747 
 (0.06189) (0.06184) (0.06245) 
Male 0.02713 0.03527 0.03353 
 (0.05728) (0.05724) (0.05718) 
nonwhite 0.25721 0.33507* 0.32258* 
 (0.13949) (0.14012) (0.14001) 
Screened 0.27766*** 0.28633*** 0.31266*** 
 (0.06434) (0.06427) (0.06441) 
 (0.16393) (0.16355) (0.16355) 
Age x Number of F508 alleles: 
0/2 
-0.04467 -0.04279 -0.06150* 
 (0.03089) (0.03088) (0.03102) 
Age x Number of F508 alleles: 
1/2 
-0.02603 -0.02331 -0.03841* 
 (0.01686) (0.01687) (0.01716) 
Age x male 0.06098*** 0.05831*** 0.06010*** 
 (0.01566) (0.01568) (0.01565) 
age x nonwhite -0.15834*** -0.17607*** -0.17066*** 
 (0.04014) (0.04040) (0.04036) 
Age x screened -0.06142*** -0.06239*** -0.07167*** 
 (0.01666) (0.01666) (0.01675) 
age2 x Number of F508 alleles: 
0/2 
0.04677 0.04497 0.06298* 
 (0.03200) (0.03199) (0.03213) 
age2 x Number of F508 alleles: 
1/2 
0.03860* 0.03611* 0.05105** 
 (0.01754) (0.01755) (0.01784) 
age2 x male -0.07615*** -0.07335*** -0.07568*** 
 (0.01634) (0.01636) (0.01634) 
age2 x nonwhite 0.14914*** 0.16692*** 0.16188*** 
 (0.04227) (0.04254) (0.04249) 
age2 x screened 0.05920*** 0.06005*** 0.06914*** 
 (0.01769) (0.01769) (0.01779) 
Deprivation score  -0.00932*** -0.00949*** 
  (0.00169) (0.00169) 
Age x Deprivation score  0.00168*** 0.00174*** 
  (0.00045) (0.00045) 
Age2 x Deprivation score  -0.00173*** -0.00179*** 
  (0.00047) (0.00047) 
Pseudomonas colonisation   0.42669*** 
   (0.10238) 
CFRD   -1.99523*** 
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   (0.56705) 
Pancreatic insufficiency   0.21250*** 
   (0.05401) 
Age x Pseudomonas colonisation   -0.12952*** 
   (0.03593) 
Age x CFRD   0.80867*** 
   (0.19694) 
Age x Pancreatic insufficiency   -0.08365*** 
   (0.02015) 
age2 x Pseudomonas colonisation   0.12339*** 
   (0.03666) 
age2 x CFRD   -0.84934*** 
   (0.19948) 
age2 x Pancreatic insufficiency   0.08199*** 
   (0.02145) 
Log-likelihood -
25550.15779 
-
25528.81159 
-
25475.60363 
Deviance 51100.31558 51057.62317 50951.20726 
AIC 51204.31558 51167.62317 51079.20726 
BIC 51635.03792 51623.19488 51609.32706 
N 29235 29235 29235 
Groups 5775 5775 5775 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile 
age2 is the coefficient for the split line at age three in the weight analysis 
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Table 21: Final regression models for weight SD score in >18 age group 
 baseline final final_plus 
Constant -0.92805*** -0.81353*** -0.72702*** 
 (0.09886) (0.10244) (0.10417) 
Age-18 0.01834*** 0.01839*** 0.01688*** 
 (0.00390) (0.00391) (0.00445) 
Number of F508 alleles: 0/2 0.02131 0.02906 0.01587 
 (0.06528) (0.06518) (0.06498) 
Number of F508 alleles: 1/2 0.22333*** 0.22908*** 0.21717*** 
 (0.04983) (0.04973) (0.04953) 
Male -0.33035*** -0.33225*** -0.33590*** 
 (0.04727) (0.04714) (0.04684) 
Non-white -0.59068*** -0.54262*** -0.54116*** 
 (0.14073) (0.14092) (0.14011) 
Screened 0.06358 0.06145 0.05919 
 (0.07901) (0.07886) (0.07848) 
 (0.16002) (0.15959) (0.15848) 
Age-18 x Number of F508 alleles: 0/2 0.01222 0.01236 0.01280* 
 (0.00633) (0.00633) (0.00633) 
Age-18 x Number of F508 alleles: 1/2 0.00123 0.00123 0.00131 
 (0.00446) (0.00446) (0.00446) 
Age-18 x male 0.01059* 0.01053* 0.01072* 
 (0.00425) (0.00425) (0.00423) 
Age-18 x nonwhite 0.01448 0.01385 0.01372 
 (0.01430) (0.01431) (0.01426) 
Age-18 x screened -0.01288 -0.01328 -0.01223 
 (0.00897) (0.00897) (0.00895) 
Deprivation score  -0.00537*** -0.00538*** 
  (0.00130) (0.00129) 
Pseudomonas colonisation   -0.06166*** 
   (0.01563) 
CFRD   -0.07284** 
   (0.02509) 
Pancreatic insufficiency   -0.04669 
   (0.02421) 
Age-18 x Pseudomonas colonisation   0.00292 
   (0.00158) 
Age-18 x CFRD   0.00439 
   (0.00229) 
Age-18 x Pancreatic insufficiency   -0.00042 
   (0.00233) 
Log-likelihood -18655.24983 -18646.75337 -18619.45472 
Deviance 37310.49966 37293.50675 37238.90944 
AIC 37410.49966 37395.50675 37352.90944 
BIC 37806.46524 37799.39164 37804.31020 
N 20319 20319 20319 
Groups 4041 4041 4041 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birth year coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile 
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Height 
Figure 83: Spaghetti plot of height for age SD score versus age in paediatric age 
group.  
Mean smoother in red. 
 
Figure 84: Exploratory analysis showing smoothed means of height for age Z 
score versus age, stratified by covariates 
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Figure 85: Spaghetti plot of height for age Z score versus age in adult age group.  
Mean smoother in red. 
 
 
Figure 86: Exploratory analysis showing smoothed means of height for age Z 
score versus age, in adult age group, stratified by covariates 
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Table 22: Final regression models for height SD score in <18 age group 
 baseline final final_plus 
Constant -0.81565*** -0.69634*** -0.75521*** 
 (0.07383) (0.07615) (0.08023) 
Age 0.01171*** 0.01154*** 0.01899*** 
 (0.00296) (0.00296) (0.00368) 
Number of F508 alleles: 0/2 -0.06081 -0.05825 -0.04948 
 (0.07076) (0.07068) (0.07080) 
Number of F508 alleles: 1/2 -0.00061 -0.00004 0.00507 
 (0.04436) (0.04431) (0.04436) 
Male 0.17876*** 0.17969*** 0.18414*** 
 (0.04099) (0.04094) (0.04089) 
Non-white 0.20212* 0.23514* 0.24153* 
 (0.10059) (0.10062) (0.10047) 
Screened 0.27200*** 0.27879*** 0.28415*** 
 (0.05060) (0.05056) (0.05050) 
Age x Number of F508 alleles: 0/2 0.00172 0.00184 0.00113 
 (0.00529) (0.00529) (0.00529) 
Age x Number of F508 alleles: 1/2 0.00562 0.00582 0.00538 
 (0.00348) (0.00347) (0.00347) 
Age x male -0.01225*** -0.01218*** -0.01287*** 
 (0.00332) (0.00331) (0.00329) 
Age x non-white -0.02714*** -0.02756*** -0.02747*** 
 (0.00805) (0.00804) (0.00802) 
Age x screened -0.01691*** -0.01710*** -0.01787*** 
 (0.00407) (0.00407) (0.00405) 
Deprivation score  -0.00526*** -0.00527*** 
  (0.00086) (0.00086) 
Pseudomonas colonisation   0.06316** 
   (0.02094) 
CFRD   0.18810* 
   (0.09121) 
Pancreatic insufficiency   0.02859 
   (0.02637) 
Age x Pseudomonas colonisation   -0.00578*** 
   (0.00175) 
Age x CFRD   -0.02129*** 
   (0.00620) 
Age x Pancreatic insufficiency   -0.00450 
   (0.00235) 
Log-likelihood -22676.57348 -22657.81459 -22622.62490 
Deviance 45353.14697 45315.62917 45245.24980 
AIC 45445.14697 45409.62917 45351.24980 
BIC 45825.77234 45798.52902 45789.79644 
N 28983 28983 28983 
Groups 5750 5750 5750 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birth year coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile 
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Table 23: Final regression models for height SD score in >18 age group 
 
 baseline final final_plus 
Constant -0.34842*** -0.22411** -0.23732** 
 (0.08095) (0.08435) (0.08488) 
Age-18 -0.00509*** -0.00508*** -0.00376* 
 (0.00140) (0.00140) (0.00167) 
Number of F508 alleles: 0/2 0.11255** 0.11796** 0.11780** 
 (0.03632) (0.03626) (0.03627) 
Number of F508 alleles: 1/2 0.09951** 0.10350** 0.10411** 
 (0.03236) (0.03227) (0.03228) 
Male -0.23973*** -0.24207*** -0.24325*** 
 (0.03487) (0.03474) (0.03473) 
Non-white -0.40991*** -0.38022*** -0.38249*** 
 (0.08556) (0.08558) (0.08553) 
Screened -0.07661 -0.07743 -0.07910 
 (0.04345) (0.04337) (0.04336) 
Age-18 x Number of F508 alleles: 0/2 -0.00197 -0.00191 -0.00214 
 (0.00238) (0.00238) (0.00239) 
Age-18 x Number of F508 alleles: 1/2 0.00006 0.00006 -0.00012 
 (0.00165) (0.00165) (0.00165) 
Age-18 x male 0.00019 0.00018 0.00031 
 (0.00155) (0.00155) (0.00155) 
Age-18 x non-white -0.00109 -0.00119 -0.00110 
 (0.00528) (0.00528) (0.00527) 
Age-18 x screened -0.00333 -0.00347 -0.00327 
 (0.00336) (0.00336) (0.00336) 
Deprivation score  -0.00530*** -0.00529*** 
  (0.00105) (0.00105) 
Pseudomonas colonisation   0.01101 
   (0.00674) 
CFRD   -0.02267* 
   (0.01079) 
Pancreatic insufficiency   0.01229 
   (0.01046) 
Age-18 x Pseudomonas colonisation   -0.00035 
   (0.00068) 
Age-18 x CFRD   0.00180 
   (0.00096) 
Age-18 x Pancreatic insufficiency   -0.00158 
   (0.00099) 
Log-likelihood -3722.83080 -3710.19476 -3704.59670 
Deviance 7445.66160 7420.38951 7409.19340 
AIC 7545.66160 7522.38951 7523.19340 
BIC 7941.48919 7926.13366 7974.43686 
N 20263 20263 20263 
Groups 4046 4046 4046 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birth year coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile 
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BMI  
Figure 87: Spaghetti plot of BMI for age Z score versus age in paediatric age 
group.  
Mean smoother in red. 
 
 
Figure 88: Exploratory analysis showing smoothed means of BMI for age Z 
score versus age, stratified by covariates 
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Figure 89: Spaghetti plot of BMI for age Z score versus age in adult age group. 
Mean smoother in red. 
 
 
Figure 90: Exploratory analysis showing smoothed means of BMI for age Z 
score versus age, in adult age group, stratified by covariates 
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Table 24: Final regression models for BMI SD score in <18 age group.  
 baseline final final_plus 
Constant -0.53677*** -0.48286*** -0.72782*** 
 (0.09942) (0.10110) (0.12972) 
age 0.15859*** 0.15798*** 0.26685*** 
 (0.02777) (0.02777) (0.04093) 
age2 -0.17618*** -0.17570*** -0.28421*** 
 (0.02879) (0.02880) (0.04268) 
Number of F508 alleles: 0/2 -0.03001 -0.03069 0.04315 
 (0.15024) (0.15020) (0.15239) 
Number of F508 alleles: 1/2 -0.21116* -0.21288* -0.16805 
 (0.08859) (0.08857) (0.08997) 
Male -0.09253 -0.09166 -0.09316 
 (0.08161) (0.08159) (0.08170) 
Non-white -0.04359 -0.02379 -0.03729 
 (0.18742) (0.18750) (0.18782) 
Screened 0.09886 0.10080 0.12893 
 (0.08736) (0.08734) (0.08783) 
Age x Number of F508 alleles: 0/2 0.00079 0.00141 -0.02586 
 (0.05455) (0.05455) (0.05519) 
Age x Number of F508 alleles: 1/2 0.05595 0.05660 0.03889 
 (0.03192) (0.03192) (0.03236) 
Age x male 0.11392*** 0.11384*** 0.11436*** 
 (0.02947) (0.02947) (0.02947) 
Age x non-white -0.11929 -0.12099 -0.11714 
 (0.07002) (0.07002) (0.07004) 
Age x screened -0.03121 -0.03067 -0.04176 
 (0.03215) (0.03215) (0.03230) 
age2 x Number of F508 alleles: 0/2 0.00089 0.00036 0.02685 
 (0.05688) (0.05688) (0.05750) 
age2 x Number of F508 alleles: 1/2 -0.04799 -0.04850 -0.03104 
 (0.03332) (0.03332) (0.03376) 
age2 x male -0.13391*** -0.13381*** -0.13414*** 
 (0.03079) (0.03079) (0.03079) 
age2 x non-white 0.13173 0.13337 0.13029 
 (0.07400) (0.07400) (0.07400) 
age2 x screened 0.03530 0.03464 0.04640 
 (0.03406) (0.03407) (0.03420) 
Deprivation score  -0.00229** -0.00229** 
  (0.00079) (0.00079) 
Pseudomonas colonisation   0.29458* 
   (0.14939) 
CFRD   -0.73942 
   (0.89849) 
Pancreatic insufficiency   0.25291** 
   (0.08457) 
Age x Pseudomonas colonisation   -0.10559* 
   (0.05176) 
Age x CFRD   0.31656 
   (0.30612) 
Age x Pancreatic insufficiency   -0.10866*** 
   (0.03139) 
age2 x Pseudomonas colonisation   0.10529* 
   (0.05251) 
age2 x CFRD   -0.32927 
   (0.30825) 
age2 x Pancreatic insufficiency   0.10736** 
   (0.03291) 
Log-likelihood -28162.34270 -28158.12899 -28131.32222 
Deviance 56324.68539 56316.25798 56262.64444 
AIC 56434.68539 56428.25798 56392.64444 
BIC 56889.77526 56891.62221 56930.47792 
N 28980 28980 28980 
Groups 5745 5745 5745 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birth year coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile. 
Age2 is the coefficient for the split line at age three  
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Table 25: Final regression models for BMI SD score in >18 age group.  
 baseline final final_plus 
Constant -0.21805* -0.17173 -0.04328 
 (0.09144) (0.09519) (0.10561) 
Age-18 -0.07687*** -0.07677*** -0.08689*** 
 (0.01117) (0.01117) (0.01768) 
age2 0.10160*** 0.10152*** 0.11180*** 
 (0.01333) (0.01333) (0.02018) 
Number of F508 alleles: 0/2 -0.06500 -0.06111 -0.08529 
 (0.07590) (0.07592) (0.07637) 
Number of F508 alleles: 1/2 0.17795*** 0.18013*** 0.16327** 
 (0.05348) (0.05347) (0.05346) 
Male 0.00526 0.00446 -0.00124 
 (0.04935) (0.04934) (0.04908) 
Non-white -0.29930* -0.27837 -0.26552 
 (0.15130) (0.15174) (0.15084) 
Screened 0.04868 0.04777 0.04648 
 (0.08262) (0.08260) (0.08210) 
Age-18 x Number of F508 alleles: 0/2 0.02560 0.02537 0.02874 
 (0.02020) (0.02019) (0.02046) 
Age-18 x Number of F508 alleles: 1/2 -0.00979 -0.00980 -0.00837 
 (0.01363) (0.01363) (0.01374) 
Age-18 x male -0.03936** -0.03934** -0.03862** 
 (0.01252) (0.01252) (0.01254) 
Age-18 x non-white 0.03474 0.03412 0.02954 
 (0.03951) (0.03951) (0.03952) 
Age-18 x screened 0.02545 0.02532 0.02815 
 (0.02234) (0.02234) (0.02236) 
age2 x Number of F508 alleles: 0/2 -0.01458 -0.01423 -0.01810 
 (0.02384) (0.02384) (0.02412) 
age2 x Number of F508 alleles: 1/2 0.01498 0.01497 0.01297 
 (0.01618) (0.01618) (0.01633) 
age2 x male 0.06502*** 0.06495*** 0.06441*** 
 (0.01495) (0.01495) (0.01497) 
age2 x non-white -0.02736 -0.02708 -0.02163 
 (0.04853) (0.04852) (0.04855) 
age2 x screened -0.05167 -0.05189 -0.05556 
 (0.02884) (0.02884) (0.02887) 
Deprivation score  -0.00203 -0.00202 
  (0.00117) (0.00116) 
Pseudomonas colonisation   -0.07043* 
   (0.03202) 
CFRD   -0.16322** 
   (0.05294) 
Pancreatic insufficiency   -0.07341 
   (0.05079) 
Age-18 x Pseudomonas colonisation   0.00154 
   (0.00984) 
Age-18 x CFRD   0.04219** 
   (0.01520) 
Age-18 x Pancreatic insufficiency   0.00480 
   (0.01517) 
age2 x Pseudomonas colonisation   0.00147 
   (0.01105) 
age2 x CFRD   -0.04591** 
   (0.01662) 
age2 x Pancreatic insufficiency   -0.00577 
   (0.01681) 
Log-likelihood -19862.44785 -19860.93596 -19827.07408 
Deviance 39724.89570 39721.87192 39654.14815 
AIC 39842.89570 39841.87192 39792.14815 
BIC 40309.06561 40315.94301 40337.32991 
N 19954 19954 19954 
Groups 4029 4029 4029 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile. 
Age2 is the coefficient for the split line at age 22 years  
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%FEV1  
 
Figure 91: Exploratory analysis showing smoothed means of %FEV1 score 
versus age, stratified by covariates 
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Table 26: Final regression models for %FEV1 in >18 age group 
 baseline final final_plus 
Constant 66.36305*** 66.98845*** 67.28886*** 
 (1.92358) (2.00681) (2.10252) 
Age-18 -0.83027*** -0.82954*** -0.48092** 
 (0.12041) (0.12040) (0.18083) 
age2 0.17202 0.17140 -0.35969 
 (0.17310) (0.17309) (0.25009) 
Number of F508 alleles: 0/2 0.76615 0.81024 0.78226 
 (1.49731) (1.49776) (1.48700) 
Number of F508 alleles: 1/2 4.25191*** 4.28061*** 4.14929*** 
 (1.10186) (1.10210) (1.08994) 
Male 7.33010*** 7.32078*** 7.18506*** 
 (1.02742) (1.02738) (1.01269) 
Non-white -5.03984 -4.78147 -4.64612 
 (3.08501) (3.09386) (3.05171) 
Screened 2.92309 2.91567 2.81094 
 (1.72673) (1.72665) (1.70461) 
Age-18 x Number of F508 alleles: 0/2 0.52820* 0.52810* 0.46467* 
 (0.21359) (0.21357) (0.21391) 
Age-18 x Number of F508 alleles: 1/2 -0.03008 -0.03021 -0.07093 
 (0.14545) (0.14543) (0.14551) 
Age-18 x male -1.44383*** -1.44444*** -1.44413*** 
 (0.13344) (0.13343) (0.13260) 
Age-18 x nonwhite 0.22305 0.21989 0.20467 
 (0.42572) (0.42569) (0.42259) 
Age-18 x screened -0.54162* -0.54524* -0.51555* 
 (0.24882) (0.24882) (0.24715) 
age2 x Number of F508 alleles: 0/2 -0.70699* -0.70463* -0.58411 
 (0.30242) (0.30240) (0.30309) 
age2 x Number of F508 alleles: 1/2 0.09007 0.09044 0.17869 
 (0.20501) (0.20500) (0.20603) 
age2 x male 1.83791*** 1.83810*** 1.85091*** 
 (0.19072) (0.19071) (0.18987) 
age2 x nonwhite -0.11155 -0.11334 -0.03015 
 (0.68181) (0.68174) (0.67764) 
age2 x screened 0.49587 0.49778 0.48840 
 (0.43627) (0.43623) (0.43358) 
Deprivation score  -0.02720 -0.02632 
  (0.02491) (0.02448) 
Pseudomonas colonisation   -1.28927** 
   (0.49353) 
CFRD   -3.37204*** 
   (0.82035) 
Pancreatic insufficiency   0.74468 
   (0.77510) 
Age-18 x Pseudomonas colonisation   -0.16789 
   (0.09803) 
Age-18 x CFRD   0.32658* 
   (0.14804) 
Age-18 x Pancreatic insufficiency   -0.23598 
   (0.14847) 
age2 x Pseudomonas colonisation   0.18743 
   (0.13566) 
age2 x CFRD   -0.09181 
   (0.19179) 
age2 x Pancreatic insufficiency   0.32312 
   (0.19945) 
Log-likelihood -79717.51480 -79716.91908 -79639.43492 
Deviance 159435.02959 159433.83816 159278.86984 
AIC 159547.02959 159547.83816 159410.86984 
BIC 159989.57167 159998.28278 159932.43729 
N 19981 19981 19981 
Groups 4026 4026 4026 
*P < 0.05, ** P < 0.01, *** P < 0.001 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile 
age2 is the coefficient for the split line at age 25 years  
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Pseudomonas colonisation 
Table 27: Final regression models for P. aeruginosa colonisation in <18 age 
group  
 baseline final final_plus final_plus2 final_plus3 
Constant -3.645*** -3.918*** -5.002*** -5.138*** -4.933*** 
 (0.318) (0.326) (0.354) (0.581) (0.355) 
Age 0.216*** 0.218*** 0.230*** 0.352*** 0.231*** 
 (0.038) (0.038) (0.038) (0.083) (0.038) 
Age^2 -0.005** -0.005** -0.005*** -0.009** -0.006*** 
 (0.002) (0.002) (0.002) (0.003) (0.002) 
Number of F508 alleles: 0/2 -0.500** -0.520** -0.328 -0.700*** -0.351* 
 (0.179) (0.179) (0.179) (0.200) (0.179) 
Number of F508 alleles: 1/2 -0.468*** -0.478*** -0.353** -0.550*** -0.341** 
 (0.115) (0.115) (0.114) (0.128) (0.114) 
Male -0.334** -0.338** -0.335** -0.326** -0.328** 
 (0.106) (0.106) (0.105) (0.118) (0.105) 
Deprivation score  0.011*** 0.011*** 0.012*** 0.012*** 
  (0.003) (0.003) (0.004) (0.003) 
CFRD   0.588***  0.584*** 
   (0.147)  (0.147) 
Pancreatic insufficiency   1.027***  1.030*** 
   (0.134)  (0.134) 
%FEV1    -0.032***  
    (0.002)  
Screened     -0.576*** 
     (0.150) 
Log-likelihood -10119.281 -10112.984 -10072.582 -7783.267 -10064.161 
Deviance 20238.562 20225.968 20145.163 15566.534 20128.322 
AIC 20316.562 20305.968 20229.163 15636.534 20214.322 
BIC 20635.959 20633.556 20573.130 15909.659 20566.478 
N 26627 26627 26627 18098 26627 
Groups 5648 5648 5648 4334 5648 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile 
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Table 28: Final regression models for P. aeruginosa colonisation in >18 age 
group.  
 baseline final final_plus1 final_plus2 final_plus3 
Constant 1.482*** 1.274*** -1.273*** -1.297*** 1.307*** 
 (0.217) (0.227) (0.245) (0.245) (0.221) 
Age-18 0.005 0.005 0.022* 0.022* -0.022* 
 (0.010) (0.010) (0.011) (0.011) (0.010) 
Number of F508 alleles: 0/2 -1.110*** -1.138*** -0.640*** -0.637*** -0.987*** 
 (0.150) (0.150) (0.151) (0.151) (0.146) 
Number of F508 alleles: 1/2 -0.713*** -0.723*** -0.273* -0.275* -0.534*** 
 (0.111) (0.111) (0.110) (0.110) (0.107) 
Male -0.188 -0.182 -0.217* -0.221* -0.168 
 (0.102) (0.102) (0.101) (0.101) (0.099) 
Deprivation score  0.010** 0.012*** 0.012*** 0.008** 
  (0.003) (0.003) (0.003) (0.003) 
CFRD   0.703*** 0.707***  
   (0.086) (0.086)  
Pancreatic insufficiency   2.389*** 2.385***  
   (0.097) (0.097)  
Screened    0.394  
    (0.204)  
%FEV1      -0.040*** 
     (0.002) 
Log-likelihood -10017.703 -10013.739 -9657.853 -9656.182 -9344.819 
Deviance 20035.407 20027.477 19315.706 19312.364 18689.638 
AIC 20115.407 20109.477 19401.706 19400.364 18773.638 
BIC 20430.169 20432.108 19740.075 19746.602 19102.732 
N 19323 19323 19323 19323 18687 
Groups 4020 4020 4020 4020 3981 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile. 
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Any IV antibiotic therapy 
The presentation of the model tables for treatment outcomes follows the same basic 
format. The severity model is presented first, adjusted for baseline covariates, and 
disease severity. Then deprivation is added (final model – the main results are from 
these models), and then other covariates of potential interest are added (final_plus). 
  
Table 29: Final regression models for any IV therapy age 18 to <40 
 severity final final_plus 
Constant -1.541*** 0.587** 0.515** 
 (0.162) (0.186) (0.188) 
Age-18 0.122*** -0.011 -0.009 
 (0.018) (0.019) (0.019) 
(Age-18)^2 -0.004*** -0.001 -0.001 
 (0.001) (0.001) (0.001) 
Number of F508 alleles: 0/2 0.016 -0.527*** -0.553*** 
 (0.106) (0.114) (0.116) 
Number of F508 alleles: 1/2 -0.153* -0.341*** -0.326*** 
 (0.077) (0.083) (0.084) 
Male -0.305*** -0.743*** -0.752*** 
 (0.070) (0.077) (0.078) 
%FEV1  -0.034*** -0.043*** -0.041*** 
 (0.001) (0.001) (0.002) 
Pseudomonas colonisation 1.053*** 1.617*** 1.599*** 
 (0.054) (0.055) (0.056) 
Deprivation  0.011*** 0.011*** 
  (0.002) (0.003) 
BMI SD score   -0.142*** 
   (0.029) 
Log-likelihood -9721.856 -9040.389 -8948.984 
Deviance 19443.712 18080.777 17897.969 
AIC 19529.712 18168.777 17987.969 
BIC 19866.439 18513.335 18339.961 
N 18599 18599 18436 
Groups 3971 3971 3962 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log(IV days) 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
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Table 30: Robustness test: regression models for use of any IV therapy 5 to <18 
 final Deprivation z score Data <2000 excluded  Cepacia added Care centre 
Constant -1.800*** -1.459*** -1.812*** -1.803*** -1.035*** 
 (0.202) (0.195) (0.205) (0.202) (0.270) 
Age-5 0.340*** 0.340*** 0.336*** 0.339*** 0.213*** 
 (0.036) (0.036) (0.037) (0.036) (0.038) 
(Age-5)^2 -0.016*** -0.016*** -0.016*** -0.016*** -0.006* 
 (0.002) (0.002) (0.003) (0.002) (0.003) 
Number of F508 alleles: 0/2 -0.533*** -0.533*** -0.509*** -0.526*** -0.243* 
 (0.127) (0.127) (0.128) (0.127) (0.119) 
Number of F508 alleles: 1/2 -0.388*** -0.388*** -0.385*** -0.389*** -0.294*** 
 (0.079) (0.079) (0.080) (0.079) (0.074) 
Male -0.374*** -0.374*** -0.352*** -0.378*** -0.400*** 
 (0.073) (0.073) (0.074) (0.073) (0.068) 
fev_cent -0.036*** -0.036*** -0.036*** -0.035*** -0.040*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Pseudomonas colonisation 1.720*** 1.720*** 1.684*** 1.725*** 1.842*** 
 (0.065) (0.065) (0.066) (0.065) (0.065) 
Deprivation 0.016***  0.016*** 0.016*** 0.010*** 
 (0.002)  (0.002) (0.002) (0.002) 
Deprivation Z score  0.247***    
  (0.036)    
B.Cepacia    1.095***  
    (0.240)  
Log-likelihood -9447.085 -9447.356 -8978.788 -9436.327 -8996.254 
Deviance 18894.170 18894.711 17957.576 18872.655 17992.507 
AIC 18966.170 18966.711 18023.576 18946.655 18322.507 
BIC 19246.877 19247.418 18279.144 19235.159 19609.079 
N 17987 17987 17060 17987 17987 
Groups 4321 4321 4220 4321 4321 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile. 
The deprivation effect in Z scores is multiplied by 3.56 to generate the contrast between the mid point of the least and most 
deprived quintile 
Any home IV therapy 
Table 31: Final regression models for any home IV therapy age 5-18 
 severity final 
Constant -3.705*** -4.002*** 
 (0.247) (0.296) 
Age-5 0.187*** 0.247*** 
 (0.014) (0.022) 
Number of F508 alleles: 0/2 -0.882*** -0.836*** 
 (0.190) (0.192) 
Number of F508 alleles: 1/2 -0.282* -0.256* 
 (0.115) (0.116) 
Male -0.291** -0.308** 
 (0.107) (0.108) 
%FEV1  -0.022*** -0.022*** 
 (0.002) (0.002) 
Pseudomonas colonisation 1.190*** 1.203*** 
 (0.074) (0.074) 
Deprivation  0.012 
  (0.007) 
Age-5 x deprivation  -0.003*** 
  (0.001) 
Log-likelihood -7773.296 -7767.323 
Deviance 15546.592 15534.646 
AIC 15614.592 15606.646 
BIC 15879.704 15887.353 
N 17987 17987 
Groups 4321 4321 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
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The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile. 
Table 32: Final regression models for any home IV therapy age 18-40 
 severity final 
Constant -0.762*** -0.770*** 
 (0.186) (0.186) 
Age-18 0.034 0.034 
 (0.020) (0.020) 
(Age-18)^2 -0.003** -0.003** 
 (0.001) (0.001) 
Number of F508 alleles: 0/2 -0.894*** -0.869*** 
 (0.125) (0.125) 
Number of F508 alleles: 1/2 -0.245** -0.234** 
 (0.088) (0.088) 
Male -0.972*** -0.978*** 
 (0.081) (0.081) 
%FEV1  -0.031*** -0.031*** 
 (0.001) (0.001) 
Pseudomonas colonisation 1.195*** 1.199*** 
 (0.057) (0.057) 
Deprivation  -0.009*** 
  (0.003) 
Log-likelihood -9617.911 -9612.461 
Deviance 19235.821 19224.922 
AIC 19321.821 19312.922 
BIC 19658.548 19657.480 
N 18599 18599 
Groups 3971 3971  
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
 
 
Table 33: Final regression models for amount of any IV therapy age 5 to <18 
 severity final final_plus 
Constant 2.962*** 2.900*** 2.901*** 
 (0.045) (0.048) (0.048) 
Age-5 0.031*** 0.031*** 0.031*** 
 (0.003) (0.003) (0.003) 
Number of F508 alleles: 0/2 -0.008 -0.013 -0.013 
 (0.036) (0.036) (0.036) 
Number of F508 alleles: 1/2 -0.041 -0.043* -0.043* 
 (0.022) (0.022) (0.022) 
Male -0.091*** -0.092*** -0.092*** 
 (0.020) (0.020) (0.020) 
%FEV1  -0.008*** -0.008*** -0.008*** 
 (0.000) (0.000) (0.000) 
Pseudomonas colonisation 0.224*** 0.222*** 0.223*** 
 (0.015) (0.015) (0.015) 
Deprivation  0.003*** 0.003*** 
  (0.001) (0.001) 
BMI SD score   -0.000 
   (0.002) 
Log-likelihood -7924.630 -7915.716 -7905.456 
Deviance 15849.260 15831.432 15810.912 
AIC 15919.260 15903.432 15884.912 
BIC 16166.953 16158.201 16146.712 
N 8751 8751 8740 
Groups 3004 3004 3003 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log(IV days) 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
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Table 34: Final regression models for amount of IV therapy age 18 to <40 
 severity final final_plus 
Constant 3.234*** 3.198*** 3.174*** 
 (0.044) (0.046) (0.046) 
Age-18 -0.003 -0.003 -0.002 
 (0.002) (0.002) (0.002) 
Number of F508 alleles: 0/2 -0.095** -0.098** -0.099** 
 (0.033) (0.033) (0.033) 
Number of F508 alleles: 1/2 -0.020 -0.022 -0.019 
 (0.023) (0.023) (0.023) 
Male -0.157*** -0.156*** -0.159*** 
 (0.021) (0.021) (0.021) 
%FEV1  -0.012*** -0.012*** -0.011*** 
 (0.000) (0.000) (0.000) 
Pseudomonas colonisation 0.192*** 0.191*** 0.191*** 
 (0.016) (0.016) (0.016) 
Deprivation  0.002** 0.002* 
  (0.001) (0.001) 
BMI SD score   -0.032*** 
   (0.008) 
Log-likelihood -10632.661 -10629.278 -10538.959 
Deviance 21265.322 21258.555 21077.918 
AIC 21349.322 21344.555 21165.918 
BIC 21656.068 21658.604 21486.925 
N 10976 10976 10890 
Groups 3052 3052 3046 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log(IV days) 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
 
Nutritional therapy 
Table 35: Final regression models for any nutritional support <18 age 
 severity final final_plus 
Constant -4.391*** -4.607*** -5.192*** 
 (0.229) (0.235) (0.482) 
Age 0.514*** 0.511*** 0.566*** 
 (0.029) (0.029) (0.070) 
Age^2 -0.022*** -0.022*** -0.024*** 
 (0.001) (0.001) (0.003) 
Number of F508 alleles: 0/2 -0.375** -0.396** -0.544*** 
 (0.126) (0.126) (0.148) 
Number of F508 alleles: 1/2 -0.412*** -0.419*** -0.392*** 
 (0.081) (0.081) (0.093) 
Male 0.125 0.120 0.207* 
 (0.075) (0.074) (0.086) 
BMI SD score -0.740*** -0.735*** -0.826*** 
 (0.029) (0.029) (0.038) 
Pseudomonas colonisation 1.019*** 1.012*** 1.081*** 
 (0.055) (0.055) (0.063) 
Deprivation  0.010*** 0.010*** 
  (0.002) (0.003) 
%FEV1    -0.014*** 
   (0.002) 
Log-likelihood -13462.592 -13452.527 -9645.127 
Deviance 26925.184 26905.054 19290.255 
AIC 27007.184 26989.054 19364.255 
BIC 27346.513 27336.660 19656.601 
N 29037 29037 19955 
Groups 5754 5754 4442 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
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Table 36. Final regression models for any nutritional support age 18-40 
 severity final final_plus 
Constant -3.232*** -3.563*** -3.836*** 
 (0.193) (0.208) (0.230) 
Age-18 0.133*** 0.160*** 0.200*** 
 (0.021) (0.023) (0.024) 
(Age-18)^2 -0.005*** -0.005*** -0.007*** 
 (0.001) (0.001) (0.001) 
Number of F508 alleles: 0/2 -0.543*** -0.442*** -0.487*** 
 (0.131) (0.133) (0.145) 
Number of F508 alleles: 1/2 -0.309** -0.306** -0.319** 
 (0.094) (0.096) (0.105) 
Male 0.409*** 0.388*** 0.400*** 
 (0.087) (0.088) (0.096) 
BMI SD score -0.882*** -0.853*** -0.711*** 
 (0.030) (0.031) (0.035) 
Pseudomonas colonisation 1.155*** 1.308*** 1.283*** 
 (0.058) (0.059) (0.063) 
Deprivation  0.015*** 0.016*** 
  (0.003) (0.003) 
%FEV1    -0.021*** 
   (0.002) 
Log-likelihood -9250.602 -9210.385 -8938.167 
Deviance 18501.205 18420.770 17876.333 
AIC 18591.205 18512.770 17970.333 
BIC 18947.097 18876.571 18341.341 
N 20105 20105 19807 
Groups 4040 4040 4017 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
DNase  
Table 37. Final regression models for any DNase <18 age 
 severity final final_plus 
Age 3.489*** 3.528*** 3.642*** 
 (0.109) (0.111) (0.148) 
Age^2 -0.105*** -0.106*** -0.111*** 
 (0.004) (0.004) (0.006) 
Number of F508 alleles: 0/2 -0.351 -0.427 -0.368 
 (0.331) (0.343) (0.276) 
Number of F508 alleles: 1/2 -0.758*** -0.751** -0.603*** 
 (0.226) (0.234) (0.182) 
Male -0.722*** -0.670** -0.567*** 
 (0.211) (0.219) (0.169) 
 (12.766) (12.620)  
Pseudomonas colonisation 0.935*** 0.959*** 0.918*** 
 (0.100) (0.101) (0.100) 
BMI SD score -0.217*** -0.315*** -0.010 
 (0.060) (0.062) (0.024) 
Deprivation  -0.011 -0.016** 
  (0.007) (0.005) 
%FEV1    -0.052*** 
   (0.003) 
Log-likelihood -8936.299 -8935.158 -7496.707 
Deviance 17872.598 17870.316 14993.414 
AIC 17954.598 17954.316 15067.414 
BIC 18293.940 18301.935 15359.765 
N 29046 29046 19958 
Groups 5757 5757 4443 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile. 
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Table 38: Final regression models for any DNase age 18-40 
 severity final 
Constant -2.200*** -1.845*** 
 (0.225) (0.234) 
Age-18 0.148*** 0.148*** 
 (0.009) (0.009) 
Number of F508 alleles: 0/2 -0.775*** -0.719*** 
 (0.156) (0.155) 
Number of F508 alleles: 1/2 -0.261* -0.239* 
 (0.111) (0.111) 
Male -0.289** -0.295** 
 (0.103) (0.103) 
Pseudomonas colonisation 1.292*** 1.296*** 
 (0.062) (0.062) 
%FEV1  -0.046*** -0.046*** 
 (0.002) (0.002) 
Deprivation  -0.017*** 
  (0.003) 
Log-likelihood -8932.258 -8919.771 
Deviance 17864.517 17839.541 
AIC 17948.517 17925.541 
BIC 18280.423 18265.351 
N 19981 19981 
Groups 4026 4026 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
Any inhaled therapy <18 
Table 39: Final regression models for any inhaled therapy <18 age 
 severity final 
Constant -0.265 -0.100 
 (0.379) (0.391) 
Age 0.279*** 0.262*** 
 (0.055) (0.055) 
Age^2 -0.007** -0.006** 
 (0.002) (0.002) 
Number of F508 alleles: 0/2 -0.516*** -0.642*** 
 (0.144) (0.144) 
Number of F508 alleles: 1/2 -0.342*** -0.544*** 
 (0.091) (0.091) 
Male -0.006 -0.020 
 (0.085) (0.085) 
Pseudomonas colonisation 2.126*** 2.379*** 
 (0.076) (0.079) 
%FEV1 -0.020*** -0.019*** 
 (0.002) (0.002) 
Deprivation  -0.007** 
  (0.003) 
Log-likelihood -9623.226 -9573.725 
Deviance 19246.452 19147.451 
AIC 19316.452 19219.451 
BIC 19593.039 19503.940 
N 19980 19980 
Groups 4445 4445 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
 
 
 346 
Table 40: Final regression models for any inhaled therapy 18-40 years  
 severity final 
Constant 1.889*** 2.204*** 
 (0.547) (0.550) 
ageatvisityrs -0.148*** -0.147*** 
 (0.040) (0.041) 
I(ageatvisityrs^2) 0.003*** 0.003*** 
 (0.001) (0.001) 
Number of F508 alleles: 0/2 -0.505*** -0.468*** 
 (0.076) (0.076) 
Number of F508 alleles: 1/2 -0.240*** -0.225*** 
 (0.055) (0.055) 
Male -0.101* -0.111* 
 (0.050) (0.050) 
Pseudomonas colonisation 1.391*** 1.419*** 
 (0.041) (0.042) 
%FEV1  -0.011*** -0.012*** 
 (0.001) (0.001) 
Deprivation  -0.016*** 
  (0.002) 
Log-likelihood -10255.477 -10198.083 
Deviance 20510.954 20396.166 
AIC 20600.954 20488.166 
BIC 20956.568 20851.683 
N 19981 19981 
Groups 4026 4026 
*P < 0.05, ** P < 0.01, *** P < 0.001 
NB parameters represent log-odds 
Standard errors in parentheses, birthyear coefficients not shown 
The deprivation effect is multiplied by 58 to generate the contrast between the mid point of the least and most deprived quintile.  
Illustrative regression diagnostics 
Figure 92: %FEV1 < 18 years, final model 
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Figure 93: Any IV therapy < 18 years, final model 
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Appendix 5 (Pertaining to Chapter 5) 
Table 41: Log odds for the final GLMMs, with added educational variable. 
 Baseline + 
Severity + 
Time in hospital + 
Deprivation*%FEV1  
Plus education 
variable 
(NB models not 
nested) 
Constant 2.05821*** -0.73603 
 (0.17127) (0.43094) 
Deprivation quintile 2/1 -0.27946 -0.21829 
 (0.20153) (0.23348) 
Deprivation quintile 3/1 -0.97564*** -0.70394** 
 (0.19987) (0.24049) 
Deprivation quintile 4/1 -1.42676*** -0.99734*** 
 (0.19752) (0.23896) 
Deprivation quintile 5/1 -2.66327*** -1.98129*** 
 (0.20678) (0.25776) 
%FEV1  0.01257** 0.01111 
 (0.00487) (0.00579) 
Hospital IV days -0.02309*** -0.02226*** 
 (0.00209) (0.00282) 
BMI SDS 0.10406*  
 (0.04304)  
age 0.14598*** 0.21636*** 
 (0.01616) (0.02064) 
age^2 -0.02338*** -0.02087*** 
 (0.00164) (0.00212) 
Birthyear -0.03949** -0.03994* 
 (0.01427) (0.01826) 
Male/Female 0.40087** 0.45083** 
 (0.12499) (0.15167) 
Deprivation quintile 2/1 x %FEV1  0.01031 0.00613 
 (0.00661) (0.00797) 
Deprivation quintile 3/1 x %FEV1  0.00979 0.00676 
 (0.00641) (0.00819) 
Deprivation quintile 4/1 x %FEV1  0.00581 0.01120 
 (0.00638) (0.00796) 
Deprivation quintile 5/1 x %FEV1  0.01642* 0.01814* 
 (0.00695) (0.00881) 
Ranef - id 6.92797 6.05039 
 (2.63210) (2.45980) 
Ranef  0.19489 0.18887 
 (0.44146) (0.43460) 
Highest  education:  2/1  (1  =  “less  than  high  
school”) 
 2.08872*** 
  (0.40422) 
Highest education: 3/1  3.09579*** 
  (0.44268) 
Highest education: 4/1  3.21147*** 
  (0.41106) 
Highest education: 5/1  2.76440*** 
  (0.39619) 
Log-likelihood -7545.11112 -4606.94109 
Deviance 15090.22224 9213.88218 
AIC 15128.22224 9257.88218 
BIC 15273.45955 9415.17414 
N 15430 9411 
Groups 3451 2008 
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Appendix 6 (Pertaining to Chapter 6) 
 
Statistical Package (R) Programming Code 
 
#generating spaghetti plots for 10 individuals 
 
ns <- 10 
samp <- sample(d$id,ns) 
sampd <- subset(d, d$id %in% samp) 
ids <- unique(sampd$id) 
 
plot(sampd$age[sampd$id == ids[1]],sampd$fev1[sampd$id == ids[1]], type="l", ylim=c(0,150),xlab="Age",main="REAL 
DATA",ylab="% Predicted FEV1") 
for (i in 2:ns)  
 lines(sampd$age[sampd$id == ids[i]],sampd$fev1[sampd$id == ids[i]],col=i) 
 
#generating variogram 
 
variogram<-function(id,time,residual,u.max=NULL,u.increment=1) { 
# 
# variogram function adapted from the geoR library, to deal with  
# longitudinal data-sets with long individual time series, geoR  
# library must be installed before use. 
# 
# Arguments: 
#  id: identifier for individual subjects 
#  time: time at which measurement is made 
# residual: corresponding residual from model for mean response profiles 
#  u.max: maximum time-separation at which variogram is estimated (optional, but recommended) 
# u.increment: increment between successive time-separations (not used when u.max=NULL)) 
# 
# Result: a list with components: 
#    u: time-separations at which variogram is estimated 
#    v: corresponding variogam estimates 
#    n: number of pairs contributing to each variogram estimate 
# sigmasquared: variogram-based estimate of process variance (sum of between-subject  
#     and within-subject components) 
# 
# NOTES: 1. when data include replicated measurements at a common time within one or more subjects, 
#   the geoR library generates warning messages...these can safely be ignored in the 
#   present context 
#  2. when data include subjects with only one non-missing response, variogram calculation will fail 
# 
 nid<-length(id) 
 nt<-length(time) 
 nr<-length(residual) 
 check1<-c(nid-nt,nid-nr) 
 if (max(abs(check1))>0) print("Bad data: unequal lengths amongst id, time and response") 
 check2<-table(id) 
 if (min(check2)<2) print("Bad data: at least one suject with only 1 response") 
 library(geoR) 
 uid<-unique(id) 
 nid<-length(uid)  
 if (length(u.max)==0) { 
  u1<-min(time) 
  u2<-max(time) 
  h<-(u2-u1)/40 
  u<-((1:20)-0.5)*u.increment 
  } else { 
  u<-u.increment*((1:round(u.max/u.increment))-0.5) 
  } 
 nu<-length(u) 
 u.all<-NULL 
 v.all<-NULL 
 n.within<-rep(NA,nid) 
 mean.within<-rep(NA,nid) 
 var.within<-rep(NA,nid) 
 for (i in 1:length(uid)) { 
  take<-(id==uid[i]) 
  if (sum(take)>1) { 
   x<-time[take] 
   y<-rep(0,length(x)) 
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   z<-residual[take] 
   xyz<-as.geodata(cbind(x,y,z)) 
   vario<-variog(xyz,option="cloud",messages=F) 
   u.all<-c(u.all,vario$u) 
   v.all<-c(v.all,vario$v) 
   n.within[i]<-length(!is.na(z)) 
   mean.within[i]<-mean(z[!is.na(z)]) 
   var.within[i]<-var(z[!is.na(z)]) 
   } 
  } 
 sigmasquared<-sum(var.within[n.within>=2]*(n.within[n.within>=2]-1))/sum(n.within[n.within>=2]-1) + 
  var(mean.within[!is.na(mean.within)]) 
 nugget<-min(u.all)==0 
 u.breaks<-c(0,u+0.5*u.increment) 
 if (nugget==TRUE) { 
  u.breaks<-c(0,u.breaks) 
  u<-c(0,u) 
  } 
 nu<-length(u) 
 v<-rep(NA,nu) 
 n<-rep(0,nu) 
 if (nugget==T) { 
  take<-u.all==0 
  n[1]<-sum(take) 
  v[1]<-mean(v.all[take],na.rm=T) 
  } else { 
  take<-(u.all>=u.breaks[1])&(u.all<u.breaks[2]) 
  n[1]<-sum(take) 
  v[1]<-mean(v.all[take],na.rm=T) 
  } 
 for (i in 2:nu) { 
  take<-(u.all>=u.breaks[i])&(u.all<u.breaks[i+1]) 
  n[i]<-sum(take) 
  v[i]<-mean(v.all[take],na.rm=T) 
  } 
 list(u=u,v=v,n=n,sigmasquared=sigmasquared) 
 } 
 
# Functions required for exploratory analysis 
 
average.by.age<-function(x,y,x.lowest,x.increment,x.highest) { 
 nbreaks<-ceiling((range(x)[2]-range(x)[1])/x.increment) 
 breaks<-x.lowest+x.increment*(0:nbreaks) 
 yvec<-rep(0,nbreaks) 
 for (i in 1:nbreaks) { 
  take<-(x>breaks[i])&(x<=breaks[i+1]) 
  yvec[i]<-mean(y[take],na.rm=T) 
  } 
 xvec<-(breaks[2:(nbreaks+1)]+breaks[1:nbreaks])/2 
 list(x=xvec,y=yvec) 
 } 
 
 
data <- d 
smooth.trend<-average.by.age(data$age,data$fev1,5,1,60) 
plot(data$age,data$fev1,pch=".",xlab="age (years)",ylab="%FEV1") 
lines(smooth.trend$x,smooth.trend$y,type="l",lwd=2,col="red") 
 
# add columns to data for smoothed response and residuals 
 
yfit<-smooth.trend$y 
xfit<-smooth.trend$x 
N<-dim(data)[1] 
ysmooth<-rep(NA,N) 
for (i in 1:N) { 
 take<-floor(data$age[i])==floor(xfit) 
 if (sum(take)>0) ysmooth[i]<-yfit[take] 
 } 
data$smooth<-ysmooth 
data$res<-data$fev1-data$smooth 
 
d$res <- data$res 
x<-d$age 
z<-d$res 
id<-d$id 
data.v<- variogram(id,x,z,u.max=30) 
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#plotting theoretical variogram trace (red line in Figure 70) 
 
x <- seq(0,30,0.1) 
torsq <- 0.1500497* 16.41201^2 
sigsq <- (1-0.1500497)* 16.41201^2 
nusq <- 18.87013^2 
phi <- 6.7211035 
y5 <- torsq + sigsq*(1-exp(-x/phi)) 
lines(x,y5,col="red",lwd=2) 
lines(x,rep(torsq+sigsq+nusq ,length(x)),col="red",lwd=2,lty=2) 
 
#final multivariate model specification – this runs overnight on this dataset on a 2.8GHz Intel Core 2 Mac Book Pro (8GB 
memory), running 64-bit version of R 
 
library(nlme) 
exp1 <- corExp(value=c(7,(40/300)),form=~age2|id,nugget=T) 
exp1 <- Initialize(exp1,d) 
m15co <- lme(fev1 ~ sex+DM2+ age2*(cohort + PIb) +age3, data=d, random= ~ 1|id, method="ML",correlation=exp1) 
summary(m15co) 
intervals(m15co) 
 
# simulation of data from a class of longitudinal models, irregularly 
# observed in time 
# 
mu<-function(t,theta) { 
# 
# Arguments 
#  t: time (vector of non-negative real numbers) 
# theta: vector of parameters that define the mean response as a function of time 
# 
# Result 
# Vector giving the values of the mean response at times corresponding to 
# each element of the vector t 
# 
# Comment 
# The following code is indicative only: it defines the mean repsonse as 
# linear in time, with intercept theta[1] and slope theta[2] but can be  
# replaced by any other code that operates on vectors t and theta supplied  
# as arguments 
# 
 theta[1]+theta[2]*t 
 } 
# 
vmat<-function(t,nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa=0.5) { 
# 
# Arguments 
#  t: time (vector of non-negtive real numbers) 
# nusqA: variance of random intercept 
# nusqB: variance of random slope 
# rhoAB: correlation between random intercept and slope 
# tausq: measurement error variance 
# sigmasq: variance of serially correlated component  
#  phi: scale parameter of Matern correlation function 
# kappa: shape parameter of Matern correlation function (defaults to exponential) 
# 
# Result 
# Variance matrix of sequence of measurements at times corresponding to 
# each element of the vector t 
 nt<-length(t) 
 vAB<-matrix(c(nusqA,rep(rhoAB*sqrt(nusqA*nusqB),2),nusqB),2,2) 
 xmat<-cbind(rep(1,nt),t) 
 V1<-xmat%*%vAB%*%t(xmat) 
 V2<-sigmasq*matern(abs(outer(t,t,"-")),phi,kappa) 
 V3<-tausq*diag(rep(1,nt)) 
 V1+V2+V3 
 } 
simulate<-function(t,theta,nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa=0.5) { 
# 
# Arguments 
# 
#  t: time (vector of non-negative real numbers) 
# theta: vector of parameters that define the mean response as a function of time 
# nusqA: variance of random intercept 
# nusqB: variance of random slope 
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# rhoAB: correlation between random intercept and slope 
# tausq: measurement error variance 
# sigmasq: variance of serially correlated component  
#  phi: scale parameter of Matern correlation function 
# kappa: shape parameter of Matern correlation function (defaults to exponential) 
# 
# Result 
# Vector containing simulated realisation for a single subject 
# 
 mean.vector<-mu(t,theta) 
 var.matrix<-vmat(t,nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa) 
 rmvnorm(1,mean.vector,var.matrix) 
 } 
 
simulate.balanced<-function(ns,t,theta,nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa=0.5) { 
# 
# Arguments 
# 
#  ns: number of subjects 
#  t: time (vector of non-negative real numbers), common to all subjects 
# theta: vector of parameters that define the mean response as a function of time 
# nusqA: variance of random intercept 
# nusqB: variance of random slope 
# rhoAB: correlation between random intercept and slope 
# tausq: measurement error variance 
# sigmasq: variance of serially correlated component  
#  phi: scale parameter of Matern correlation function 
# kappa: shape parameter of Matern correlation function (defaults to exponential) 
# 
# Result 
# Matrix containing simulated realisations for ns subjects (rows) at 
# nt times (columns) 
# 
 mean.vector<-mu(t,theta) 
 var.matrix<-vmat(t,nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa) 
 rmvnorm(ns,mean.vector,var.matrix) 
 } 
 
simulate.unbalanced<-function(ns,tlist,theta,nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa=0.5) { 
# 
# Arguments 
# 
#  ns: number of subjects 
# tlist: times (list of vectors of non-negative real numbers) unique to each subject 
# theta: vector of parameters that define the mean response as a function of time 
# nusqA: variance of random intercept 
# nusqB: variance of random slope 
# rhoAB: correlation between random intercept and slope 
# tausq: measurement error variance 
# sigmasq: variance of serially correlated component  
#  phi: scale parameter of Matern correlation function 
# kappa: shape parameter of Matern correlation function (defaults to exponential) 
# 
# Result 
# List containing simulated realisation for each subject 
# 
 result<-as.list(1:ns) 
 for (i in 1:ns) { 
  mean.vector<-mu(tlist[[i]],theta) 
  var.matrix<-vmat(tlist[[i]],nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa) 
  result[[i]]<-rmvnorm(1,mean.vector,var.matrix) 
  } 
 result 
 } 
# 
 
##code to generate realizations in Figure 72 
 
theta<-c((66.02327 + 25.18973), (-0.26051+-0.72041)) 
nusqA<- 16.33969^2 
nusqB<- 0 
rhoAB<- 0 
tausq<- 0.1664673*15.57728^2 
sigmasq<- (1-0.1664673)*15.57728^2 
phi<- 5.9045003 
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kappa<-0.5 
 
ns<-4 
 
samp <- sample(d$id,ns) 
sampd <- subset(d, d$id %in% samp) 
ids <- unique(sampd$id) 
tlist<-as.list(1:ns) 
for (i in 1:ns)  
{ tlist[[i]] <- sampd$age[sampd$id==ids[i]] } 
 
x<-simulate.unbalanced(ns,tlist,theta,nusqA,nusqB,rhoAB,tausq,sigmasq,phi,kappa=0.5) 
 
par(mfrow=c(1,2)) 
 
plot(tlist[[1]],x[[1]],type="l", ylim=c(0,120),xlab="Age",main="MODEL",ylab="% Predicted FEV1") 
for (i in 2:ns)  
 lines(tlist[[i]],x[[i]],col=i) 
  
plot(sampd$age[sampd$id == ids[1]],sampd$fev1[sampd$id == ids[1]], type="l", ylim=c(0,120),xlab="Age",main="REAL 
DATA",ylab="% Predicted FEV1") 
for (i in 2:ns)  
 lines(sampd$age[sampd$id == ids[i]],sampd$fev1[sampd$id == ids[i]],col=i) 
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The eff ect of social deprivation on clinical outcomes and the 
use of treatments in the UK cystic fi brosis population: 
a longitudinal study
David C Taylor-Robinson, Rosalind L Smyth, Peter J Diggle, Margaret Whitehead
Summary
Background Poorer socioeconomic circumstances have been linked with worse outcomes in cystic fi brosis. 
We assessed whether a relation exists between social deprivation and individual’s clinical and health-care outcomes. 
Methods We did a longitudinal registry study of the UK cystic fi brosis population younger than 40 years (8055 people 
with 49 337 observations for weight, the most commonly collected outcome, between Jan 1, 1996, and Dec 31, 2009). We 
assessed data for weight, height, body-mass index, percent predicted forced expiratory volume in 1 s (%FEV1), risk of 
Pseudomonas aeruginosa colonisation, and the use of major cystic fi brosis treatment modalities. We used mixed eﬀ ects 
models to assess the association between small-area deprivation and clinical and health-care outcomes, adjusting for 
clinically important covariates. We give continuous outcomes as mean diﬀ erences, and binary outcomes as odds ratios, 
comparing extremes of deprivation quintile.
Findings Compared with the least deprived areas, children from the most deprived areas weighed less (standard 
deviation [SD] score –0·28, 95% CI –0·38 to –0·18), were shorter (–0·31, –0·40 to –0·21, and had a lower body-
mass index (–0·13, –0·22 to –0·04), were more likely to have chronic P aeruginosa infection (odds ratio 1·89, 
95% CI 1·34 to 2·66), and have a lower %FEV1 (–4·12 percentage points, 95% CI –5·01 to –3·19). These inequalities 
were apparent very early in life and did not widen thereafter. On a population level, after adjustment for disease 
severity, children in the most deprived quintile were more likely to receive intravenous antibiotics (odds ratio 2·52, 
95% CI 1·92 to 3·17) and nutritional treatments (1·78, 1·44 to 2·20) compared with individuals in the least 
deprived quintile. Patients from the most disadvantaged areas were less likely to receive DNase or inhaled 
antibiotic treatment.
Interpretation In the UK, children with cystic fi brosis from more disadvantaged areas have worse growth and lung 
function compared with children from more aﬄ  uent areas, but these inequalities do not widen with advancing age. 
Clinicians consider deprivation status, as well as disease status, when making decisions about treatments, and this 
might mitigate some eﬀ ects of social disadvantage.
Funding Medical Research Council (UK).
Introduction
Cystic fi brosis is the most common life-limiting 
inherited disease in white populations, with most 
patients dying prematurely from respiratory failure. 
Children with cystic fi brosis in the UK and in other 
high-income countries are usually diagnosed in the fi rst 
year of their life,1 and subsequently need intensive 
support from family and health-care services.
Cystic fi brosis is of particular interest in the study of 
health inequalities, because it is a genetic disease and 
there is no social gradient in incidence of the disorder—it 
aﬀ ects all socioeconomic groups equally (appendix). 
Inequalities can develop, however, in the outcomes 
experienced by people with the disease. People with cystic 
fi brosis from socioeconomically disadvantaged back-
grounds, for example, die younger than do those in more 
advantaged social positions in the UK and the USA.2–5 
Between 1986 to 1994, the adjusted risk of death was 
3·65 times higher in patients with cystic fi brosis in the 
USA with Medicaid cover (taken as an indicator of poverty) 
than it was in those without Medicaid cover.2 In England 
and Wales, between 1959 and 2008, Barr and Fogarty 
recorded an increased risk of dying later, at an age above 
the median of all deaths due to cystic fi brosis, in more 
advantaged social classes, a pattern that has persisted for 
more than four decades.5 As with other chronic diseases, 
this social patterning of survival in cystic fi brosis implies 
that social and environmental factors aﬀ ect outcomes.6,7 
Inequalities in access to specialist health care might also 
be important, because in many health-care systems 
provision and use of services decreases with patients’ 
income,8,9 the so-called inverse care law.10
To gain a better understanding of when and how 
inequalities in outcomes develop in cystic fi brosis, we 
undertook a longitudinal registry study to explore the 
eﬀ ect of deprivation on growth, nutrition, lung function, 
risk of Pseudomonas aeruginosa colonisation, and the use 
of major cystic fi brosis treatment modalities in a UK-
wide population cohort, in the context of a universal 
health-care system, free at the point of use.
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Methods
Study design and data sources
We undertook a longitudinal retrospective cohort study of 
individuals in the UK cystic fi brosis registry who were 
younger than 40 years at last follow-up, with at least one 
outcome measurement and a valid postcode between 
Jan 1, 1996, and Dec 31, 2009. The UK cystic fi brosis 
registry is supported and coordinated by the UK Cystic 
Fibrosis Trust.11,12 The UK cystic fi brosis registry is 
maintained to a high standard of data quality, and is 
estimated to include nearly all people thought to have 
cystic fi brosis in the UK population13 and is therefore 
ideally suited to the study of outcomes and treatments 
across the whole socioeconomic spectrum in the UK 
(appendix).
NHS research ethics approval (Huntingdon Research 
Ethics Committee 07/Q0104/2) was granted for the 
collection of data into the UK database. The Cystic 
Fibrosis Trust database committee approved the use of 
anonymised data in this study.
Primary outcome and covariates
The primary clinical outcomes were weight, height, 
body-mass index (BMI), percent predicted forced expiratory 
volume in 1 s (%FEV1), and prevalence of P aeruginosa 
colonisation. Anthropometric values were converted into 
standard deviation [SD] scores using the UK reference 
population.14 The primary health-care outcomes were use 
of treatments in the previous year (yes or no): intravenous 
antibiotics, supplemental nutritional support, DNase, or 
inhaled antibiotic treat ment. Conditional on the use of 
intravenous treatment, we also used the log total number 
of days on intravenous treatment as a secondary outcome.
The primary exposure measure was a small-area-
based measure of deprivation of area of residence. 
Postcodes were used to derive Index of Multiple 
Deprivation scores for the constituent UK countries15 
and each person was allocated to a deprivation score on 
the basis of the fi rst recorded postcode on entry to the 
dataset. Other baseline covariates in the analysis were: 
sex, genotype coded as the number of delta F508 alleles 
(0, 1, or 2), year of birth, screening status (diagnosis by 
neonatal screening or otherwise), and ethnic origin 
(white or other). Time-varying covariates were age, 
presence of cystic fi brosis related diabetes (CFRD), and 
presence of pancreatic insuﬃ  ciency (ie, whether or not 
an individual used pancreatic enzyme supplementation). 
In our health-care use analyses, we adjusted for disease 
severity on the basis of current %FEV1, P aeruginosa 
status, and BMI SD score.
Statistical analysis
Full details are provided in the supplementary appendix. 
Briefl y, we fi tted separate longitudinal models in the 
paediatric (<18 years) and adult (18–40 years) age ranges. 
We then approximated time-trends using linear func tions 
(eg, for %FEV1), piecewise or broken-stick functions 
(weight, BMI), or quadratics (eg, any intravenous treat-
ment), as appropriate. For instance, population 
weight SD score increased to about age 3 years, and then 
decreased subsequently (appendix). The modelling ap-
proach involved fi rst fi tting a model adjusted for age and 
the baseline covariates defi ned above, and then testing for 
the signifi cance of adding deprivation. Finally, the time-
varying covariates were added to the model, to assess 
whether the deprivation coeﬃ  cient was modifi ed. We 
1 (least 
deprived)
2 3 4 5 (most 
deprived)
All p value
Number of patients 1537 (19%) 1563 (19%) 1591 (20%) 1736 (22%) 1628 (20%) 8055 0·0018 
Observations (for weight SD score) 9500 (19%) 9706 (20%) 9708 (20%) 10 550 (21%) 9873 (20%) 49 337 <0·0001
Female sex 712 (46%) 726 (46%) 728 (46%) 825 (48%) 773 (48%) 3764 (47%) 0·38
Age in days at diagnosis (IQR) 121 (30–731) 121 (30–670) 113 (30–730) 109 (30–728) 120 (30–730) 120 (30–730) 0·39
Number of delta F508 alleles
2 824 (54%) 827 (53%) 822 (52%) 907 (52%) 779 (48%) 4159 (52%) 0·0022
1 543 (35%) 556 (36%) 560 (35%) 609 (35%) 594 (37%) 2862 (36%) 0·63
0 170 (11%) 180 (12%) 209 (13%) 220 (13%) 255 (16%) 1034 (13%) <0·0001 
Non-white 31 (2%) 31 (2%) 52 (3%) 73 (4%) 120 (7%) 307 (4%) <0·0001
Screened 233 (15%) 272 (17%) 245 (15%) 282 (16%) 277 (17%) 1309 (16%) 0·39
Birth cohort 
1957 to 1966 62 (4%) 49 (3%) 64 (4%) 51 (3%) 35 (2%) 261 (3%) <0·0045
1967 to 1976 157 (10%) 172 (11%) 182 (11%) 171 (10%) 153 (9%) 835 (10%) 0·23
1977 to 1986 329 (21%) 384 (25%) 369 (23%) 426 (25%) 396 (24%) 1904 (24%) 0·09
1987 to 1996 496 (32%) 478 (31%) 489 (31%) 535 (31%) 530 (33%) 2528 (31%) 0·82
1997 to 2006 396 (26%) 393 (25%) 396 (25%) 427 (25%) 410 (25%) 2022 (25%) 0·62
2007 to <2010 97 (6%) 87 (6%) 91 (6%) 126 (7%) 104 (6%) 505 (6%) 0·32
Data are n (%) unless otherwise stated. 
Table 1: Unadjusted characteristics of study population by deprivation quintile (UK cystic fi brosis registry 1996 to 2009)
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estimated all model parameters by maximum likelihood, 
using linear or generalised linear mixed eﬀ ects models.16 
We used generalised likelihood ratio statistics to compare 
nested models, and Wald statistics to test hypotheses about 
model parameters. We used R (version 2.9.2) for all 
statistical analyses.
Role of the funding source
The study sponsor had no role in the design, collection, 
analysis, or interpretation of the data, in the writing of 
the report, or in the decision to submit the article for 
publication. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
The fi nal dataset for weight SD scores, the most 
commonly collected outcome, contained information 
collected at 49 337 annual reviews for 8055 patients 
between Jan 1, 1996 and Dec 31, 2009, in the UK (table 1 
and appendix). 5324 (66%) individuals had fi ve or more 
follow-up measures (appendix), with a total of 
48 425 person-years of follow-up. We recorded no relation 
between sex ratios, birth cohort, neonatal screening and 
deprivation status (table 1), or number of incident cases, 
and age at diagnosis and deprivation status (appendix). 
We recorded a slight trend towards fewer heterozygote 
delta F508 carriers (p=0·0022), more people with no delta 
F508 genes (p<0·0001), and a greater proportion of non-
white patients with increasing level of deprivation 
(p<0·0001). Compared with the UK reference population, 
the population of patients with cystic fi brosis weighed 
less (SD score –0·37, 95% CI –0·43 to –0·35 [35th centile]), 
were shorter (–0·50, –0·53 to –0·47 [30th centile]), and 
had a lower BMI (–0·08, –0·11 to –0·06 [46th centile]; in 
models ignoring time trends).
Weight SD scores increased from diagnosis up to about 
the age of 3 years, decreasing thereafter (appendix). After 
adjustment for baseline factors, at diagnosis, the weight 
of children in the most deprived quintile was lower than 
that of children in the least deprived quintile (weight SD 
score –0·54, 95% CI –0·73 to –0·34). The deprivation gap 
diminished with increasing age up to age 3 years, and 
from then on remained constant (table 2 and appendix). 
A higher weight SD score was associated with male sex, 
screened patients, heterozygotes for delta F508, and 
white patients (appendix). In adults, adjusted weight-for-
age was lower in more deprived groups (table 2).
The average height of individuals in the most deprived 
quintile compared with the least deprived quintile was 
also about a third of an SD score shorter in the adjusted 
analysis, a diﬀ erence that remained constant across all 
ages (table 2 and appendix). In patients younger than 
18 years, a bigger height SD score was statistically 
signifi cantly associated with male sex and screened 
patients, and statistically signifi cantly increased in white 
patients with age (appendix).
We modelled BMI SD score much like we modelled 
weight SD score, with a split-line at age 3 years. In the 
paediatric age range, there was a deprivation gap (with 
lower scores in the most derived groups) of –0·13 
(–0·22 to –0·04; table 2). Higher BMI was associated with 
male sex in the paediatric age range (individuals ages 
0–18 years), and had a steeper rate of decline in delta F508 
homozygotes after the age of 3 years (appendix). In the 
adult age range, we recorded no association between BMI 
SD score and deprivation status (–0·12, –0·25 to 0·01; 
fi gure 1 and table 2).
Addition of the time-varying covariates did not 
substantially alter the deprivation eﬀ ects for growth 
outcomes, and the esti mates were consistent with a 
monotonic dose-response relation between deprivation 
and both weight and height.
In the fi nal model for %FEV1, we detected a diﬀ erence 
of –4·1 percentage points (–5·0 to –3·1) when comparing 
children (<18 years) in the most deprived quintile with 
those in the least deprived quintile (a diﬀ erence that was 
apparent from as soon as %FEV1 can be measured at about 
5 years of age), but there was no evidence of an increased 
rate of decline in children from more deprived quintiles. 
Higher %FEV1 was associated with male sex, screened 
patients, heterozygote delta F508 status, white patients, no 
CFRD, no P aeruginosa colonisation, and higher BMI 
(fi gure 2 and appendix). Further adjustment for 
Burkholderia cenocepacia status and care centre did not 
change the deprivation eﬀ ect on %FEV1 (appendix). The 
addition of BMI SD score to the model reduced the %FEV1 
deprivation gap to –3·5 percentage points (–5·2 to –1·8). 
There was no statistically signifi cant asso ciation between 
%FEV1 and social deprivation in the adult age range 
(table 2). The cross-sectional proportion of people with 
chronic P aeruginosa infection increased steadily with age 
Patients younger than 
18 years
Patients aged 
18 years to <40 years
Clinical outcomes*
FEV1 (percentage points [95% CI]) –4·12 (–5·01 to –3·19) –1·6 (–4·41 to 1·25)
Weight-for-age (SD score [95% CI]) –0·28 (–0·38 to –0·18) –0·31 (–0·46 to –0·16)
Height-for-age (SD score [95% CI]) –0·31 (–0·40 to –0·21) –0·31 (–0·43 to –0·19)
BMI-for-age (SD score [95% CI]) –0·13 (–0·22 to –0·04) –0·12 (–0·25 to 0·01)
Pseudomonas aeruginosa colonisation (OR [95% CI]) 1·89 (1·34 to 2·66) 1·78 (1·26 to 2·51)
Treatments
Any intravenous treatment (OR [95% CI])† 2·52 (1·92 to 3·17) 1·89 (1·51 to 2·38)
Total intravenous days per year (% change [95% CI])† 15·9 (8·2 to 24) 10·6 (2·5 to 19·2)
Supplemental feeding (OR [95% CI])‡ 1·78 (1·42 to 2·2) 2·38 (1·69 to 3·36)
DNase treatment (OR [95% CI])† 0·40 (0·21 to 0·72) 0·37 (0·26 to 0·52)
Use of inhaled antibiotics (OR [95% CI])† 0·66 (0·47 to 0·93) 0·40 (0·31 to 0·5)
All estimates compare the most deprived quintile to the least deprived (reference) quintile. *The outcomes are from 
separate longitudinal models adjusted for time trends, sex, genotype, screening status, and ethnic origin. †Adjusted for 
time trends, sex, genotype, screening status, (FEV1), and Pseudomonas aeruginosa colonisation status. ‡Adjusted for time 
trends, sex, genotype, screening status, and body mass index (BMI) SD score. 
Table 2: Summary of adjusted eff ects of deprivation on clinical outcomes and use of treatments in 
patients with cystic fi brosis in the UK
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to about 60% by the age of 20 years, and was more common 
in the most deprived quintile, with an odds ratio (OR) of 
1·9 (95% CI 1·3 to 2·7) in the adjusted paediatric analysis 
for the most deprived quintile (table 2 and fi gure 2). An 
increased likelihood of P aeruginosa colonisation was 
associated with female sex, homozygote delta F508 status, 
CFRD, pancreatic in suﬃ  ciency, and lower %FEV1, but 
adjustment for these factors did not substantially alter the 
deprivation eﬀ ect (data not shown). The estimates were 
consistent with a monotonic dose-response relation 
between deprivation and %FEV1 (appendix) and risk of 
P aeruginosa colonisation (data not shown).
The use of any intravenous treatment, after adjustment 
for disease severity, was more than twice as common in 
the most deprived children cohort compared with the least 
deprived children cohort (table 2), and this deprivation 
diﬀ erence was also present in adults (table 2 and fi gure 3). 
Further adjustment for care centre did not change this 
eﬀ ect. Conditional on receipt of intra venous treatment, 
and after adjustment for disease severity, people in the 
most deprived quintile had more days of intravenous 
treatment in both the paediatric and adult age range 
(table 2). We analysed the receipt of hospital and at-home 
intravenous treatment separately and noted that the higher 
prevalence of any intravenous treatment seen in the most 
deprived quintile was almost entirely due to delivery of 
such treatment in hospital rather than home (fi gure 3). For 
intravenous treatment at home, the association with social 
deprivation was much less strong, and, in the cross-
sectional analysis, at-home intravenous treatment was 
more common in the least deprived quintile compared 
with the most deprived quintile in patients between the 
ages of 10 years and 27 years (fi gure 3). Prevalence of any 
supplemental feeding therapy in the previous year was 
more common in the most deprived quintile, compared to 
the least, across the entire age range from age 0 years to 
age 40 years (OR 1·78, 95% CI 1·42 to 2·2, adjusted for 
baseline variables, P aeruginosa infection status, and BMI, 
in the 5–18 age group, fi gure 3).
We detected no statistically signifi cant association 
between DNase use and deprivation in the paediatric age 
range before we adjusted for disease severity. After ad-
justment for disease severity, treatment was less likely in 
the most deprived quintile, in both children and adults, 
although the association with deprivation was stronger in 
adults. We saw a similar pattern for inhaled antibiotic 
treat ment (table 2 and fi gure 3). The estimates were con-
sist ent with a monotonic dose-response relation between 
socioeconomic status and treatment outcomes (appendix).
Discussion
Our fi ndings show that children with cystic fi brosis from 
the most disadvantaged areas in the UK have lower weight, 
height, and BMI in the fi rst years of life after diagnosis, are 
more likely to have chronic P aeruginosa infection, and 
have a lower %FEV1 than do children in the least 
disadvantaged areas. These social inequalities persist into 
adulthood but do not widen.
Our fi ndings suggest evidence of positive discrim-
ination, or so-called pro-poor bias, in the provision of some 
key treatments, on the basis of socioeconomic circum-
stances. We show that in the NHS, compared with children 
with cystic fi brosis in the least dis advantaged areas, 
children with cystic fi brosis from the most disadvantaged 
areas are about twice as likely, after adjustment for disease 
severity, to receive intravenous antibiotics (specifi cally in 
hospital) and nutritional support. Our fi ndings also show 
some apparent bias in favour of wealthier populations, a 
so-called pro-rich bias, in two other treatments, DNase and 
inhaled antibiotics, with patients from the most aﬄ  uent 
areas being more likely to receive these treatments after 
adjustment for disease severity.
Key strengths of this study include the population-wide 
coverage of the UK cystic fi brosis registry, the high quality 
of the data, and the longitudinal analysis. However, our 
study does have limitations. First, it relies on 
−1·5
−1·0
−0·5
0·0
0·5
W
ei
gh
t S
D 
sc
or
e
−1·5
−1·0
−0·5
0·0
0·5
He
ig
ht
 S
D 
sc
or
e
0 10 20 30 40
−1·5
−1·0
−0·5
0·0
0·5
Age (years)
BM
I S
D 
sc
or
e
A   Weight
B   Height
C   BMI
Least-deprived quintile
Most-deprived quintile
Figure 1: Comparison of anthropometric outcomes, by age and socioeconomic status
Mean cross-sectional (A) weight, (B) height, and (C) body-mass index (BMI).
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retrospective, routinely collected data and we used a 
standard measure of deprivation of area of residence. 
Each small area contains about 1500 people, and, in this 
respect, the Index of Multiple Deprivation scores allowed 
much fi ner resolution than US analyses3,17,18 that have 
used ZIP-code-linked income data, because every ZIP 
code contains about 30 000 people (panel).19 There is 
always the possibility of ecological fallacy (whereby 
inferences made at the group level do not apply to the 
individual), but this possibility is unlikely in view of the 
fact that similar associations have been seen in the US 
studies that use both area and individual measures of 
socioeconomic status.3,17,18 Second, we had valid postcodes 
for only 90% of the sample, although our sample size 
was large, with no pronounced gradient in the proportion 
of patients by deprivation quintile. The excluded 
population—those with no valid postcode—were largely 
older birth cohorts, owing to the improved collection of 
postcodes by clinical staﬀ  over time, but we do not believe 
that this has biased the associations detected in our 
analysis (appendix). Third, there is a strong cohort eﬀ ect 
in cystic fi brosis and, with datasets of this type, age and 
cohort eﬀ ects confound one another, and cannot be 
completely separated.20 We have adjusted for both in our 
analysis, to estimate the adjusted eﬀ ect on deprivation.
Overall, the UK cystic fi brosis population is under-
weight and shorter compared with the UK reference 
population, by about a third of an SD score. Deprivation 
roughly doubles this eﬀ ect, lowering the SD score by 
another third. How much of the eﬀ ect of socioeconomic 
status on growth outcomes is specifi c to cystic fi brosis, 
and how much is attributable to socioeconomic status 
eﬀ ects in the general population is unclear. Comparable 
data in contemporary representative cohorts in the UK is 
absent, but the age-related changes in growth in the 
general population are characterised by increasing 
obesity in childhood from the age of 4 years onwards, 
with higher BMI in the more deprived populations,21,22 
fi ndings which contrast with the patterns seen in our 
study. The projected weight diﬀ erence at intercept in our 
study (–0·54) by socioeconomic status is also larger than 
those in other recent studies,23,24 but direct comparison 
between these studies and ours is complicated by the use 
of diﬀ erent socioeconomic status measures. We speculate 
that having cystic fi brosis is likely to amplify the eﬀ ects 
of socioeconomic status on nutritional status at birth and 
in the fi rst few years of an individual’s life.
The inequality in weight is greatest at around the time 
of diagnosis, and becomes narrower over the fi rst 
3 years of life. This is an important fi nding, because a 
widening of inequalities over time is often the norm.7,25,26 
These fi ndings suggest that extending the period of 
diﬀ erential weight gain for as long as possible might 
reduce in equalities, further lending support to neonatal 
screening programmes to enable early diagnosis and 
treatment.27 We speculate that by extending this period 
of catch-up for as long as possible by early diagnosis (ie, 
screening) we might see an attenuation of the 
deprivation eﬀ ect over time. In this study, we detected 
no diﬀ erence in the age at diagnosis by deprivation, but 
screening was associated with increased weight and 
height and improved lung function in children. 
Furthermore, our fi nding that the prevalence of 
supplemental feeding treatment was higher, after 
adjusting for disease severity, in the most disadvantaged 
patients suggests that NHS professionals are actively 
engaged in trying to boost the nutrition of poorer 
patients, recognising their health disadvantage.
Figure 2: Comparison of respiratory outcomes, by age and socioeconomic status
Mean cross-sectional (A) FEV1 and (B) Pseudomonas aeruginosa colonisation prevalence. 
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The socioeconomic gradient in lung function, evident 
as soon as it can be routinely measured at the age of 
5 years, points to the crucial role of environmental and 
health-care factors operating in the early years of life to 
produce inequalities. It further reinforces the need for 
early diagnosis and action to prevent adverse con-
sequences for children with cystic fi brosis living in 
disadvantaged circumstances. In Schechter and col-
leagues’ cross-sectional study of US data,2 inequalities in 
%FEV1 by Medicaid status widened slightly from age 
5 years to age 20 years. The magnitude of the inequalities 
in lung function at the age of 5 years seen in Schechter’s 
study was larger (about a 9% diﬀ erence) than in our UK 
study (4%), as was the magnitude of inequalities in lung 
function seen in O’Connor and colleagues’ US study,3 
which showed a diﬀ erence of 5·5% between the most 
and least deprived quintiles. Methodological diﬀ erences 
between the studies, however, make a direct comparison 
between these UK and US fi ndings inappropriate. This 
study is the fi rst to examine the relation between 
deprivation and %FEV1 in a population-level, adult 
cohort. We did not detect an association, despite the 
higher prevalence of P aeruginosa. We speculate that this 
fi nding might relate to the complication of progressive 
drop-out in older patients, and the insensitivity of %FEV1 
as an outcome measure in adults.20
The increased prevalence of chronic P aeruginosa 
infection in patients from more deprived areas, after 
adjusting for %FEV1, is a new fi nding in a population-level 
cohort. In Schechter and colleagues’ study,2 Medicaid-
insured patients were more likely to have P aeruginosa 
infection than were patients who were not eligible for 
Medicaid insurance, but when adjusted for %FEV1 there 
was no statistically signifi cant diﬀ erence—another US 
cohort study did not detect an association either.28 
Previously identifi ed risk factors for P aeruginosa 
acquisition, which is associated with worse lung func tion, 
include female sex and genotype (both associations shown 
in this study), and exposure to other patients with 
P aeruginosa colonisation.29 Our fi nding that more deprived 
Figure 3: Comparison of treatment methods, by age and socioeconomic status
Proportion of patients who received (A) any intravenous antibiotic treatment, (B) home intravenous antibiotic treatment, (C) hospital intravenous antibiotic 
treatment, (D) supplemental feeding, (E) DNase, and (F) inhaled antibiotics.
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groups are more likely to receive intravenous treatment in 
hospital might result in more deprived patients having 
greater exposure to other patients with chronic 
P aeruginosa, therefore increasing their risk of infection.
We saw substantial socioeconomic diﬀ erences in the 
reported use of key cystic fi brosis treatments in two 
contrasting ways. First, children from the most deprived 
quintile were about twice as likely to receive hospital 
intravenous antibiotic treatment and nutritional support, 
after adjustment for disease severity, compared with those 
from the least deprived quintile. We can speculate, from 
our knowledge of UK cystic fi brosis services, that clinicians 
in the NHS are more likely to bring children from more 
deprived areas into hospital for intravenous treatment 
because of concerns about the diﬃ  culties in delivering 
treatments in their homes. Conversely, children living in 
more aﬄ  uent areas might receive intravenous treatment 
at home because of judgments about the adequacy of 
support and adherence to treatment in their home or 
because of their families’ wish to avoid disruption to 
schooling and family life. This equitable model of care, 
with positive discrimination for socially disadvantaged 
children and adults with cystic fi brosis, is an uncommon 
fi nding in health systems, when access, particularly to 
secondary care for adults, often decreases with increasing 
deprivation, after ad justing for diﬀ erential need.8,30 While 
several studies have seen use of health services by level of 
deprivation to be more equal in relation to children than 
adults,31 we have detected evidence in children with cystic 
fi brosis that goes even further with a pro-poor bias in the 
NHS for specifi c treatments. Coupled with our fi ndings of 
inequalities in outcomes by deprivation, which do not 
widen over time, we speculate that the treatment decisions 
being made by clinicians might mitigate some eﬀ ects of 
social dis advantage. This provides encourage ment that 
there are interventions that health services can make to 
reduce the adverse eﬀ ects of deprivation on chronic 
disorders such as cystic fi brosis. In the USA, with use of 
ZIP-code-linked income of an area as the socio economic 
indicator, there was no gradient in intravenous treatment 
use in children younger than 12 years, but in young people 
aged 13–18 years, those living in more aﬄ  uent areas were 
more likely to be treated (13·8% in the lowest income 
category compared with 19·2% in the highest).18
Our second, and contrasting, set of fi ndings on cystic 
fi brosis treatments, however, point to an apparent pro-
rich bias in two other treatments, which were more 
evident in adults than in children: more aﬄ  uent adults 
in the UK were more likely to receive DNase and inhaled 
antibiotics than were their more disadvantaged counter-
parts. DNase is an expensive treatment to reduce viscosity 
of sputum and to aid sputum expectoration, and some 
evidence exists that it prevents decrease in %FEV1.32 
These treatments, although expensive, are free of charge 
to all patients in the NHS. One possibility for the social 
disparity in access to them is that they are both home-
based treatments, requiring regular and long-term 
administration. Socially disadvantaged patients with 
cystic fi brosis are less likely to adhere to treatments,29 and 
if they report poor adherence, clinicians might be less 
likely to prescribe these drugs because they are unlikely 
to be as eﬀ ective if taken inconsistently. Evidence from 
the USA shows no diﬀ erence in use of DNase in children 
by area income quintile, but Medicaid-insured children 
(ie, those receiving free or subsidised care) were more 
likely to receive DNase than were children who were not 
eligible for Medicaid insurance.17
Further research is needed to clarify which elements 
of the cystic fi brosis care model might contribute to a 
reduction in the adverse outcomes associated with 
deprivation. A cause for concern is the fact that the most 
disadvantaged families have a higher burden of treatment, 
in terms of time spent in hospital, which increases 
disruption to school and family life. Furthermore, the link 
with P aeruginosa colonisation requires further 
investigation. Higher socioeconomic status, as measured 
by parental education status, is associated with improved 
adherence to treatment in cystic fi brosis,29 and further 
research is needed to investigate the processes that lead to 
these diﬀ erences. Systems to support the provision of 
intra venous treatment at home for more deprived groups 
in the UK should be explored.
Diﬀ erences in access to health care cannot explain the 
diﬀ erences in weight and height, by socioeconomic 
status, that are evident at the time of diagnosis, and are 
Panel: Research in context
Systematic review
We searched PubMed with the terms “(cystic fi brosis) and (inequality OR equity OR inequity 
OR socioeconomic OR disadvantage OR vulnerable OR poverty OR social class OR disparity)” 
to identify relevant studies on the eff ect of socioeconomic status on outcomes and 
treatment in people with cystic fi brosis. We applied no date or language restrictions. We 
identifi ed a review that summarises all studies,29 much of which were done in the USA, where 
the health-care system is diff erent to that in the UK. People with cystic fi brosis from 
socioeconomically disadvantaged backgrounds die younger than do those in more 
advantaged social positions in the UK5 and the USA.2 The key challenge is to understand how 
and when these inequalities develop, and to understand how the health-care system in the 
UK can mitigate or perpetuate these eff ects to identify promising options for intervention.
Interpretation
This study has identifi ed important longitudinal diff erences in weight, height, body-mass 
index, forced expiratory volume in 1 s, and risk of Pseudomonas aeruginosa colonisation by 
deprivation in people with cystic fi brosis in the UK, which start early in life, but do not 
increase over time. We detected socioeconomic diff erences in the reported use of key 
treatments in the UK. People from more deprived areas are about twice as likely to receive 
in-hospital intravenous antibiotic treatment and nutritional support, but less likely to 
receive DNase and inhaled antibiotics. Interventions to reduce inequalities in outcomes in 
cystic fi brosis need to be focused in the antenatal period and the early years of life. Such 
interventions include smoking prevention and public health initiatives to address 
inequalities in maternal and child health. Further research is needed to clarify which 
elements of the cystic fi brosis care model in the UK might contribute to a reduction in the 
adverse outcomes associated with deprivation, and to investigate identifi ed diff erences in 
access to inhaled treatments.
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unlikely to explain the gradient in lung function evident 
at around the age of 5 years. The UK cystic fi brosis 
registry does not capture data about smoking in the home 
and these early eﬀ ects might be associated with the 
known diﬀ erences in smoking prevalence by socio-
economic status in the UK.33 The eﬀ ect of socioeconomic 
status on growth in utero and in the early years of life in 
people with cystic fi brosis, might be mediated, at least in 
part, by maternal smoking, thus aﬀ ecting subsequent 
outcomes and ultimately survival.
Future studies should focus on the assessment of 
interventions, such as the reduction of exposure to 
environmental tobacco smoke,34 which might mitigate the 
eﬀ ects of deprivation during the critical early years of life, 
and on the identifi cation of aspects of health-care provision 
in cystic fi brosis that would help overcome the extra burden 
of adverse consequences of cystic fi brosis faced by patients 
living in economically-disadvantaged circumstances.
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Abstract
Background: People with Cystic Fibrosis (CF) in the UK and elsewhere are increasingly surviving into adulthood, yet there is
little research on the employment consequences of having CF. We investigated, for the first time in a UK-wide cohort,
longitudinal employment status, and its association with deprivation, disease severity, and time in hospital.
Methods: We did a longitudinal registry study of adults with CF in the UK aged 20 to 40 (3458 people with 15,572
observations between 1996 and 2010), using mixed effects models.
Results: Around 50% of adults with CF were in employment. Male sex, higher lung function and body mass index, and less
time in hospital were associated with improved employment chances. All other things being equal, being in the most
deprived quintile was associated with a reduction of employment prevalence of 17.6 percentage points compared to the
prevalence in the least deprived quintile. Having poor lung function was associated with a reduced employment prevalence
of 7.2 percentage points compared to the prevalence for people with relatively good lung function. Acting synergistically,
deprivation modifies the effect of lung function on employment chances – poor lung function in the least deprived group
was associated with a 3 percentage point reduction in employment chances, while poor lung function in the most deprived
quintile was associated with a 7.7 point reduction in employment chances.
Conclusions: Greater deprivation, disease severity, and time in hospital are all associated with employment chances in
adults with CF. Furthermore, our analysis suggests that deprivation amplifies the harmful association of disease severity on
employment. Future studies should focus on understanding and mitigating the barriers to employment faced by people
with CF.
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Introduction
Cystic fibrosis (CF) is the commonest life-limiting inherited
disease among Caucasian populations, with most patients dying
prematurely from respiratory failure. Children with CF in the UK
and other high-income countries are usually diagnosed in the first
year of life [1], and subsequently require intensive support from
family and healthcare services. People with CF in the UK and
elsewhere are increasingly surviving into adulthood, with the
median age of survival estimated to be over fifty years for a person
born in this century [2]. One implication of this improved survival,
is that increasing attention needs to be paid to the experiences of
people with CF when they reach adulthood and enter employ-
ment.
Employment is one of the ‘‘social determinants’’ of health [3].
Work influences health in a number of ways; it provides income to
meet material needs, but also fulfils critical psycho-social functions,
increasing self-worth, sense of identity and opportunities for social
interaction. Numerous studies have identified unemployment as a
potent risk factor for poor health, and equally, poor health can
lead to reduced employment chances [4,5]. People with chronic
illnesses face numerous barriers to entering the labour market, and
CF provides a case in point. Factors related to disease severity,
such as reduced lung function may restrict employment choices for
adults with CF, and the treatment burden further compounds this:
adults with CF are generally expected to perform physiotherapy
regularly and there are the added demands of taking large
numbers of therapies, including frequent visits to hospital [6].
Despite these potential challenges, the evidence about patterns
of employment for adults with CF is limited [7], and mainly based
on cross-sectional studies of single centres, which cannot delineate
the relationships between chronic illness and employment
outcomes or whether these relationships indicate causality.
Furthermore, Edwards et al [8], adopting the social model of
disability, have criticised the approach taken to understanding
employment outcomes in CF. They point out that most of the
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research, to date, has been restricted to the effects of disease
severity on employment chances, ignoring the significant structural
and societal barriers to employment for people with chronic
illness.
Exploring inequalities by socio-economic status (SES) in
employment outcomes in people with CF is a key step in
understanding how health and social inequalities are generated
and perpetuated. Because CF is a classically inherited genetic
disease, unlike most chronic diseases, there is no difference in the
incidence of the condition with socioeconomic status [9,10].
However, inequalities develop over the course of people’s lives, as
a consequence of having the disease. Informed by Diderichsen’s
analytic framework of the pathways from social context to health
outcomes [11], we have demonstrated that in the UK CF
population there are clinically important differences in growth,
and lung function by deprivation, which are evident early on in
children’s lives [9,10]. Furthermore, people with CF from socio-
economically disadvantaged backgrounds die at a younger age
than those in more advantaged social positions in the UK and the
US [12–15]. The social patterning of outcomes in cystic fibrosis
implies that the mechanism of differential exposure to social and
environmental risk factors is playing an important role in
influencing outcomes [3,11,16].
Building on these findings, the next step is to look for any
‘‘differential social consequences’’ of ill-health in the context of CF
[11]. Our aims in this study were to explore the association of
prior deprivation, disease severity, and time in hospital on
longitudinal employment chances in people with CF and to
investigate whether changes in lung function have differential
effects on employment chances by deprivation (‘differential social
consequences’ in Diderichsen’s model). For instance, is poor lung
function in CF more damaging to employment chances in people
from more disadvantaged areas? We undertook a longitudinal
population level registry study of employment status in adults with
CF in the UK to address this question.
Methods
Ethics statement
NHS research ethics approval (Huntingdon Research Ethics
Committee 07/Q0104/2) has been granted for the collection of
data into the UK database. Each patient provided written
informed consent for collection of data in the registry, and for
use of anonymised data in research. The CF Trust database
committee approved the use of anonymised data in this study,
under the terms of the NHS ethics approval.
Design, setting and data source
We undertook a longitudinal retrospective cohort study of
annual review data on individuals between the ages of 20 and 40
with at least one outcome measurement and a valid postal code in
the UK CF Registry between 1996 and 2010. The UK CF
Registry, co-ordinated by the Cystic Fibrosis Trust [17,18], is
maintained to a high standard of data quality, and includes nearly
all people with CF in the UK population [19], with an estimated
coverage of over 99% [9], and is therefore ideally suited to the
study of prior exposures on subsequent employment outcomes
across the whole socioeconomic spectrum in the UK society.
Primary outcome and covariates
The primary longitudinal outcome was any employment
(defined as ‘‘full’’ or ‘‘part-time’’ as specified in the drop-down
menu in the UK CF registry) in the preceding year (yes or no)
recorded at annual review. The primary exposure measures were
deprivation of small-area of residence, as commonly used in
epidemiological studies in the UK [9], lung function (as measured
by forced expiratory volume in one second -%FEV1), and time in
hospital. Postcodes were used to derive Index of Multiple
Deprivation (IMD) scores for the constituent UK countries [20]
and each person was allocated to a deprivation quintile on the
basis of first recorded postcode. These indices combine economic,
social and housing indicators measured at the census into a
composite deprivation score for small areas in the UK constituent
countries. Baseline covariates in the analysis were: sex; genotype
coded as the number of delta F508 alleles (0, 1 or 2); and year of
birth. We adjusted for disease severity on the basis of degree of
impaired lung function measured by %FEV1, as this measure is
strongly predictive of survival [21], and deviation from expected
Body Mass Index (as measured by Body Mass Index standard
deviation score (BMI SD score). As a measure of time spent
administering therapies, we included the number of intravenous
(IV) therapy days in the past year in our analysis, further
disaggregated into therapy days in hospital, and therapy days at
home. We first fitted a model adjusted for age and the baseline
covariates, which are unlikely to be in the causal path from SES to
employment status. We then tested for the significance of adding
disease severity measures, and service use measures, which may be
in the causal path, and finally added deprivation score to the
model. The logic model for the analysis is shown in Figure S1.
Statistical Methods
Repeated measures on individuals are correlated, and this must
be accommodated to obtain valid inferences. For a full description
see the appendix S1. In brief, we applied advanced statistical
methods that have been specifically developed for the analysis of
longitudinal data, after Diggle et al, 2002 (24). Exploratory
statistical analysis involved: fitting generalized additive models
(GAMs) [22] to visualize the shape of associations; plotting
empirical logits; and plotting stratified raw data. We then fitted
generalised linear mixed models (GLMMs) to the data across the
age range. These procedures model the log-odds of employment
status as a linear function of the measured covariates and
individual level random-effects, and adjust the standard errors of
the regression parameters to take account of the correlation
structure of the repeated measurements. We fitted sequential
models adjusting for the covariates of interest, and estimated
model parameters by maximum likelihood, using generalized
likelihood ratio statistics to compare nested models, and Wald
statistics to test hypotheses about model parameters [23]. These
longitudinal analyses take into account drop-out due to death, and
implicitly estimate the chances of employment in a hypothetical
drop-out free population [24]. We present effect estimates as log-
odds with confidence intervals, since odds ratios can be mis-
interpreted when outcomes are common [25]. To aid interpreta-
tion, we display population-averaged employment chances in the
plots, by averaging individual-level fitted values over the popula-
tion.
Results
The final dataset contained 3,458 people, with 15,098 person-
years of follow-up, and data collected at 15,572 annual reviews.
1940 (56%) individuals had four or more follow-up measures
(median 4, interquartile range 2 to 7). The baseline characteristics
of individuals at first recorded entry into the cohort are shown in
table 1.
At any one time, about 50% of the UK CF population were
recorded as being in full or part-time employment for all ages, but
Longitudinal Study of Deprivation and Employment
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patterns differed by age, sex, and deprivation status (Figure 1).
Across the entire age range, men and women with CF from the
most deprived quintile were much less likely to be in employment
that their counterparts in the least deprived quintile (Figure 1).
Figure 2 illustrates the modelled independent population
averaged relationship between deprivation, sex, lung function,
weight and time in hospital, and employment chances for people
with CF in the UK, on the basis of the final interaction model
(table 2, column 5). There are significant age-related effects. The
general pattern was for the proportion of people in employment to
increase to around age 30, and decrease subsequently. Genotype
and use of home intravenous therapy were not associated with
employment chances in any of the analyses, and were dropped
from the final models.
Of the covariates in the model, deprivation status explained
more of the variance, and there was a dose-response relationship,
in that the greater the level of deprivation the lower the chances if
employment (figure 2, table 2). People in the most deprived
quintile were less likely to be in employment, after adjusting for
disease severity, compared to their more advantaged counterparts
(log-odds –2.66 95%CI –3.1 to –2.26, comparing the most to the
least deprived quintile). For men with a middling level of lung
function (%FEV1 of 60) at the age of 30, this equates to 67.7%
employment in the least deprived quintile, compared to 50.2% in
the most deprived, a difference of 17.6 percentage points (figure 2).
Comparing a population with relatively good lung function
(a%FEV of 80), to one with poor lung function (a%FEV1 of 30),
with all other things being equal (i.e. deprivation quintile 3, male
sex), at the age of 30 there was a difference of 7.2 percentage
points in employment chances (log-odds –0.63 95%CI –1.1 to –
0.15 comparing poor to good lung function (figure 2).
Men were more likely than women to be in employment (log-
odds 0.40 95%CI 0.16 to 0.64 in adjusted model), which
corresponds to 61.7% employment in men, compared to 58.7%
employment in women at age 30, for people with a%FEV1 of 60,
in the middle deprivation quintile – a difference of 3 percentage
points. People with better lung function were more likely to be in
employment, and this followed a monotone dose response
relationship. Higher BMI was associated with improved employ-
ment chances (log-odds 0.1 95%CI 0.020 to 0.188 per 1 unit
increase in BMI SD score), and more days in hospital were
associated with lower employment chances (log-odds –0.023
95%CI –0.027 to –0.019, per day in hospital).
Figure 3 illustrates the interactive effect of degree of disease
severity (as measured by level of lung function) and social
deprivation on population averaged employment chances in men
and women. In the final model, a composite test for interaction
between level of lung function and deprivation quintile was not
significant (p = 0.2), but the contrast between the most deprived
quintile and level of lung function was significant (log-odds 0.016
95% CI 0.0028 to 0.03, per unit increase in %FEV1, p= 0.018)
(table 2). This suggests that having poor lung function was more
damaging to the employment chances of the most disadvantaged
quintile than for the least disadvantaged. At age 30, for example,
Table 1. Characteristics of study population in UK CF Registry by employment status at baseline.
Not in employment Employed Total
Number of adults with CF (%) 1845 (53.4) 1613 (46.6) 3458
Observations (%) 7287 (46.8) 8285 (53.2) 15572
Deprivation quintile 1 (least deprived) 295 (16) 344 (21.3) 639 (18.5)
Deprivation quintile 2 319 (17.3) 370 (22.9) 689 (19.9)
Deprivation quintile 3 357 (19.3) 354 (21.9) 711 (20.6)
Deprivation quintile 4 417 (22.6) 321 (19.9) 738 (21.3)
Deprivation quintile 5 (most deprived) 457 (24.8) 224 (13.9) 681 (19.7)
Number of F508 alleles:2 (%) 952 (51.6) 744 (46.1) 1696 (49)
Number of F508 alleles:1 (%) 632 (34.3) 616 (38.2) 1248 (36.1)
Number of F508 alleles:0 (%) 261 (14.1) 253 (15.7) 514 (14.9)
Female 856 (46.4) 672 (41.7) 1528 (44.2)
Non-white 54 (2.9) 27 (1.7) 81 (2.3)
Birth cohort 1959 – 1968 152 (8.2) 211 (13.1) 363 (10.5)
Birth cohort 1969 – 1978 409 (22.2) 573 (35.5) 982 (28.4)
Birth cohort 1979 – 1988 1203 (65.2) 780 (48.4) 1983 (57.3)
Birth cohort .1988 81 (4.4) 49 (3) 130 (3.8)
Median age at baseline (years) (IQR) 21 (20.4,24.5) 23 (20.7,29.3) 21.5 (20.5,27)
Median %FEV1 at entry (IQR) 61.8 (41.8,82.2) 68.4 (49.9,85.2) 65.3 (45.8,83.7)
%FEV1 .90 (normal) 286 (15.5) 302 (18.7) 588 (17)
%FEV1 .70 and ,90 (mild) 457 (24.8) 458 (28.4) 915 (26.5)
% FEV1 .40 and ,70 (moderate) 678 (36.7) 619 (38.4) 1297 (37.5)
% FEV1 ,40 (severe) 424 (23) 234 (14.5) 658 (19)
Pseudomonas colonization at entry 1123 (60.9) 836 (51.8) 1959 (56.7)
Median BMI SDS at entry (IQR) –0.6 (–1.4,0.1) –0.4 (–1.2,0.4) –0.5 (–1.3,0.3)
Died 223 (12.1) 115 (7.1) 338 (9.8)
doi:10.1371/journal.pone.0073322.t001
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poor lung function in men in the least deprived quintile was
associated with 3.1 percentage points lower employment chances
than for their counterparts in the same quintile with good lung
function (66.1% employment prevalence compared with 69.2%).
For men in the most deprived quintile, however, there is 7.7
percentage points difference in employment chances between
those with poor and good lung function (46.4% compared with
54.1%).
Discussion
We undertook a longitudinal registry-based study of employ-
ment status in the UK CF population, and found that lower social
deprivation, male sex, higher level of lung function and BMI, and
less time in hospital were associated with improved employment
chances. All other things being equal, being deprived was
associated with lower employment chances (17.6 percentage
points lower than least deprived quintile). Having poor lung
function was also associated with lower employment chances (7.2
percentage points lower in people with poor versus good lung
function). When people with CF have a double burden of high
deprivation and poor lung function, however, the impact on
employment chances is magnified. In other words,, deprivation
appears to modify the effect of lung function on employment
chances - poor lung function is more harmful to employment
chances in people living in the most deprived areas, compared to
the least. As people are living longer, healthier lives with CF, it is
more important than ever for strategies to promote employment to
focus on the broader societal barriers to engagement in the
workforce for people with CF, rather than taking a narrow
‘impairment’ focus solely on the impact of disease severity on
employment chances, as critiqued by Edwards et al [8].
Key strengths of this study include the population-wide
coverage of the UK CF registry, the high quality of the data,
the longitudinal analysis, and the theoretical approach that
responds to previous criticisms of the illness-focussed approach
to understanding employment outcomes in CF. Our findings are
particularly relevant to the UK population, but could be cautiously
generalised to other high-income countries. There are limitations:
it relies on retrospective, routinely collected data and although we
used a standard, fine-grained measure of deprivation of area of
residence, employed widely in epidemiological studies in the UK
as a measure of socio-economic status (SES) [9,26,27], it was not
possible to separate effects of socioeconomic circumstances
operating at the individual and area level. There is thus the
possibility of ecological bias, and this limits the possibilities to
Figure 1. Overall employment prevalence by age and year of people with CF aged 20–40 in UK CF Registry. 95% confidence intervals
(top row). Bottom row shows employment prevalence by age, stratified by deprivation quintile (most deprived quintile in red), for men and women.
doi:10.1371/journal.pone.0073322.g001
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disentangle the mechanisms by which socioeconomic disadvantage
operates. However, this possibility is minimized using the
established Index of Multiple Deprivation methodology in the
UK [9]. Secondly, we only had valid postcodes on 90% of the
sample, though our sample size was large, with no pronounced
gradient in the proportion of patients with valid postcodes by
deprivation quintile i.e. missing postcode information was
unrelated to deprivation. Finally the analysis did not include data
for people aged over 40 years, because less than 5% of the annual
clinical reviews occurred in patients over 40 years, so, although
including these data would extend the age range for the analysis
considerably, there would be small numbers.in the over-40 age-
range.
A recent review concluded that further research on CF and
employment is necessary to improve occupational outcomes [7].
The systematic review identified nine studies that have looked at
the relationship between CF and employment status, all of which
were small, and based at one or two care centres only. Six studies
reported employment rates, all of around 50%. This systematic
review did not include the largest study to date, by Walters et al
[28], which was a cross-sectional questionnaire survey of 1052
adults over 16 years of age with CF in the UK in 1990. Walters et
al found that 55% of responders were working, whilst of those not
employed, half gave ill health as the reason [28]. In our study we
find that the annual employment rate among CF adults in the UK
appears to have remained unchanged between 50% and 55% over
the last decade. Five previous studies in the systematic review
analysed the association between disease severity, as measured by
lung function, and employment status, but with no analysis by
SES. The results were mixed: three studies conducted in the US
[29], Canada [30] and Australia [31] concluded that lung function
was not related to employment status, and two from the US [32]
and Belgium [33] suggested that it was related. The studies by
Burker et al. [29], Gillen et al. [32], and Hogg et al. [31] suggested
that frequency of hospital admissions, demographic variables,
mental health, and education level, may also influence employ-
ment status.
Our study suggests that disease severity and time in hospital
influence employment chances in the UK CF population, but
these effects are not as large as one might have predicted. It is
evident that people with significant respiratory impairment
continue to work, and disease severity alone does not predict
employment outcomes. Furthermore, there is a large amount of
variability between individuals with similar characteristics (large
Figure 2. Longitudinal employment trajectory versus age of people with CF in UK CF Registry, by deprivation quintile, sex, %FEV1,
BMI SD score and days in hospital. The lines show the final modelled longitudinal trajectories from the final interaction model (table 2, column
5), contrasting the adjusted effects of deprivation, sex, %FEV1, BMI SD score and days in hospital. These effects are plotted at the reference levels for
the other covariates in the analysis.
doi:10.1371/journal.pone.0073322.g002
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random effects), which suggests that there are other important
factors related to employment status that we have been unable to
account for in our study. Highest educational attainment is one
such factor, but these data were available only for 60% of the
individuals in the UK CF Registry. Adjusting for educational
attainment did not change any of the substantive effects in our
analysis, though it did reduce the random effects variance further
(table S1). Other studies have also suggested that individual
Table 2. Log odds for the final nested generalised mixed effects models (GLMMs) for the effects of disease severity, time in
hospital and level of deprivation on employment chances.
Baseline Baseline +severity
Baseline +Severity
+Time in hospital
Baseline +Severity +Time in
hospital +Deprivation
Baseline +Severity +Time in hospital
+Deprivation*%FEV1
Constant 0.663*** 0.761*** 0.997*** 2.047*** 2.058***
(0.105) (0.106) (0.105) (0.172) (0.171)
age 0.128*** 0.143*** 0.144*** 0.146*** 0.146***
(0.016) (0.016) (0.016) (0.016) (0.016)
ageˆ2 –0.022*** –0.024*** –0.023*** –0.023*** –0.023***
(0.002) (0.002) (0.002) (0.002) (0.002)
Birthyear –0.057*** –0.059*** –0.046** –0.039** –0.039**
(0.014) (0.014) (0.014) (0.014) (0.014)
Male/Female 0.446*** 0.485*** 0.443*** 0.410** 0.401**
(0.129) (0.128) (0.125) (0.125) (0.125)
Random intercept SD (3.016) (2.893) (2.779) (2.640) (2.632)
Random slope SD (0.450) (0.451) (0.438) (0.442) (0.441)
%FEV1 0.026*** 0.020*** 0.021*** 0.013**
(0.002) (0.002) (0.002) (0.005)
BMI SDS score 0.163*** 0.121** 0.106* 0.104*
(0.043) (0.043) (0.043) (0.043)
Hospital IV days –0.024*** –0.023*** –0.023***
(0.002) (0.002) (0.002)
Deprivation quintile 2/1 –0.270 –0.279
(0.202) (0.202)
Deprivation quintile 3/1 –0.967*** –0.976***
(0.200) (0.200)
Deprivation quintile 4/1 –1.422*** –1.427***
(0.198) (0.198)
Deprivation quintile 5/1 –2.650*** –2.663***
(0.207) (0.207)
Deprivation quintile 2/1
x%FEV1
0.010
(0.007)
Deprivation quintile 3/1
x%FEV1
0.010
(0.006)
Deprivation quintile 4/1
x%FEV1
0.006
(0.006)
Deprivation quintile 5/1
x%FEV1
0.016*
(0.007)
Log-likelihood –7885 –7720 –7645 –7548 –7545
N 15572 15430 15430 15430 15430
Groups 3458 3451 3451 3451 3451
Baseline variance
explained (%)
- 7.9 15.1 23.3 23.8
*p,0.05, ** p,0.01, *** p,0.001.
Standard errors in parentheses.
doi:10.1371/journal.pone.0073322.t002
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psychological factors and education status are correlated with
employment status in CF [29].
These previous studies on employment chances in people with
CF tend to portray CF as a ‘serious illness’, which causes
employment problems. In contrast, Edward et al explored the
employment experiences of adults with CF from a social model
perspective. They demonstrated barriers to employment that were
similar to those experienced by other disabled people, as well as
barriers related to the ‘impairment effects’ of CF, and concluded
that adults with CF have valuable perspectives to contribute to
social model analysis and the development of employment-related
policy solutions [8]. Our results not only corroborate, but also
extend these observations, by demonstrating the interaction
between disease severity related factors, and deprivation.
Our findings add to the extensive literature on the inter-
relationship between chronic illness, socioeconomic status, and
employment opportunities [34]. In the UK in 2005 the age
standardized employment rate for people of working age (25–59)
was 80% in healthy women, compared to 50% in those with
limiting long-standing illness (LLSI), and 93% compared to 59%
in men [34]. Furthermore there was a striking social gradient for
those with LLSI - the prevalence of employment was 66% in
highly educated women with LLSI compared to 18% in those with
low education, and in men 72% compared to 30% [35]. In our
study, the unadjusted prevalence of employment was around 60%
in the most affluent quintile, compared to 30% in the most
deprived quintile in women, and 70% versus 30% in men (figure
1).
Low employment in people with CF is a serious concern.
Despite there being no difference in incidence of CF by
socioeconomic status (SES), there are important differences in
outcomes such as growth and lung function, and ultimately
survival, in people with CF by SES in the UK and US [9,12,15].
Being out of work increases the risk of poverty and social
exclusion, and is likely to further damage the health of the most
disadvantaged people with CF. In this study we have demonstrat-
ed differential social consequences of illness in the context of CF, by
which people with the double burden of chronic illness and low
SES are more likely to be excluded from the labour market. We
speculate that this may be an important pathway for the
amplification of health inequalities in CF, whereby disadvantage
builds on disadvantage. It is of particular concern that the most
disadvantaged women have the poorest employment chances,
since female sex is also an important risk factor for poor survival in
CF [15].
In conclusion, this study has identified important longitudinal
inequalities in employment outcomes in people with CF in the
UK. Future studies should focus on policy interventions that would
help overcome the extra burden of adverse consequences of CF
faced by patients living in disadvantaged circumstances.
Supporting Information
Figure S1 Logic model to inform analysis of employment status.
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Table S1 Log odds for the final generalised mixed effects models
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Figure 3. Longitudinal employment trajectory versus age, demonstrating the interaction between deprivation and lung function.
The lines show the final modelled longitudinal trajectories from the interaction model (table 2, column 5), contrasting the adjusted effects of
deprivation, and %FEV1.
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ORIGINAL ARTICLE
Understanding the natural progression in %FEV1
decline in patients with cystic fibrosis:
a longitudinal study
David Taylor-Robinson,1 Margaret Whitehead,1 Finn Diderichsen,2
Hanne Vebert Olesen,3 Tania Pressler,4 Rosalind L Smyth,5 Peter Diggle6
ABSTRACT
Background Forced expiratory volume in 1 s as
a percentage of predicted (%FEV1) is a key outcome in
cystic fibrosis (CF) and other lung diseases. As people
with CF survive for longer periods, new methods are
required to understand the way %FEV1 changes over
time. An up to date approach for longitudinal modelling
of %FEV1 is presented and applied to a unique CF dataset
to demonstrate its utility at the clinical and population
level.
Methods and findings The Danish CF register contains
70 448 %FEV1 measures on 479 patients seen monthly
between 1969 and 2010. The variability in the data is
partitioned into three components (between patient,
within patient and measurement error) using the
empirical variogram. Then a linear mixed effects model is
developed to explore factors influencing %FEV1 in this
population. Lung function measures are correlated for
over 15 years. A baseline %FEV1 value explains 63% of
the variability in %FEV1 at 1 year, 40% at 3 years, and
about 30% at 5 years. The model output smooths out the
short-term variability in %FEV1 (SD 6.3%), aiding clinical
interpretation of changes in %FEV1. At the population
level significant effects of birth cohort, pancreatic status
and Pseudomonas aeruginosa infection status on %FEV1
are shown over time.
Conclusions This approach provides a more realistic
estimate of the %FEV1 trajectory of people with chronic
lung disease by acknowledging the imprecision in
individual measurements and the correlation structure of
repeated measurements on the same individual over
time. This method has applications for clinicians in
assessing prognosis and the need for treatment
intensification, and for use in clinical trials.
INTRODUCTION
Understanding the long-term natural history of
changes in lung function in people with lung
diseases is a research priority.1 In order to do this,
objective measures of disease progression are
necessary. The per cent predicted forced expiratory
volume in 1 s (%FEV1) is commonly used to
monitor lung function, and to describe disease
severity in cystic ﬁbrosis (CF)2 and chronic
obstructive pulmonary disease (COPD).3 %FEV1 is
used to inform clinical decisions about changing or
intensifying treatment, and as an outcome measure
in clinical studies.4e6 Furthermore %FEV1 has been
shown to be related to survival in CF. Kerem et al’s
study in 1992 demonstrated that patients with
a %FEV1 <30 had a 2-year mortality over 50%,7
though a more recent study shows that survival
rates at low levels of lung function have improved
in subsequent cohorts.8
Interpreting the signiﬁcance of changes in %FEV1
in CF to inform patient management and to
counsel patients regarding prognosis requires an
understanding of the inherent variability of %FEV1
measures within individuals, to determine what
constitutes a clinically signiﬁcant deterioration in
%FEV1, rather than a change due to measurement
error, or recoverable day-to-day ﬂuctuation in lung
function.9 10 Furthermore, this variability needs to
be understood to make valid inferences about the
association between covariates and %FEV1 in
observational studies.
As survival in CF improves with successive
cohorts, there are many more people surviving into
late adulthood. An implication of this, coupled
with the availability of long-term follow-up data in
CF registers, is that up to date methods should be
adopted to interpret the long-term dynamics of
lung function in CF. Statistical techniques for
Key messages
What is the key question?
< Now that people with cystic fibrosis are living
much longer, how can we optimally describe the
changes in forced expiratory volume in 1 s as
a percentage of predicted (%FEV1) over time in
a way that is useful for clinicians at the
individual and the population level?
What is the bottom line?
< We describe a novel modelling approach for
analysing changes in %FEV1 over time that can
be applied at the individual level to interpret the
clinical significance of sudden changes in %
FEV1, and at the population level to quantify the
effect of factors such as Pseudomonas aerugi-
nosa acquisition.
Why read on?
< Lung function measures are correlated for over
15 years, and a baseline %FEV1 value explains
63% of the variability in %FEV1 at 1 year, 40% at
3 years and about 30% at 5 years.
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longitudinal data analysis have been the subject of much
methodological development over the past 20 years, and the
random intercept and slope model has become a popular analysis
framework.4 5 11e14 While this is often appropriate for relatively
short follow-up periods, there are theoretical reasons to suggest
that this approach makes assumptions that will lead to incorrect
inferences if applied over longer follow-up periods. One central
assumption is that the variability in %FEV1 increases as
a quadratic function over time (in proportion to time squared),
which leads to estimates that diverge unrealistically over longer
time periods. Methods for undertaking these analyses over
longer time periods have been described,15 but have not been
commonly applied.
In this study we analyse a unique population-level dataset of
people with CF that includes longitudinal %FEV1 measures
taken monthly for up to 30 years. We apply these methods to
develop a general model for %FEV1 decline that goes beyond the
popular random-intercept and slope approach, and explicitly
describes the variability in %FEV1 within individuals over time.
We show how this could be applied clinically to help interpret
the signiﬁcance of changes in lung function, and at a population
level to explore the association of covariates (eg, Pseudomonas
aeruginosa acquisition) with %FEV1 decline.
METHODS
Subjects
All patients aged over 5 years whose %FEV1 data were entered
on the Danish CF database between 1969 and 2010 were eligible.
Post-transplant data from patients who had received a lung
transplant were excluded. Patients attending the two Danish CF
centres (Copenhagen and Aarhus) are seen routinely every
month in the outpatient clinic for evaluation of clinical status,
pulmonary function and microbiology of lower respiratory tract
secretions. It is estimated that coverage of people with CF
resident in Denmark is almost complete from 1990 when CF
care was centralised. This coverage and the unparallelled
frequency of measurement make this a unique dataset for
epidemiological research. The study was approved by the Danish
Data Inspectorate (Datatilsynet).
Lung function testing
The primary outcome for this analysis was %FEV1. Pulmonary
function tests were performed according to international
recommendations,16 measuring FEV1, expressed as a percentage
of predicted values for sex and height using reference equations
from Wang or Hankinson.17 18
Covariates
Covariates in the analysis were age, sex, genotype coded as the
number of Delta F508 alleles (0, 1 or 2), onset of chronic Pseu-
domonas infection (coded 0 or 1 as a time-varying covariate),
pancreatic insufﬁciency determined on the basis of pancreatic
enzyme usage (coded 0 or 1 as a baseline covariate), birth cohort
(six 10-year cohorts starting at 1948), and CF-related diabetes
(CFRD) diagnosed using the WHO criteria (coded 0 or 1 as
a time-varying covariate).
Statistical analysis
A detailed explanation is given in the online appendix. Repeated
%FEV1 measures on individuals are correlated, and this must be
accommodated to obtain valid inferences. We used a linear
mixed effects model with longitudinally structured correla-
tion,15 19 and contrasted our approach with the widely used
random intercept and slope model.20 We modelled random
variation in %FEV1 over time for an individual subject so that
the strength of the correlation of the random variation between
two values depends on the corresponding time separation. The
model decomposed the overall random variation in the data into
three components: between subjects, between times within
subjects, and measurement error.
First, we ﬁt a provisional model for the mean response by
ordinary least squares and used the empirical variogram of the
residuals (see ﬁgure E1 in the online appendix) to provide initial
estimates for the three components of variation, and for the
shape of the correlation function of the between-times-within-
subjects component. We then re-estimated all of the model
parameters by maximum likelihood estimation, and used
generalised likelihood ratio statistics to compare nested models,
and Wald statistics to test hypotheses about model parameters.
We assessed associations between single or multiple covariates
and the population mean %FEV1 over time, and explored alter-
natives to a linear function for the population-averaged time
trend.
RESULTS
Population characteristics
The dataset contained 70 448 lung function measures on 479
patients seen between 1969 and 2010 in Denmark (table 1). The
median number of %FEV1 measures per person was 101 (range
2e597). The median follow-up period was 10.5 years (range
0.1e31.5), with a total of 6500 person-years of follow-up. Forty-
two patients were followed up for more than 30 years (see also
ﬁgures E2 and E3 in the online appendix).
Table 1 Baseline characteristics of the Danish cystic fibrosis (CF) population
Birth cohort
‡1948 ‡1958 ‡1968 ‡1978 ‡1988 ‡1998 Total
N (%) 7 (1.5) 42 (8.8) 110 (23) 105 (21.9) 141 (29.4) 74 (15.4) 479 (100)
Women 1 (14.3) 19 (45.2) 48 (43.6) 52 (49.5) 74 (52.5) 42 (56.8) 236 (49.3)
No. Delta F508 ¼ 0 0 (0) 0 (0) 1 (0.9) 4 (3.8) 5 (3.5) 5 (6.8) 15 (3.1)
No. Delta F508 ¼ 1 2 (28.6) 14 (33.3) 26 (23.6) 24 (22.9) 42 (29.8) 19 (25.7) 127 (26.5)
No. Delta F508 ¼ 2 5 (71.4) 28 (66.7) 83 (75.5) 77 (73.3) 94 (66.7) 50 (67.6) 337 (70.4)
Developed chronic Pseudomonas 6 (85.7) 31 (73.8) 84 (76.4) 55 (52.4) 20 (14.2) 5 (6.8) 201 (42)
Missing infection information 0 (0) 5 (11.9) 2 (1.8) 2 (1.9) 1 (0.7) 0 (0) 10 (2.1)
Pancreatic insufficient 7 (100) 42 (100) 105 (95.5) 99 (94.3) 133 (94.3) 73 (98.6) 459 (95.8)
Copenhagen 7 (100) 38 (90.5) 83 (75.5) 72 (68.6) 79 (56) 50 (67.6) 329 (68.7)
Alive 4 (57.1) 27 (64.3) 79 (71.8) 77 (73.3) 132 (93.6) 74 (100) 393 (82)
Developed CFRD 3 (42.9) 21 (50) 41 (37.3) 31 (29.5) 22 (15.6) 1 (1.4) 119 (24.8)
CFRD, cystic fibrosis related diabetes.
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Limitations of random intercept and slope model
The high degree of short-term and long-term variation in
predicted %FEV1 is illustrated in ﬁgure 1. The standard random
intercept and slope model approach is illustrated over long and
short follow-up periods in ﬁgure 1A,C. This approach assumes
that any deviation of an individual’s trajectory from the popu-
lation mean is linear in time over the whole of the follow-up
period apart from independent random errors. One can see that
this assumption is reasonable over short time periods, as illus-
trated by the ﬁt of the shorter dotted-line segments (ﬁgure 1A,
C), but over longer time periods the individual data traces
diverge unrealistically from their ﬁtted linear mean trajectories
(long solid line). Our proposed model produces a much closer
ﬁt to the data (ﬁgure 1B,D), and one that better reﬂects
the relative magnitude of the three estimated components of
variation in %FEV1 over time.
Quantifying the variability in %FEV1 over time
The empirical variogram quantiﬁes the variability in the dataset
(ﬁgure 2A). The intercept at time zero represents measurement
error because there can be no true within-person variation at
a time lag of zero. Of the total variance in the Danish dataset,
about half is due to systematic differences between patients (eg,
genotype, sex or pancreatic status), two-ﬁfths is within patients,
representing change over time (disease progression), and one-
tenth is ‘measurement error ’. In practice, this last component
represents the combined effects of technical errors, and physi-
ological variability occurring at time intervals less than the
monthly interval of measurement, for example, day-to-day
variability. This error variance equates to an average SD of 6.3%
for repeated measures on the same individual at short time
intervals. Figure 2B shows the proportion of the within-person
variability in %FEV1 at follow-up time (t), which can be
explained by their %FEV1 value at baseline. For example, about
50% of the within-patient variability at t¼2.5 years is explained
by the baseline measurement, and about 30% at t¼5 years.
Overall, the dependence on baseline measures gradually decays
and is negligible at 15 years.
Clinical utility of our proposed model
The model can be used to guide interpretation of sudden changes
in lung function. Consider seeing the person in ﬁgure 1B at
Figure 1 Comparison of conventional
random intercept and slope model over
short and long follow-up periods,
versus our proposed Gaussian process
model. (A) Data for a single individual,
illustrating that a linear trend fits
reasonably well over short time
periods, but gives a very poor fit to this
individual’s complete data; linear trends
are fitted by ordinary least squares. (B)
The same data with the fitted trajectory
of the stationary Gaussian process
model. The smoothed fitted trace is
a better representation of the ‘true’
underlying lung function, and could be
used in real time to guide the
interpretation of sudden changes in lung
function. For instance, the sudden drop
to under 30% indicated by the arrow is
not mirrored in the model trace,
suggesting that this may be recoverable
random fluctuation. (C, D)
Corresponding plots for a second
individual. %FEV1, forced expiratory
volume in 1 s as a percentage of
predicted.
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around age 9 (as indicated by the arrow in the ﬁgure), when her
lung function has dropped to below 30%. On the basis of this
one-off measurement, one might be quite guarded in terms of
prognosis. However, our modelled trace (thick black line in ﬁgure
1B) suggests that her underlying lung function is changing less
dramatically, with a modelled %FEV1 of around 50%. We suggest
that this estimate provides a more realistic assessment of
underlying lung function by smoothing out the short-term
variability. This could be a useful adjunct to clinical decision-
making. As well as providing information about the signiﬁcance
of a sudden change in lung function, ﬁgure 2B also quantiﬁes the
predictive value of a contemporary %FEV1 measure. In terms of
counselling patients, this means that a higher %FEV1 today is
associated with a higher %FEV1 at subsequent time points, but
the predictive value deteriorates over time as illustrated in the
ﬁgure.
Effect of covariates on lung function in the Danish population
We explored the effect of covariates that have been associated
with %FEV1 in previous studies to demonstrate how this model
can be used to answer questions at the population level (see
table E1 online appendix for univariate associations).4 There was
no evidence to suggest that covariate effects were nonlinear (see
ﬁgure E4 in online appendix). The ﬁnal model included age,
Pseudomonas status, pancreatic status, cohort and CFRD
(table 2). Note that the estimated covariate effects in table 2 are
population-averaged effects, that is, they describe average values
of %FEV1 for sub-populations of individuals sharing the same
explanatory characteristics, rather than for any one individual.
The most prominent effects are associated with birth cohort,
pancreatic function and the onset of Pseudomonas infection
(ﬁgure 3). There is clear separation between the three most
recent birth cohorts, with a successive increase in the intercept
term at age 5 (83% in the 1978e88 cohort vs 96% in the post-
1998 cohort) (ﬁgure 3A and ﬁgures E9eE10 in online appendix).
There is a large change in the point estimate for the rate of
change of lung function in the post-1998 (0.24%) compared with
the 1988e98 cohort (!1% per year), such that the post-1998
cohort appears to be improving over the period of measurement.
The three cohorts spanning the years 1948e1978 have a similar
overall rate of decline around !0.3% per year, with an intercept
at age 5 of 66%. Pancreatic insufﬁciency is associated with
a signiﬁcantly steeper rate of decline of lung function (!0.92%
per year, 95% CI !1.7 to !0.3), as is acquisition of Pseudomonas
Figure 2 Quantifying the variability in
forced expiratory volume in 1 s as
a percentage of predicted (%FEV1) with
the variogram approach. (A) Scaled
empirical variogram for the Danish data.
The solid line (variogram function)
represents the variance of the
difference between residual errors
within individuals at time lags from 0 to
30 years. The variogram function
increases up to about 15 years,
corresponding to a decreasing
correlation between paired lung
function measures with
increasing time separation. The
variogram partitions the variability in
the data into three components: within
person, between person, and error. (B)
Proportion of variability in an individual’s %FEV1 at follow-up time t that is explained by their %FEV1 at baseline. This shows that the variogram can
predict 63% of the variability from the population average at 1 year, which decreases to around 60%, 40%, 30% and 10% at 2, 3, 5 and 10 years
respectively.
Table 2 Estimates from final multivariate model
Point estimate Lower 95% CI Upper 95% CI p Value
Intercept at age 5 years 66.02 61.13 70.92 <0.001
CFRD !2.47 !3.58 !1.37 <0.001
Age !0.26 !0.49 !0.03 0.025
Cohort$1948 (reference 1968) 1.20 !25.50 27.90 0.930
Cohort$1958 !0.75 !10.01 8.51 0.874
Cohort$1978 16.60 10.15 23.05 <0.001
Cohort$1988 25.19 19.11 31.27 <0.001
Cohort$1998 29.81 22.85 36.78 <0.001
Pancreatic sufficiency 2.78 !10.43 15.99 0.679
Pseudomonas aeruginosa infection !0.51 !0.72 !0.29 <0.001
Age3cohort$1948 !0.03 !0.67 0.61 0.920
Age3cohort$1958 0.06 !0.23 0.34 0.699
Age3cohort$1978 !0.72 !1.00 !0.44 <0.001
Age3cohort$1988 !0.72 !1.09 !0.35 <0.001
Age3cohort$1998 0.50 !0.41 1.42 0.280
Age3pancreatic sufficiency 0.98 0.29 1.67 0.005
CFRD, cystic fibrosis related diabetes.
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infection (!0.5% per year, 95% CI !0.72 to !0.3) (ﬁgure 3B and
ﬁgure E8 in online appendix). CFRD is associated with a drop in
intercept of !2.5% (95% CI !3.6% to !1.37%), but has no
effect on the rate of decline of lung function.
DISCUSSION
We describe a novel longitudinal modelling technique speciﬁcally
aimed at analysing long sequences of repeated measurements,
and apply this to %FEV1 from a CF population. We show how
this approach could be used to inform patient management, by
aiding the interpretation of sudden changes in lung function,
and by quantifying the predictive value of a baseline %FEV1
measure up to 15 years later. At the population level, we show
how our model can be used to quantify the effect of covariates
on populations or sub-populations. Translation of these methods
into clinical practice is important because people with CF are
living longer, and we have shown how commonly applied
approaches are unhelpful over long follow-up periods.
This study quantiﬁes the short-term variability in %FEV1 in
this population (SD 6.3%), and demonstrates that %FEV1
measures within individuals are correlated over time lags of
15 years or more. We have also explored the effect of previously
studied risk factors for lung function decline in the Danish CF
population, and have demonstrated signiﬁcant effects of birth
cohort, pancreatic status and Pseudomonas infection status.
The ﬁndings from this study have a number of clinical
applications. Quantifying the variability in lung function
measures is essential to make correct clinical interpretation.10
Exploiting the unusually high frequency of data collection in
Denmark, this study implies that on average a change in %FEV1
of >13% (ie, twice the error SD, to give a 95% conﬁdence range)
is likely to represent true within-patient variation over time
(disease progression), whereas anything less than this could be
due to short-term ﬂuctuation, which may recover. Stanbrook
et al21 found a pooled within-subject %FEV1 SD of 4.5% when
measured over a 9-day period in 21 stable adults with CF. This
population is different to the population in our study, who were
measured regardless of clinical status, and one would therefore
expect greater variability. Other studies have shown that people
with CF, asthma and COPD have more short-term variability in
lung function tests22e24 and that more impaired lung function is
associated with greater variability.25
Our model can be used to generate an underlying represen-
tation of an individual’s ‘true’ lung function trajectory (ﬁgure
1B,D) that smoothes out the noise inherent in %FEV1 measures.
These smoothed traces could be used to inform clinical decision-
makingdthe model ﬁt curves in ﬁgure 1 provide more realistic
estimates of underlying lung function, and more valid criteria for
clinical decisions. We propose that this model could be used to
develop a real-time smoothing tool embedded in electronic
patient records to aid clinical interpretation of spirometry data.
We suggest that access to this information would provide some
re-assurance to patents experiencing lower than expected lung
function values, since lung function can recover quite dramati-
cally, and these data suggest that a linear or stepwise decline in
lung function over time is not the norm.
We have generated, for the ﬁrst time to our knowledge, the
variogram function for %FEV1 in people with CF over long
follow-up periods. This precisely quantiﬁes how %FEV1
measures are correlated over time. Furthermore we have done
this for the whole CF population of Denmark. This quantiﬁes
the degree to which a baseline %FEV1 measure can be used
to predict subsequent %FEV1 measures over long follow-up
periods, and is likely to be of interest to clinicians and
patients. We demonstrate a long-term correlation between levels
of %FEV1 within an individual. This suggests that there is long-
term predictive value in a high %FEV1 measuredpeople with
CF with a high %FEV1 at baseline are more likely to have a high
%FEV1 up to 15 years later than individuals with a lower
baseline %FEV1 (ﬁgure 2B). However, the predictive value of a
%FEV1 measure drops away rapidly over this period. We can say
that on average a %FEV1 reading today explains about 63% of
the variability in %FEV1 at 1 year, 40% at 3 years, and about
30% at 5 years.
This corroborates Rosenthal’s study,26 which found that
baseline %FEV1 explains 66% of the variability in %FEV1 at
1 year, and Mastella et al’s study of European registry data in
which differences in lung function at enrolment at age 5, cate-
gorised as mild, moderate or severe, tracked through the study to
age 40.27 Konstan et al also describe how a lower %FEV1 for
a given age can be used to characterise the aggressiveness of lung
disease.28 Other studies have shown a high %FEV1 to be an
independent risk factor for a greater rate of decline of %FEV1
over the next few years.4 29 This is not at odds with our ﬁndings
here; a high %FEV1 can be a risk factor for greater decline in
the short term, while still being associated with a relatively
higher %FEV1 over the longer term.28
At the population level we show how our approach can be
applied to quantify the effect of covariates on changes in
lung function. Furthermore, the partitioning of the variability in
%FEV1 and the precise description of the correlation structure
captured in the model provide important information for sample
Figure 3 Effect of covariates on
forced expiratory volume in 1 s as
a percentage of predicted (%FEV1). (A)
Birth cohort effect in the final model.
There is clear separation between the
three most recent birth cohorts, with
a successive increase in the intercept
term at age 5 years. (B) Effect of
pancreatic insufficiency and
Pseudomonas infection on the
predicted population trajectory for
a person born in the 1988e1998
cohort. CF, cystic fibrosis; PA,
Pseudomonas aeruginosa.
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size calculations in longitudinal clinical studies with %FEV1 as
an outcome. Increasingly longitudinal outcomes are being used
in randomised control trials, and to undertake an a priori sample
size calculation it is essential to have information on the
correlation structure. Furthermore, our modelled %FEV1 trace
could be used as an outcome in its own right.
As with other studies of patients with CF,30 there is a striking
cohort effect evident in this population. The treatment of CF
lung disease has been transformed over the period captured in
this analysis, from 1969 to the present day. Particularly
impressive is the improvement in lung function in the post-1998
cohort by comparison with preceding birth cohorts. Although
patients in this group are early in their disease progression, the
overall picture suggests that new therapeutic strategies are
continuing to provide improvements in respiratory function in
CF.
Our approach to modelling changes in %FEV1 can be applied
over long follow-up periods. This is in contrast to the widely
used random intercept and slope approach that has been applied
in studies of CF and COPD over short-term4 27 31 32 and longer-
term follow-up periods.10 11 14 33 The development and testing
of the new approach is facilitated by the nature of the Danish
CF registerdto our knowledge there are no other datasets that
contain such frequent (monthly) measures of lung function on
individuals measured over very long periods (up to 31.5 years).
However, the fact that the data are from Denmark does not
inﬂuence the validity of the methods we have described, since
these are essentially context free. Furthermore, this method does
not exploit any features of our data that are unique to CF, and is
equally applicable to other clinical areas that generate long
sequences of repeated measurements. As a next step we
recommend that this method be applied to longitudinal data
collected in other CF registries, such as the UK, to clarify how
robust this approach is in terms of predicting changes in %FEV1
over time, and to better understand how this might inform
clinical decision making. Future research could explore the
utility of our proposed model in other diseases such as COPD.
A limitation of this study is the likely inﬂuence of survivor
bias on lung function estimates in the earlier birth cohorts. In
the 1948e1978 period, the intercept at age 5 appears signiﬁ-
cantly lower than in the other cohorts, but there is also a shal-
lower rate of decline of lung function. This is likely to be due to
the incomplete capture of patients in earlier cohorts, with
censoring due to death leaving only the more stable survivors.
This is a common problem in datasets of this type.34 Fitting the
model by maximum likelihood automatically corrects for selec-
tion bias that depends on a patient’s observed lung function
measurements prior to death, although not for any additional
dependence on unmeasured features of their lung function
trajectory.15 19
Pancreatic sufﬁciency had an important effect on the overall
rate of decline of lung function (+0.9% per year). In Konstan’s
study4 pancreatic sufﬁciency was the most important protective
factor in the age group 6e8 years (+1.33% per year). The small
number of pancreatic-sufﬁcient individuals in the Danish
dataset (n¼20, 5%) have a notably different lung function
phenotype, maintaining near-normal lung function over the
period of follow-up (see plot in online appendix). The onset of
Pseudomonas infection was associated with a signiﬁcant increase
in the rate of decline of lung function, by around "0.5% per year,
similar to that reported in the study by Konstan, in which
Pseudomonas colonisation was associated with an increased rate
of decline of FEV1 of "0.31% per year in the 6e8-year-old age
group, and "0.22 in the 9e12-year-old age group.4
In conclusion, our modelling approach provides a more real-
istic estimate of the %FEV1 trajectory in CF, which could be
applied in real time to help clinicians interpret the signiﬁcance of
changes in %FEV1. Furthermore, our approach quantiﬁes the
predictive value of a baseline %FEV1 measure, over three
decades. This method is equally applicable to the longitudinal
assessment of %FEV1 in other lung diseases, and can enable more
robust comparisons of populations, including groups studied in
clinical trials. As people are now living for many decades with
these diseases, the development of tools to better understand the
natural history of this important outcome will be essential for
improved clinical care, as well as being a key research priority.1
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.Author’s response:
understanding the natural
progression in %FEV1 decline
in patients with cystic ﬁbrosis:
a longitudinal study
We thank Professor Miller for his com-
ments1 regarding our paper,2 in which we
outline a novel approach to modelling
repeated lung function measures in people
with cystic ﬁbrosis (CF) over long
follow-up periods. We agree that it would
be interesting to apply our methodology
using alternative methods of expressing
lung function across the age range, and
reiterate that our approach can be usefully
applied to any clinical outcome measured
repeatedly over extended periods.
While the merits of different approaches
are appreciated, we chose to model forced
expiratory volume in 1 s as a percentage
of predicted (%FEV1) for a number of
reasons. First, %FEV1 is still currently recog-
nised as a key outcome measure in CF3 as it
is predictive of survival, and is currently an
important criterion in international lung
transplant guidelines.4 Second, %FEV1 has
been modelled previously over long
follow-up periods, across the paediatric
and adult age range in CF using a
random-intercept and slope approach,5 and
we wanted to compare our method with
this. Third, standardised %FEV1 was the
most commonly collected outcome measure
in the Danish CF registry.
While we agree that use of recently
developed all-age equations, such as those
published by Stanojevic6 or Quanjer7
would be advantageous in avoiding arbi-
trary breaks, for the purposes of this ana-
lysis, we adhered to the approach that is
currently used in Denmark to facilitate
comparisons with previously published
data. Irrespective of the precise outcome
used, our ﬁnding that the error in
repeated measurements of %FEV1 within
individuals is large (average within-person
SD of 6 percentage points) remains valid.
Furthermore, our approach provides more
realistic estimates of the underlying lung-
function trajectory of people with chronic
lung disease, by acknowledging the impre-
cision in individual measurements over
time, and the correlation structure of
repeated measurements on the same indi-
vidual, issues that have all too often been
disregarded in the past.
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Health inequalities and cystic fibrosis
Even for genetic diseases, social conditions are still important determinants of outcome
David Taylor-RobinsonMedical Research Council population health scientist 1, Michael S Schechter
associate professor 2
1Department of Public Health and Policy, University of Liverpool, Liverpool L69 3GB, UK; 2Department of Pediatrics, Emory University School of
Medicine and Children’s Healthcare of Atlanta, Atlanta, GA, USA
Cystic fibrosis is the most common serious inherited disease in
white populations. Intensive support from family and healthcare
services is needed from the time of diagnosis onwards, and most
patients die prematurely from respiratory failure. Survival has
dramatically improved over successive birth cohorts, such that
British children born in the 21st century will have a median
survival of over 50 years.1 However, disease progression and
survival still vary greatly, mostly as a result of social and
environmental, rather than genetic, determinants.2 It has been
known for more than 20 years that people with cystic fibrosis
from socioeconomically disadvantaged backgrounds die younger
than those in more advantaged positions.3
In a linked observational study (doi:10.1136/bmj.d4662), Barr
and colleagues used death registration data in England and
Wales to show that this socioeconomic divide in premature
mortality in cystic fibrosis has persisted with no substantial
narrowing for over four decades.4 They also show that female
patients continue to die at a younger age than men. What can
we learn from this, and what are the implications for policy and
for clinicians?
Cystic fibrosis offers a valuable case for understanding how
health inequalities develop. It is an autosomal recessive disease
with an asymptomatic (and, until recently, undetectable) carrier
state, so unlike many other diseases, socioeconomic status does
not influence who gets the disease. Inequalities related to
socioeconomic status result from the different patterns of
exposure to harmful and protective or therapeutic influences
that occur over the course of people’s lives. Studies from the
United States and United Kingdom show that significant
inequalities in key intermediate outcomes in cystic fibrosis,
such as growth and lung function, begin early in childhood and
persist over time.5 6 The early appearance and persistence of
inequalities support the need for interventions that are targeted
at the early (and perhaps prenatal) years and reinforce the
importance of screening for cystic fibrosis in newborns. This,
incidentally, is also true for sex related inequalities, which are
probably caused as much by socially determined gender roles
as by biologically determined sex characteristics.7
A key question for practising clinicians is what role healthcare
delivery plays in mitigating or potentiating health inequalities
in cystic fibrosis. In the US, studies have failed to identify
important socioeconomic status related differences in the use
of chronic treatment for cystic fibrosis, treatment of pulmonary
exacerbations, or hospital admissions,2 5 8 although there is some
evidence that affluent groups may be earlier recipients of newly
developed cystic fibrosis drugs.8 The adoption of system based
methods to optimise consistency in the use of best care practices
might help to minimise variations in prescribed care.9 Other
than tackling any residual socioeconomic status related
differences in access and provision of healthcare to patients
with cystic fibrosis, how else can inequalities be reduced?
Some underused tools are available to cystic fibrosis clinicians.
One obvious target for action is to protect newly diagnosed
children from environmental tobacco smoke. There are striking
and persistent differences in the prevalence of smoking
according to socioeconomic status.10 Exposure to environmental
tobacco smoke is associated with poorer growth and lung
function in cystic fibrosis,2 and it may be the most important
explanatory factor for inequalities related to socioeconomic
status in this disease.11 Early identification of family members
who smoke, and appropriate counselling and referral to smoking
cessation services, would be an effective intervention for all
patients, regardless of social position. This should be coupled
with support to develop disease self management skills in the
patient and the family,12 in addition to targeted input from social
workers who work with the multidisciplinary cystic fibrosis
team.
Ultimately, however, although individually focused interventions
may have some limited success, the more effective long term
solution to health inequalities in people with cystic fibrosis and
in the general population is likely to be one that takes broader
action to tackle the social determinants of health. These are the
“conditions in which we are born, grow up, work, and live,”
and they include income and income distribution, education,
employment and working conditions, housing, food insecurity,
race and ethnicity, and sex and gender roles. These factors
provide a particularly important context for a family dealing
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with the stresses of caring for a child with a complex chronic
illness like cystic fibrosis over a lifetime.
The evidence is clear, unfortunately, that we have made little
progress over the past few decades in reducing health
inequalities generated by social gradients,11 and this evidence
is strengthened by Barr and colleagues’ study. Future research
should assess the mechanisms that generate socioeconomic
status related inequalities and the interventions that are most
likely to reduce them, bearing in mind that investigating
interventions at the population level is likely to have greater
impact. The current political discourse in the US suggests that
any insight into effective social interventions is unlikely to come
from that side of the Atlantic; the discussion on the UK side,
inspired by documents such as the Marmot report,11 will
hopefully provide a first step towards investigating and putting
into practice the most effective ways to reduce the
socioeconomic gradient in health.
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THE EFFECT OF SOCIOECONOMIC STATUS ON OUTCOMES IN CF
David Taylor-Robinson, MB Ch.B.(Hons), B.Sc.(Hons), MPH1, Hanne V. Olesen2, Tania Pressler3, Karsten Thielen4,
Finn Diderichsen4, Peter Diggle1,5, Rosalind Smyth1 and Margaret Whitehead1
1. University of Liverpool, Liverpool, United Kingdom; 2. Aarhus University Hospital, Aarhus, Denmark; 3.
Rigshospitalet, Copenhagen, Denmark; 4. University of Copenhagen, Copenhagen, Denmark; 5. Lancaster
University, Lancaster, Denmark
Overview: This study investigates the effect of
socioeconomic status (SES) on outcomes in people with
cystic fibrosis (CF) in the UK and Denmark. People
with CF from socio-economically disadvantaged back-
grounds die younger than those in more advantaged
social positions in the UK and the U.S. The key chal-
lenge is to understand how and when these inequalities
develop, in order to identify promising options for inter-
vention. We demonstrate the importance of social fac-
tors for key outcomes in CF, in the context of the uni-
versal health systems in the UK and Denmark, and con-
trast these findings with those from the US and other
settings.
Background: Studies across the world have con-
sistently shown that people from socio-economically
disadvantaged backgrounds experience worse health
than those in more socio-economically advantaged
positions [1]. In the UK and internationally, policies
have been implemented to try to reduce these inequal-
ities, with limited success [2]. In order to develop
more effective interventions we need a better under-
standing of how these health differences are generated
and maintained. CF is a valuable case for understand-
ing how and when health inequalities develop, since
unlike other childhood respiratory disorders CF does
not discriminate by social class: SES does not affect
disease risk but does affect the health outcomes of hav-
ing CF [3].
The improvement in survival over successive birth
cohorts in CF has been striking, but these improvements
have not been shared evenly, both within and between
countries [4]. Evidence from the U.S. indicates higher
survival rates in the 1980s and 1990s among more advan-
taged socioeconomic groups, measured by Medicaid sta-
tus and area-based income, compared with their less
advantaged counterparts [5-7]. For instance the adjusted
risk of death was almost four times higher in CF patients
with Medicaid cover, a surrogate for low socioeconomic
status, compared to those without Medicaid cover [5]. In
the UK a cross-sectional study by Britton found a con-
sistent trend from 1959 to 1986 toward higher age at
death in CF patients in non-manual, compared with man-
ual occupations [8]. Barr and colleagues recently updat-
ed this study, using death registration data in England
and Wales, and showed that the socioeconomic divide in
premature mortality in CF has persisted with no substan-
tial narrowing for over four decades [9].
There are significant differences in intermediate CF
outcomes such as %FEV1 and weight centile in young
people with CF in the U.S. For instance Schechter et al.
found a cross sectional difference of 6.7% in %FEV1 by
Medicaid status, which increased to 9.2% with adjust-
ment for various confounders [5]. Furthermore O’Con-
nor et al report a stepped social gradient in %FEV1 and
weight centile, with an absolute difference of 5.5%
between highest and lowest income quintiles in the under
18 age group [7]. A key issue is the role of the healthcare
system in mitigating or perpetuating inequalities in CF.
Michael Schechter’s studies from the U.S. have shown
mixed patterns of access to treatment by SES [10,11].
Young people on Medicaid appear more likely to access
care (sick hospital visits, chronic therapies and IV antibi-
otics). Children living in low-income areas are more like-
ly to receive oral nutritional supplementation, but less
likely to receive macrolide therapy, and IV antibiotics.
The authors conclude that inequalities in CF outcomes
are not explained by differences in healthcare or chronic
therapy use. In their study of the effect of socioeconom-
ic status on hospitalisation rates in CF in Ontario
Stephenson et al suggest that the provision of universal
healthcare in Canada may explain the lack of a socioeco-
nomic differential in hospitalisations [12].
To investigate these issues in the UK and Denmark,
we undertook retrospective cohort studies of population
level cohorts.
Methods: For the UK analysis we studied around
9000 people with CF aged under 40 years, with data cap-
tured at 58,000 annual reviews between 1996 and 2010.
Standardised census-based indices of multiple deprivation
(IMD) from the UK constituent countries were used as
small area measures of SES. In Denmark the analysis cap-
tured 479 patients seen between 1969 and 2010 at the two
CF centers in Denmark, with data measured on a monthly
basis on around 70,000 occasions. The Danish dataset was
linked to population level registers in order to collect indi-
vidual level socioeconomic data, on patients and their par-
ents (e.g., employment, income, healthcare expenditure).
In both countries we explored the effects of socioeconom-
ic status measures on key clinical outcomes (%FEV1,
growth and nutritional measures), healthcare use (access
to care, use of chronic therapies), and social outcomes
(employment and educational outcomes). The analyses
employed longitudinal data modelling techniques to
examine changes in outcomes over time in groups and
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individuals whilst allowing for correlation within patients,
and potentially informative missing values [13,14].
Findings: We have, for the first time, characterised
key outcomes over time in people with CF in the UK and
Denmark, and explored the impact of social deprivation,
as well as other covariates. Our findings, to date, have
shown important differences in outcomes by socioeco-
nomic status in the UK, which appear early, and vary
across the life-course, perhaps as a consequence of good
access to treatment in children from families living in
areas with greater social deprivation. The early appear-
ance of inequalities supports the need for interventions
that are targeted at the early years and reinforce the
importance of screening for cystic fibrosis in newborns.
Research to identify interventions to address the early
appearance of inequalities needs to be focussed on the
early years.
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ACCESS TO GOVERNMENT BENEFITS OR CO-PAY ASSISTANCE
INCREASES ACCESS TO COVERAGE & CARE
Beth Sufian, J.D.
Sufian & Passamano, LLP, HOUSTON, TX, USA
Children and adults without health insurance coverage
or who have inadequate coverage visit their CF care cen-
ter less frequently and may take less medication than
those who have access to comprehensive insurance cov-
erage with low cost share and co-pays.
These individuals with CF have less access to care
and treatment than their CF counterparts who either have
access to government benefits which provide compre-
hensive coverage without any cost share or co-pays or
whose employer provides health insurance coverage with
a low cost share for policyholders.
Individuals with CF who have inadequate or no
insurance coverage can benefit from direction from their
CF care centers to resources and programs that can help
them access assistance with co-pays or obtaining health
insurance. Many people with CF and their families are
not aware that there are resources that may be able to
assist with co-pays for medication or options for free or
low cost health insurance coverage. These individuals
go without medication or treatment due to financial con-
cerns when they could be benefitting from programs
that would allow them access to such medication and
treatment.
A study of calls to the CF Legal Information Hotline
(“Hotline”) and the CF Social Security Project exempli-
fies the increase in problems related to treatment cost
